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Abstract 
Chemotherapy-induced alopecia (CIA) is widely regarded as the most traumatic side effect 
associated with cancer treatment and the associated stress can be detrimental to overall outcomes. 
Yet there has been little research into its pathobiology and no pharmaceutical intervention is available. 
CIA is caused by chemotherapy-mediated damage of the rapidly dividing cells of the hair follicle and 
although it is normally reversible, on regrowth the hair is often different in colour and/or texture and 
only grows gradually. The only effective treatment for CIA currently available is scalp cooling. It has 
been hypothesised that scalp cooling works by a combination of vasoconstriction, a reduction in the 
metabolic rate and/or reduced drug uptake by cells in the hair bulb.  
The ability of cooling to protect from CIA has been clinically demonstrated for years yet, to date, 
no cell biology is available to support its cytoprotective effects. The overall aim of this work was to for 
the first time provide a systematic investigation of the effects of cooling on chemotherapy-induced 
toxicity in human cells. The work established cellular models to determine the efficacy of cooling in 
rescuing from toxicity, investigate the temperature conditions providing maximal rescue and 
understand not only the mechanisms responsible for drug-mediated cytotoxicity, but also the way in 
which cooling regulates such mechanisms. Various human keratinocyte models were established, 
including normal (epidermal, NHEK, and follicular, HHFK) cells and adapted HaCaT (HaCaTa) cells. 
Viability, cell cycle and apoptosis assays were used, alongside Reactive Oxygen Species (ROS) 
detection, mitochondrial integrity assays and Western blotting, as well as functional pharmacological 
inhibition experiments. A panel of chemotherapy drugs commonly used in the clinic were employed, 
including doxorubicin, docetaxel and active metabolite of cyclophosphamide, 4-hydroxy-
cyclophosphamide (4-OH-CP) and 5-FU, whilst a series of temperature conditions were tested, 
including 22°C as well as more severe cooling, particularly 18°C and 14°C (and even extreme cooling 
at 10°C).  
This study showed that cooling dramatically reduces or completely prevents the cytotoxic 
effects of docetaxel (T), doxorubicin (A), 5-FU (F) and particularly 4-OH-CP (C); however, optimal 
rescue was observed in conjunction with mono-therapy treatments (and substantial rescue with dual 
therapies, e.g. AC), whereas combinatorial treatment (TAC) showed relatively poor response to 
cooling, in agreement with clinical observations. Importantly, the work demonstrated that lowering the 
temperature below the widely accepted 22C threshold, even by a small number of degrees (e.g. 
18C), resulted in significantly improved or even complete cytoprotection, a striking observation 
strongly suggesting that the scalp temperature achieved clinically is of critical importance in dictating 
the success of head cooling in CIA prevention. 
The panel of chemotherapy drugs tested caused differential effects on keratinocyte cell cycle 
progression and drug-mediated cell cycle arrest was significantly attenuated by cooling. Notably, 
cooling alone appeared to decelerate cell cycle progression, providing evidence for metabolic effects. 
More importantly, protective pre-conditioning (PPC) achieved either by growth factor removal or 
pharmacological inhibition of EGFR activation enhanced the cytoprotective effects of cooling and 
significantly reduced the effects of the chemotherapy drugs. As the ability of PPC to enhance 
protection from drug cytotoxicity could be attributed to its propensity to regulate the cell cycle 
progression, the work provided evidence that one mechanism via which cooling cytoprotects might be 
due to its ability to decelerate cell cycle progression.  
Disruption of mitochondrial membrane potential and elevation of ROS indicated the activation of 
an apoptotic pathway, which was confirmed by cell death-specific assays that confirmed a 
mitochondrial apoptotic pathway, as evident by plasma membrane disruption, caspase activation and 
DNA fragmentation. Importantly, cooling at a variety of temperatures (but mainly at or below 18C) 
attenuated drug-mediated apoptosis. To further investigate the precise mechanisms of growth arrest 
and/or cytotoxicity, activation/regulation of critical intracellular signalling mediators was investigated at 
the protein level. The majority of the drugs used induced activation of p53 and subsequent induction of 
p53-inducible mediators such as p21, as well as pro-apoptotic mediators associated with the 
mitochondrial pathway, such as Bak, PUMA and Noxa, whilst induction of pro-apoptotic FasL and Bid 
cleavage was detected, suggesting possible cross-talk with the extrinsic apoptotic pathway. Strikingly, 
cooling attenuated or blocked in a time- and, more importantly, temperature-dependent fashion 
induction of these pro-apoptotic mediators (an effect that became more marked as the temperature 
was reduced from 37C, to 22C, 18C and 14C); these results have provided for the first time a more 
detailed mechanistic explanation for the cytoprotective effects of cooling.  
As ROS appeared to be important in cytotoxicity, the hypothesis raised was that the 
cytoprotective effect of cooling might be enhanced via co-treatment with an antioxidant (e.g. NAC), 
aimed at enhancing the cytoprotective capacity of cooling at sub-optimal temperatures (such as 26°C). 
The findings presented here suggested that cooling plus topical treatment with antioxidants might 
represent a promising approach to improve the cytoprotective effects without compromising the 
anticancer effects of chemotherapy. 
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Overall, despite their reductive nature, these in vitro models have provided experimental 
evidence for the ability of cooling to rescue from chemotherapy drug-mediated toxicity and shown that 
the choice of temperature may be critical in determining the efficacy of cooling in the clinic. This, whilst 
generating a novel combinatorial approach that has the potential to significantly enhance the ability of 
scalp cooling to protect against CIA in the clinic. 
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1.1 An introduction to hair and the hair follicle (HF)  
The HF is a multicellular, self-renewing, tubular cavity located in the layers of the 
skin. The HF has been classified as a mini-organ, due to consisting of broad cell type 
diversity, ranging from epithelial to mesenchymal and neural crest cells. Furthermore, it 
has its own immune system and hormonal milieu (Schmidt‐Ullrich and Paus, 2005; Paus, 
2011). The HF produces the hair shaft, which is commonly referred to as ‗hair‘ (Paus et 
al., 1999). Hair covers the majority of the human body, at an estimated total of around 5 
million hairs, of which approximately 80,000 to 150,000 are located on the scalp (Krause 
and Foitzik, 2006). In adult humans, there are two types of morphologically distinct HFs. 
These are: 1) vellus follicles, which contain short, fine, light-coloured, barely visible hair, 
such as that found on the bodies of children and adult women and 2) terminal follicles, 
which assemble thick and pigmented hair (Paus et al., 1999; Whiting, 2004). Hair plays an 
critical role in protecting the skin and various internal cavities against external factors, 
including sunlight and dust, and also thermo-regulates the body (Winters, 2002).  
1.1.1 HF structure 
Human skin comprises of three layers: the epidermis, the dermis and the subcutis. 
Each layer has a unique structure and function. The epidermis is largely composed of 
cells migrating to the skin surface and includes an array of sub-layers, with the order of 
layers from deepest to the most superficial being the stratum basal, spinosum, 
granulosum, lucidum and corneum (Mihm et al., 1976; Odland 1991). The dermis is 
comprised of dense, irregular connective tissue, blood vessels, oil and sweat glands, 
lymph vessels, nerves endings and the HF, with the layer dominating the mechanical 
behaviour of the skin overall. The dermis is distinguished into two additional layers, with 
the upper layer called the papillary dermis and the lower layer being the reticular dermis 
(Parish 2011). The subcutis is the skin‘s innermost layer, consisting of loose connective 
tissue and lobules of fat. The subcutis acts as a conduit for nerves and blood vessels, 
while also serving the function of body temperature regulation (Odland 1991; Douglas et 
al., 2004). 
Skin-associated structures (skin appendages) consist of the HF, hair shaft, 
sebaceous gland, apocrine sweat gland, and arrector pili muscle, which are known 
collectively as a pilo-sebaceous unit (Figure 1-1). The hair shaft and its manufacturing 
apparatus, the HF, make up one entity (Widelitz et al., 2006). The hair shaft of the human 
terminal hair is composed of three concentric parent layers. These are, from externally to 
internally, the cuticle, cortex and cord (medulla) (Paus and Cotsarelis, 1999; Whiting, 
3 
 
2004). The hair growth cycle comprises three distinct phases: active growth (anagen), 
apoptosis-driven regression (catagen) and rest (telogen). The structure of the HF reflects 
the different stages of its growth cycle. The anagen VI HF morphology, is most commonly 
invoked to describe adult hair human (Paus and Cotsarelis, 1999). 
HFs in anagen consist of three anatomical segments, which are from distil to 
proximal: the infundibulum, isthmus and inferior segment (Figure 1-1). The infundibulum is 
a funnel-shaped cavity through the epidermis that allows for an opening for the hair shaft. 
The lower part of the infundibulum is defined by an opening of a duct from the sebaceous 
gland, through which, sebum is excreted into the HF and from here it spreads across the 
skin surface (Schneider et al., 2009; Whiting, 2004). The isthmus extends from the duct of 
the sebaceous gland to the exertion of the arrector pili muscle (Ronald et al., 2004). The 
only function currently attributed to the arrector pili muscle, is the contraction under stress 
such as low temperature and fear (Sevadjian, 1985). The isthmus and the infundibulum 
contain very few dividing cells (Cotsarelis, 2006).  
Below the isthmus is the bulge region, which is a specialised compartment of the 
outer root sheath; here the epithelial stem cells (also known as follicular trochanter cells) 
(Winters, 2002) and melanocytic stem cells reside that differentiate into the hair bulb 
matrix, epidermal and sebaceous gland regions. In the event of stem cell damage, loss of 
hair shaft production is likely to occur, resulting in conditions including permanent alopecia 
(Randall and Botchkareva, 2008).  
The HF is separated from the surrounding dermis by dermal cylinder sheaths, also 
referred to as follicular sheaths, consisting of concentric layers of cells that surround the 
HF (Zillikens, 2010). The sheath is composed of an external and internal layer known as 
the outer root sheath (ORS) and the inner root sheath (IRS). The ORS starts from the 
matrix cells and extends to the entry level of the sebaceous duct (Schneider et al., 2009). 
The innermost cuticle layer of the IRS is interlocked with the cuticle of the hair shaft 
surface (Krause and Foitzik, 2006) and extends from the lower part of the hair bulb to the 
lower part of the isthmus. In this layer, cornified cells (terminally differentiated 
keratinocytes) form a rigid, funnel-like structure that surrounds the growing hair enabling 
its protection (Joshi, 2011). Overall, the IRS is important in determining the appropriate 
shape, adherence and keratinisation of the growing hair fibre (Piérard et al., 1991; Steffen, 
2001). The hair bulb is located in the inferior segment and is the centre of the hair shaft 
production site. The hair bulb contains hair matrix melanocytes that are scattered between 
hair matrix keratinocytes and together these surround the dermal papilla. Matrix cells in 
the lower part of the hair bulb boast a higher mitotic rate compared to those of the upper 
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segment, as the matrix cells are required to migrate upwards, whilst differentiating into 
both the hair shaft and IRS (Randall and Botchkareva, 2008). The dermal papilla is an 
oval mass of specialised fibroblasts that are embedded in an extracellular matrix with 
extensive vacuolisation (Stenn and Paus, 2001; Tobin et al., 2003; Whiting, 2004). There 
is an association between the size of the dermal papilla and the size of the HF. Indeed, a 
larger dermal papilla can create larger HF capable of generating a thicker hair shaft 
(Legué and Nicolas, 2005; Lemenager et al., 1997). 
 
Figure ‎1-1 The mature human HF 
The schematic illustrates the structure of the terminal hair anagen in longitudinal section 
including the hair shaft, bulge region, arrector pilli, sebaceous gland, outer root sheath 
(ORS), inner root sheath (IRS), and the hair bulb that includes the hair matrix keratinocyte 
compartment and the dermal papilla region. Figure adopted from (Geras, 1990).  
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1.1.2 HF morphogenesis 
The term morphogenesis originates from the Greek words morphê (shape) 
and genesis (creation) and is the biological process by which an organism develops its 
shape. HF development normally requires epithelial–mesenchymal (epidermal 
keratinocytes and dermal papilla fibroblasts) interactions in utero (during the embryonic 
stage). This interaction plays a pivotal role in morphogenesis leading to hair shaft 
production. Different types of HFs have distinct time courses of induction during 
morphogenesis (Ronald et al., 2004). 
Formation of the HF occurs during morphogenesis and budding of the embryonic 
epidermis forms each HF. This formation requires a series of molecular interactions 
between the embryonic epidermis and underlying mesenchymal cells (Figure ‎1-2; Hardy, 
1992; Pispa and Thesleff, 2003). Several molecules induce signals specific for cells in the 
epidermis, including embryonic mesenchymal cells. This involves molecules encoding 
transcription factors Wnt/LEF-1, Hairless, Sonic hedgehog (Shh) signalling pathways and 
Notch, in addition to growth factors of the EGF family, FGF, and TGF-b. Follicular growth 
occurs in waves, compromising of a growth phase (anagen), a regression phase 
(catagen) and a resting phase (telogen). The cellular and molecular mechanisms 
observed in embryogenesis are often identical to those involved during the hair cycle 
(Millar, 2002; Schmidt‐Ullrich and Paus, 2005).  
1.1.2.1 Mesenchymal-epithelial interactions during morphogenesis and 
HF cycling 
The epithelial and mesenchymal interactions during the hair cycle are directed by 
a distinct set of molecular signals, which are unique to each phase of the hair cycle 
(Botchkarev and Kishimoto, 2003). During the telogen phase, inhibitory signals are 
predominant, maintaining the HF in a quiescent state. However, during the anagen phase 
several growth stimulatory pathways are activated in the epithelium and in the 
mesenchyme, the organisation of which is vital for HF formation. The termination of 
anagen-signalling interactions between the epithelium and the mesenchyme during the 
catagen phase leads to apoptosis in the HF matrix (Botchkarev and Kishimoto, 2003).  
Development of HFs is governed by growth factors triggering a signalling cascade 
between epithelium and mesenchymal cells to form the connective tissue compartment of 
the developing HF (Ronald et al., 2004). These signals include Wnt family members 
(which are ligands acting through their cognate cell surface receptors), TGF-/BMP, 
Hedgehog (a signalling pathway that transmits information to embryonic cells required for 
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development), EGF, FGF, Notch (single-pass trans-membrane receptor protein), TNF and 
neurotrophins (Millar, 2002). There are regulatory interactions between these signalling 
pathways and cross-talk (as they modulate each other‘s activities at the extracellular, 
cytoplasmic or at nuclear level) (Von Bubnoff and Cho, 2001). During the anagen phase, 
the interaction between the HF epithelium and the mesenchyme increases gradually and 
peaks in the late anagen HF. Transition from the anagen to the catagen phase is 
associated with the down-regulation of signalling activity between hair matrix cells and the 
dermal papilla (Botchkarev and Kishimoto, 2003). 
In telogen HFs, the cells are relatively dormant, with low DNA synthesis in the 
germinative epithelium region of the bulb area (Wilson et al., 1994). In addition, the 
secondary hair germ and the mesenchymal stem cells form a ball-like cluster with a poorly 
developed extracellular matrix (Müller-Röver et al., 2001; Young, 1980). Moreover, the 
basement membrane of the telogen HF is relatively thick and multi-layered, separating 
epithelial cells of the secondary hair germ and mesenchymal cells of the follicular papilla 
(Jahoda et al., 1992).  
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Figure ‎1-2 The morphogenesis of the HF 
Schematic diagram of the 9 stages of HF morphogenesis. In stage 0 there are no visible 
morphological signs that HF formation is taking place. HF morphogenesis starts by the 
initial budding of the embryonic epidermis after a series of molecular interactions between 
it and the underlying mesenchymal cells. In stage 1, morphogenetic signals derived from 
the mesenchymal cells, trigger a thickening of the basal layer of epidermis, resulting in the 
formation of an epidermal placode (the pregerm of the hair) the cells of which elongate. In 
stage 2 and 3 the cells of the epidermal hair placode proliferate and grow down into the 
dermis to form the hair peg, which eventually surrounds a cluster of mesenchymal cells 
known as the germinal matrix. In stage 4, the mesenchymal cells that surround the 
germinal matrix form the dermal papilla. The dermal papilla is a richly vascularised and 
innervated structure essential for the effective renewal of hair. The dermal papilla supplies 
the nutritional elements that allow the growth and differentiation of the keratinocytes. 
These keratinocytes in the hair bulb migrate upwards and differentiate into the hair shaft 
and inner root sheath. In stage 5 sebocytes, which are precursors of the apocrine gland, 
are visible in the distal parts of the HF and the first melanin granules and hair shaft 
develop above the dermal papilla. In stages 6-7, the HF proliferates and moves 
downwards into the sub-cutis layer of the skin, the hair shaft then reaches the level of the 
sebaceous gland and at this point, the hair canal becomes visible in the skin. In stage 8, 
the HF has all the characteristics of an anagen-phased hair and has reached its maximal 
length. At the end of this stage the hair shaft begins to emerge through the skin. Figure 
adopted from (Mcelwee and Hoffmann, 2000; Paus et al., 1999).  
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1.1.3 The hair growth cycle and its phases  
The hair cycle starts immediately following morphogenesis. There are three main 
phases during the hair growth cycle: the active growth phase (anagen), the transition 
phase (catagen) and the rest phase (telogen), there is also a shedding phase (exogen). 
These phases are schematically shown in Figure 1-3 (Paus and Foitzik, 2004). 
The process of .. The chronology of HF cycling is from catagen to telogen, to 
anagen, and returning to catagen. However, the HF alters its normal cycling behaviour in 
response to damage, such as chemotherapy, so that HF cycling can continue later (Paus 
and Foitzik, 2004).  
1.1.3.1 Anagen  
During anagen, the HF passes through six sub-stages (anagen I-VI), which mainly 
comprise extensive matrix keratinocyte cell proliferation and differentiation. The matrix 
keratinocytes differentiate into the keratin rich hair shaft and IRS, with the hair shaft 
elongating from the bottom causing it to extend upwards (Randall and Botchkareva, 
2008). During the anagen phase, several growth stimulatory pathways are activated in the 
epithelium and mesenchyme and the execution of these is vital for hair fibre formation 
(Botchkarev and Kishimoto, 2003). In early anagen, the stem cells at the base of the 
telogen follicle structure also proliferate in a manner that causes them to migrate 
downward into the dermis, where they begin to differentiate into the hair shaft and IRS. 
Once the early anagen follicle reaches its predetermined depth, cells reverse their growth 
direction and progress upward, creating the IRS and the hair shaft. During anagen, the 
process of the hair shaft pigmentation also occurs by melanogenesis and follicular 
vascularisation is significantly increased (Slominski et al., 2005). Additionally, numerous 
growth factors including; insulin like growth factor-1 (IGF-1), keratinocyte growth factor 
(FGF7), stem cell factor (SCF) and hepatocyte growth factor (HGF) are secreted by 
dermal papilla fibroblasts to maintain active proliferation and differentiation of the hair 
matrix keratinocytes (Botchkarev and Kishimoto, 2003; Rudman et al., 1997). 
The human scalp hair remains in the anagen phase for approximately 2 to 6 years 
(Paus and Foitzik, 2004) and typically up to 80-85% of HFs are in this phase at single 
period of time (Randall and Botchkareva, 2008). During anagen, the interactions between 
the HF epithelium and the mesenchyme increase, reaching its highest in the follicles 
during late anagen. Consequently, the dermal papilla combines within the centre of the 
epithelial hair bulb. During anagen, the HF is sensitive to its environment and therefore, 
this needs to be carefully controlled to allow normal hair growth. For example, sudden 
9 
 
stress, including psychological or metabolic, can instigate a large number of anagen 
follicles to move to the telogen phase, where hair falls out and alopecia may be 
accelerated (Phillips et al., 1986). The normal transition of the anagen phase to catagen is 
associated with the down-regulation in the signalling exchange between hair matrix cells 
and the dermal papilla (Botchkarev and Kishimoto, 2003). Due to the termination of 
signalling interactions between the epithelium and the mesenchyme during the 
progressive catagen phase, apoptosis in the HFs matrix cells begins (Botchkarev and 
Kishimoto, 2003). 
1.1.3.2 Catagen 
For reasons currently unknown to science, following anagen a regressive phase of 
the hair cycle occurs, known as catagen, during which, the HF ceases production. 
Catagen can be subdivided into eight stages and is characterised by apoptosis in the 
lower two thirds of the HF, including the matrix keratinocytes IRS cells and ORS cells, 
leading to the overall regression of the hair bulb and isthmus. In addition, apoptosis of the 
hair matrix melanocytes occurs, thus causing cessation of melanin production and hair 
pigmentation (Slominski et al., 2005). One dictator of HF apoptosis is the hairless gene, 
which controls apoptosis across the various HF compartments. In the absence of hairless 
protein, the HF is destroyed the first time it enters the catagen (Zillikens, 2010). This 
process may also be triggered by the withdrawal of dermal papilla delivered growth 
factors, or by death inducing signals derived from immunocytes (Brajac et al., 2003; Ryan 
and Christiano, 2004). Catagen leads to the separation of the dermal papilla from the hair 
bulb and the upward movement of the HF with the IRS beginning to shorten and leaves 
the ORS. Collectively, this results in the formation a specialised structure known as the 
hair club (Randall and Botchkareva, 2008; Rudman et al., 1997). In the later stages of 
catagen, the dermal papilla develops into a cluster of quiescent cells, located near the 
regressing HF matrix cells. After its formation, the hair club moves from the subcutis to the 
dermis/subcutis edge to maintain contact with the distal portion of the HF matrix cells, 
including the hair bulge. In addition, follicle compartments are reduced in size by 70%, 
although they can regenerate in the next hair cycle after the appropriate growth 
stimulation (Randall and Botchkareva, 2008). In total, this phase lasts between 7-14 days, 
with approximately 2% of scalp HFs estimated to be in catagen at any one time (Randall 
and Botchkareva, 2008).  
1.1.3.3 Telogen  
Following catagen, the HF enters telogen, a phase where no major structural 
changes occur (Randall and Botchkareva, 2008) and where the HF is about half of its 
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maximum length. During this stage, below the secondary hair germ, the mesenchymal 
stem cells form a ball-like cluster with a poorly developed extracellular matrix (Müller-
Röver et al., 2001; Young, 1980). The basement membrane of the telogen HF is relatively 
thick and multi-layered, separating the epithelial cells of the secondary hair germ and the 
mesenchymal cells of the dermal papilla (Couchman and Gibson, 1985; Geraghty et al., 
2014). At the lower end of the HF, the club-shaped hair shaft can remain as a distinct 
structure within the follicular canal for several months, although it can now be depilated 
much more easily compared to its preceding stages. During the telogen phase, epithelial-
mesenchymal interactions serve to deliver dominant inhibitory signals to maintain the HF 
in a quiescent state (Botchkarev and Kishimoto, 2003). Telogen phased cells have low 
rates of DNA synthesis in the germinative parts of the epithelium around the bulb region 
(Wilson et al., 1994). Although there is no significant change in synthesis of DNA, RNA or 
of the anagen proteins, the expression of a cell cytoskeletal protein keratin 14 remains 
driven (Bowden et al., 1998), thus telogen is not fully classified as a phase of dormancy. 
At their cycle end, the end of the telogen phase, a new anagen phase begins by sending 
signals from the dermal papilla to the follicle. These signals trigger the activity of stem 
cells and recruit those who are going to grow down, forcing the follicle to lengthen and 
wrap the dermal papilla. Immediately after the signal has been sent, the vascular 
endothelial growth factor (VEGF) activates the number and growth of blood vessels in the 
papilla and start producing a new line of hair, during which, three other proteins are 
involved: the Insulin-like growth factor (IGF1), keratinocyte growth factor (KGF), and 
telomerase RNA component (TERC) (Blanpain et al., 2004; Oh and Smart, 1996; Tumbar 
et al., 2004). Telogen HFs can be activated through mechanical depilation or in some 
cases pharmacologically (Müller-Röver et al., 2001) through the use of cyclosporine A and 
FK506 compounds that stimulate a return to anagen (Blume-Peytavi et al., 2008; Spencer 
and Callen, 1987). It has been estimated that 10-15% of HFs are in the telogen phase and 
that it lasts for at least 3-4 months (Botchkareva et al., 2001; Randall and Botchkareva, 
2008).  
1.1.3.4 Exogen 
The ‗shedding‘ of the hair shaft at the end of the telogen phase is known as 
exogen and occurs when the hair shaft is shed from the telogen follicle, resulting in the 
formation of a new hair shaft from the next cycle in the HF canal (Higgins et al., 2009; 
Milner et al., 2002; Stenn et al., 1998). 
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Figure ‎1-3 The hair cycle  
 Schematic diagram of the three main phases of hair cycle: growth phase (anagen), 
dystrophic phase (catagen), an extremely shortened resting phase (telogen) and the 
shedding phase (exogen). In anagen, the hair bulb is located deep inside the skin and 
then grow towards the skin surface; matrix cells in the hair bulb have high mitotic activity. 
Catagen is a phase activated when the anagen phase is complete, the follicle no longer 
produces hair, and it undergoes involution. Cell division stops and in the apoptosis-driven 
process the follicle retracts to the surface. Telogen is the resting phase, during which the 
hair shaft is removed. In telogen, epidermal stem cells of the HF, which are located in an 
area just above the hair bulb, will migrate deep to the bulb to reactivate a new phase 
anagen hair. Exogen is the shedding phase during which the old hair is shed. Adopted 
from (Schneider et al., 2009). 
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1.1.3.5 Regulation of HF growth and survival  
Growth factors and associated pathways that specifically regulate epidermal cells 
have been shown to include transcription factors LEF-1, Hairless, the Shh signalling 
pathway, Wnt, Notch, EGF/FGF and TGF-β. The cellular and molecular mechanisms 
observed in HF morphogenesis appear undistinguishable to those involved during the hair 
cycle (Millar, 2002; Schmidt‐Ullrich and Paus, 2005). Other factors important in HF growth 
include cathepsin L, an enzyme involved in the initiation of protein degradation and an 
important regulator of keratinocyte and melanocyte differentiation in HF morphogenesis 
and the Hairless protein, which is an important transcription factor that orchestrates 
follicular regeneration, whilst the anti-apoptotic proteins Bcl-2 and survivin are equally 
important mediators of growth by inhibiting cell death (Figure 1-4) (Botchkareva et al., 
2006a; Tobin et al., 2002). Survivin, an inhibitor of apoptosis is expressed in the 
proliferative keratinocytes of the anagen hair matrix and the ORS, and its expression is 
reduced during catagen progression (Botchkareva et al., 2006b). 
 
 
 
13 
 
 
Figure ‎1-4 Molecular control of apoptosis in the distinct HF compartments 
The diagram illustrates the expression pattern of pro-apoptotic (e.g. Fas, p53, Bax) and 
anti-apoptotic (Bcl-2, Survivin) molecules in the different HF compartments. Adopted from 
(Randall and Botchkareva, 2008).  
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1.2 Chemotherapy  
The term chemotherapy is now synonymous with anticancer drug therapy and can 
be defined as the use of compounds/drugs with the aim of destroying rapidly dividing cells 
by targeting DNA, RNA, protein synthesis, or a combination of these. Since the Food and 
Drug Administration (FDA) approved mechlorethamin in 1949 for the treatment of non-
small cell lung cancer, more than 100 chemotherapy agents have been approved for 
cancer treatment in the United States (Payne et al., 2006). In contrast to surgery and 
radiation therapy, which are directed at the primary tumour in a local manner, 
chemotherapy is a systemic treatment and as such, it targets both primary and metastatic 
tumour cells (Symonds and Foweraker, 2006). Generally, chemotherapeutic agents are 
administered intravenously; however, some are administered orally (or topically). The 
distribution of any given drug within the body depends on many factors such as blood flow 
to the different organs, drug diffusion, protein binding, tissue penetration and lipid 
solubility, but in general, drugs with extensive tissue penetration (e.g. doxorubicin) or high 
lipid solubility tend to exhibit prolonged elimination phases due to the slow release of 
drugs from tissue (Tannock and Hill, 1998). 
Most chemotherapy drugs are administered at close to the maximum tolerated 
dose (MTD) and administration is relative to the body‘s surface area, as it is suggested 
that this standardises the pharmacokinetics to normalise for physiological factors, such as 
cardiac output, body fat, and size, and as such the standard dosage units are mg/m2 
(Tannock and Hill, 1998). The frequency of treatments and the intervals between them 
also depends on the type of cancer and the treatment regime. Chemotherapy is often 
administered in cycles that include rest periods so that the body is able to recover from 
the side effects, by allowing production of new cells in healthy tissues (Tannock and Hill, 
1998). Clinical trials have suggested that most cancers cannot be cured with a single 
chemotherapy agent and that a combination of these offers the optimal way to manage 
cancer (Trigg and Flanigan-Minnick, 2011). The advantages of such combinations are: i) 
they provide maximal cancer cell death within the range of tolerated toxicity; ii) cells in 
different phases of the cycle will be targeted; and iii) there is a reduced chance of the cells 
developing some form of drug resistance (Lilenbaum et al., 2005). Normal cells such as 
HF keratinocytes, intestinal epithelial cells and bone marrow cells, also divide rapidly and 
thus are affected by the cytotoxic properties of most chemotherapy, resulting in off-target 
side-effects (Skeel and Khleif, 2011). In the case of bone marrow toxicity, this is 
associated with neutropenia, thrombocytopenia and anaemia. Damage to the alimentary 
canal results in oral mucositis, nausea, vomiting and diarrhoea and keratinocyte damage 
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causes chemotherapy-induced alopecia (CIA), and nail bed damage (Symonds and 
Foweraker, 2006).  
1.2.1 Classification of chemotherapy drugs 
Common drugs used for chemotherapy are classified based on their chemical 
structure and mechanism of action, as discussed in detail below (Table 1-1). 
1.2.1.1 Alkylating agents 
Alkylating agents were the first compounds identified as potential anti-cancer 
agents and there are different classes including: nitrogen mustards (e.g. 
cyclophosphamide), nitrosoureas (e.g. streptozocin), alkyl sulfonates (e.g. busulfan), 
triazines (e.g. dacarbazine and temozolomide) and ethylenimines (e.g. thiotepa and 
Altretamine) (Tannock and Hill, 1998). Alkylating agents work by various mechanisms: 1) 
alkyl group attachment to DNA bases, 2) crosslinks formation between single DNA atoms 
or between two different DNA molecules and 3) prompting mispairing of nucleotides i.e. 
mutation induction (Trigg and Flanigan-Minnick, 2011).  
1.2.1.2 Platinum-based heavy metal alkylators 
Platinum-based heavy metal alkylators are one of the most beneficial groups of 
anticancer agents and thus are traditionally the favoured choice therapy for testicular, 
urothelial, and lung cancers (Pinedo and Schornagel, 1996). The first member identified 
called cisplatin, acts by cross-linking DNA and as this is irreparable, cells undergo 
apoptosis (Trigg and Flanigan-Minnick, 2011). However, normal cell toxicities limit the 
clinical application of cisplatin, although this has been partly alleviated through the 
introduction of the less toxic alternative carboplatin (Symonds and Foweraker, 2006).  
1.2.1.3 Antimetabolites 
Antimetabolites are drugs that interfere with nucleotide metabolism, which results 
in RNA and particularly DNA synthesis inhibition. Therefore, they are predominantly 
specific to cells in S phase, causing abnormal nucleotide insertion obstructing 
transcription and translation, or manufacturing DNA that requires resection and repair. 
This class encompasses 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP) and capecitabine 
(Takimoto and Calvo, 2008; Trigg and Flanigan-Minnick, 2011).  
1.2.1.4 Anti-microtubular agents 
Anti-microtubular agents are compounds that bind to tubulin, the integral protein 
involved in this process preventing the formation of new cells through mitotic process. 
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These include taxanes (e.g. paclitaxel and docetaxel), epothilones (e.g. ixabepilone) 
(Diana and Vahdat, 2008) and vinca alkaloids (e.g. vinblastine, estramustine) (Takimoto 
and Calvo, 2008; Trigg and Flanigan-Minnick, 2011). 
1.2.1.5 Topoisomerase inhibitors 
DNA topoisomerases are ubiquitous nuclear enzymes that help facilitate 
unwinding of the DNA double helix, which allows for DNA replication and RNA 
transcription. There are two types topoisomerase -I and -II (Takimoto and Calvo, 2008) 
and inhibitors of these ultimately prevent DNA repair, leading to cell death. Examples of 
topoisomerase I inhibitors are topotecan and irintecan, and of topoisomerase II are 
etoposide and teniposide (Trigg and Flanigan-Minnick, 2011). 
1.2.1.6 Anticancer antibiotics  
Anticancer antibiotics are derived from the bacterial species Streptomyces and 
essentially function as antibiotics within cancer cells (Payne and Miles, 2008). The most 
important family of this drug class are the anthracyclines (e.g. doxorubicin and epirubicin), 
but some non-anthracyclines such as bleomycin and mitomycin-C are used clinically. 
These drugs interfere with enzymes involved in DNA replication, but also take effect in all 
phases of the cell cycle (Payne and Miles, 2008; Symonds and Foweraker, 2006). 
Common to all anthracyclines, doxorubicin intercalates within the strands of DNA and this 
inhibits the progression of the topoisomerase II which prevents the unwinding and the 
replication of DNA (Trigg and Flanigan-Minnick, 2011). These compounds consequently 
also lead to the formation of the free radicals such as reactive oxygen species (ROS) 
(Takimoto and Calvo, 2008). The specific molecular target of many of the anticancer 
antibiotics is unknown, however two possibilities have been proposed: a) the binding to 
DNA that prevents its replication and thus cell division and b) the inhibition of mRNA 
formation preventing protein synthesis (Trigg and Flanigan-Minnick, 2011). 
1.2.1.7 Miscellaneous agents 
This category includes drugs that act in a number of different ways and also for 
those that have an unknown mechanism (Trigg and Flanigan-Minnick, 2011). An example 
is L-asparaginase, a non-essential amino acid required by both normal and malignant 
cells, however certain cells such as leukaemic cells cannot synthesize asparagine, in 
which case the administration of L-asparaginase results in asparagine depletion, causing 
damage cells that have a high dependency on it, or those that may already contain a low 
concentration (Mccredie et al., 1973). 
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Table ‎1-1 List of anticancer compounds and their mechanism of action 
Adapted from (Trigg and Flanigan-Minnick, 2011) 
  
Anticancer compound type Generic name 
 
Alkylating 
agents 
Nitrogen mustard 
derivatives 
Mechlorethamine, Melphalan, 
Ifosfamide, Cyclophosphamide  
Nitrosoureas Carmustine (BiCNU) 
Heavy metal alkylators Cisplatin, Carboplatin, Oxaliplatin 
Other Dacarbazine, Temozolomide 
Antimetabolites Pyrimidine analogues Gemcitabine, 5-Fluorouracil, 
Cytarabine, Capecitabine 
Purine analogues Mercaptopurine (6-MP) 
Folic acid antagonists Methotrexate (MTX), Pemetrexed 
Mitotic/spindle inhibitors and plant alkaloids Paclitaxel, Docetaxel, Ixabepilone, 
Vinblastine, Vincristine, Vinorelbine 
Topoisomerase inhibitors Irinotecan (CPT-11), Topotecan, 
Etoposide 
Antitumor antibiotics Mitoxantrone, Dactinomycin, 
Doxorubicin, 
Epirubicin, Bleomycin 
Signal transduction inhibitors Cetuximab, Trastuzumab, Erlotinib, 
Bevacizumab 
Sorafenib, Imatinib, Dasatinib, 
Temsirolimus 
Hormonal agents Tamoxifen 
Epigenetic agents Vorinostat, Azacitidine 
Immunomodulators Interferon alpha-2a and alpha-2b 
Rituximab 
Miscellaneous agents  Lenalidomide, Bexarotene, 
Tretinoin, Arsenic trioxide, 
Asparaginase, Bortezomib 
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1.2.2 Molecular targets of chemotherapeutic drugs 
Chemotherapeutic drugs primarily target DNA synthesis and the proteins critical 
for normal mitosis by targeting specific stages of the cell cycle, as explained below and 
summarised in Figure 1-5 (Nicolson and Conklin, 2008). The G1 phase, for actively 
dividing cells, is the longest and most varied stage, and where most anabolism and cell 
growth occurs. However, there are few known drugs clinically tested that are able to target 
G1 apart from rapamycin (Symonds and Foweraker, 2006). S phase follows G1 and is 
characterised by rapid DNA replication, following this, the cells enter G2 when the mitotic 
apparatus is formed (Alkan et al., 2014). M phase, or mitosis, is the culmination of the S 
and G2 phases, during which there is a succession of prophase chromosome 
condensations and the subsequent breakdown of the nuclear membrane, meta-phase 
depolymerisations and polymerisation. Furthermore, microtubule formation occurs leading 
to chromosome localisation and equatorial division (Halliwell, 2014). The cells then enter 
anaphase, which is defined by the polar migration of the chromosomes and then finally, 
telophase, when cell division occurs (Halliwell, 2014). Drugs that target certain parts of the 
cell cycle will be discussed with the specific class of drugs in the following section. 
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Figure ‎1-5 Chemotherapy drugs and their point of action in the cell cycle 
The diagram is a schematic representation of the cell cycle and its phases, illustrating the 
point of action during the cell cycle for a number of chemotherapy drugs commonly used 
in clinics. It should be noted that although all drugs are denoted as linked with specific cell 
cycle stages, there is often a phase-overlap as some chemotherapy agents may target 
more than one phase (and/or overlapping phases) of the cell cycle, whilst others act on 
cells irrespective of the phase they are in (cell cycle independent). G0: the cell is out of 
cycle (quiescence); G1: the cell prepares for division and produces a variety of proteins 
required for DNA replication; S: DNA double-stranded breaks induced by topoisomerase 
enzymes, DNA replication takes place; G2: the cell prepares the components that make 
up the spindle required during mitosis; M: nuclear division, chromosome separation, and 
cytokinesis to ultimately separate the dividing cell into two new daughter cells. Adopted 
from (Symonds and Foweraker, 2006) 
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1.2.3 The mechanisms of apoptosis in HF in normal conditions and under 
pathological circumstances  
Programmed cell death is, particularly within all tissue structures with high 
proliferation and differentiation rate, strongly characterised (Paus et al., 1993; Zakeri and 
Lockshin, 2002). It is dependent on genetically encoded signals or cellular activity within 
the dying cell and provides a cascade of events that induce cell death (Fink and Cookson, 
2005). In the biology of the skin, apoptotic pathways have an important place, serving to 
maintain the homeostasis of the skin. The differentiation of keratinocytes is a unique form 
of apoptosis, leading to the presence of the typical stratification of the skin and tissue 
functioning as a termination. At the end of this process of transformation (Magerl et al., 
2001) is the formation of corneocytes (terminally differentiated keratinocytes). Apoptosis 
plays a role in the development of the skin and skin appendages (skin-associated 
structures) and a central role in the spontaneous HF regression (catagen) (Lindner et al., 
1997).  
Apoptosis is a form of genetically programmed cell death, which is controlled 
enzymatically by proteolytic enzymes with a cysteine residue in the catalytic site (these 
enzymes are therefore called caspases) (Boatright and Salvesen, 2003; Lavrik et al., 
2005). The process leads to morphological condensation and fragmentation of the nuclear 
DNA in the cell nucleus, the condensation of cytoplasm and for the encapsulation of cell 
components, which have been described as being apoptotic bodies (Fink and Cookson, 
2005). 
The mechanism of apoptosis is well studied for the eukaryotes (Lockshin and 
Zakeri, 2004; Oltvai and Korsmeyer, 1994). Apoptosis can be triggered both in vivo and in 
vitro (Aurelian, 2005; Mcgregor et al., 1997). Causes for the apoptosis can be loss of 
growth factors or cell-cell contacts, specific cell-substrate interactions, changes in cytokine 
expression, as well as the effect of neurotrophins, hormones, and various exogenous 
noxious factors (Krajewski et al., 1994; Raj et al., 2006). Moreover, external factors that 
stimulate apoptosis include UV light, X-rays, extreme temperature, toxins, lytic viruses and 
toxic chemicals, including drugs such as cyclophosphamide, doxorubicin, 5-fluorouracil, 
vincristine, methotrexate, cis-platinum. Under such influences, the phenomenon of 
oncosis also occurs (Fink and Cookson, 2005; Majno and Joris, 1995). Oncosis or 
accidental cell death with swelling of the nucleus, mitochondria and the cytoplasm and 
karyolysis (Majno and Joris, 1995), making it the morphological contrast to apoptosis. 
Oncosis is often a result of ischemia (Jaeschke and Lemasters, 2003) and can occur (and 
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be enhanced by) toxic influences, in particular, through the application of 
chemotherapeutic agents (Selleri et al., 2004).  
There are two major pathways that lead to apoptosis: the extrinsic (death receptor-
mediated), the intrinsic (mitochondrial) (Figure 1-6). The extrinsic pathway of apoptosis is 
regulated by TNF receptor (TNFR) members such as Fas, TNFRI and TRAIL-RI/TRAIL-
RII, which are referred to as ‗death‘ receptors and contain a death domain which plays a 
specific role in cell apoptosis and these receptors are activated by their cognate ligands 
(Ashkenazi and Dixit, 1998; Danial and Korsmeyer, 2004). This leads to activation of 
initiator caspase-8 and effector caspase-3 progresses the definitive death of the cell. 
Negative induction (the intrinsic pathway) is initiated by loss of an inhibitor and activation 
of pro-apoptotic factors. The process is the active involvement of mitochondria and 
caspase-9 (Schultz and Harringto Jr, 2003). Finally, both mechanisms lead to the 
activation of effector caspases 3, 6 and 7, the cleavage of a wide variety of substrates in a 
cytosol, including deoxyribonuclease, which is responsible for the cleavage the nuclear 
DNA (Schultz and Harringto Jr, 2003).  
The intrinsic pathway is controlled by members of the Bcl-2 family, which have 
been divided as inhibitors (e.g., bcl-2) (Petros et al., 2004; Van Gurp et al., 2003) and pro-
apoptosis such as Bax, Bak, puma Noxa and Bid, characterised by the release of 
cytochrome c from mitochondria (Van Gurp et al., 2003). Cytochrome c will form an 
apoptosome with the Apaf-1 and caspase-9 (Li et al., 2000a). Extracellular and 
intracellular signals through radiation, oxidative stress, and DNA damage due to chemical 
substance exposure may cause a malfunction of the mitochondria and put the intrinsic 
mechanism in motion (Raj et al., 2006; Schultz and Harringto Jr, 2003). Zamzami et al., 
(1995) reported that an early step in apoptosis was a reduction in mitochondrial 
membrane potential (Zamzami et al., 1995). It is generally believed that factors such as 
p53 and Nur77 / TR3 / NGFB-1 diffuse from the nucleus to the mitochondria and 
cytochrome c and continue induce apoptosis via the induction of PUMA and Noxa 
(Fridman and Lowe, 2003; Li et al., 2000a).  
Apoptosis is a natural part of the hair cycle and has been studied intensively using 
both in vivo and in vitro models (Lindner et al., 1997; Peters et al., 2005; Soma et al., 
1998). Apoptosis takes place within all structural components of the HF, with the 
exception of DP fibroblasts (Botchkareva et al., 2006a) and is a normal process in the 
reformation of HF architecture, particularly it acts as a mediator for catagen (Botchkarev, 
2003; Lindner et al., 1997; Payne et al., 2006). Among the factors with established pro-
apoptotic effect of the HF are the neurotrophins of the nerve growth factor (NGF) family, 
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transforming growth factor (TGF) -ß 1 and 2, the DR Apo-1 / Fas, DR3 / DR4, L-Catepsin, 
hairless, p53, TNF-α / TNFR p55, FGF-5, and the acting pro-apoptotic members of the 
Bcl-2 family (Bax, Bak, etc) (Botchkareva et al., 2006a). The apoptotic processes within 
the HF are controlled by caspase-1, caspase-3, caspase-4, and caspase-7 (Botchkareva 
et al., 2006a; Lindner et al., 1997; Soma et al., 1998).  
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Figure ‎1-6 The main mechanisms of apoptotic cell death 
Apoptosis may be triggered by the extrinsic (TNF receptor-mediated) pathway by specific 
ligand-receptor interaction or via the intrinsic (mitochondrial) pathway in response to 
different types of stress (e.g. genotoxic stress). Both the extrinsic and intrinsic pathways 
can lead to disruption of mitochondrial outer membrane potential or MOMP. MOMP is 
controlled by the pro-apoptotic Bcl-2 family proteins Bak and Bax (as well as or voltage 
dependant anion channels or VDACs – not shown), which facilitate the release of 
cytochrome c, SMAC/DIABLO or apoptosis inducing factor (AIF) into the cytoplasm. Once 
in the cytoplasm, cytochrome c mediates the formation of the apoptosome (via Apaf-1 
engagement), which activates caspase-9 and in turn caspase-3/7 resulting in apoptotic 
death. SMAC/DIABLO binds to inhibitors of apoptosis (IAPs) and blocks their capacity to 
attenuate caspase activation and thus promotes apoptosis. AIF translocates from the 
mitochondrial intermembrane space to the nucleus where it interacts with Endo G to 
initiate DNA fragmentation Adopted from (Raj et al., 2006). 
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1.2.4 Chemotherapy-induced HF apoptosis 
As described previously, many anticancer agents such as cyclophosphamide, 
doxorubicin and cisplatin induce DNA damage (Müller et al., 1998). During this process, 
the transcription factor and tumour suppressor protein p53 plays a critical role in cell 
protection and apoptosis induction. Specifically, DNA damage can break the p53-MDM2 
interaction leading to p53 phosphorylation, which turns p53 into a gene expression 
enhancer (Moll and Petrenko, 2003). In this situation, p53-induces the expression of the 
pro-apoptotic genes Fas, Bax, insulin-growth factor receptor type I and insulin like growth 
factor binding protein 3, IGFBP3 and can also down-regulate anti-apoptotic proteins such 
as Bcl-2 (Lindner et al., 1997). In light of the fact that many of these proteins can be 
located in hair follicular cells, it appears that this pathway plays a significant role in 
regulating hair production. In adult mice, p53 has been shown to be essential in the 
regulation of the HFs response to DNA damage by cyclophosphamide. In p53 knockout 
mice, hair loss was not observed and the HF remained cycling (Botchkarev et al., 2000). 
In addition, it was shown in the same study that the TNFR ―death‖ receptor Fas plays a 
key role in mediating the cytotoxic response as it was shown that Fas knockout mice had 
significant protection from chemotherapy-induced alopecia (CIA) caused by 
cyclophosphamide (Botchkarev et al., 2000), although this may be unique to 
cyclophosphamide. Furthermore, the report highlighted that in response to 
cyclophosphamide DNA damage induction, the hair matrix cells growth arrested in G1 via 
binding and inactivation of the CDK2/cyclin E complex, which is known to be regulated by 
both p21 and p53. Thus p53 may induce p21 leading to inhibition of G1/S cell cycle 
progression (Botchkarev, 2003).  
Several studies suggest p53 mediates apoptosis following growth factor 
withdrawal without DNA damage in hematopoietic cells and neurons (Gottlieb and Oren, 
1998), yet whether this applies to the HF remains unclear. The p53 protein is up-regulated 
and co-localises with apoptotic cells in the HF during catagen. Furthermore, p53 
deficiency in HFs leads to a decrease in Bax and IGFBP3, and an increase in Bcl-2 
protein expression (Botchkarev et al., 2001). In addition, it has been suggested that 
oxidative damage of mitochondrial DNA (Bodo et al., 2007) and inhibition of endothelial 
proliferation of the vascular network surrounding the HF can cause chemotherapy-induced 
alopecia (Amoh et al., 2007). Moreover, Fas and c-kit signalling is involved in HF 
melanocyte apoptosis and both proteins are up-regulated after cyclophosphamide 
treatment (Sharov et al., 2003). It is worth noting that approximately 50% of cancers are 
p53 negative, and thus the stimulation of this pathway may not kill tumour cells, however, 
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as the HFs are more likely to express p53 they may be more sensitive to some 
chemotherapy drugs than cancerous cells.  
1.2.4.1 Reactive oxygen species (ROS) in hair follicular apoptosis 
Reactive oxygen species (ROS) are a group of molecules, which contain an 
oxygen atom with an unpaired electron, making them highly unstable, very reactive, and 
damaging to other molecules as they remove their electrons. Cells utilise ROS as a 
second messenger for a number of processes, however at high concentrations ROS 
cause cell stress and loss of normal function, thus, as a protective mechanism, cells have 
evolved to become apoptotic in such conditions. N-acetyl-cysteine (NAC) is a potent ROS 
scavenger, which can provide protection from CIA in animal models and thus it appears 
that ROS may have a role in CIA (Simon et al., 2000). In addition, a range of 
chemotherapeutic drugs have been shown to induce ROS via various mechanisms, 
including phosphorylation of the NADPH oxidase system member and by impacting on 
mitochondrial function. Agents shown to augment ROS production to apoptotic levels 
include anthracyclines (e.g. doxorubicin, epirubicin), alkylating agents (e.g. 
cyclophosphamide), and platinum-based drugs (e.g. cisplatin, carboplatin and oxaliplatin) 
(Nicolson and Conklin, 2008). Interestingly, it is these agents that induce alopecia at a 
greater frequency and severity than most of other drugs, indicating that there could be a 
strong relationship between ROS production and CIA (Simon et al., 2000).  
1.3 Alopecia  
Historically, even ancient as Rome, people were admired for thick, well-groomed 
hair, as this was associated with male masculinity or female beauty and femininity. By 
contrast, hairlessness was degrading or humiliating and it has been documented that a 
concerned Julius Caesar combed his thinning hair over the crown of his head to try to 
cover his balding scalp. In the modern era, as it has in the past, a lack of hair, or even 
more so hair loss (alopecia), reflects a significant degree of personal importance. The 
term alopecia came from the Greek ―alopex,‖ which means, "fox.‖ This is because a fox 
often undergoes alopecia during the course of skin pathology (Joss et al., 1988; Schmidt, 
1994; Wagner and Bye, 1979). 
1.3.1 Types of alopecia 
There are two types of alopecia; congenital and acquired (Phillips et al., 1986). 
Congenital alopecia is a genetic predisposition to hair loss and therefore is more 
frequently observed in the population. Acquired alopecia is not genetically predisposed, 
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but rather is progressively augmented only by factors that may include iron deficiency, 
endocrine disorders, androgenic disorders, skin infectious agents, physical damage, 
inflammation, autoimmunity (Schmidt, 1994), smoking (Trüeb, 2003), stress (Tallon et al., 
2010), chemotherapy and/or radiotherapy (Organization, 1979; Van Den Hurk et al., 
2012b), genetic mutations (Epstein Jr and Lutzner, 1969), and systemic disease 
(Sevadjian, 1985). Regardless of the primary cause, the pathophysiology of alopecia 
results in the cessation of hair shaft production and hair loss.  
1.4 Chemotherapy-induced alopecia (CIA) 
Hair loss induced by chemotherapy compromises patients‘ quality of life and can 
negatively impact body image, sexuality and self-esteem, as well as depriving patients of 
their privacy (Hesketh et al., 2004). CIA is often a particular burden for those with young 
children, of who have reported that CIA is the most traumatising aspect of treatment, 
despite the previously mentioned complications (Forrest et al., 2006). Collectively, these 
issues mean that CIA is often one of the most emotionally difficult side effects and female 
patient feedback has implied that some find losing their hair more difficult to accept than 
the loss of their breast (Pickard-Holley, 1995). These factors are believed to negatively 
impact on therapeutic outcome, as severe stress and depression can be linked to a 
weakening of the immune system, a key factor in cancer survival and prevention (Spiegel 
and Giese-Davis, 2003). Moreover, strikingly, a report revealed that up to 8% of female 
patients may refuse chemotherapy for fear of CIA (Hesketh et al., 2004; Tierney et al., 
1992). Although most of the research on the emotional effects of CIA have been 
conducted on females, the research that has been undertaken in males, indicates that at 
least for younger males, the impact of CIA is the same as that experienced by females 
(Hilton et al., 2008). Considerable efforts have been expended in order to treat other side 
effects of chemotherapy, but the pathobiology of CIA has been overlooked (Paus, 2006) 
and to date, there are no efficacious drug-based treatments available for its management 
(Luanpitpong and Rojanasakul, 2012).  
The HF is particularly sensitive to chemotherapy because up to 90% of their cell 
population are in the active growth phase, anagen (Batchelor, 2001). The mitotic rate of 
the matrix keratinocytes is reported to be greater that of cancer cells (Paus et al., 2013) 
thus they are especially targeted by cell replication-targeting agents. Moreover, as 
mentioned previously there is a high blood perfusion around the hair bulb (supplied by the 
dermal papilla) leading to an increased drug accumulation in all the HF cell populations, 
with drug concentration and toxicity invariably linked. CIA usually begins 2-4 weeks after 
chemotherapy and is complete with 1-2 months (Batchelor, 2001). The varying degrees 
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and severity of CIA depends on the type of chemotherapy drug, dose, route of 
administration and treatment schedule (Table 1-2) (Luanpitpong and Rojanasakul, 2012). 
High intravenous doses usually cause more rapid and extensive hair loss, whereas oral 
therapy (despite administration at a higher total dosage) is likely to cause less severe 
alopecia (Wilkes, 1996). CIA extent is classified using a WHO classification system and is 
as follows; grade 0 implies no hair loss, grade 1 is minor, grade 2 is moderate but with wig 
requirement grade 3 is severe with wig requirement and grade 4 is complete hair loss 
(Organization, 1979). Alopecia occurs at an estimated incidence of >60% for alkylating 
agents (e.g. cyclophosphamide), >80% for anti-microtubular agents (e.g. docetaxel), 60-
100% for topoisomerase inhibitors (e.g., doxorubicin), and 10-50% for antimetabolites 
(e.g., 5-fluorouracil and leucovorin) (Trüeb, 2010). Severe alopecia was reported after 
treatment with daunorubicin, adriamycin, vincristine, ifosfamide and etoposide (Table 1-2) 
(Batchelor, 2001). Yun and colleagues found that alkylating agents produced the most 
alopecia, followed by inhibitors of topoisomerase and vinca alkaloids. No significant 
differences in the pattern of alopecia relating to age, associated symptoms, or 
chemotherapeutics combinations were observed (Yun and Kim, 2007). High doses of 
cyclophosphamide and busulfan have been reported to produce irreversible damage to 
the HF and concurrent alopecia in approximately half of patients (Tosti et al., 2005). As 
expected, combination therapies consisting of two or more CAs produce a higher 
incidence and more severe CIA compared to mono-therapy (Luanpitpong and 
Rojanasakul, 2012). For instance, severe CIA has been reported after treatment with the 
drug combination florouracil-epirubicin-cyclophosphamide (FEC) and also docetaxel, 
particularly in patients with breast cancer (Kluger et al., 2012). Stem cells of HFs are 
normally not affected irreversibly, as evidenced by hair regrowth 3-6 months after 
discontinuation of antineoplastic chemotherapy in the majority of cases when the normal 
hair cycle begins and new hair production occurs (Batchelor, 2001; Oshima et al., 2001). 
Permanent CIA or incomplete regrowth, though rare, has been reported after 6 months, 
thus acute damage to the stem cells is possible. In permanent CIA there is a large 
decrease in the total number of HF (Cotsarelis et al., 1990; Tosti et al., 2005; Tran et al., 
2000).  
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More common or severe CIA Less common or severe CIA 
Bleomycin Cyclophosphamide Amscarine Busulfan 
Cytarabine Cisplatin Carmusine Chlorambucil 
Dacarbazine Dactinomycin Carboplatin Epirubicin 
Docetaxel Doxorubicin Gemcitabine Hydroxyurea 
Etoposide Fluorouracil Interleukin-2 Melphalan 
Idarubicin Ifosfamide Mercaptopurine Methotrexate 
Interferon-α Irinotecan Mitomycin C Mitoxantrone 
Mechlorethamine Nitrosoureas Procarbazine Teniposide 
Paclitaxel Thiotepa Vinorelbine Busulfan 
Topotecan Vinblastine Amscarine Chlorambucil 
Vincristine Vindesine Carmusine  
 
Table ‎1-2 Cytotoxic agents known to induce alopecia 
Adapted from (Apisarnthanarax and Duvic, 2003; Cline, 1984) 
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1.4.1 Pathophysiology of CIA 
Chemotherapeutic agents often induce CIA by interfering with the transition 
between the stages of the HF development, stimulating follicular dystrophy or the 
induction of premature follicle regression (Paus et al., 1994), which is triggered by a 
number of different mechanisms based on the precise mechanism of action of the 
chemotherapy drug used (Trüeb, 2009a; Trüeb, 2009b; Yeager and Olsen, 2011). 
Telogen effluvium occurs when a larger proportion of hairs in anagen progress 
prematurely into the telogen phase, for example cyclophosphamide causes CIA by this 
mechanism (Patel et al., 2014). This results in an increase in diffuse hair shedding over 
the scalp causing significant hair thinning, with this being reportedly more distressing to 
the patient than complete hair loss (Olsen, 2011). Lower concentrations of 
cyclophosphamide, methotrexate or doxorubicin can promote the HF into the catagen 
phase, without significant changes in HF morphology, but this also produces visible hair 
loss (telogen effluvium) (Kligman, 1961). Anagen effluvium is the most common kind of 
CIA, because at a given time up to 90% of scalp hair is in anagen and occurs within days 
to few weeks after the administration of cytotoxic agents (Olsen, 2011) and it is stimulated 
by alkylating agents, antimetabolites, vinca alkaloids, topoisomerase inhibitors, 
anthracyclines and taxanes (Espinosa et al., 2003; Yun and Kim, 2007). In contrast, 
telogen effluvium has a latency period of months. The high doses of cytotoxic agents 
leads to change the HF morphology to dystrophic anagen and cause a localised transition 
from anagen to telogen with a subsequent release of telogen hairs and the hair loss is 
usually subclinical involving less than 50% of hairs (Trüeb, 2009b). 
Scalp HFs are more affected by chemotherapy drugs than other terminal HFs, for 
example those of the eyebrows, eyelashes, beard, auxiliary and pubic hairs that are 
variably affected (Paus & Cotsarelis, 1999). HFs across various regions of the body have 
variable durations of anagen. For example, scalp HFs stay in the anagen stage for 2-6 
years and ultimately produce long hairs, whereas actively growing eyebrow follicles 
remain in the anagen stage for between 2-3 months. In the HFs of eye lashes, this stage 
lasts between 30 and 45 days, producing short hairs (Thibaut et al., 2010; Valeyrie-
Allanore et al., 2007). Furthermore, in terms of eyelash HFs, only around 40% of the 
upper lashes and 15% of the lower lashes are in the anagen phase at any point, whereas 
for scalp hair, 80-85% are undergoing the anagen phase (Thibaut et al., 2010). Eyebrow 
and eyelash HFs maintain the slowest hair growth rate for any area of the body. As a 
consequence of increased mitotic activity, anagen follicles are the most vulnerable to toxic 
effects. Therefore, regions with the greatest proportion of anagen follicles, for example the 
scalp, are traumatised more severely by noxious events compared with regions 
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comprising a lower proportion of anagen follicles, for example the eyelashes (Patel & 
Tosti, 2014; Remesh, 2012).  
1.4.1.1 Permanent alopecia induced by chemotherapeutic drugs 
Few studies have explored the histology of irreversible CIA (Tosti et al., 2005; Tran 
et al., 2000) despite the psychological impact. In most cases, HF stem cells appear to be 
largely unaffected by chemotherapy agents, demonstrated by hair regrowth 3-6 months 
post-treatment (Tallon et al., 2010). However, some cases have been reported as an 
absence of or incomplete hair regrowth after 6 months of completion of chemotherapy 
(Dorr, 1998). High doses of cyclophosphamide and busulfan may produce irreversible 
damage to the HF and alopecia occurs in approximately half of patients after receiving 
these drugs (Tosti et al., 2005). Permanent alopecia also has been reported after 
treatment with combinatorial drugs FEC (fluorouracil /epirubicin /cyclophosphamide) and 
docetaxel in patients with breast cancer (Kluger et al., 2012).Hair loss after FEC treatment 
is observed with a moderate or intense androgentic-like pattern (Kluger et al., 2012).  
All the permanent alopecia cases showed that there was a severe decrease in the 
total number of HFs (Tallon et al., 2010), however, no inflammation or fibrosis was 
exhibited. Permanent alopecia was observed in another study, which was assessed by a 
4-mm punch biopsy. This was taken from the frontal scalp; studies of this biopsy showed a 
reduction in anagen HFs and the presence of multiple linear aggregates of basaloid 
epithelium. Another study highlighted that in cases of permanent alopecia the density of 
the HF reduced, however, the number of vellus hairs were increased (Prevezas et al., 
2009). This was similar to telogen HFs however, they differed in structure with a more 
slender and branched arrangement with no hair shaft (Tallon et al., 2010).  
1.4.2 Experimental models of CIA  
CIA remains an important unmet clinical challenge and as such, there is a need to 
develop robust experimental models of CIA so that new treatment strategies can be 
developed. Currently there are no ideal pre-clinical models, however, a number of very 
useful experimental approaches have been developed.  
1.4.2.1 Animal models 
Difficulties obtaining scalp biopsies from patients undergoing chemotherapy 
treatment means that little is known about the true mechanisms of apoptosis and hair loss 
caused by chemotherapy. Research into CIA has thus heavily exploited the use of animal 
models, usually neonatal rats or adult mice (Luanpitpong and Rojanasakul, 2012). 
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However, one fundamental difference exists in the hair growth pattern between humans 
and rodents as human HF growth cycles occur in a mosaic pattern, with each follicle 
having its own growth cycle, which behaves independently of its follicle neighbours. In 
contrast, rodents HFs grow in a wave pattern, starting from the head moving towards the 
tail. Also in adult mice, HFs are mostly in the telogen phase and only 10% are in the 
anagen, compared to 90% of follicles on a normal human (Luanpitpong and Rojanasakul, 
2012).  
1.4.2.1.1 Newborn and young rat models 
As CIA occurs when HFs are in anagen, animal models would require a 
synchronised induction of HFs into the anagen phase. One way of simulating this is the 
use of young rat or mice models after the physical depletion of hair as this causes all HFs 
to re-start their growth in anagen (Wikramanayake et al., 2012). A second technique, 
established by Hussein and colleagues is the new born rat CIA model (Hussein et al., 
1990). Seven to eight day-old rats exhibit spontaneous anagen hair growth for 
approximately a week, and this has been used to test the effect of several 
chemotherapeutic agents; arabinoside, doxorubicin, cyclophosphamide, and etoposide. It 
was reported that alopecia occurred within one week after the initially administered dose 
and the severity of CIA was dependent on the category of drug infused (Hussein et al., 
1990). The advantage of this model is the rapid and obvious onset of hair follicular CIA. 
The disadvantage is that the HFs are in their first cycle and, as such, they have a different 
structure and expression of growth factors compared to mature HFs. Furthermore, HFs in 
the newborn rat lack pigmentation, which is known to limit the effect of drugs on 
melanocytes (Jimenez and Yunis, 1992b). Thus, this model may be used to demonstrate 
that chemotherapeutic drugs damage HFs in anagen, but these data cannot be directly 
extrapolated to man. Following high dose administration of cyclophosphamide, rats show 
a mitotic reduction in the hair bulb cells, which led to narrowing of the hair shaft and its 
breakage, thus showing how cytotoxic cyclophosphamide is to the HF (Patel et al., 2014).  
1.4.2.1.2 Adult mouse model 
To overcome some of the limitations of newborn and young models, the adult 
C57BL-6 mouse model was developed by Paus and colleagues (Paus et al., 1994). The 
advantage of this model is that the hair shafts are well pigmented and thus their response 
to chemotherapy agents is more comparable to humans. In addition, the stage of hair 
growth cycle can be identified by the skin colour, as it is pink during the telogen phase, 
and in anagen, it turns black (Paus et al., 1994). In this model, administration of 
cyclophosphamide caused dose dependent mild or severe CIA (Paus et al., 1994). Mild 
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drug-induced toxicity results in a longer than normal anagen phase which initiates a 
dystrophic anagen response. By contrast, if chemotherapy induces severe toxic effects, 
HFs are transitioned into a dystrophic catagen (Bodo et al., 2007; Bodo et al., 2009), and 
although this is caused by greater toxicity, HFs recover faster from dystrophic catagen 
than dystrophic anagen (Paus et al., 2013).  
1.4.2.1.3 Xenografts of human skin samples into nude mice 
Due to the different properties of the human and rodent HF, a method of grafting 
human skin on to nude mice has been developed (Manning et al., 1973). This potentially 
powerful model has been used to study CIA as it has the advantages of a whole animal 
model whilst at the same time allowing the unique physiology of the human scalp HF to be 
studied (Manning et al., 1973). After grafting human scalp skin onto a mouse the hairs are 
initially shed within a month, but the hair regrows over the next few months (Neste et al., 
1991). This model has been used to study the HF biology and also the effects that 
chemotherapy has on human HFs (Domashenko et al., 2000) and thus represents a 
useful in vivo tool for studying CIA (Kyoizumi et al., 1998).  
1.4.2.2 Non-animal (ex vivo and in vitro) culture models 
1.4.2.2.1 Organ culture model 
Due to the limitations of animal models discussed above, a system of human HF 
cultured ex vivo was developed by Bodo et al and has been utilised for the study of CIA 
(Bodo et al., 2007). In this model, human HFs in anagen phase were micro-dissected from 
excess normal human scalp skin obtained from healthy adults undergoing routine face-lift 
surgery. In a previous study, these human HFs were treated with 4-OH-CP, the active 
metabolite of cyclophosphamide, and this treatment was shown to reduce matrix 
keratinocyte proliferation as well as induce apoptosis (Bodo et al., 2007). Therefore, this 
model represents a potentially powerful tool for the study of CIA in a well-controlled in vitro 
environment whilst maintaining the in vivo characteristics of human HFs.    
1.4.2.2.2 Cell culture models  
Commercially available cultured primary normal human epidermal keratinocytes 
(NHEK) and, more rarely normal hair follicular keratinocytes (HHFK), have been used as a 
model to study chemotherapy-induced damage and apoptosis in skin cells. NHEK are 
isolated from juvenile foreskins and maintain many of the characteristics of the tissue from 
which they are derived and have been used as a model to study various aspects of skin 
physiology. This population of cells is similar to the matrix keratinocytes of the HF, which 
are damaged by chemotherapy and causing CIA in vivo, thus the rationale for this model 
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is that there is some reciprocation of the clinical scenario. Studies have exploited these 
finite NHEK and HHFK cultures to examine the effects of commonly used chemotherapy 
drugs, in particular doxorubicin, docetaxel and the active metabolite of cyclophosphamide 
(4-OH-CP), as well as combinations of these such as TAC and FAC (Deyrieux and 
Wilson, 2007; Janssen et al., 2008; Janssen et al., 2007).  
A well-established, immortalised human keratinocyte cell line, HaCaT, has also 
been used to study CIA (Liu et al., 2012; Luanpitpong et al., 2011). As the HaCaT cell line 
is spontaneously immortalised, it can be cultured in serum-containing media indefinitely. 
Mitotic or oncogenic mutations are not responsible for the immortalised HaCaT phenotype 
(Boukamp et al., 1988), but the p53 gene is known to have a UV-specific mutation in both 
alleles (Lehman et al., 1993). A fundamental difference between NHEK/HHFK and HaCaT 
is their cell culture conditions; HaCaT cells are cultured in standard, bovine serum-
containing medium containing ~2mM calcium (physiological levels), whereas NHEK and 
HHFK cells are cultured in Keratinocyte Serum Free Medium (KSFM), which contains 
EGF and BPH and ~0.09 mM calcium (Georgopoulos et al., 2010). The concentration of 
extracellular calcium has a major effect on keratinocyte growth and differentiation because 
calcium induces terminal differentiation, specific structural changes, cell cycle withdrawal 
and induction of terminal differentiation (Boelsma et al., 1999).  
1.4.3 Treatment options for CIA 
Since the 1970s, there have been numerous attempts to prevent chemotherapy-
induced hair loss by means of mechanical, physical, and pharmacological intervention 
(Grevelman and Breed, 2005; Sredni et al., 1996) and these are discussed below.  
1.4.3.1 Pharmacological prevention 
Several classes of pharmacological agents with different mechanisms of action 
have been evaluated in animal models of CIA; these include drug-specific antibodies, hair 
growth cycle modifiers, cytokines and growth factors, antioxidants, cell cycle or 
proliferation modifiers and inhibitors of apoptosis. Their potential applications and 
limitations have been reviewed previously (Wang et al., 2006) and are briefly discussed 
below. 
1.4.3.1.1 Drug-specific antibodies  
To reduce the severity of doxorubicin-induced alopecia in the neonatal rat model, 
antibodies to doxorubicin and other anthracycline agents incorporated in liposomes have 
been explored. Topical administration of these anti-anthracyclines prevented doxorubicin 
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induced CIA in 31 of 45 rats (Balsari et al., 1994). The limitation to this strategy is that it 
would require a range of antibodies to prevent alopecia caused by the different drugs 
usually used in chemotherapy.  
1.4.3.1.2 Hair growth cycle modifiers 
Immunosuppressive immunophilin ligands such as cyclosporine, are used in the 
treatment of autoimmune disease and post-organ transplantation, however, these drugs 
also induce anagen and inhibit the catagen phase of the hair cycle leading to hair growth 
activity in several normal and pathogenic alopecia conditions (Taylor et al., 1993). 
Neonatal rats and mice have been used to investigate the effects of cyclosporine on CIA. 
Topical application of cyclosporin protected against local alopecia induced by 
cyclophosphamide, cytosine arabinoside and etoposide in rats (Hussein et al., 2009). 
Another immunomodulator, AS101, has shown a reduction in the severity of alopecia in 
patients treated with a combination therapy of carboplatin and etoposide (Sredni et al., 
1996). Topical minoxidil is used for the treatment of male pattern baldness and modifies 
hair cycle dynamics by shortening the telogen hair phase, thus facilitating anagen phase 
and encouraging hair growth (Duvic et al., 1996). Several studies have examined the 
effect of minoxidil on CIA. In a rodent model, local application of minoxidil protected 
against CIA induced by arabinosylcytosine, but showed no protection to doxorubicin and 
cyclophosphamide-induced CIA (Hussein, 1995). In a clinical study in breast cancer 
patients, minoxidil has been shown to speed recovery from CIA, but does not prevent it 
(Duvic et al., 1996). 
1.4.3.1.3 Cytokines and growth factors  
Interleukin 1 (IL-1), which plays a role in the regulation of inflammatory and 
immune responses to infections and ImuVert, a biological response modifier with immune 
stimulatory properties, derived from the bacterium S. marcescens have both been 
reported to protect rats from CIA induced by cell cycle-specific agents, namely; cytosine 
arabinoside and doxorubicin, but not from cell cycle-nonspecific agents such as 
cyclophosphamide (Jimenez et al., 1992). Both ImuVert and IL-1 induce the release of 
multiple cytokines or growth factors and it has been suggested that the action of ImuVert 
is via IL-1 (Hussein, 1993). Screening of various cytokines and growth factors has found 
that acidic fibroblast growth factor (aFGF) and epidermal growth factor (EGF) protect from 
CIA, but again, only if induced by cell cycle specific agents (Jimenez and Yunis, 1992a).  
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1.4.3.1.4 Cell cycle or proliferation modifiers  
As previously stated, rapid cell proliferation in HFs during anagen and the lack of 
cancer cell selectivity of anticancer agents is the main factor for CIA. Hence, one 
approach to protect against the CIA is to inhibit cell proliferation in order to decrease the 
sensitivity of HFs to chemotherapy (Davis et al., 2001). An example of this method is the 
administration of calcitriol (1,25-dihydroxyvitamin D3) that has multiple effects on 
keratinocytes; it stimulates cell differentiation, inhibits DNA synthesis and leads to G0/G1 
cell cycle arrest (Kobayashi et al., 1998; Wang et al., 2006). Therefore, it is probable that 
calcitriol induces changes in keratinocyte proliferation and/or terminal differentiation, 
subsequently altering cellular susceptibility to apoptosis. It has been shown that calcitriol 
protects neonatal rats from alopecia induced by cyclophosphamide, etoposide and a 
combination of cyclophosphamide and doxorubicin (Jimenez and Yunis, 1992b). 
Furthermore, in the adult mouse model, it was demonstrated that calcitriol could enhance 
the normal pigmented hair shaft regrowth and reduce apoptosis in the hair bulb, however, 
it failed to prevent or retard hair loss after the administration of cyclophosphamide (Paus 
et al., 1996; Schilli et al., 1998).  
Cyclin-dependent kinase 2 (CDK2) plays a key role from G1 phase to late G2 
phase of the cell cycle. Inhibitors of CDK2, by inhibiting the progression from late G1 
phase into S phase, reduce the sensitivity of HFs to chemotherapy agents and inhibits 
apoptosis induced by etoposide, 5-fluorouracil, taxol, cisplatin and doxorubicin. In 
neonatal rats, topical application of a CDK2 inhibitor reduced etoposide mediated hair loss 
by 50% at the site of application and by 33% in CIA induced by of doxorubicin and 
cyclophosphamide (Davis et al., 2001).  
1.4.3.2 Physical intervention 
1.4.3.2.1 Scalp tourniquets  
Scalp tourniquets are special bands that tightly fit the scalp region with the aim of 
occluding the superficial blood flow to reduce the amount of drug delivered to the HFs 
(O'brien et al., 1970). Scalp tourniquets are applied when the plasma drug levels are at 
their peak, i.e. from the last 10 min of infusion to 10 min after the cessation of drug 
administration (Maxwell, 1980). Tourniquets have achieved a small to moderate degree of 
rescue from CIA induced by vincristine, cyclophosphamide, and doxorubicin. However, it 
is no longer recommended due to the high pressure applied resulting in patient discomfort 
(Maxwell, 1980; Wang et al., 2006). 
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1.4.3.2.2 Scalp (head) cooling 
1.4.3.2.2.1 The principle of scalp cooling and its proposed mechanism(s) of 
action 
Scalp cooling throughout the administration of chemotherapy drugs in most cases 
reduces CIA in patients undergoing anticancer chemotherapy (Protiere et al., 2002) since 
it was introduced in the 1970s at a few hospitals in the Netherlands (Grevelman and 
Breed, 2005). The methods for application of scalp cooling and the clinical evidence for its 
efficacy in preventing CIA will be discussed in subsequent sections.  
Several hypotheses have been proposed to explain how scalp cooling reduces 
CIA. Firstly, cooling causes rapid vasoconstriction, which has been shown to reduce blood 
flow in the scalp significantly and perfusion can be reduced to even 20-40% of normal 
levels (Janssen et al., 2007); thus it has been suggested that this will result in less 
chemotherapeutic drug perfusing to the dermal papilla (Bülow et al., 1985). A second 
hypothesis is that, as the general rate of drug diffusion across a plasma membrane is 
reduced at cooler temperatures (due to low kinetic energy) and also as membrane lipid 
fluidity is lower (thus impacting on diffusion), consequently less chemotherapy drug would 
enter HF cells overall (Lane et al., 1987). In addition, some drugs may enter cells via 
active transport mechanisms (for instance doxorubicin) which would equally be reduced 
by cooling. Moreover, as cell division is an energy-requiring metabolic process, it is highly 
likely that its enzyme-dependent reactions are slowed down by cooling. Indeed, it has 
been reported that temperature can particularly affect the G1 and S phases of the cell 
cycle (Watanabe and Okada, 1967) and this could be especially important for drugs that 
target specific phases of the cell cycle, such as mitosis-targeting microtubule-destructive 
drugs. In support, it has been shown that doxorubicin-induced damage to DNA is reduced 
at lower temperatures (Vichi et al., 1989). Finally, a general decrease in the metabolic 
activity of the cells in the HF could cause a reduction in the cytotoxicity of chemotherapy 
drugs as a range of cellular processes slow (Bülow et al., 1985). In practice, it is likely that 
a combination(s) of several (or all) of these methods have a role in reducing CIA. 
1.4.3.2.2.2 Scalp cooling using cool caps 
Initially cooling of the scalp was achieved using crushed ice in a plastic bag fixed 
into position with elasticated bandages (Guy et al., 1982). However, because heat from 
the head rapidly warms the ice packs, these need to be replaced regularly, which is time 
consuming, and does not maintain a consistently reduced temperature (Katsimbri et al., 
2000). The number of countries and hospitals using scalp cooling has increased 
substantially mainly following the introduction of improved commercially available 
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products. One uses a refrigerated cryogel cap, which is placed in a freezer at -25°C 
before being fitted to the head (e.g. Penguin cold cap) (Katsimbri et al., 2000). However, 
because of the very low initial temperature, these gel-caps are reported to be 
uncomfortable, and although they are better than the use of ice packs, they still thaw 
rapidly and must be changed regularly (approximately every 20 min) in order to maintain a 
consistently reduced scalp temperature. Thus, several changes are required during most 
standard chemotherapy perfusion protocols (Katsimbri et al., 2000). The most recent 
development to scalp cooling is the use of a refrigerated unit that circulates a refrigerant 
solution through a specially designed close-fitting cooling cap.  
1.4.3.2.2.3 Modern scalp cooling devices 
Refrigeration unit-fitted machines, designed to circulate liquid refrigerant through a 
cooling cap, are the modern day choice in scalp cooling. These caps are available in a 
range of sizes to ensure a suitable fit as patient head sizes (and shapes) vary (e.g. 
Paxman PSC system) (Massey, 2004). This modern type of application offers several 
advantages. The coolant flow achieves and maintains a constant, reduced scalp 
temperature throughout drug infusion without the need for cap replacement/re-application. 
This reduces medical staff burden and also, because the caps are not cooled to such 
unnecessarily low temperatures and they are not as heavy, they are overall more 
comfortable. Studies examining the Paxman Coolers Orbis head cooling device have 
shown that 18°C can be consistently achieved in the scalp of patients throughout the 
course of chemotherapy infusion, and most patients tolerate this intervention very well, 
with the majority indicating either low or moderate levels of discomfort (Komen et al., 
2013b). Advantageously, throughout its application, only the outer part of the scalp to a 
depth of 2 cm is affected with no subsequent alteration of core temperature, thus posing 
no risk of hypothermia (Janssen et al., 2005). 
1.4.3.2.2.4 Efficacy of cooling in protecting from drug-mediated toxicity 
1.4.3.2.2.4.1 Clinical evidence for the efficacy of scalp cooling in cancer 
patients  
Scalp (head) cooling (or scalp hypothermia) is currently the only technique for 
which there is clinical evidence-based efficacy for CIA reduction (Breed et al., 2011). 
Numerous clinical studies have demonstrated that the efficacy of scalp cooling can range 
from 0-90% depending on the chemotherapy agent and cooling technique used 
(Grevelman and Breed, 2005). 
Auvinen et al., (2010) showed that scalp cooling resulted in a significant reduction 
in CIA with a 100% of patients maintaining their hair after doxorubicin treatment, 83.3% 
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after docetaxel, 76.5% after FEC (5-fluorouracil, epirubicin and cyclophosphamide) and 
78% after docetaxel together with FEC (Auvinen et al., 2010). A larger and prospective 
multi-centre study conducted by van den Hurk et al., (2012) explored the effect of scalp 
cooling on hair preservation in 1411 chemotherapy patients between 2006 and 2009 (Van 
Den Hurk et al., 2012c). The data were collected by the Dutch scalp-cooling registry, the 
mean age of the subjects was 53 (18-81 years), with 86% having treatment for breast 
cancer and 96% of these being female. Treatments varied depending on the different 
stages and progression of the cancer and consisted of the following: 5-fluorouracil, 
epirubicin, cyclophosphamide, the combinatorial regimes FEC and TAC (doxorubicin, 
docetaxel and cyclophosphamide), plus several different anthracyclines and taxanes 
(given as monotherapy or combination). Patients in the study used the Paxman PSC-1, 
PSC-2 or ORBIS scalp cooling devices, the median number of chemotherapy and cooling 
sessions was four (Van Den Hurk et al., 2012c). The results were evaluated by 
questionnaires, with patients scoring their own hair loss according to a WHO scale 
(outlined in previous sections) (Organization, 1979). The best results were obtained 
following monotherapy treatments, for instance taxanes such as docetaxel (75 mg/cm2) or 
paclitaxel (70-90 mg/cm2) with 94% and 81%, respectively, of patients not requiring a wig 
or some form of head cover. The results were less impressive in the case of the TAC 
combo-therapy, even when used at low doses, as only 8% of patients did not require a 
form of head cover (Van Den Hurk et al., 2012c). Overall, ~50% of all 1411 scalp-cooled 
patients did not use head covering at the time of their last round of chemotherapy 
treatment. Moreover, van den Hurk et al.,  (2010) have reported that besides the specific 
chemotherapy protocol, other factors can have an influence on the use of head cover, 
such as patient age (generally it is higher in those over 50), gender, ethnicity, hair length, 
quantity, waving, colouring, dyeing and wetting before scalp cooling (Van Den Hurk et al., 
2012c). The duration of cooling further influences the protection provided by scalp cooling, 
thus where possible the timing of cooling periods should be based on the drug 
pharmacokinetics (Tollenaar et al., 1994). However, in the case of combination therapies, 
the plasma half-life of a number of drugs would have to be considered and thus the 
optimal duration of scalp cooling has not been systematically addressed. In most studies, 
the pre-cooling time (i.e. the time between the start of scalp cooling and the administration 
of chemotherapy) is between 5 and 30 min to ensure that the scalp is cool when the drugs 
reach the HFs (Anderson et al., 1981; Johansen, 1985; Lemenager et al., 1997). Another 
equally important consideration during scalp cooling is the period of time necessary to 
maintain cooling following completion of drug administration (infusion). Routinely, the cap 
remains in place during the administration of the chemotherapy drugs and also for a 
period after this, referred to as the post-infusion cooling time (or PICT), which allows the 
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drug concentration to drop below toxic levels before the HFs warm up. Although until 
recently, a 90 min PICT was recommended to ensure maximal efficacy, van den Hurk et 
al.,  (2012) specifically examined the effect of post infusion scalp cooling time in reducing 
CIA after docetaxel treatment and found that better results were obtained by reducing 
PICT from 90 min to 45 min (Table 1-3) (Van Den Hurk et al., 2012a). This is presumably 
because once the plasma concentration of docetaxel drops below toxic levels, the 
warming of the scalp allows any drug that has accumulated during the course of 
chemotherapy to be more rapidly ‗flushed out‘ of the scalp. This study indicates that some 
optimisation of cooling protocols might be required to improve the efficacy for different 
chemotherapy regimens (Van Den Hurk et al., 2012c). In line with this, very recently, a 
study by Kemon et al., (2016) has reported that even a 20 min PICT is as effective and 
tolerable as the 45 min period (Komen et al., 2016). Therefore, both of these studies 
represent potentially significant improvements in the scalp cooling protocols.  
It should be noted that in the past, some concern was raised as to whether scalp 
cooling could be associated with a higher incidence of scalp metastasis, however no 
studies provide any near statistical evidence for a positive correlation between metastasis 
and scalp cooling (Lemieux et al., 2011). Lemieux et al., (2009) found a very low 
incidence of scalp metastases (Lemieux et al., 2009). Additionally, studies that have been 
conducted to specifically address this issue in patients with breast cancer firstly, confirmed 
that scalp metastasis occurs very rarely, with an incidence between 0.03% and 3% in 
individuals that did not receive cooling, and that this is no different to that for individuals 
who received scalp cooling 0.04–1% (Van Den Hurk et al., 2013). In most cases reported 
so far, scalp metastases after scalp cooling were not the first metastatic site and the scalp 
metastasis observed might then only be the result of widespread metastatic disease and 
unrelated to scalp cooling. Finally, all these observations are further supported by studies 
demonstrating that use of scalp cooling has no effect on the breast cancer patient survival 
(Lemieux et al., 2015). 
1.4.3.2.2.4.2 Evidence for a cytoprotective role of cooling from in vitro 
models  
Previous studies by Janssen et al., (2008), was shown using NHEK cells treated 
with doxorubicin that cytoprotection could be achieved at 26 and 22°C and cooling to 10°C 
had no further effect on cell protection. Based on those observations, it was proposed that 
with the optimal temperature for scalp cooling being approximately 20-22°C, a further 
decrease in temperature would be unnecessary and would only result in potential patient 
discomfort (Janssen et al., 2008). Interestingly, this ‗cut off‘ point in the protective effect of 
cooling at ~20°C has been shown to occur for doxorubicin at both the level of the cell 
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membrane (Lane et al., 1987) and damage to DNA (Vichi et al., 1989). The finding that 
lowering the temperature further results in improved cytoprotection suggests that the scalp 
temperature achieved in cancer patients may be critical in determining the success of 
scalp cooling in CIA prevention (Janssen et al., 2008). Collectively, these in vitro studies 
have provided evidence that, despite their reductive nature, such culture models provide 
clinically relevant data and may thus be useful in understanding the mechanisms of 
human CIA as well as designing novel strategies to counteract the cytotoxic effects of 
chemotherapy drugs in the clinic.  
 
 PICT (min) Number % no wig or head cover 
Observational 90 53 81 
Randomised 90 38 79 
 45 38 95 
 
Table  1-3 : Post infusion cooling times (PICTs) 
Use of wig or head cover in scalp-cooled patients after treatment with docetaxel with 
different PICTs. *p00.04 (90 vs 45 min). Adapted from (Van Den Hurk et al., 2012a). 
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1.5 Thesis aims 
Despite the available clinical evidence, for a positive effect of cooling and direct 
protection from CIA, the mechanisms by which cooling protects remain not understood. 
The overall the aim of this work was to for the first time establish in vitro models to study 
the effect of cooling in chemotherapy drug induced cytotoxicity and to provide a detailed 
understanding at the cellular level of the biological mechanisms involved. 
More specifically: 
 Chapter 3: Establish in vitro culture models for the study of chemotherapy-
induced cytotoxicity; these models involved the use of normal human 
keratinocytes and the non-finite cell line HaCaT; investigate the effect of cooling 
on cell growth after treatment with a panel of representative chemotherapy 
drugs used in cancer chemotherapy (and combinations thereof) and establish 
whether the in vitro data are in agreement with clinical observations. 
 Chapter 4: Investigate the effects of cooling on HaCaTa cell cycle and the 
distribution of cell cycle phase at cooling conditions in the presence or absence 
of chemotherapy drugs.  
 Chapter 5: Investigate the effect of chemotherapy drugs on mitochondrial 
membrane potential and the influence of cooling; study the effect of 
chemotherapy drugs in the context of oxidative stress (reactive oxygen species, 
ROS) and the effects of cooling on ROS induction. Detect chemotherapy drug-
mediated cell death using appropriate apoptosis assays and assess the effect 
of cooling.  
 Chapter 6: Investigations on the effects of cooling on the activation and 
functional involvement of key intracellular mediators in chemotherapy drug-
mediated apoptosis in human keratinocytes. 
 Chapter 7: Investigations on the effect of antioxidant-mediated blockade of 
ROS in cooling-mediated cytoprotection. 
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2 CHAPTER 2: Materials and Methods 
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2.1 General 
All practical work was carried out in the School of Applied Sciences, at the 
University of Huddersfield.  
2.1.1 Suppliers  
Commercial suppliers and manufacturers are indicated at the first mention of the 
reagent or equipment in the text. A comprehensive list of all suppliers is provided in 
Appendix I.  
2.1.2 Disposable plasticware 
Sterile and non-sterile plasticware was obtained from different suppliers (Sarstedt, 
Fisher Scientific, Greiner Bio-One or Alpha Laboratories). Non-sterile, disposable 
plasticware was sterilised by autoclaving in a Prior Clave/London Autoclave at 121°C 
under pressure for 15 min and then left to dry at room temperature. 
2.1.3 Stock solutions 
All chemical reagents were either of analytical or tissue culture grade as 
appropriate for the experiment and were supplied by Sigma Aldrich unless otherwise 
stated. General laboratory stock solutions were prepared in the laboratories with 
deionised water (dH2O). All solutions, which were used in tissue culture, were prepared 
with ultra-pure water from a LabStar Ultra Violet purification unit. Heat stable solutions 
were sterilised by autoclaving at 121°C for 15 min. Otherwise, to ensure lack of microbial 
contamination, stock solutions were filter sterilised using Acrodisc (VWR) low-protein 
binding Tuffryn® HT syringe filters with a pore size of 0.2 µm. Recipes for all stock 
solution can be found in Appendix II.  
2.1.4 Safe handling of cytotoxic (chemotherapy) drugs 
Cytotoxic drugs were handled with extreme care at all times to reduce any risk of 
exposure, as these drug can be absorbed through the skin and acute exposure can cause 
severe cytotoxicity such as nausea and vomiting, abdominal pain, headache and long 
period exposure can cause reproductive losses and cancer later in life. As part of 
standard cell culture procedures, all work involving use of cytotoxic drugs was carried 
whilst wearing disposable nitrile gloves, particularly when dealing with concentrated 
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stocks and drug-related excess/waste material. A particular amount of each drug was 
utilised in this work for each experiment, with the drugs adopted comprising of the 
following: doxorubicin (Sigma Cat # D1515-10MG), which was dissolved in water; 
docetaxel (Sigma Cat # 01885-5MG-F), which was dissolved in DMSO, as well as 
cyclophosphamide (4-OH-CP) (supplied by Niomech, Germany), which was also 
dissolved in DMSO. Following the dissolution procedures, aliquots of each of these drugs 
were stored in the dark at 4°C for ~1 week. Additional aliquots of each dissolved drug 
were also stored in the dark at -20°C, as a means of long-term storage over a period of 12 
months. Subsequently, the potency of each of the drugs following storage was tested. 
Such analysis revealed that there was no loss of potency among any of the drugs when 
tested, whether they were stored at 4°C or when stored at -20°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.2 Reagent 
2.2.1 Primary antibodies  
Primary antibodies used in this study are listed in Table 2-1.These antibodies were 
aliquoted and stored as recommended by the manufacturer until required. Working stocks 
were diluted in Tris buffered saline (TBS; Appendix II) with 0.1% (v/v) Tween 
(TWEEN® 20; Sigma Aldrich) and stored at 4°C. When blocking buffers were included in 
the antibody dilutions, these were specified under ‗dilution‘. 
 
Antigen 
Catalogue 
no/ Clone 
Host 
Supplier 
(product of) 
Dilution Application 
MW 
(kDa) 
BAX 
2282-MC-100 
(YTH-2D2) 
Ms 
R&D systems 
(Trevigen) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 23 
Bak AF816 Rb R&D systems 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 28 
TRAIL 3219 Rb NEB (CST) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 28 
FasL 4273 Rb NEB (CST) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 26, 40 
Bid  2002 Rb NEB (CST 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 15-22 
P53 9284 Rb NEB (CST) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 53 
Puma 4976 Rb NEB (CST) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 23 
Noxa 
ALX-804-408-
C100 
Ms ENZO 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 11 
P21 2946 Ms NEB (CST) 
1:1000 in TBS 
0.1% 
TWEEN® 20 
WB 21 
 actin 
Clone 
AC15 
A5441-2mL Ms Sigma 
1:20,000 in 
TBS 0.1% 
TWEEN® 20 
WB 42 
Table ‎2-1 Primary antibodies 
A list of all primary antibodies used in this study, their catalogue number, host origin, 
supplier or manufacturer, optimal dilution, type of blocking buffer and the range of their 
applications is shown here. (Abbreviations - WB: Western blotting, NEB: New England 
BioLabs, CST: Cell Signalling Technologies). 
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2.2.2 Secondary antibodies  
For visualisation of primary monoclonal antibody binding in Western blotting, the 
molecular probe Alexa Fluor® 680 Goat anti-mouse IgG antibody was used (Invitrogen 
Cat # A21057). Detection of polyclonal antibodies (all rabbit immunoglobulins) was 
achieved using the Goat anti-Rabbit IgG IRDYE800 antibody (Tebu-bio Cat # 039611-
132-122). Fluorochrome conjugated secondary antibodies were titrated prior to use and 
are listed in Table 2-2. 
 
Antigen Catalogue no/ 
Clone 
Host Supplier 
(product of) 
Dilution Application 
Mouse IgG 
A21057 Rb Invitrogen 
1:10,000 in TBS 
0.1% TWEEN® 20 
WB 
Rabbit IgG 
039611-132-122 Goat Tebu-bio 
1:10,000 in TBS 
0.1% TWEEN® 20 
WB 
 
Table ‎2-2 Secondary antibodies 
All secondary antibodies used in this study, their catalogue number, host, origin, supplier 
or manufacturer, optimal dilution, type of blocking buffer and the range of their 
applications are listed (Symbols - WB: Western blotting). Fluorescence detection at 
wavelengths 680nm and 800nm was performed using the Licor Odyssey Infra-red imaging 
system. When not in use, antibodies were stored in the dark at 4°C. 
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2.2.3 Pharmacological agonists and antagonists 
Pharmacological agonists and antagonists (Table 2-3) were reconstituted in either 
tissue culture grade dimethyl sulphoxide (DMSO; Sigma) or sterile distilled water (dH2O) 
according to the manufacturer‘s instructions. These were stored in single-use aliquots at -
20°C as recommended. Prior to use, all compounds were titrated using the cell viability 
assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay; Promega, UK, Cat # 
G3581) to determine the effective and non-toxic dosage. All reagents used in this study 
were purchased from the indicated supplier.  
 
 
 
Table ‎2-3 Agonists & antagonists 
Agonists and antagonists used in this study, their target molecule, the supplier, the stock 
and effective concentrations are shown. *NB. NAC reacts with the CellTiter MTS substrate 
and has to be removed and washed before addition of the MTS reagent. 
Compound Target Supplier 
Stock 
concentration 
Effective 
concentration 
Staurosporine Protein Kinases Sigma 100 µM 5 µM 
NOK1 
FasL (CD95L) Gift of Prof 
Yagita, Japan 
1 mg 100 µg 
MR106 
Control Ab for 
anti-FasL 
labelling 
Gift of Prof 
Yagita, Japan 
1 mg 100 µg 
N-acetyl L-
cysteine (NAC) 
ROS 
Sigma 
20 mM (culture 
media) 
0.625 mM 
 
Pifithrin-α 
hydrobromide 
P53 Santa Cruz 
Biotechnology 
1000 µg/mL 1 µg/mL 
PD153035 
hydrochloride 
 
Epidermal 
Growth Factor 
Receptor 
(EGFR) 
Sigma 5 mg 3 µM 
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2.3 Tissue culture 
2.3.1 General 
All tissue culture work was undertaken using aseptic techniques within a HEPA filtration 
CellGard class II biological safety cabinet (NUAIRE). Prior to and after use, internal working 
areas within the hood were disinfected using 70% (w/v) ethanol (Fisher). To do so, 99% 
ethanol was diluted appropriately (150mL: 350mL) with autoclaved dH2O. Internal hood 
spillages were disinfected using Mikrozid® (Gompel Healthcare Cat # 32644) and this was 
also used for monthly routine disinfection of the safety cabinet. Any unwanted cells, 
exhausted media or solutions were aspirated into a large conical flask containing 10% (w/v) 
Virkon and were then left for a minimum of 30 min before being decanted and washed into 
sewage.  
All cell culture reagents were of tissue culture grade and were from Sigma unless otherwise 
stated. To separate cells from solution, cell suspensions were centrifuged for 5 min at 1500 
rpm using a Hettich Zentrifugen Universal 320 bench top centrifuge. Cell counts were 
performed from cell suspensions using a Marienfield Neubauer improved bright line 
haemocytometer before cells were seeded at the required cell density. When cells were not 
being manipulated they were kept in an Iso class 5 Nuaire Autoflow direct heat, CO2 
incubator with a HEPA filtration system at 37°C in a 5% CO2 humidified atmosphere 
(incubator contained dH2O supplemented with Sigma clean (Sigma Cat # S5525-40Z). 
Cultured cells were routinely observed by phase contrast microscopy using an EVOS XL 
(PeqLab) inverted microscope at x100 magnification. 
2.4 Cell culture 
2.4.1 Normal human epidermal keratinocytes (NHEK) and Human hair follicular 
keratinocytes (HHFK) 
Neonatal human epidermal keratinocytes (HEKn), referred to in this study as normal 
human epidermal keratinocytes (NHEK), were obtained from Life Technologies (supplied by 
Fisher Scientific) and were cultured in keratinocyte serum free medium (KSFM) (Gibco, Life 
Technologies Cat # 17005-034) supplemented with epidermal growth factor (EGF) and 
bovine pituitary extract (BPE) (Gibco, Life Technologies Cat # 10450-013) as recommended 
by the manufacturer. Human hair follicular keratinocytes (HHFK) were purchased from 
ScienCell Research Laboratories (supplied by Caltag MedSystems) and were cultured in 
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Keratinocyte Medium kit (ScienCell Cat # 2101) according to the manufacturer‘s 
recommendations.  
2.4.2 HaCaT cell line 
As a model for human proliferating keratinocytes were HaCaT cells was purchased 
from Cell Line Services (CLS). The HaCaT cells are a transformed, spontaneously 
immortalised, tumorigenic cell line (Boukamp et al., 1988). HaCaT cells possess mutation in 
both alleles of the p53 gene (Lehman et al., 1993).  
HaCaT cells were grown in DMEM medium (DMEM Sigma cat # D6546-6X500ML) 
10% fetal calf serum FBS (FCS Biosera Cat # S1810/500) with 1% L-Glutamine (Sigma Cat 
# G7513-100ML). Cells were maintained in T75 flasks with 12-14mL medium or T25 flasks in 
5mL medium and were incubated at 37ºC under 5% CO2. Cells were sub-cultured every 3-4 
days, when they were 80-95% confluent. At all times cell lines were cultured in the above 
mentioned medium and incubated at 37°C in 5% CO2 unless otherwise stated. For all 
experiments, HaCaT cells were used at passages 1–15 to ensure maximal proliferative 
capacity. 
2.4.3 HaCaT adaptation to serum-free medium (HaCaTa) 
A sequential adaptation methodology was followed to switch the culture conditions of 
HaCaT cells from a serum-supplemented to a serum-free, low calcium medium (KSFM). This 
involved culture and passaging whilst gradually reducing the proportion of standard culture 
medium DMEM/10% FBS (DMEM complete, DMEMc) and replacing it with KSFM/EGF/BPE 
(KSFM complete, KSFMc) and lasted a period of six passages. Briefly, this involved: 
medium-change of cells (p1) from DMEMc to 3:1 (v/v) DMEMc:KSFMc medium and passage 
(p2); medium-change to 1:1 (v/v) DMEMc:KSFMc followed by passage (p3); medium change 
to 1:3 (v/v) DMEMc:KSFMc and passage in this medium (p4), medium-change to 1:9 (v/v) 
DMEMc:KSFMc (p4) and passage (p5); final medium-change to KSFMc and subsequent 
passage (p6). After this, HaCaT cells had fully adapted to the new culture medium and were 
named HaCaTa. Adapted HaCaT (HaCaTa) cells (see below) were cultured in the same 
medium as NHEK cells. For all experiments, HaCaTa cells were used at passages 9–15 to 
ensure maximal proliferative capacity. 
2.4.4 Cell maintenance  
For all experiments, NHEK and HHFK cells were used at passages 1–3 to ensure 
maximal proliferative capacity. All cells were routinely cultured at 37°C in a humidified 
atmosphere of 5% CO2, whereas for cooling experiments the temperature was altered as 
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indicated. Cells were passaged at approximately 80–90% confluence by removing media, 
washing with 0.1% (w/v) EDTA in phosphate buffered saline PBS (without Ca2+ and Mg2+) 
(Invitrogen Cat # 14200-067) to aid disaggregation; this was carried out for 15 min for HaCaT 
cells and for 2 min for HaCaTa, HHFK, and NHEK cell lines. Cells were lifted using trypsin–
EDTA solution (Sigma Cat # T41474-20mL) in Ca2+ and Mg2+ free Hanks-balanced salt 
solution (HBSS, Sigma Cat # H9394-6X500ML) until cells detached from the culture flasks. 
In the case of NHEK, HHFK and HaCaTa cells the trypsin was inactivated using trypsin 
inhibitor (Sigma Aldrich Cat #T6522-100MG) then cells were centrifuged at 1200 rpm for 5 
min. The supernatant was aspirated, and the cells gently resuspended in fresh medium. For 
routine maintenance and experiments, NHEK and HHFK cells were cultured in Primaria™ 
(Scientific Laboratory Supplies) or Cell Plus (Sarstedt) plasticware, whereas original and 
adapted HaCaT cells were maintained in standard plasticware (Sarstedt).  
2.4.5 Cryo-preservation and recovery of cell lines 
Cells were cryo-preserved and kept in liquid nitrogen in a Statebourne storage dewar 
at -196°C. For cryopreservation of cell lines, cultures were collected as for passaging (as 
explained in section 2.4.4) and collected by centrifugation. The cell pellet was re-suspended 
in the appropriate ice-cold growth medium supplemented with 10% (v/v) FBS and 10% (v/v) 
dimethylsulphoxide (DMSO) at a cell density not less than 1x106 cells/mL. Cells were 
aliquoted in a total of 1-1.5mL into polypropylene cryovials (Sarstedt) and then transferred to 
an ice-cold Nalgene ―Mr Frosty‖ (Fisher) containing 250mL of isopropanol (Fisher) to control 
the cooling rate to 1°C per minute. Cells were then placed within a -80°C freezer for 4-6h 
prior to transfer to liquid nitrogen. Cells were recovered by thawing rapidly at 37°C, before 5-
10mL of pre-warmed growth medium was added. Cells were centrifuged at 1500 rpm for 5 
min; after that the media aspirated and fresh media were added then incubated at 37°C in a 
5% CO2 humidified atmosphere.  
2.5 Assessment of cell growth  
The effect of chemotherapy drugs on keratinocyte cell growth and viability was 
determined by measuring cell biomass (the mass of living biological organisms in a specific 
area at a given time (Gold et al., 1997)). Cell biomass was measured using the CellTiter 96® 
AQueous One cell proliferation assay (Promega Cat # G3580) and following the 
manufacturer‘s instructions. The CellTiter 96® AQueous One Solution Cell Proliferation 
assay involves the use of the MTS tetrazolium (yellow) which is reduced to a formazan 
derivative (brown colour) by respiring cells (Figure 2-1). The observed change in color is 
proportional to the total number of viable/proliferating cells. Keratinocytes cells lines (HaCaT, 
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HaCaTa, HHFK and NHK) were seeded into 96 well plates in 6 replicate wells for each 
condition and then left to adhere overnight before the addition of culture medium containing 
chemotherapy drugs, with or without pharmacological agonists or inhibitors. Following 
treatment of cells as described above, 20 µL of reagent (CellTiter reagent) was added to 
each well and plates were incubated at 37°C in 5% CO2 conditions for 4h. Total levels of 
formazan formation, which corresponds to relative cell biomass, was assessed using a 
FLUOstar OPTIMA (BMG Labtech) plate reader at a wavelength of 492 nm following 
background subtraction. Percentage (%) cell biomass was calculated using the formula: (Abs 
T/Abs C) x 100, where ‗Abs T‘ is absorbance value for drug-treated cells and ‗Abs C‘ 
corresponds to the absorbance value for controls cultures.  
 
 
Figure ‎2-1 The structure of MTS tetrazolium and its reaction product 
This assay is a colorimetric method containing only one solution reagent. The tetrazolium 
compound includes 3-(4,5-dimethythiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyle)-2H-tetrazolium, inner salt: MTS and also contains phenazine ethosufate (PES), 
which uses as an electron coupling reagent that can bind with MTS to form a constant 
solution. This reagent can be reduced by cells into coloured product, which is soluble in the 
medium, which is known as formazan. The amount of formazan produced is 
directly proportional to the number of living/viable cells. 
 
2.6 Observation of cell viability by microscopy  
In addition to CellTiter assays, cell viability was also routinely monitored by phase 
contrast microscopy. In particular, HaCaTa cells were seeded at 5 x 103 cells per well in 96-
well tissue culture plates, whilst HaCaTa cells were seeded in 10 cm tissue culture dishes at 
9 x105 cells per dish. Test cultures were treated at 37°C or 22°C, 18°C and 14°C with the 
indicated drug concentrations alongside negative controls (as described above) and cells 
were incubated at 37°C for the indicated time period observed at 100x and 200x 
magnification.  
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2.7 Assessment of the role of temperature conditions on 
chemotherapy-mediated cytotoxicity  
Keratinocytes were seeded into 96-well tissue culture plates at a density of 5 x 103 
(HaCaT and HaCaTa) or 7.5 x 103 (NHEK and HHFK) cells per well – optimal density for 
each cell type was determined by pre-titration experiments – and incubated for 24h at 37°C. 
For individual drugs treatment experiments, cells were subjected to a range of concentrations 
of docetaxel (Sigma Cat # 01885-5MG-F), doxorubicin (Sigma Cat # D1515-10MG) and 4-
hydroxycyclophosphamide (4-OH-CP), the active metabolite of cyclophosphamide (supplied 
by Niomech, Germany) and 5- fluorouracil (5-FU) (Sigma Cat # F6627-1G), for a period of 2h 
at 37°C (control conditions) or under cooling conditions (22°C, 18°C or 14°C) in the 
appropriate culture medium and as detailed in the Results. Solvent (DMSO) controls 
(representing the maximal amount of DMSO that corresponded to the highest drug 
concentration) were included in all experiments. Following treatment, drugs were removed; 
cells washed twice using PBS by careful aspiration and fresh culture medium added. 
Cultures were then incubated at 37°C for 72h before cell growth was assessed (below). For 
combinatorial TAC, ACT and FAC therapy experiments, sequential treatment with docetaxel 
(T), doxorubicin (A) and 4-OH-CP the active metabolite of cyclophosphamide (C) and 5- 
fluorouracil (F) was carried out, with the exact concentration of each drug being dependent 
on the cell type (as explained in the main text). In particular:  
2.7.1 (A) NHEK cells challenged with the following three TAC regimes: 
(a) Docetaxel 0.05 µg/mL (2h), doxorubicin 3 g/mL (1h), and 4-OH-CP 25 µg/mL (1h), termed 
‗TAC‘. 
(b) Docetaxel 0.05 µg/mL (2h), doxorubicin 3 µg/mL plus docetaxel 0.005 µg/mL (1h), 4-OH-
CP 25 µg/mL plus doxorubicin 0.3 µg/mL (1h), termed ‗TAC (+10%)‘. 
(c) Docetaxel 0.05 µg/mL (2h), doxorubicin 3 µg/mL plus docetaxel 0.05 µg/mL (1h), 4-OH-
CP 25 µg/mL plus doxorubicin 3 µg/mL (1h), termed ‗TAC (+100%)‘. 
2.7.2 (B) HaCaTa cells challenged with the following three TAC regimes: 
(a) Docetaxel 0.01 µg/mL (2h), doxorubicin 0.3 µg/mL (1h), and 4-OH-CP 5 µg/mL (1h), 
termed ‗TAC‘. 
(b) Docetaxel 0.01 µg/mL (2h), doxorubicin 0.3 µg/mL plus docetaxel 0.001 µg/mL (1h), 4-
OH-CP 5 µg/mL plus doxorubicin 0.03 µg/mL (1h), termed ‗TAC (+10%)‘.  
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 (c) Docetaxel 0.01 µg/mL (2h), doxorubicin 0.3 µg/mL plus docetaxel 0.01 µg/mL (1h), 4-
OH-CP 5 µg/mL plus doxorubicin 0.3 µg/mL (1h), termed ‗TAC (+100%)‘. 
(d) Docetaxel 0.01 µg/mL (1.5h), doxorubicin 0.3 µg/mL plus docetaxel 0.01 µg/mL (1.5h), 4-
OH-CP 5 µg/mL plus doxorubicin 0.3 µg/mL (1.5h), termed ‗TAC (+10% incubation time for 
each drug 1.5h)‘. 
2.7.3 (C) HaCaTa cells challenged with the following three ACT regimes: 
 (a) Doxorubicin 0.3 µg/mL (1.5h), 4-OH-CP 5 µg/mL plus doxorubicin 0.03 µg/mL (1.5h), 
docetaxel 0.01 µg/mL (1.5h) plus 4-OH-CP 0.5 µg/mL termed ‗ACT (+10% with 1.5h 
incubation time) ‘.  
(b) Doxorubicin 0.3 µg/mL (1h), 4-OH-CP 5 µg/mL plus doxorubicin 0.03 µg/mL (1h), 
docetaxel 0.01 µg/mL (2h) plus 4-OH-CP 0.5 µg/mL termed ‗ACT (+10% with 1.5h incubation 
time) ‘. 
2.7.4 (D) HaCaTa cells challenged with the following three FAC regimes: 
(b) 5FU 25 µg/mL (1.5h), doxorubicin 0.3 µg/mL plus 5FU 2.5 g/mL (1.5h), 4-OH-CP 5 µg/mL 
plus doxorubicin 0.03 µg/mL (1h), termed ‗FAC (+10%)‘. 
Cells were then washed and medium was replaced as described above, before cell growth 
was assessed 72h later. 
2.8 Functional inhibition experiments 
For functional inhibition experiments involving biological (NOK-1) or pharmacological 
(NAC, Pifithrin-α hydrobromide and PD153035 (Epidermal Growth Factor Receptor (EGFR)) 
antagonists, the appropriate concentration of inhibitor was added to culture for the indicated 
period of time before cytotoxic drug treatment. The inhibitor was then removed, and drug 
added as a 2x concentration with 2x concentration of inhibitor. Cells were incubated either for 
2h or for 72h with this drug-inhibitor combination, after which time cell viability was 
determined using the CellTiter assay. 
2.9 Supplement starvation 
Cells were seeded at a density of 9x105 in petri dishes one day prior to treatment. 
Cells were carefully washed with sterile PBS three times and then incubated in KSFM media 
without supplements for 24h, after which time cells were treated with cytotoxic drugs for 2h. 
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After that, the cells were washed and incubated with fresh medium, then CellTiter and cell 
cycle analysis experiments were performed. 
2.10 Detection of cell growth, death (apoptosis) and reactive oxygen 
species (ROS) production  
2.10.1 General 
Previously published guidelines regarding the use and interpretation of assays for 
monitoring cell death (Galluzzi et al., 2009) have recommended that a minimum of two 
assays are utilised for the detection of cell apoptosis. The current research made use of a 
cell proliferation assay (MTS CellTiter) in addition to three apoptosis detection-specific 
assays; (a) CytoTox-Glo, (b) Anaspec Caspase-3/7 and (c) DNA fragmentation.  
These assays were based on measurement of absorbance, fluorescence, or 
luminescence. 96-well Nunc white, tissue culture treated plates (Fisher Cat # TKT-186-010C) 
were used for luminescence-(CytoTox-Glo) and fluorescence (Anaspec Caspase-3/7)-based 
assays, 96-well Costar transparent tissue treated culture plates (Fisher Cat # TKT-186-010C) 
for absorbance (CellTiter), and 96-well ELISA microplates (Greiner bio one Cat # 655101) for 
ELISA (DNA fragmentation).  
2.10.2  Detection of cell death using the CytoTox-Glo™ assay 
The CytoTox-Glo assay is based on detection of the activity of a proprietary, specific 
protease normally present inside cells. During apoptosis, as the cell membrane is 
compromised the protease is released and it cleaves the AAF-Glo™ substrate, thus 
generating a luminescence signal (Figure 2-2). The intensity of the luminescence signal 
indicates the degree of apoptotic cells in a population. Before the experiment, all reagents 
were thawed at room temperature and all components mixed to ensure homogeneity. The 
CytoTox-GloTM cytotoxicity reagent was prepared by transferring the contents of one bottle 
of assay buffer to the AAF-GloTM substrate bottle, and then mixed to ensure homogeneity.  
Cells were treated with 4-OH-CP, doxorubicin, and docetaxel as described (in section 
2.7) and after 2h cells were washed and fresh drug- free medium were added and then cells 
were incubated for 24h and 48h, before 50 µL CytoTox-Glo substrate were added. 
Luminescence was detected using a FLUOstar OPTIMA (BMG Labtech) plate reader, 
following calibration of the reader using the Gain function on the MARS software to ensure 
the measurements were taken within the dynamic range of the instrument. The plates were 
kept away from light and left at RT for 15 min before measurements were taken. Data was 
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acquired using MARS software (BMG Labtech) and analysed by Microsoft Excel. To 
calculate percentage cell death the equation used was (treated cells RLU / control RLU), 
where RLU indicates relative luminescence units. 
 
Figure ‎2-2 The principle of the CytoTox-GloTM assay 
The first cleavage of luminogenic AAF-GloTM substrate occurs by dead-cell protease activity 
and the second cleavage, and a substrate for luciferase (aminoluciferin) is released resulting 
in the luciferase-mediated production of light. 
 
 
2.10.3  Detection of apoptosis using caspase-3/7 assays 
The activation of caspases-3/7 is a well-established feature of cell apoptosis. 
caspases-3 and -7 target a specific amino acid sequence located on many proteins, which 
leads to overall cell demise by an organised apoptotic event. The activation of caspases-3/7 
was determined using the SensoLyte® Homogenous AFC caspase-3/-7 substrate (Anaspec 
Cat # 71114, supplied by Cambridge Bioscience). The assay utilises the cleavage of the 
recognition sequence of caspase-3/-7 that is Asp-Glu-Val-Asp (DEVD). The SensoLyte® 
Homogeneous AFC Capase-3/7 assay kit uses Ac-DEVD-AFC as the fluorogenic indicator 
for assaying caspase-3/7 activity. Upon caspase-3/7-mediated cleavage, Ac-DEVD-AFC 
generates the AFC fluorophore, which has bright blue fluorescence and can be detected at 
Excitation / Emission = 380nm/500nm. The degree of production of the strongly fluorescent 
fluorophore is relative to total levels of caspase-3/7 activation as shown in Figure 2-3.  
Cells were treated with 4-OH-CP, doxorubicin and docetaxel in 96-well plates as 
described (in section 2.7) before the addition of 50 µL SensoLyte® Homogenous AFC 
caspase-3/7 substrate. Fluorescence was measured using a FLUOstar OPTIMA (BMG 
Labtech) plate reader using Excitation/Emission 355nm/520nm filters, following calibration of 
the reader using the Gain function on the MARS software to ensure the measurements were 
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taken within the dynamic range of the instrument. The plates were kept away from light and 
left at room temperature (RT) overnight after which fluorescence measurements were taken. 
To account for the activity of caspase-3/7 after treating with chemotherapeutic drugs, the cell 
these were cultured alone (without treatment) and their relative fluorescent units (RFU) 
subtracted from the treated cells (as explained in section 2.7).  
 
Figure ‎2-3 proteolytic cleavage of Ac-DEVD-AFC substrate 
The amount of fluorescent product generated is proportional to the amount of caspase-3/7 
cleavage activity present in the sample. Cleavage of the weakly fluorescent caspase-3/7 Ac-
DEVD-aminoluciferin substrate Z-DEVD by caspase-3/7 to create the strongly fluorescent 
compound.  
 
2.10.4  Detection of apoptosis using the DNA fragmentation ELISA 
The fragmentation of DNA is often a hallmark of apoptosis and the DNA 
fragmentation ELISA assay uses 5-bromo-2'-deoxyuridine (BrdU) specific antibodies to 
detect BrdU-labelled fragments of DNA. Greater amounts of fragmented DNA labelled with 
BrdU represent a greater number of cells that have undergone apoptosis (the principle of the 
assay is schematically illustrated in Figure 2-4.  
Exponentially growing cells were loaded with the DNA labelling agent BrdU for 2h at a 
concentration of 10 µM according to the manufacturer‘s instructions. Cells were then seeded 
in 96-well plates and incubated overnight. Then the cells were treated with 7.5 µg/mL 4-OH-
CP, 0.5 µg/mL doxorubicin, 0.05 µg/mL docetaxel and 5 µM staurosporine as positive control 
as described (in section 2.7) and then cells were incubated for 24 and 48h. An ELISA plate 
(96 well flat bottom MTP) (Fisher Scientific Cat # E951040308 ) was coated with an anti-DNA 
antibody and then blocked to remove any non-specific binding sites. After washing of the 
ELISA plate to remove any blocking buffer, supernatants from cell cultures were added; 
these may contain DNA fragments pulsed with BrdU. The labelled fragments of DNA stick to 
the plate via the anti-DNA antibody and then a secondary, enzyme-linked antibody that 
specifically recognises BrdU was added. Finally, an enzyme TMB substrate was added 
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which is converted into a blue colour by the secondary, enzyme-linked antibody. The 
increased amount of colour change is relative to the amount of secondary antibody bound to 
BrdU labelled fragments of DNA. TMB substrate (High Sensitive) detects horseradish 
peroxidase (HRP) activity when TMB substrate is reacted with peroxidase, a soluble blue 
reaction product is obtained. Dilute sulphuric acid (H2SO4) was used to stop the reaction after 
sufficient colour change, and following this, a deep yellow colour represented the degree of 
cell apoptosis. The plates were used to measure absorbance using a 455-10nm filter on a 
FLUOstar OPTIMA (BMG Labtech) plate reader. Data was acquired using MARS software 
and analysed by Microsoft Excel. Staurosporine-treated cells were used as positive control (5 
µM). 
Fold of DNA fragmentation = Treated cells / control (staurosporine) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2-4 Principle of DNA fragmentation assay 
Microtiter plate was coated with anti-DNA antibody. Brdu-labelled fragments of DNA from 
supernatants were fixed by denaturing using a microwave (500watt for 5 min). This was 
followed by a secondary antibody labelling (anti-BrdU-Fab). The plate was incubated 90 min 
at room temperature and substrate was added. Following yellow colour formation, sulphuric 
acid was added to stop the reaction. 
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2.11 SDS-PAGE and Immunoblotting (Western Blotting) 
2.11.1 General  
Western blotting is a powerful technique widely used in different fields in biological research 
to detect specific proteins in whole cell lysates. Under denaturing conditions, proteins are 
size-fractionated using SDS-PAGE, a form of gel electrophoresis.  
SDS-PAGE separation was performed under denaturing conditions due to the addition of 
SDS (sodium dodecyl sulfate). SDS is a strong detergent having a long hydrophobic 
hydrocarbon tail and a negatively charged end. By binding to proteins, SDS prevents protein 
folding and imparts a net negative charge, so all proteins migrate towards the anode. This 
means that only the molecular weight of the protein is the factor of separation. Proteins 
separated by this method are then transferred onto a membrane, which has high protein 
binding affinity. Stably bound to a membrane, size fractionated and denatured proteins are 
detected using epitope specific primary antibodies. A near-infrared (NR) fluorophore 
conjugated secondary antibody raised against the primary antibody is then added to the 
membrane and the membrane is scanned using an infrared scanner. 
2.11.2  Protein extraction  
Cells treated with chemotherapeutic drugs and non-treated (control) cells were grown 
in 10cm2 culture dishes and lysed in situ. Culture medium was aspirated and cell sheets were 
washed 2x in ice-cold PBS to remove any excess proteins. 20 µL of ice-cold 2x sodium 
dodecyl sulphate (SDS) buffer (Appendix III) containing 2 mg/mL DTT and 0.2% (v/v) 
protease inhibitor cocktail set 3 (Calbiochem) was pipetted onto the cell monolayer and the 
cells were scraped using a cell scraper (Fisher Cat # FB55199) into a lysate. The solution 
was then transferred to a chilled micro-centrifuge tube kept on ice. Samples were sonicated 
using an ultrasonic probe (Sonics Vibra cell) for 10-second bursts (until the lysate showed 
froth like consistency) and it was then cooled on ice for 30 min. The lysates were centrifuged 
at 12,000-14000g at 4°C for 30 min to pellet the insoluble material, before aliquoting the 
supernatant and storing at -20°C.  
2.11.3  Protein Quantification 
The protein concentration of each sample was determined using a Coomassie protein 
reagent assay kit (Pierce Cat # PN23236). Samples were diluted 4:46 in dH2O and 10 µL 
was aliquoted in quadruplicates into a transparent 96-well flat bottomed plate. A seven point 
standard curve of 0-1 mg/mL (0, 25, 125, 250, 500, 750 1000 µg/mL) BSA (Cat # PN23208) 
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was included on each plate. 200 µL of ambient temperature coomassie reagent was added 
to each well and mixed gently by pipetting. The absorbance was then measured using a 
FLUOstar OPTIMA (BMG Labtech) plate reader at Abs 595 nm against a dH2O control. 
MARS analysis software 2.0 (BMG Labtech) was used to plot a standard curve for the BSA 
and to estimate the protein concentration for each lysate (Appendix III).  
2.11.4  SDS-Polyacrylamide gel Electrophoresis (SDS-PAGE) 
20 µg of protein lysate was made up to 13 µL with dH2O then this was totalled to 20 
µL by the addition of 5 µL 4x lithium dodecyl sulphate sample buffer (LDS; Invitrogen Cat # 
NP0007) and 2 µL of 10x reducing agent (500 mM Dithiothreitol) (Invitrogen Cat#NP0009). 
The sample was denatured by heating for 10 min in a 70°C water bath. 10-well NuPAGETM 
Novex electrophoresis pre-cast gels (Invitrogen Cat # NP0321) were placed into an Xcell 
SurelockTM mini-cell upright electrophoresis tank (Invitrogen). 200mL and 600mL of 1x 
NuPAGETM MES SDS running buffer (Invitrogen Cat # NP0002) was poured into the inner 
and outer chambers, respectively. 200 µL of NuPAGETM antioxidant (Invitrogen Cat # 
NP0005) was added to the inner chamber prior to loading of the samples. 5 µL of All-Blue 
Precision Plus ProteinTM standard (Bio-Rad Cat # 161-0373) was loaded alongside the 
samples as a marker of protein size (Figure 2-5) and gel was run at 200V for 35 min. 
 
 
 
 
Figure ‎2-5 Precision plus Protein standard 
All Blue standards are a mixture of ten blue-stained recombinant proteins (10–250 kDa), 
including three reference bands (25, 50, and 75 kDa). 
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2.11.5  Electrophoretic membrane transfer 
Electrophoretically-seperated proteins were transferred onto Immobilon-FLTM 
polyvinylidine difluoride membrane (PVDF; Millipore) using an Xcell IITM blot module 
(Invitrogen). PVDF membranes were dipped in methanol, rinsed in dH2O and then soaked in 
0.5x ―Towbin‖ transfer buffer with 20% (v/v) methanol along with the required number of 
blotting pads and WhatmanTM filter paper (Fisher). The gel membrane sandwich was 
assembled cathode to anode as follows; 2x blot pads, filter paper, gel, PVDF membrane, 
filter paper and 2x blot pads (Figure 2-6). The blot module was secured into the Xcell 
SureLockTM Mini-Cell and filled with transfer buffer. The outer chamber was filled with ice-
cold dH2O and the transfers were performed on ice at 25V for 2h.  
 
Figure ‎2-6 Single sandwich 
The diagram illustrates protein transfer during immunoblotting.  
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2.11.6  Membrane immunolabelling and visualisation using the Li-Cor Odyssey 
system 
To minimise non-specific binding, membranes were blocked in 50:50 (v/v) Odyssey 
blocking buffer (Li-Cor Cat # 927-4000): 10 mM TBS pH 7.6 at ambient temperature on a 
plate rocker for 1h. Membranes were then probed with 5-8mL of pre-titrated primary antibody 
diluted in TBS+0.1% (v/v) Tween-20. All primary antibody incubations were performed on a 
rocking platform overnight at 4°C. Membranes were then washed 3x for 5 min in TBS+0.1% 
(v/v) Tween-20 prior to addition of 10mL appropriate infra-red secondary antibodies (Table 2-
2) for 1h at ambient temperature on a rocker. Membranes were washed as for primary 
antibody and then washed 3x for 5 min with TBS prior to visualization using an OdysseyTM 
Infra-red Imaging system (Li-Cor). Densitometry was performed using Image Studio 4.0 
software and protein expression was normalised relative to -actin (housekeeping control 
protein).  
2.11.7  Membrane stripping and re-probing 
PVDF Membranes were incubated in 5mL of 1x western blot recycling reagent 
(Autogen Bioclear) for 20-30 min at ambient temperature on an orbital shaker. Membranes 
were then washed in TBS, re-blocked with 50:50 (v/v) Odyssey blocking buffer: TBS.  
2.11.8  Detection of Reactive oxygen species using H2DCFDA  
6-carboxy-2', 7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen Cat # 
c2938) is a cell permeable, chemically reduced, acetylated form of fluorescein used as an 
indicator for reactive oxygen species (ROS) in cells. This non-fluorescent molecule is readily 
converted into a green-fluorescent form when the acetate groups are removed by 
intracellular esterases and ROS-associated oxidation within the cell. As it is oxidation 
sensitive, H2DCFDA was reconstituted in oxygen-free conditions (in a nitrogen environment) 
before aliquoting and storage at -80°C, as recommended by the manufacturer (Figure 2-7). 
Cells were treated with chemotherapeutic drugs as described in section 2.7. 
Thereafter, cells were first washed with PBS to remove any culture medium and were then 
treated with 5 µM of H2DCFDA in pre-warmed (37°C) PBS for 30 min 37°C in 5% CO2. The 
reduced forms of the substrate lack any fluorescence until acetyl groups are removed by 
intracellular esterases and oxidation is occurring in the cell. When this occurs, the charge of 
the molecule makes much less likely to leave the cell and it emits detectable fluorescence. 
Following treatment with H2DCFDA for the indicated time periods, fluorescence was 
measured on a FLUOstar OPTIMA (BMG Labtech) plate reader at excitation 485 nm/ 
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emission 520 nm, following calibration of the reader using the gain function on the MARS 
software to ensure the measurements were taken within the dynamic range of the 
instrument.  
 
 
Figure ‎2-7 Conversion of non-fluorescent dye DCFH-DA in the fluorescent dye DCF by 
ROS 
http://www.cellbiolabs.com/reactive-oxygenspecies-ros-assay 
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2.12  Flow Cytometry  
2.12.1  Background  
Flow cytometry is used to analyse the chemical/physical characteristics of particles 
and cells, and has several applications, including quantification of specific cellular proteins 
and detection of dead or alive cells. The particles/cells are detected by movement at high 
speed by exposure to a laser beam, and a computer analyses their characteristics and 
properties.  
2.12.2  Detection of the mitochondrial membrane potential 
One of the early events in apoptosis is the depolarisation of electrochemical gradient 
of the inner mitochondrial membrane, providing a valuable indicator of the cells‘ health and 
functional status (Perelman et al., 2012). 
Mitochondrial membrane potential was measured using the MitoProbe™ JC-1 Assay 
Kit (Life Technologies Ltd. Cat # M34152). This assay contains 5', 6, 6'- tetrachloro-1, 1', 3, 
3'-tetraethyl-benzimidazolylcarbocyanine iodide (JC-1). JC-1 dye is a lipophilic dye that 
accumulates and is dependent on the mitochondrial membrane potential in the mitochondria. 
At a low membrane potential, mitochondria take up very little of the dye and the dye remains 
in its monomeric green fluorescent form. A high mitochondrial membrane potential leads to 
the accumulation of JC-1 and formation of so-called J-aggregates that emit red fluorescence 
(Smiley et al., 1991). The degree of mitochondrial depolarisation is determined by 
fluorescence measurements using flow cytometry (Figure 2-8). Differences in membrane 
potential are established by a shift in the fluorescence emission from green to red in 
depolarised mitochondria to polarised (Cossarizza et al., 1993; Smiley et al., 1991). The 
events can be visualised by flow cytometry using scatter diagrams ("dot plots"), where each 
cell appears as a point in a two-dimensional x / y diagram. Different cell populations can be 
detected depending on size (FSC) and granularity (SSC) and marking ("gating") can be 
employed. The state of the mitochondrial membrane potential was determined by staining 
keratinocyte cells with JC-1. The events in the green fluorescence channel (fluorescence of 
JC-1 monomers) were plotted on the x-axis against the red fluorescence channel (J-
aggregates) on the y-axis. Comparisons were made with non-treated cells (negative controls) 
and cells treated with carbonyl cyanide m-chlorophenyl hydrazine (CCCP) as a positive 
control (Bortoletto et al., 2004; Cossarizza et al., 1993). 
Cells were treated with chemotherapeutic drugs as in section 2.7. Following this, cells 
were stained with JC-1 according to the manufacturer‘s protocol and analysed using 
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subsequent flow cytometry. Cells were washed with EDTA for approximately 2 min and 
collected after incubation with 1x Trypsin-EDTA for approximately 3 min. Then cells were 
centrifuged at 1200 rpm for 5 min and resuspended in medium. Living-control cells were left 
untreated and damage-control cells were treated with 1 µL CCCP (included in the 
MitoProbe™ JC-1 Assay Kit) 5 min before staining to induce mitochondrial membrane 
depolarisation. Then 10 µL of JC-1 (of final concentration 2 μM) was added to medium. Cells 
were incubated at 37°C with 5% CO2 and 95% air for 30 min. JC-1 fluorescence at ~525 nm 
(JC-1 ―green‖) and ~590 nm (JC- 1 ―red‖ or ―J-aggregates‖) was determined for each sample. 
Cellular fluorescence was determined 12h, 24h, 36h and 48h after treatment by flow 
cytometry and for each sample, a minimum of 20,000 events was recorded. JC-1 fluoresces 
green when the mitochondrial potential is lost as they are depolarised in the dead cells. 
However, in living cells with intact mitochondria (mitochondrion is polarised) JC-1 is reduced 
and forms aggregates, which are detected by red fluorescence. Cells were acquired on an 
EasyCyte (Guava) flow cytometer and data were analysed by Cyte 26 Guava software 
(Millipore). 
 
 
 
Figure ‎2-8 Mechanism of action of the JC1 dye 
http://lcbim.epfl.ch/research 
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2.12.3  Detection of oxidative stress  
In addition to spectrophotometry (section 2.11.8), intracellular reactive oxygen 
species (ROS) were detected by H2DCFDA dichlorodihydrofluoresceine-diacetate 
(Invitrogen Cat # c2938) using flow cytometry. Cells were seeded and left to adhere 
overnight, after which, cells were treated with the target compound (4-OH-CP, doxorubicin 
and docetaxel) for 2h (as optimised). The culture medium was aspirated and cells washed 
twice with PBS at room temperature. 5 µM of H2DCF-DA (optimised by pre-tritration 
experiments) was diluted in PBS or Phenol Red-free/serum-free medium. Treatments were 
performed for no more than 30 min at 37°C. Then the PBS containing H2DCF-DA was 
aspirated and the samples were washed twice with PBS. Cells were then harvested using 
Trypsin/EDTA, centrifuged at 1200 rpm for 5 min, supernatants removed, the pellets washed 
once in 500 µL PBS, centrifuged and resuspended in cold PBS, then kept on ice until 
acquisition. Flow cytometry was performed in the green fluorescence channel. Data were 
collected from at least 10,000 cells per treatment/condition. Treated cells in which induction 
of ROS occurred demonstrated a shift to green fluorescence that was detected by flow 
cytometry.   
2.12.4  Cell cycle analysis by propidium iodide (PI) labelling  
In culture, cells are asynchronous populations, i.e. a mixed population of cells in all 
four distinct cell cycle phases G0/G1, S, G2 and M phases. Cell cycle analysis is used to 
determine the relative cellular DNA content, which enables discrimination between the 
different phases of the cell cycle. Cell cycle measurement and distribution were performed by 
flow cytometry using propidium iodide (PI) (Sigma Cat # P4170), which is an intercalating 
agent and a fluorescent molecule that can be used to stain DNA. PI binds to DNA by 
intercalating between the bases, forming complexes with double stranded DNA and RNA. 
RNAse is used in cell cycle analysis to ensure that the PI staining is DNA-specific.  
Cells were treated with chemotherapeutic drugs as in section 2.7 and incubated for 
the indicated periods. Cells were harvested and thoroughly resuspended in solution 
(ensuring single cell suspension), and cells were washed twice in ice-cold PBS. The pellet 
was resuspended by the addition of ice-cold 70% ethanol, and then the samples were 
incubated for 1.5h on ice or overnight at 4°C (at this stage samples could be kept at 4°C for 
~1 week). Then the fixed cells were centrifuged at 1500 rpm for 5 min at 4°C. The ethanol 
was aspirated and the cells pellet were washed with PBS and centrifuged at 1500 rpm for 5 
min at 4°C. The residual PBS was removed and the cell pellet was resuspended gently in 
200 µg/mL PBS containing RNase (Sigma Cat # R4875). Following this, 20 µg/mL of PI in 
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PBS was added and incubated for 30 min at 37°C. The samples were analysed by flow 
cytometry to determine PI (red staining) in the FL2 (yellow) channel. In total, three 
independent experiments were conducted. Guava cell cycle analysis software was used 
following sample acquisition on a Guava easyCyteTM system (Millipore) (Figure 2-9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2-9 Change in the cell cycle were determined by PI staining 
 
 
 
2.13 Statistical analysis 
Data analysis was carried out using Excel® (Microsoft) and most results presented as 
the mean of all replicates (minimum 5-6), with error bars representing ± the standard error of 
mean (S.E.M.). Statistical analysis was performed using Minitab 16 statistical software. Two 
tailed, paired, or unpaired t-tests were used to compare two sample means with levels of 
significance cited in the text. Comparisons were assumed to be biologically significant where 
*, p < 0.05. 
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3 CHAPTER 3: Effect of cancer chemotherapy drugs on 
the viability of human keratinocyte cell lines and the 
effect of cooling on drug-mediated cytotoxicity 
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3.1 Background  
Chemotherapy-induced alopecia (CIA) is the most common and distressing side 
effect of anticancer chemotherapy (Wang et al., 2006) and the anxiety caused by the 
prospect of CIA can cause patients to even refuse treatment in certain cases (Münstedt et 
al., 1997). Thus development of an effective CIA preventative regime represents an 
important challenge in oncology (Paus et al., 2013). CIA occurs due to damage to the HFs, 
which comprise various cell types including hair matrix keratinocytes, which represent the 
most rapidly dividing HF cell subset that contributes to HF structure and function and in 
particular hair generation (Roh et al., 2005). As chemotherapeutic drugs such as taxanes 
(e.g. docetaxel), alkylating agents (e.g. cyclophosphamide) and anthracyclines/DNA 
intercalating agents (e.g. doxorubicin) target cancer cells due to their rapid division rate, 
these drugs also target the matrix keratinocytes and induce their apoptosis, which results in 
hair loss (Paus et al., 2013).  
Currently the only available preventative treatment for CIA is head (scalp) cooling. 
Scalp cooling (or scalp hypothermia) during the administration of chemotherapy drugs can 
substantially reduce hair loss (Protiere et al., 2002) and has been used since the 1970s 
(Dean, 1979). Clinically it has been shown that scalp cooling can substantially reduce the 
incidence of hair loss in response to individual drugs, including cyclophosphamide, 
doxorubicin and cisplatin (Breed et al., 2011; Van Den Hurk et al., 2012c). However, for 
combined treatment regimes, such as sequential treatment with docetaxel (taxotere), 
doxorubicin (adriamycin) and cyclophosphamide (clinically also referred to as TAC), scalp 
cooling has limited reported efficacy (Grevelman and Breed, 2005). Despite the fact that 
scalp cooling can be effective, its overall mechanism of action is not fully understood. 
In order to improve the efficacy of scalp cooling, particularly in the case of 
combinatorial drug treatments that do not respond well to cooling (such as TAC), it is 
necessary to achieve a better understanding of the cellular mechanisms that underlie drug-
induced cytotoxicity and study the effects of cooling in this context. Several experimental in 
vivo models have been used to help understand CIA; however, rodent-based models 
demonstrate inherent physiological and practical limitations (Paus et al., 2013). Ex vivo 
models, such as those established by Paus and colleagues that are based on isolation and 
culture of human HFs, represent an elegant model for studying cyclophosphamide-induced 
CIA (Bodo et al., 2007). A more reductive model to study chemotherapy drug-induced 
cytotoxicity involves the use of human neonatal epidermal keratinocytes cultured in vitro and 
a previous report has provided some, though limited, evidence for an effect of culture 
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temperature on the cytotoxicity of doxorubicin on such cells (Janssen et al., 2008). The 
principle behind the use of human epidermal keratinocytes is that they are maintained under 
culture conditions that render them highly proliferative, thus resembling (in terms of growth 
characteristics) the rapidly dividing population of native matrix keratinocytes. However, 
because of the finite nature of such primary cultures, the well-characterised cell line HaCaT, 
that shows similar characteristics and cell behaviour to normal keratinocytes ((Deyrieux and 
Wilson, 2007); and references therein), has also been used to study drug-induced 
cytotoxicity (Luanpitpong et al., 2011). 
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3.2 Chapter Aims  
 Establish biological models that will allow the study of chemotherapy drug-induced 
cytotoxicity in vitro. The in vitro models established included: a) normal human 
epidermal keratinocytes (NHEK), b) human hair follicular keratinocytes (HHFK), c) the 
keratinocyte cell line HaCaT and d) HaCaT derivatives that were gradually adapted to 
culture conditions identical to those for NHEK cells (serum-free and low-calcium 
medium). 
 Examine the cytotoxicity of a panel of commonly used chemotherapeutic modalities 
and the effect of temperature on cytotoxicity  
 Perform systematic investigations on the optimal culture temperature (cooling 
conditions), which achieve optimal rescue from drug induced cytotoxicity after 
administration of a panel of chemotherapeutic agents. 
 Examine the cytotoxicity and ability of cooling to cytoprotect for combinations of 
chemotherapy drugs (such as TAC, TCA, FAC, and AC). 
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3.3 The effect of chemotherapy drugs on normal human epidermal 
keratinocyte viability and the role of cooling on drug-mediated 
cytotoxicity 
A single, and very limited, study has previously addressed the effect of chemotherapy 
drugs on normal human epidermal keratinocytes (NHEKs) and examined the effect of cooling 
conditions on doxorubicin-mediated cytotoxicity on NHEKs (Janssen et al., 2008). NHEK 
cells were cultured in low calcium (0.09 mM) serum-free medium, under conditions where 
they adopt a highly-proliferative basal, non-differentiated phenotype. In this work for the first 
time the cytotoxic effect of a panel of three routinely used cancer chemotherapy drugs were 
assessed (Grevelman and Breed, 2005), in particular the taxane docetaxel, the anthracycline 
doxorubicin and the alkylating agent cyclophosphamide, all of which are associated with CIA. 
Because in vivo cyclophosphamide requires enzymatic conversion to its active form 4-
hydroxy-cyclophosphamide (4-OH-CP), was used in our study and as previously described 
elsewhere (Bodo et al., 2007). 
The effect of each of these drugs over a wide range of concentrations at standard 
culture temperature 37°C and, to mimic cooling conditions, at 22°C was examined. This was 
primarily because it has been suggested by various studies that a scalp temperature of 22°C 
or less is required for hair preservation (Komen et al., 2013a) and also it was the temperature 
previously tested in vitro by Janssen et al. (2008). As shown in Figure ‎3-1, all three drugs 
caused increasing cytotoxicity (indicated by loss of viability) in NHEKs in a dose-dependent 
fashion, although in the case of docetaxel the maximum relative loss of cell biomass was 
~75%. Also the results confirmed that the decrease in biomass was the result of active 
induction of cell death (apoptosis) using apoptosis detection assays (not shown). 
Interestingly, and despite the fact that these drugs act via different molecular mechanisms, 
cooling dramatically rescued cells from cytotoxicity for all three compounds (Figure ‎3-1, 
upper panels), with the observation for doxorubicin being in agreement with previous studies 
(Janssen et al., 2008). The ability of cooling to protect from cytotoxicity was striking for 
several, mid-range drug concentrations, particularly for doxorubicin and 4-OH-CP; in fact for 
some drug doses cell biomass returned from below 20% to nearly 100% of the control value 
(Figure ‎3-1, lower panel). 
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Figure ‎3-1 Cytoprotective role of cooling against chemotherapy drug-mediated toxicity 
in NHEK cells 
NHEK cells (passages 1–3) were seeded in 96 well plates at 7500 cells/well in KSFM 
medium and were incubated overnight at 37°C/5% CO2. NHEK cells were treated for 2h with 
a range of concentrations of doxorubicin, 4-OH-CP, and docetaxel at 37°C and 22°C 
(representing normal and cooling conditions, respectively) compared with vehicle control 
(cells treated with medium containing DMSO, in which the reagent was dissolved. The 
solvent represents the maximum amount of DMSO corresponding to the highest drug 
concentration). The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, and after which 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Representative results from the dose response curves (upper panels) are also 
shown in bar graph form (lower panels) for clarity and presentation of statistical significance. 
Data points correspond to mean % cell biomass (±S.E.M.) for three independent biological 
experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p < 0.05; ***, 
p < 0.001. 
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3.4 The cytotoxicity of chemotherapy drugs on human hair 
follicular keratinocytes and the effect of cooling on drug-
mediated effects 
A potential weakness of our approach of using ‗generic‘ keratinocytes of epidermal 
origin is that such cells, despite their ability to grow as a basal, highly-proliferative cell 
population (thus mimicking in terms of their growth characteristics the rapidly-dividing 
population of native matrix keratinocytes), they are not specifically isolated from the HF area. 
To circumvent this limitation, we used the only Human Hair Follicular Keratinocyte (HHFK) 
cultures currently commercially available (see Materials and Methods section 2.7). Upon 
routine culture and observation, HHFK cells showed virtually identical morphological and 
growth properties to NHEK cells (not shown). When the effects of doxorubicin and 4-OH-CP 
were tested, as with keratinocytes of epidermal origin. The data showed that both drugs 
caused a dose-dependent cytotoxicity in HHFKs and cooling dramatically rescued HHFK 
cells from this significantly (Figure ‎3-2), the response of cells under cooling conditions was 
strikingly similar to that observed for NHEK cells for these drugs (Figure ‎3-1). Therefore, 
these experiments confirmed the validity of our approach of using NHEK cells as a 
representative keratinocyte in vitro model. 
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Figure ‎3-2 Cytoprotective role of cooling against chemotherapy drug-mediated toxicity 
in HHFK cells 
HHFK cells (passages 1–3) were seeded in 96 well plates at 7500 cells/well in KSFM 
medium and were incubated overnight at 37°C/5% CO2. HHFK cells were treated for 2h with 
a range of concentrations of doxorubicin and 4-OH-CP at 37°C and 22°C (representing 
normal and cooling conditions, respectively) compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution 
was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods (Chapter 2). Representative 
results from the dose response curves (upper panels) are also shown in bar graph form 
(lower panels) for clarity and presentation of statistical significance. Data points correspond 
to mean % cell biomass (±S.E.M.) for three independent biological experiments, each 
consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001. 
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3.5 The effect of the combinatorial chemotherapy treatment TAC on 
normal human keratinocyte growth and the role of cooling 
Having shown that cooling can protect keratinocytes from cytotoxicity caused by 
docetaxel, and particularly doxorubicin and cyclophosphamide, the combinatorial drug 
therapy TAC in this context was investigated. Clinical data demonstrate that, although scalp 
cooling provides good protection from CIA caused by these drugs when applied as 
monotherapies in the clinic (an observation mirrored by our in vitro findings), scalp cooling is 
less effective for patients undergoing the combinatorial use of these drugs, i.e. TAC therapy 
(Grevelman and Breed, 2005; Van Den Hurk et al., 2012c). 
 To test for the first time in vitro the potential cytotoxic effect of the TAC regimen and 
assess the influence of cooling, cells were treated with docetaxel (T), doxorubicin (A) and 4-
OH-CP (C) as detailed in Materials and Methods section 2.7.1. One approach (‗TAC‘) 
involved sequential treatment with the individual drugs at doses for which significant or 
maximal in vitro rescue was achieved by cooling when each drug was tested separately 
(Figure ‎3-1). In an attempt to simulate drug exposure in vivo (as during TAC therapy infusion 
not all the previous drug would be expected to be cleared systemically by the time the 
subsequent drug is infused), two modifications of this protocol were also employed (as 
outlined in detail in section 2.7.1). Specifically, following initial treatment (T), cells were 
exposed to each subsequent drug (A and C) whilst being also supplemented with 10% 
(denoted ‗TAC (+10%)‘) or 100% (denoted ‗TAC (+100%)‘) of the previous drug. As shown in 
Figure ‎3-3, combinatorial treatment at 37°C resulted in nearly complete loss of NHEK 
biomass for all three TAC protocols. Notably, upon cooling (22°C), although substantial (in 
some cases 100%) rescue was previously observed for individual drug treatments 
(Figure ‎3-1), only a modest degree of cytoprotection was observed following the ‗TAC‘ and 
‗TAC (+10%)‘ treatments. By contrast, cooling provided little detectable rescue from the 
extensive cytotoxicity observed following ‗TAC (+100%)‘ treatment (Figure ‎3-3). 
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Figure ‎3-3 Effect of cooling on TAC-mediated cytotoxicity in NHEK cells 
NHEK cells (passages 1–3) were seeded in 96 well plates at 7500 cells/well in KSFM 
medium and were incubated overnight at 37°C/5% CO2. NHEK cells were treated with the 
combinatorial drug protocols ‗TAC‘, ‗TAC (+10%)‘ or ‗TAC (+100%)‘ at 37°C and 22°C 
(representing normal and cooling conditions, respectively) compared with vehicle control 
(cells treated with medium containing DMSO, in which the reagent was dissolved. The 
solvent represents the maximum amount of DMSO corresponding to the highest drug 
concentration). The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Representative results shown in bar graph form for clarity and presentation of 
statistical significance. Data points correspond to mean % cell biomass (±S.E.M.) for three 
independent biological experiments, each consisting of 6–8 technical replicates. n.s., non-
significant; ***, p < 0.001. 
 
 
 
 
 
 
77 
 
3.6 Chemotherapy drug-mediated effects on HaCaT keratinocyte 
viability and the role of cooling 
Our observation that by using cooling conditions highly-proliferative, cultured normal 
keratinocytes (a) could be efficiently rescued from chemotherapy drug-induced cytotoxicity, 
yet (b) could only be protected to a limited degree from combinatorial TAC treatment, are 
concordant with the data reported in the clinic (Grevelman and Breed, 2005). However, the 
finite nature of these cells (NHEK and HHFK cells display a decrease in proliferative potential 
by passages 5–6 and senesce soon after) poses a significant experimental obstacle. 
Therefore the well-characterised, immortalised, non-malignant human keratinocyte line 
HaCaT was exploited, as it shows characteristics and behaviour similar to normal 
keratinocytes (Boukamp et al., 1988) and has been used to study drug-induced cytotoxicity 
(Luanpitpong et al., 2011). 
Similarly to our studies using NHEK cells, the effect of the same panel of 
chemotherapy drugs on HaCaT cell growth and examined the potential protective role of 
cooling by comparing treatments at 37°C and, to mimic cooling conditions, at 22°C were 
assessed. Upon morphological examination, there was a clear correlation between drug 
concentration and number of phase-bright, non-adherent, apoptotic/dead cells; however, 
under cooling conditions there was a noticeable reduction in dead cell numbers for all three 
drugs, and particularly in the case of doxorubicin and 4-OH-CP. These observations are 
illustrated in Figure ‎3-4, which shows representative phase contrast photomicrographs of 
HaCaT cultures 72h after treatment with doxorubicin, 4-OH-CP and docetaxel at both 
temperature conditions. When the role of cooling over a wide range of drug concentrations 
using cell biomass assays was assessed, data showed that, in agreement with our NHEK 
experiments, cooling conditions provided significant and consistent protection against 
cytotoxicity (Figure ‎3-5). However, the observed cooling-mediated rescue from drug 
cytotoxicity, although occurring over a wide range of drug doses, was noticeably less 
dramatic in HaCaT (Figure ‎3-5) than in NHEK (Figure ‎3-1) and HHFK cells (Figure ‎3-2). 
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Figure ‎3-4 Cytoprotective role of cooling against chemotherapy drug-mediated toxicity 
in HaCaT cells 
HaCaT cells were seeded in 96 well plates at 5000 cells/well in DMEM medium 
supplemented with 5% FBS and 1%LG were incubated overnight at 37°C/5% CO2. HaCaT 
cells were treated for 2h with a range of concentrations of doxorubicin, 4-OH-CP, and 
docetaxel at 37°C and 22°C (representing normal and cooling conditions, respectively) 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which 20 µL of CellTiter 96® AQueous One solution was added to the wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was measured 
spectrophotometrically at a wavelength of 492nm and % cell biomass was calculated as 
described in Materials and Methods (Chapter 2). Representative results from the dose 
response curves (upper panels) are also shown in bar graph form (lower panels) for clarity 
and presentation of statistical significance. Data points correspond to mean % cell biomass 
(±S.E.M.) for three independent biological experiments, each consisting of 6–8 technical 
replicates. n.s., non-significant; *, p < 0.05; ***, p < 0.001. 
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Figure ‎3-5 Microscopic observation of cooling-mediated cytoprotection of HaCaT cells 
from chemotherapy drug-mediated toxicity 
HaCaT cells were treated with the indicated doses of doxorubicin (A), 4-OH-CP (B) and 
docetaxel (C) at 37°C and 22°C. Solvent alone-treated (control) HaCaT cultures served as 
negative controls. Phase contrast light microscopy was used to assess the viability of control 
and drug-treated cultures and representative photomicrographs are provided from two 
independent series of experiments. The presence of non-adherent, phase-bright cells 
following drug treatment was indicative of drug-mediated cytotoxicity. Phase contrast images 
were obtained using an EVOS XL core inverted microscope and at x100 magnification.  
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3.7 Adaptation of HaCaT keratinocytes to low-calcium, serum-free 
culture conditions and investigation of the role of cooling in 
chemotherapy drug-induced effects in the adapted cells 
The differences in the ability of cooling to protect primary NHEK and HHFK cells 
versus the HaCaT cell line from drug-induced cytotoxicity, with NHEK showing a far more 
pronounced ‗response‘ to cooling, prompted us to investigate the possibility of adapting the 
HaCaT cell line to culture conditions identical to those of NHEK. A previous study has 
reported that reduction of calcium levels in serum-containing culture medium allows HaCaT 
cells to adopt a more basal, less differentiated phenotype (Deyrieux and Wilson, 2007), 
consistent with the important role of calcium in mediating keratinocyte differentiation. In order 
to render the HaCaT cell model more closely representative to primary cells, HaCaT cells 
were adapted to grow in both low calcium (0.09 mM) and serum-free conditions (KSFM 
medium) by sequential medium adaptation and passage, as described in detail in section 
2.4.3 and this new cell line was named HaCaTa. 
Figure ‎3-6A shows representative phase contrast photomicrographs of fully adapted 
HaCaTa cells during routine maintenance in comparison to the original HaCaT cell line as 
well as primary NHEK. By observing all three cell types at different culture densities (low, 
medium and high), it was apparent that HaCaTa cells exhibited a phenotype that was more 
representative of that of NHEKs. At low/medium densities (Figure ‎3-6A), upper and middle 
panels), HaCaT cells were less phase-bright, formed strong cell contacts and showed a clear 
tendency to form colonies; by contrast, HaCaTa cells were very phase-bright and showed 
reduced tendency to form cell contacts. The similarity of HaCaTa cells to NHEK was even 
more pronounced when cultures approached full confluence (Figure ‎3-6A, lower panels); at 
such density HaCaTa remained phasebright and were nearly indistinguishable from NHEK 
cultures. More importantly, when the proliferation rate of the HaCaTa derivative to the HaCaT 
line was compared, cell biomass assays demonstrated that adapted cells grew much more 
rapidly than the parental cell line, with HaCaTa showing a nearly 50% higher proliferation 
rate (Figure ‎3-6B), which was comparable to that of early-passage NHEK cells (not shown). 
Then the response of the HaCaTa line to the same panel of chemotherapy drugs 
(above) and using the cooling regime (22°C) previously tested for HaCaT (and NHEK) cells 
was investigated. As shown in Figure ‎3-7, cooling during drug treatment provided consistent 
and significant protection from drug-mediated cytotoxicity for nearly all concentrations tested 
for doxorubicin, 4-OH-CP and, though to a lesser extent, docetaxel. Importantly, however, 
unlike our findings with HaCaT cells (Figure ‎3-4), the cytoprotection observed for HaCaTa 
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cells resembled more closely that seen with NHEK, with the results for 4-OH-CP (Figure ‎3-7) 
being particularly similar to those observed with NHEK (Figure ‎3-1). In support of our 
quantitative assays, phase-contrast microscopic observation of HaCaTa cells treated with 4-
OH-CP at 37°C versus 22°C showed clear, cooling-mediated protection against drug-
mediated cytotoxicity (Figure ‎3-8). Futhermore, the response of the HaCaTa line to 5-
Fluorouracil (5-FU) and using the same cooling regime (22°C) was investigated. 5-FU is an 
anticancer drug that belongs to the family of drugs called antimetabolites and it is the most 
commonly used drug as first-line chemotherapy for various stages of colorectal cancer 
(Chansky et al., 2005). Alopecia occurs at an estimated reported incidence of 10-50% after 
treatment with 5-FU (Batchelor, 2001). As shown in Figure 3-9 cooling during drug treatment 
provided a significant protection from 5-FU-mediated cytotoxicity for nearly all concentrations 
tested.  
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Figure ‎3-6 Establishment of the HaCaTa cell line and assessment of its phenotypic 
and growth characteristics 
(A) The HaCaTa cell line was derived as described in the text and detailed in Section 2.4.3. 
HaCaTa derivatives, the original cell line HaCaT and primary NHEK cells at increasing cell 
densities (‗Low‘, ‗Medium‘ and ‗High‘) under routine culture conditions were examined by 
Phase contrast images were obtained using an EVOS XL core inverted microscope and at 
x100 magnification and representative photomicrographs are provided. (B) Adapted HaCaTa 
and the original HaCaT cell line were seeded at the indicated cell densities (‗Cell number‘ 
represents number of cells seeded per well) before cell growth was assessed 72h later on 
the basis of total cell biomass as described in section 2.7. Bars correspond to mean 
absorbance at 492 nm ((±SD) for three independent biological experiments, each consisting 
of 6–8 technical replicates. ***, p < 0.001.  
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Figure ‎3-7 Cytoprotective role of cooling against chemotherapy drug-mediated toxicity 
in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of doxorubicin, 4-OH-CP, and docetaxel at 37°C and 22°C (representing 
normal and cooling conditions, respectively) compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution 
was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods (Chapter 2). Representative 
results from the dose response curves (upper panels) are also shown in bar graph form 
(lower panels) for clarity and presentation of statistical significance. Data points correspond 
to mean % cell biomass (±S.E.M.) for three independent biological experiments, each 
consisting of 6–8 technical replicates. n.s., non-significant; *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
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Figure ‎3-8 Microscopic observation of cooling-mediated cytoprotection of HaCaT cells 
from chemotherapy drug-mediated toxicity 
HaCaTa cells were seeded in 10cm dishes and treated with 7.5 g/mL of 4-OH-CP at 37°C 
and 22°C as described in the section 2.7. Solvent alone-treated (control) HaCaTa cultures 
served as negative controls. Phase contrast images were obtained using an EVOS XL core 
inverted microscope at x100 magnification to assess the viability of control and drug-treated 
cultures 36h post-treatment and representative photomicrographs from two independent 
experiments are provided.  
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Figure ‎3-9 Cytoprotective role of cooling against Fluorouracil (5FU)-mediated toxicity 
in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of Fluorouracil (5FU) at 37°C and 22°C (representing normal and cooling 
conditions, respectively) compared with vehicle control (cells treated with medium containing 
DMSO, in which the reagent was dissolved. The solvent represents the maximum amount of 
DMSO corresponding to the highest drug concentration). The drugs were then removed, 
wells were rinsed with PBS to remove any traces of drug and cultures incubated for a further 
72h, after which 20 µL of CellTiter 96® AQueous One solution was added to the wells and 
plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm and % cell biomass was 
calculated as described in Materials and Methods (Chapter 2). Representative results from 
the dose response curves (upper panels) are also shown in bar graph form (lower panels) for 
clarity and presentation of statistical significance. Data points correspond to mean % cell 
biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. **, p < 0.01; ***, p < 0.001. 
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3.8 The effect of the combinatorial TAC chemotherapy treatment on 
HaCaTa cell viability and the role of cooling 
Our observations of TAC indicated that, unlike the parental cell line, HaCaTa cells 
closely resembled NHEK in their responses to chemotherapy drugs and in the extent of their 
protection by cooling, the effect of combinatorial treatment TAC on HaCaTa were tested. To 
do so, the previously tested three treatment regimes were followed, i.e. TAC, ‗TAC (+10%)‘ 
and ‗TAC (+100%)‘ and the drug concentrations chosen were doses that corresponded to the 
maximal observed cytoprotection upon cooling in HaCaTa cells (Figures ‎3-7 and ‎3-8). As 
shown in Figure ‎3-10, treatment with all TAC protocols caused substantial loss of cell growth, 
which was particularly evident following treatment using the ‗TAC (+100%)‘ protocol. In 
concordance with our findings with NHEKs (Figure ‎3-2), some, though modest, 
cytoprotection by cooling was observed for the ‗TAC‘ and ‗TAC (+10%)‘ treatments (30–35% 
relative biomass). Moreover, cooling provided even less rescue from the extensive 
cytotoxicity observed following ‗TAC (+100%)‘ treatment (Figure ‎3-10).  
Collectively, our findings demonstrated that HaCaTa cells showed results that closely 
resembled those obtained with NHEK (and HHFK) cultures, attesting to the suitability of 
HaCaTa for our studies. Therefore, a large proportion of subsequent experiments performed 
in this thesis involved use of HaCaTa cells; however, where appropriate, important biological 
findings were confirmed using NHEK (and/or HHFK) cultures (see subsequent sections and 
chapters).  
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Figure ‎3-10 Effect of cooling on TAC-mediated cytotoxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with the combinatorial drug 
protocols ‗TAC‘, ‗TAC (+10%)‘ or ‗TAC (+100%)‘ at 37°C and 22°C (representing normal and 
cooling conditions, respectively) compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a further 72h, after which 20 µL of CellTiter 96® AQueous One solution was added to the 
wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm and % cell biomass was 
calculated as described in Materials and Methods (Chapter 2). Representative results shown 
in bar graph form for clarity and presentation of statistical significance. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001. 
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3.9 Investigations into the differences in keratinocyte cytotoxicity 
caused between TAC versus ACT combinatorial regimes  
Combinatorial therapy holds the potential for enhanced anticancer activity compared 
with monotherapy, as mentioned previously in chapter 1. However, the effectiveness of this 
approach is more strongly associated with side effects such as alopecia. After establishing 
an in vitro system to assess the effects of a specific treatment sequence for the TAC (via 
sequential treatment with docetaxel, doxorubicin, and 4-OH-CP), only a modest degree of 
cytoprotection was observed following ‗TAC‘ treatments in agreement with clinical 
observations. There are many different modes of cytotoxic action for anticancer drugs, 
hypothetically these drugs produce various degrees of cytotoxicity depending on 
administered sequences (Rowinsky et al., 1993). Both TAC and ACT are types of 
combinatorial chemotherapies for breast cancer. However, so far there has been no study 
that compares ACT and TAC (Buyukhatipoglu et al., 2015) and it appears that different 
hospitals treat breast patients with these three drugs in different orders, resulting in various 
degrees of CIA (Paxman personal communication). Therefore, in this study, the TAC and 
ACT combinatorial regimes were investigated and their effects on HaCaTa cells were 
compared. The combinations of drugs with different duration periods of administration (cell 
treatment period) were tested and the effect of cooling was assessed in comparison to 
physiological temperature. HaCaTa cells were treated with a combination of doxorubicin, 4-
OH-CP, and docetaxel ‗‘ACT‘‘ and ‗‘TAC‘‘ for 1.5h for each drug compared with TAC (see 
section 2.7.3). Data showed that there was no increase in the viability of the cells that were 
treated with ACT when compared to TAC treatments (Figure 3-11).   
Istomin et al. showed that the drug exposure time and concentration are important in 
vitro and in vivo (Istomin et al., 2008). Therefore, it is important to compare the combined 
therapy of ACT in equal treatment conditions at different drug exposure times for each drug 
and the impact of cooling. To test for the first time in vitro the cytotoxic effect of the ‗‘ACT‘‘ at 
different drug exposure duration and assess the influence of cooling as detailed in section 
2.7.1. As shown in Figure 3-12, there was no effect observed as a result of drug sequence or 
duration of treatment on drug effectiveness, and biomass at both 37°C and 22°C. 
Furthermore, the effect of cooling on HaCaTa cells treated with FAC combinatorial regimes 
(5-FU, doxorubicin and cyclophosphamide) was investigated. As shown in Figure 3-13, 
HaCaTa cells were exposed to the combination drug FAC, and cooling showed almost 50% 
increase in cell biomass and improved the relatively modest protection observed when 
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compared with FAC at 37°C, which is in agreement with the clinical data (Van Den Hurk et 
al., 2012c). 
 
 
Figure ‎3-11 Effect of cooling on ACT and TAC-mediated cytotoxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with the combinatorial drug 
protocols ‗TAC (+10%) compared ACT (+10%) for treatment 1.5h for each drug at 37°C and 
22°C (representing normal and cooling conditions, respectively) compared with vehicle 
control (cells treated with medium containing DMSO, in which the reagent was dissolved. 
The solvent represents the maximum amount of DMSO corresponding to the highest drug 
concentration). The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, and after which 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Representative results shown in bar graph form for clarity and presentation of 
statistical significance. Data points correspond to mean % cell biomass (±S.E.M.) for three 
independent biological experiments, each consisting of 6–8 technical replicates. ***, p < 
0.001. 
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Figure ‎3-12 Effect of cooling on modified ACT-mediated cytotoxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with the combinatorial drug 
protocols ACT (+10%) for treatment 1.5h for each drug and ACT 1.1.2h (1h doxorubicin, 1h 
4-OH-CP and 2h docetaxel) at 37°C and 22°C (representing normal and cooling conditions, 
respectively) compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which 20 µL of CellTiter 96® AQueous One solution was added to the wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was measured 
spectrophotometrically at a wavelength of 492nm and % cell biomass was calculated as 
described in Materials and Methods (Chapter 2). Representative results shown in bar graph 
form for clarity and presentation of statistical significance. Data points correspond to mean % 
cell biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. ***, p < 0.001. 
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Figure ‎3-13 The ability of cooling to protect from combined therapy FAC (5FU, 
doxorubicin and cyclophosphamide)-mediated cytotoxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with the combinatorial drug 
protocols FAC (+10%) at 37°C and 22°C (representing normal and cooling conditions, 
respectively) compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which 20 µL of CellTiter 96® AQueous One solution was added to the wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was measured 
spectrophotometrically at a wavelength of 492nm and % cell biomass was calculated as 
described in Materials and Methods (Chapter 2). Representative results shown in bar graph 
form for clarity and presentation of statistical significance. Data points correspond to mean % 
cell biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. ***, p < 0.001. 
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3.10 Effects of dual drug chemotherapy exposure and the impact of 
cooling in combinatorial drug-induced cytotoxicity  
Adriamycin/doxorubicin, cyclophosphamide/Cytoxan (AC) chemotherapy is a 
common chemotherapy administered to breast cancer patients (Land et al., 2004). Most 
patients will lose all their hair after AC therapy (Partridge et al., 2001), yet scalp cooling has 
showed a good ability to prevent or minimise hair loss (Grevelman and Breed, 2005). 
Therefore, the dual drug chemotherapy AC and its effects was investigated on HaCaTa cells 
at 37°C vs cooling conditions. Cells were treated with drugs for 1h for each drug and also for 
2h with the same drugs. As shown in Figure 3.14, there was significant reduction in cell 
viability at 37°C for all the groups compared with cell treated at 22°C.  
 
Figure ‎3-14 Effect of cooling on dual drug-mediated cytotoxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with the combinatorial drug 
protocols 1h and 2h for each drug see section 2.7.1 at 37°C and 22°C (representing normal 
and cooling conditions, respectively) compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a further 72h, after which 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods (Chapter 2). Representative 
results shown in bar graph form for clarity and presentation of statistical significance. Data 
points correspond to mean % cell biomass (±S.E.M.) for three independent biological 
experiments, each consisting of 6–8 technical replicates. ***, p < 0.001. 
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3.11 The importance of temperature (cooling conditions) in 
determining the efficacy of cooling in protecting from 
chemotherapy drug-mediated cytotoxicity 
It has previously been reported that cooling below 22°C did not provide any further 
protection against doxorubicin-mediated keratinocyte cytotoxicity, even when the culture 
temperature was reduced to 10°C during drug treatment (Janssen et al., 2008). Using 
HaCaTa cells, we tested whether temperature values below 22°C could provide further 
protection against doxorubicin, 4-OHCP and docetaxel, and 5FU. As evident by 
representative results shown in Figure 3-15 and 3-16, lowering the temperature from 22°C to 
18°C and even further to 14°C, resulted incrementally in a better degree of rescue from drug 
cytotoxicity. Strikingly, cytoprotection was detectable even for the maximal drug doses 
tested, which had previously resulted in complete loss in cell biomass that was non-
recoverable by cooling at 22°C. Decreasing the cooling temperature further to 10°C (‗severe 
cooling‘) did not provide any significantly better protection than did cooling at 14°C (Figure 3-
17). Interestingly, cooling even at 14°C did not substantially improve the relatively modest 
protection observed for the ‗TAC‘ and ‗TAC (+10%)‘ protocols or the minimal protection from 
the ‗TAC (+100%)‘ treatment when experiments were performed in either NHEK or HaCaTa 
cells (data not shown). 
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Figure ‎3-15 The role of temperature on the efficacy of cooling in protecting from 
chemotherapy drug-mediated cytotoxicity 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of doxorubicin, 4-OH-CP, and docetaxel at 37°C and 22°C, 18°C and 14°C 
(representing normal and cooling conditions, respectively) compared with vehicle control 
(cells treated with medium containing DMSO, in which the reagent was dissolved. The 
solvent represents the maximum amount of DMSO corresponding to the highest drug 
concentration). The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Representative results from the dose response curves (upper panels) are also 
shown in bar graph form (lower panels) for clarity and presentation of statistical significance. 
Data points correspond to mean % cell biomass (±S.E.M.) for three independent biological 
experiments, each consisting of 6–8 technical replicates. n.s., non-significant; **, p < 0.01; 
***, p < 0.001. 
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Figure ‎3-16 The role of cooling in protecting from 5-fluorouracil (5-FU)-mediated 
cytotoxicity 
 HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of 5-FU at 37°C and 22°C, 18°C and 14°C (representing normal and cooling 
conditions, respectively) compared with vehicle control (cells treated with medium containing 
DMSO, in which the reagent was dissolved. The solvent represents the maximum amount of 
DMSO corresponding to the highest drug concentration). The drugs were then removed, 
wells were rinsed with PBS to remove any traces of drug and cultures incubated for a further 
72h, after which 20 µL of CellTiter 96® AQueous One solution was added to the wells and 
plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm and % cell biomass was 
calculated as described in Materials and Methods (Chapter 2). Representative results from 
the dose response curves (upper panels) are also shown in bar graph form (lower panels) for 
clarity and presentation of statistical significance. Data points correspond to mean % cell 
biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. 
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Figure ‎3-17 The role of ‘severe cooling’ conditions on the ability of cooling to protect 
from chemotherapy drug-mediated cytotoxicity 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of doxorubicin, 4-OH-CP, and docetaxel at 37°C and 10°C (representing 
normal and cooling conditions, respectively) compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a further 72h, after which 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods (Chapter 2). Representative 
results from the dose response curves (upper panels) are also shown in bar graph form 
(lower panels) for clarity and presentation of statistical significance. Data points correspond 
to mean % cell biomass (±S.E.M.) for three independent biological experiments, each 
consisting of 6–8 technical replicates. 
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3.12  Summary  
 The work described in this chapter allowed the establishment of in vitro models for 
the study of the effects of chemotherapy drug-induced cytotoxicity in vitro and to 
assess the role of cooling in protecting from drug-mediated cytotoxicity  
 Normal human epidermal keratinocytes (NHEK) and human hair follicular 
keratinocytes (HHFK) were initially used, as well as the keratinocyte cell line 
HaCaT and HaCaT cells that were adapted to culture conditions identical to those 
for NHEK cells (serum-free and low-calcium medium)  
 Cooling-mediated rescue from drug cytotoxicity after treatment with a wide range 
of doxorubicin, 4-OH-CP and docetaxel concentrations, a protection that was 
noticeably less dramatic in HaCaT cells in comparison to NHEK and HHFK cells. 
 For this purpose, and for the first time, HaCaT cells were adapted to grow in both 
low calcium and serum-free conditions (KSFM medium) by sequential medium 
adaptation and passage, resulting in the new cell line named HaCaTa. HaCaTa 
cell proliferation rates were higher than the parental cell line HaCaT line. 
Furthermore, HaCaTa cells exhibited a phenotype that was more representative of 
that of NHEKs.  
 Cooling dramatically reduced or completely prevented the cytotoxic effects of 
docetaxel, doxorubicin, 5-FU, and particularly cyclophosphamide. Optimal rescue 
was observed in conjunction with mono-therapy treatment whilst combinatorial 
treatment (TAC) showed relatively poor response to cooling, findings that are in 
agreement with clinical observations. 
 There was no impact of changing the sequences of the drugs and duration of the 
treatment of each drug on effectiveness at both temperature 37°C and 22°C.  
 Adriamycin/doxorubicin, cyclophosphamide/Cytoxan (AC) related experiments 
showed that the cell under cooling conditions showed significantly better viability in 
comparison to 37C controls.  
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3.13 Discussion 
Chemotherapy-induced alopecia (CIA) is the most common and distressing side 
effect of anticancer chemotherapy (Wang et al., 2006) and due to the fear caused by the 
prospect of CIA, cancer patients may even refuse treatment in some cases (Münstedt et al., 
1997). Therefore, with cancer chemotherapy, still representing the most widely employed 
therapeutic approach; development of CIA preventative regimes represents an important 
challenge in oncology (Paus et al., 2013). The only currently available preventative treatment 
is scalp cooling. Scalp cooling (scalp hypothermia) during administration of chemotherapy 
drugs can substantially reduce hair loss (Protiere et al., 2002). Clinically it has been shown 
that scalp cooling can substantially reduce the incidence of hair loss in response to individual 
drugs, including cyclophosphamide, doxorubicin, and cisplatin (Grevelman and Breed, 2005). 
However, for combination treatment regimes, such as doxorubicin (Adriamycin) and 
cyclophosphamide (clinically referred to as AC), and particularly treatment with docetaxel 
(Taxotere), doxorubicin and cyclophosphamide (clinically known as TAC), and Fluorouracil 
(5FU), doxorubicin and cyclophosphamide (clinically known as FAC), scalp cooling shows 
relatively moderate or little reported efficacy (Breed et al., 2011; Van Den Hurk et al., 2012c).  
Despite the fact that scalp cooling can be effective, its principal mechanism(s) of 
action remain not understood and several hypotheses have been raised to explain its role. 
Firstly, as cooling causes blood vessel vasoconstriction, which dramatically reduces blood 
flow to the scalp (Janssen et al., 2008), it has been suggested that the less 
chemotherapeutic drug is ‗delivered‘ to the HFs (Bülow et al., 1985). Another possibility is 
that the rate of drug diffusion across a plasma membrane may be reduced and thus lower 
the ‗effective‘ drug dose which can enter the cells (Lane et al., 1987). Finally, as cell division 
is metabolism-driven, this process could be decelerated by cooling as temperature can 
particularly affect phases G1 and S (Watanabe and Okada, 1967), which could be 
particularly important for drugs that target specific phases of the cell cycle, such as 
microtubule-destructive drugs targeting mitosis. It is possible that cooling involves a 
combination of these three mechanisms to exert its protective effect (Figure 8-1).  
Several experimental in vivo models have been used to help understand CIA, 
however, despite their clear physiological relevance; rodent-based models demonstrate a 
number of inherent limitations. For instance, in adult mice, HFs are mostly in the telogen 
phase and only 10% are in the anagen, compared to 90% of follicles on a normal human 
(Luanpitpong et al., 2012; Paus et al., 2013). For this reason ex vivo models have been 
developed, such as those by Paus (2013) that are based on the isolation and culture of 
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human HFs, which represent a physiologically-relevant and elegant approach to mimic and 
study cyclophosphamide-induced CIA (Bodo et al., 2007).  
A more reductive in vitro culture approach involves studying chemotherapy drug-
induced cytotoxicity using primary normal human epidermal keratinocytes (NHEK). The 
principle behind the use of such keratinocytes is that they are maintained under culture 
conditions that render them highly-proliferative, thus resembling the rapidly-dividing 
population of native matrix keratinocytes. Using such primary NHEKs, a previous report has 
provided evidence, that doxorubicin induces NHEK cytotoxicity over a range of 
concentrations (Janssen et al., 2008). Another in vitro approach has used the well-
characterised cell line HaCaT, which shows similar characteristics and cell behaviour to 
normal keratinocytes (Deyrieux et al., 2007). These cells have been used to study 
chemotherapy drug-induced keratinocyte cytotoxicity and such studies provided evidence on 
cisplatin-induced cytotoxicity by demonstrating Reactive Oxygen Species (ROS) -mediated 
mechanisms that induce Bcl-2 down-regulation, Bax up-regulation and subsequent induction 
of apoptosis (Luanpitpong et al., 2011). 
 
 
        Figure ‎3-18 Proposed mechanisms of action of scalp cooling 
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3.13.1 Development of in vitro models to study chemotherapy drug-induced 
cytotoxicity and assess the effect of cooling  
This study focused on the biological effects of cooling (hypothermia) following 
chemotherapy drug-treated in vitro in keratinocyte cells and demonstrated the protective 
effect of cooling at the cellular level. The study for the first time examined the cytotoxicity of a 
panel of chemotherapeutic modalities, including doxorubicin, docetaxel, and the active 
metabolite of cyclophosphamide (4-OH-CP), on NHEK cultures and investigated the possible 
influence of culture temperature on drug-mediated cytotoxicity. Importantly, our study has 
been the first to test these effects on human hair follicular keratinocytes (HHFKs). Moreover, 
this study established a derivative of the HaCaT cell line (coined HaCaTa) as an alternative 
in vitro model. The initial temperature choice of 22°C was made to mimic cooling, because 
(a) at the time our laboratory studies were being performed, the clinical evidence had 
suggested that 22°C was the temperature the skin reached (on average) in patients during 
scalp cooling (Komen et al., 2013a), (b) various studies had shown that a scalp temperature 
of 22°C or less is required for hair preservation (reviewed in (Komen et al., 2013a)) and (c) 
22°C was the temperature previously tested in vitro (Janssen et al., 2008). However, this 
thesis systematically examined a series of temperature conditions, that included 22°C as well 
as more severe cooling, particularly 18°C, 14°C (and even extreme cooling at10°C). The 
suitability of our approach has been attested very recently by published evidence (appearing 
in public databases during the preparation of this dissertation) reporting that lowering the 
temperature further (from 22°C to 18°C) is associated with improved efficacy of cooling 
(Komen et al., 2016).  
3.13.2 The effects of cooling on drug-mediated cytotoxicity  
The results of our study demonstrate that cooling can rescue HaCaTa, NHEK and 
HHFK cells from drug-mediated cytotoxicity. The cytoprotective effect of cooling was striking 
for a series of drug concentrations, particularly for doxorubicin and 4-OH-CP where for some 
doses cell biomass returned from below 20% to nearly 100% of the control value. For 
doxorubicin, this effect was particularly marked for 3 µg/mL. Interestingly, the maximal 
plasma concentration (Cmax) following routine infusion with doxorubicin in patients undergoing 
chemotherapy is reported to be ~2–4 µg/mL (Brunsvig et al., 2007; Itoh et al., 2000; Nabholtz 
et al., 2001). Although measured drug concentrations in the overall circulation may not 
necessarily correspond to those in the HFs, our finding that even at this maximal 
concentration cooling can fully protect from cytotoxicity at 22°C, explains the success of head 
cooling in preventing CIA clinically. We also show for the first time that both the active 
metabolite of cyclophosphamide, 4-hydroxy-cyclophosphamide (4-OH-CP) and docetaxel 
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induce dose-dependent cytotoxicity in human keratinocytes, an effect, which is consistent 
with the association of these drugs with CIA clinically. The dose-dependence of this toxicity is 
also in agreement with a number of clinical reports that slower infusion speeds which will 
lead to a reduced Cmax cause less severe CIA (Breed et al., 2011). More importantly, our 
findings that cooling can rescue from cytotoxicity are in concordance with clinical 
observations that scalp cooling significantly reduces the incidence of CIA following treatment 
with these drugs (Van Den Hurk et al., 2012c).  
3.13.3 The effects of cooling on combinatorial therapy 
Having demonstrated that exposure to individual chemotherapeutic drugs caused 
dose-dependent toxicity in human keratinocytes of both epidermal and follicular origin and 
that this could be significantly attenuated by cooling, we examined the response to the 
combinatorial TAC therapy (T = taxotere/docetaxel, A = adriamycin/doxorubicin, C = 
cyclophosphamide/ Cytoxan). This regimen is being increasingly used in early stage breast 
cancer, but almost always results in CIA and it has been reported that head cooling has very 
limited success in preventing TAC-mediated CIA, with ~90% of patients exhibiting CIA 
despite using scalp cooling (Breed et al., 2011). Treatment of cells in vitro to mimic clinical 
administration of TAC (or FAC) posed challenges. One challenge was the choice of 
concentration of each chemotherapy drug. Equally, as drugs are administered sequentially in 
the clinic, it would be expected (based on published pharmacokinetic data) that following 
administration of the first drug, infusion of the next drug would take place whilst the previous 
drug may still be present at high concentrations in the blood. Also, the infusion of these three 
drugs takes place in different time periods during TAC treatment; often this involves 
docetaxel for 60 min followed by doxorubicin for 15 min and cyclophosphamide for 15 min 
(Van Den Hurk et al., 2012c). However, precise timings and the order of administration can 
vary between different clinics. 
In an attempt to incorporate these parameters and make the in vitro TAC treatment 
as relevant as possible, we adopted three approaches. In all cases, cells were treated with 
chemotherapy drug doses for which significant or maximal in vitro rescue was observed 
when each drug was tested individually. The first approach (‗TAC‘) involved sequential 
treatment with the individual drugs. The other two approaches involved initial treatment with 
the first drug (T), followed by treatment with each subsequent drug (A and C) whilst being 
also supplemented with either 10% (denoted ‗TAC (+10%)‘) or 100% (denoted ‗TAC 
(+100%)‘) of the previous drug. The use of ‗TAC (+100%)‘ aimed at addressing the scenario 
where infusion with the second or third drug would take place whilst the previous drug was 
still present in maximal concentration. The rationale behind the ‗TAC (+10%)‘ protocol was 
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based on the reported observation that the plasma levels of doxorubicin and docetaxel fall on 
average by approximately 10-fold within 1–2h post-infusion in comparison to the Cmax 
(Brunsvig et al., 2007; Itoh et al., 2000; Nabholtz et al., 2001). Interestingly, all three TAC 
protocols tested caused significant toxicity to NHEKs and HaCaTa cells at 37°C consistent 
with the high levels of CIA reported for individuals undergoing TAC therapy in the clinic (Van 
Den Hurk et al., 2012c). Upon cooling to 22°C in NHEK cell, and in HaCaTa cells the TAC 
regimen was tested at 22°C and the sub-optimal temperature 26°C, data showed that despite 
some degree of cytoprotection, and although the drug concentrations used had previously 
‗responded‘ to cooling in individual treatment experiments, following combinatorial treatment 
the protection observed was modest at 22°C. Interestingly, 26°C showed improved, though 
relatively modest, cell viability compared to at 22°C.  
Of note, despite observing a cell biomass between 40% and 50% for the TAC only 
and TAC (+10%) protocols, we found little detectable rescue following treatment with the 
TAC (+100%) protocol, suggesting that this may represent the protocol that more 
appropriately reflects cytotoxicity in vivo. It is most striking that, despite the assumptions 
made when constructing the TAC protocols for cell treatment in vitro, our observations reflect 
the clinically reported inability of cooling to attenuate TAC-mediated toxicity that results in 
CIA. Also in support of these findings, is the observation that, in addition to the TAC 
protocols reported in the results section, when we tested further possible alternatives as TAC 
treatments (for instance by altering drug treatment duration and/or a drug sequence (ACT 
protocol)) our results remained unchanged. 
Due to the finite nature of NHEK and HHFK cells, we explored the possibility of using 
the well-characterised, immortalised, non-malignant human keratinocyte line HaCaT for our 
studies, as HaCaT cells show characteristics and behaviour similar to normal keratinocytes 
(Boukamp et al., 1988; Deyrieux and Wilson, 2007; Inui et al., 2000; Itami et al., 1995). They 
adopt a phenotype similar to cell sub-populations of the human HF (Inui et al., 2000) and 
have been used to study drug-induced (Luanpitpong et al., 2011) or ROS-mediated (Liu et 
al., 2012) cytotoxicity. At 37°C, the response of HaCaT cells to docetaxel was similar to that 
in NHEK and HHFK. However, for both doxorubicin and 4-OH-CP, although the general 
pattern of toxicity was similar, qualitatively there were some clear differences. HaCaT cells 
were somewhat more drug-sensitive than primary keratinocytes.  
Interestingly, we observed that low concentrations of doxorubicin and 4-OH-CP 
stimulated an overall increase in biomass compared to controls in HaCaT a response also 
observed for 4-OH-CP in NHEK and HHFK cells (Figures 3-1 and 3-2). This increase in cell 
growth in sub-lethal concentrations of otherwise cytotoxic drugs have been reported 
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previously in different cell types by our laboratory and by others (Kayamba et al., 2013; Paus 
et al., 2013).  
Cooling HaCaT cells to 22°C during drug exposure produced a general reduction in 
the toxicity of the drugs, however, this was less dramatic than NHEK cells and at no 
concentration was the nearly 100% cell rescue that we had observed with NHEK for 
singularly administered drugs replicated. These findings indicated that HaCaT cells do not 
represent an appropriate in vitro model for investigations on the role of cooling in modulating 
chemotherapy drug-induced cytotoxicity. 
The reduced efficacy of cooling in HaCaT compared to NHEK and HHFK cells, led us 
to hypothesise that the differences in responses may be due to the lower proliferative 
capacity and the more differentiated phenotype of HaCaT compared to NHEK. HaCaT cells 
are routinely cultured in standard, serum-containing medium, whereas NHEK are maintained 
in Keratinocyte Serum Free Medium (KSFM), which contains a low calcium concentration 
(~0.09 mM) – in comparison to physiological (~2 mM) calcium (Georgopoulos et al., 2010). 
The concentration of extracellular calcium has a profound role as a switch between epithelial 
growth and differentiation of keratinocytes, as calcium induces terminal differentiation, 
including specific structural changes, cell cycle withdrawal, and induction of terminal 
differentiation-related genes (Boelsma et al., 1999). It has previously been reported that 
reducing the level of calcium in the culture media of HaCaT cells resulted in a more 
proliferative/basal and less differentiated phenotype evident by the reduction of molecular 
differentiation markers, such as K1 and involucrin (Deyrieux and Wilson, 2007).  
When HaCaT cells were adapted to grow in low calcium (0.09 mM), serum-free 
conditions, the new cell line (HaCaTa) was phenotypically very similar to NHEKs and 
exhibited higher proliferation rates than HaCaT cells that were comparable to those of early-
passage NHEKs. More importantly, when we tested the effects of the panel of chemotherapy 
drugs and the capacity of cooling to protect from cytotoxicity, the results with the HaCaTa cell 
line closely resembled our observations with NHEKs, as exemplified by the results using 4-
OH-CP. When we tested the different TAC protocols on these cells and examined the ability 
of cooling to protect, again the findings with the HaCaTa cells were in concordance with 
those for NHEKs, as only modest cytoprotection by cooling was observed for the ‗TAC‘ and 
‗TAC (+10%)‘ treatments and cooling provided even less rescue from the extensive 
cytotoxicity observed following the ‗TAC (+100%)‘ protocol. Therefore, this novel, low-calcium 
and serum-free condition-adapted HaCaTa cell line represents an in vitro model that more 
closely resembles NHEKs whilst, due to its immortal nature, it has the advantage of 
maintaining a proliferative phenotype over an extended number of passages and was 
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therefore used extensively in this work for investigating the influence of cooling on 
chemotherapy drug-induced cytotoxicity.  
Previous in vitro studies by Janssen et al.,  (2008) have reported that reducing culture 
temperatures below 22°C did not provide any further protection against doxorubicin-induced 
cytotoxicity in NHEKs (Janssen et al., 2008). Using the HaCaTa line as a model, our study 
demonstrated that further reduction of culture temperature to 18°C and 14°C provided 
significantly more cytoprotection (than that at 22°C) for all drugs tested, and resulted in 
particularly marked rescue from 4-OH-CP, doxorubicin-induced cytotoxicity and 5-FU. One 
possibility for the discrepancy between our findings and those of Janssen et al., (2007) could 
be that those studies used NHEKs whereas in our experiments we used the HaCaTa line. 
However, this possibility was excluded by demonstrating that lowering the culture 
temperature below 22°C in experiments where NHEK cells were exposed to all three drugs 
employed in this study also resulted in improved cytoprotection (Chapter 4) (an observation 
also confirmed using HHFKs as well). A more likely explanation for the difference in 
observations is that in the studies by Janssen et al., (2008) the cell density used in all cell 
biomass measurement experiments was substantially lower than those we used in our 
studies. It is possible that this could result in much higher cellular stress during drug 
treatment that could ‗mask‘ the real potential of cooling in rescuing from cytotoxicity (Janssen 
et al., 2008).  
Our finding that lowering the temperature further results in improved cytoprotection 
implies that the scalp temperature that is achieved clinically may be important in dictating the 
success of head cooling in CIA prevention. Despite the lack of appropriate clinical data to 
formally demonstrate the precise temperature conditions that determine the efficacy of 
cooling, it has been suggested by various studies that a scalp temperature of 22°C or less is 
required for hair preservation during chemotherapy (Gregory et al., 1982) and reviewed in 
(Komen et al., 2013a), and as mentioned above. Recently published evidence reported that 
18°C temperature in the scalp is associated with improved efficacy of cooling in comparison 
to 22°C (Komen et al., 2016). Moreover, we have evidence that a scalp temperature <18°C 
can be achieved during cooling with commercially available scalp cooling devices such as 
the Paxman scalp cooling device (Hussain and Georgopoulos, unpublished data), not all 
subjects undergoing scalp cooling achieve this potentially critical temperature threshold. 
Thus, the ability to reach a temperature low enough to achieve cytoprotection may hold the 
key in determining the success of scalp cooling in preventing CIA in the clinic. Nevertheless, 
the lack of improvement in protecting from TAC-mediated cytotoxicity despite cooling at even 
lower temperatures indicates that for treatment types that do not respond well, further cooling 
alone might not provide an effective solution. Understanding the mechanisms of cooling-
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mediated cytoprotection may therefore provide novel avenues for combinatorial intervention 
in the future, and this was a main driver in the mechanisms investigated in this study.  
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4 CHAPTER 4: The effects of chemotherapy drugs and 
cooling alone or in combination on the human 
keratinocyte cell cycle 
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4.1 Background  
The cell cycle is the fundamental means by which every living entity divides and 
multiplies. The cell cycle is divided into four main phases: G1 phase (Gap phase 1) where 
the nucleus has the two complementary strands of DNA; S-phase (synthesis) during which 
DNA replication takes place, and G2 phase (Gap phase 2) preceding mitosis (M phase). 
Some cells are either not in an active cycle (post-mitotic) or have become quiescent enter a 
resting phase known as G0; during this time when the cell receives a mitotic signal it can re-
enter G1 phase (Pardee, 1989). In order to preserve the stability of the genome in response 
to cellular damage there are monitoring mechanisms (checkpoints) that will arrest the cycle 
at either G1/S or G2/M. Which provides additional time for cells to activate repair processes 
to remove any damage before DNA replication; alternatively, if damage is excessive and/or 
repair cannot occur, cell death by apoptosis can be stimulated (Hartwell and Kastan, 1994). 
Cell division is a complex, finely tuned mechanism. In each cell cycle phase, the cell 
monitors both its own growth as well as the external conditions. If these are unfavourable 
then growth arrest or cell cycle arrest is initiated (Sunley and Butler, 2010). 
The distribution of cells at different stages of the cycle determines cell growth rates 
and usually S phase percentage reflects the quantity of multiplying cells. Cancers tend to 
have a higher percentage of S phase cells than that of normal tissues. Furthermore, more 
aggressive cancer types have a higher proportion of cells in the S phase compared to less 
aggressive tumours (Braylan et al., 1980; Evan and Vousden, 2001).  
4.1.1 Effects of chemotherapeutic agents on the cell cycle 
Since many chemotherapy drugs are only effective on actively dividing cells and not 
those that are in a quiescent or dormant stage (and out of cycle), cell cycle analysis is 
important in helping to understand their mechanism of action. DNA damage by 
chemotherapeutic agents disrupts the cell cycle and slows down or halts the reproduction of 
dividing cells until DNA repair is completed (Gligorov and Lotz, 2004). 
 Many chemotherapeutic drugs interfere with cellular metabolism and trigger 
apoptosis (Reed, 1997). It has been shown that different degrees of stress can have a 
variety of effects on cells. Mild stress can trigger repair mechanisms, which can aid in cell 
survival. Low or moderate stress (damage) activates apoptosis; extremely high stress 
overwhelms apoptosis and leads to necrosis. An unregulated catastrophic mode of cell death 
occurs when the cell is intensely damaged or stressed. Chemotherapeutic drug treatment 
can induce apoptosis, indicating that cells initiate a controlled suicide in which the cell passes 
through different phases and eventually fragmentation (DNA) in cells is observed, thus 
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apoptosis is a means that can allow an organism to eliminate damaged cells in an orderly 
fashion (Reed, 1997). 
Chemotherapeutic drugs can be classified as cell cycle specific and non-specific 
drugs. Some chemotherapeutic agents specifically affect dividing cells during one or more 
phases of the cell cycle, by triggering arrest either in G1/S or G2/M phases; for example 
docetaxel acts on cells in G2 and M phases by exhibiting high affinity to β-tubulin and 
targeting centrosome organization (Gligorov and Lotz, 2004). By contrast docetaxel has 
minimal effects on cells in G1 phase and as a result there is an accumulation of the cells in 
G2/M phase (Gligorov and Lotz, 2004). Doxorubicin induces G2/M arrest in cell cycle 
progression (Tyagi et al., 2002). Other drugs, such as cyclophosphamide, may affect dividing 
cells in all phases of the cycle, and as such are non-cell cycle specific (Alkan et al., 2014).  
4.1.2 Effects of hypothermic conditions on the cell cycle 
For cells to proliferate they need both stimulating and progression factors (Rozengurt, 
1986) to enter the cycle. If one or more of these factors is thermally labile then non-optimal 
temperature might be leading to the rate of its loss being greater than its enzymatic 
production and as a result of that the cell cycle will be affected (Dewey, 1987). Cold 
treatment (cooling) has been divided into five categories; mild (35-33°C), moderate (31-
29°C), low (24-20°C), very low (20°C) and hypothermia (10-4°C) (Pardi et al., 2004; Shibano 
et al., 2002).  
In 1956, Cheveremont found that in primary embryo skeletal muscle cell cultures after 
24h incubation at 16-20°C the number of cells undergoing mitosis dropped to zero. However, 
after 3h of warming at physiological temperature (37°C) cells were dividing 2-3 times faster 
than the non-cooled cells (Chevremont, 1956). The explanation provided for this was that the 
cells continue to progress through the cell cycle until they arrest at late G2. As might be 
expected, all phases of the cell cycle of mammalian cells are inhibited at temperatures lower 
than 10˚C (severe hypothermia) (Rieder and Cole, 2002). Culturing CHO (Chinese Hamster 
Ovary) cells at 30-35°C have been shown to demonstrate reduction in the number of cells in 
G1 or S phase, whilst maintaining higher cell viability (Sunley and Butler, 2010). In addition, 
after reducing the temperature of cultured cells to 16-20°C, rewarming has been found to 
increase the rate of cell division by 2-3 fold compared to non-cooled controls (Rieder and 
Cole, 2002). Despite these reports, relatively little is still known about the effects of cooling 
on the cell cycle although. It has been shown that cell cycle progression is temperature 
sensitive (Rieder and Cole, 2002); and although there is some evidence that culturing cells at 
a reduced temperature can protect from apoptotic agents (Sakurai et al., 2005), it remains 
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unknown if cooling can modulate (prevent) the effects of chemotherapy drugs on the cell 
cycle.  
4.2 Cell cycle analysis 
Flow cytometry is a conventional, fast, and simple technique for determining the relative DNA 
content of the cell by using a fluorochrome such as propidium iodide (PI) intercalated into the 
DNA and thus enables discrimination between the various phases of the cell cycle. As 
mentioned above cell cycle divides into phases G0/G1, S, and G2/M. The distinction 
between G0 (quiescent) and G1 (preparation phase DNA synthesis), and between G2 
(preparation for mitosis) and M (mitosis) is not possible because the DNA content is the 
same. The technique can, nevertheless, track the distribution of cells in other phases of the 
cycle and thus determine how cells respond to various stimuli or the addition of cytotoxic 
drugs. Moreover, during apoptosis, cell cycle analysis can highlight a subG0/G1 peak 
(located just before the peak G0/G1) indicating cell populations with fragmented DNA, which 
is used to determine the proportion of cells in apoptosis since one of the hallmarks of 
apoptotic death is DNA fragmentation (Kajstura et al., 2007). Fluorochromes, such as PI, are 
useful markers binding to DNA as the amount of PI bound to DNA is relatively proportional to 
the amount of cellular DNA content. Because PI forms complexes with double stranded DNA 
and also with RNA and thus can stain both DNA and RNA, for cell cycle analysis cells must 
be treated with RNase to ensure that PI staining is DNA-specific (Riccardi and Nicoletti, 
2006).  
4.3 Effects of the epidermal growth factor receptor pathway (EGFR) 
inhibitor in chemotherapy induced cytotoxicity  
Human skin is composed of three layers the epidermis, the dermis and the subcutis; 
in the epidermis, keratinocytes are the predominant cell type constituting 90% of all cells. 
These cells proliferate in the basal layer of the epidermis and undergo differentiation and 
migration, to the most external layer of the skin. Epidermal growth factor receptor (EGFR) is 
mainly expressed by undifferentiated, proliferating keratinocytes in the basal layers of the 
epidermis as well as in the ORS of HFs (Hansen et al., 1997). The HF matrix keratinocytes 
represent highly proliferative cells and thus these cells are especially targeted by anti-cell 
replicative agents (Paus et al., 2013). EGFR is a cell membrane growth factor receptor 
(receptor tyrosine kinase, or RTK) and is a target for anticancer drugs (Ge et al., 2012). 
Previous studies showed that EGFR signalling might be involved in cyclophosphamide-
induced alopecia because EGFR signals anagen HFs to enter catagen (Bichsel et al., 2013). 
In addition, Bichsel et al., (2013) suggested a topical inhibition of signals downstream from 
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EGFR for protection from CIA (Bichsel et al., 2013). Therefore, because ―artificial‖ 
deceleration of cell growth by blockade of the cell cycle would be expected to reduce the 
cytotoxic effects of chemotherapy drugs, ―protective pre-conditioning‖ (PPC) by 
pharmacological inhibition of EGFR signalling might represent an efficient strategy to reduce 
the effects of chemotherapy drugs in the HFs.  
4.4 Chapter Aims  
Understanding the mechanisms regulating cell cycle progression in response to drug 
treatment at physiological temperature and cooling is vital for elucidating pathways 
responsible for the protection cooling provides against drug toxicity. Using such analyses, 
investigating the response to a range of temperatures could help to optimise cooling as a 
method to protect against chemotherapy induced cell damage. The overall aim of the work 
described in this chapter was to investigate in vitro the effects of both cooling and 
chemotherapy drugs on the cell cycle and using this cell cycle analysis to determine whether 
cooling ameliorates the effects of cytotoxic drugs on the cell cycle of human keratinocytes. 
Furthermore, pharmacological inhibition of EGFR signalling (using the well characterised 
antagonist PD153035) was employed to assess whether EGFR signalling blockade could 
reduce the cytotoxic effects of chemotherapy and thus if PD153035 combined with cooling 
could provide higher protection than cooling alone.  
Specifically the aims of the work in this chapter were to:  
 Explore the effects of cooling on HaCaTa cell cycle and the distribution of cell 
cycle phases at cooling conditions 
 Investigate the effects of chemotherapeutic agents (4-OH-CP, doxorubicin, and 
docetaxel) on HaCaTa cell cycle at physiological temperatures and to compare 
with cooling conditions / low temperatures (22°C and 18°C). 
 Evaluate the ability of the EGFR tyrosine kinase inhibitor PD153035 to suppress 
cell cycle progression and reduce cytotoxicity induced by chemotherapy drugs in 
HaCaTa cells with and without cooling, as a strategy to enhance the effects of 
cooling by PPC. 
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4.5 Cell cycle analysis in HaCaTa cells using flow cytometry  
 Initially, cell cycle analysis of untreated HaCaTa cells grown under standard culture 
conditions 36h after seeding was carried out. The distribution of cells in different phases of 
the cell cycle was determined by flow cytometry after labelling with PI as detailed in the 
methods section 2.12.4. Figure 4-1 shows representative data from such analysis, including 
dot plots (for doublet discrimination) and histograms (to visualise and quantify the proportion 
of cells in the different cell cycle phases). The different stages of the cell cycle are clearly 
denoted, including the G1 phase of the cell cycle (2n DNA content), in the middle the S 
phase peak, and the right-hand peak represents cells in G2/M phase having (4n DNA 
content) just before mitosis. The apoptotic cells, which is represented by the subG0/G1 
population is seen to the left of the G1 peak (Figure 4-1).  
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Figure ‎4-1 Representative cell cycle analysis of unsynchronised proliferating HaCaTa 
cells in culture 
9x105 HaCaTa cells were harvested and fixed in 70% ethanol, DNA stained with PI and cells 
acquired by flow cytometry for cell cycle analysis using the Guava cell cycle assay software 
module. A) Representative plot from a set of three experiments, showing ―gating‖ to 
distinguish cells of interest from cells in apoptosis (subG0/G1) and to discriminate doublets. 
B) The gated data (from A) is used to plot the histogram, which shows the percentage of 
cells in G1, S, G2/M, and subG0/G1. C) Percentages of cells in G1 (42.3%), S (17.9%), 
G2/M (36.7%) and subG0/G1 (3.1%) phases are shown as bar graphs and are presented as 
mean % (±S.E.M.) from three independent biological experiments, each consisting of 2 
technical replicates. 
 
 
 
 
 
Excluded 
area
G2/M
S
G1
subG0/G1
B
C
D
e
b
ri
s
S
in
g
le
 c
e
lls
E
x
c
lu
d
e
d
 
a
re
a
A
0
10
20
30
40
50
60
70
80
90
100
subG0/1 G1 S G2/M
C
el
ls
 %
Phase in cell cycle
DNA content
115 
 
4.5.1 Flow cytometric analysis of human keratinocytes following treatment 
with chemotherapy drugs  
Several studies have shown that exposure of cell lines to chemotherapy drugs 
induces cell arrest in vitro (Jordan and Wilson, 2004; Senderowicz, 2002). In order to better 
characterise the cytotoxic effects of the chemotherapy drugs used in this study, and to 
determine whether these drugs elicited alterations in cell cycle progression, cell cycle 
analysis was performed. The effects of chemotherapeutic drugs on HaCaTa cell cycle 
distribution were examined using PI labelling and flow cytometry as above. HaCaTa cells 
were treated with 0.5 µg/mL doxorubicin, 0.01 µg/mL docetaxel, and 7.5 µg/mL 4-OH-CP 
(Figure 4-2 and 4-3). These drug concentrations were selected for analysis because they 
were the concentrations at which cooling demonstrated the greatest relative rescue of cells 
compared to the toxicity observed at 37°C. To quantify cell cycle distribution, both attached 
and floating cells were collected and analysed.  
 After treatment with doxorubicin, cell cycle analysis was performed 36h later and 
cells clearly accumulated in G2/M phase 75.7% (± 2.1) compared with the control cells 
36.7% (± 1.8). This was accompanied by a decreased G1 cell population of the treated cells 
in comparison with control cells. Furthermore, the subG0/G1 phase of cells treated with 
doxorubicin increased compared with control (Figure 4-2A 4-2B). Doxorubicin acts by 
intercalating between the paired bases in DNA, as a result, cells in the S phase are most 
sensitive to doxorubicin treatment, due to the fact that the DNA is uncoiled at this phase for 
DNA replication (Barlogie et al., 1976). Yet, interestingly, rather than showing an increase in 
S phase, as shown in Figure 4-2A, that the cells were accumulated in G2/M after 36h.  
Results for cells treated with docetaxel showed that the percentage of cells in G2/M 
phase after 36h increased to 45.5% (± 0.5) compared to 36.7% (± 1.8) for the controls 
(Figure 4-2C). There was a corresponding decrease in cells in the G1 and S phases. In 
addition, there was a striking increase in the subG0/G1 fraction 28.3% (± 1.2) in cells treated 
with docetaxel compared to untreated control cells 3.1% (± 0.3). The detection of a 
subG0/G1 peak is a specific marker of apoptosis, which is evidence that cells arrest at G2/M 
and underwent crisis, leading to irreversible arrest and subsequent activation of apoptosis.  
Upon treatment HaCaTa cells with 7.5 µg/mL 4-OH-CP there was a substantial 
accumulation of cells in the S phase 74.8% (± 0.4) compared with the control 17.9% (± 1.4); 
this was accompanied by a significant decrease in the percentage of cells in the G1 and 
G2/M phases (Figure 4-2D). These data suggested that effects of the 4-OH-CP on the 
proliferation of HaCaTa cells involved a block during the S phase. All cell cycle analysis 
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results from independent experiments are summarised in Figure 4-2 as bar graphs which 
allows direct comparison of the percentage of cells in each sample / treatment for controls 
(untreated cells) and drug (doxorubicin, docetaxel and 4-OH-CP)-treated cells. Cell cycle 
analysis revealed significant changes in the percentage of treated cells compared with the 
control cells (untreated cells) in subG0/G1, G1, S and G2/M phase of the cell cycle.  
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Figure ‎4-2 Cell cycle analysis of HaCaTa cells after 36h chemotherapeutic drug 
treatment 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in complete KSFM medium and cells 
were incubated overnight at 37°C / 5% CO2. Cells were treated with 0.5 µg/mL doxorubicin, 
0.01 µg/mL docetaxel and 7.5 µg/mL 4-OH-CP for 2h at 37°C compared with vehicle control 
(cells treated with medium containing DMSO, in which the reagent was dissolved. The 
solvent represents the maximum amount of DMSO corresponding to the highest drug 
concentration). The drugs were then removed; dishes were rinsed with PBS to remove any 
traces of drug and cultures incubated in fresh medium. Both attached and floating cells were 
harvested after 36h and fixed in 70% ethanol and DNA stained with PI. 10,000 cells were 
acquired on a Guava EasyCyte flow cytometer and results analysed using GuavaSoft 
software. Results represent plots of one set of triplicates experiments and the distribution 
and percentage of cells in subG1/G0, G1, S, and G2/M phases of the cell cycle are indicated. 
Percentages of cells in each cell cycle phase distribution means values were determined and 
indicated in each pane from three independent biological experiments, each consisting of 2 
technical replicates. Regions 1, 2, 3 and 4 on each panel represent G0/G1, S, and G2/M and 
subG0/G1 phase of the cell cycle, respectively.   
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Figure ‎4-3 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 36h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates performed as described in Figure 4-2. Bars represent 
mean values of % of cells (±S.E.M.) ***, p < 0.001.  
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4.5.2 The impact of reducing temperature on untreated cultured cells 
Cooling may lead to short term reversible cell cycle arrest in cell culture, suggesting 
that cooling might be a way to achieve selective toxicity of chemotherapeutic agents for cells 
(Matijasevic, 2001). We hypothesised that it might be possible that the cytoprotective effect 
of cooling against chemotherapy-induced toxicity was due to its ability to reduce 
cell proliferation rates. The present study thus tested the influence of cooling on cell cycle 
distribution in HaCaTa cells at 37°C and 22°C, representing the physiological temperature 
and cooling conditions, respectively, and with and without chemotherapeutic agents.  
To understand whether cooling can protect from cytotoxicity of chemotherapy drugs 
by altering the effects of these drugs on the cell cycle, we first investigated the effects of 
cooling alone on cultured human keratinocytes. These experiments involved reduction of the 
culture temperature to 22°C and 18°C in HaCaTa cells in order to determine cell cycle 
distribution after cold exposure for 2h as well as the time required for cell cycle recovery 
following rewarming at 37°C. Initially the effect of 22°C in HaCaTa cell cycle distribution was 
examined. HaCaTa cells were incubated at 22°C for 2h, the percentage of cells in each 
phase of the cycle was G1 phase 52.9% (± 2.1), S phase 27.2% (± 0.9) and G2/M phase 
16.9% (± 0.5) compared to 41.7% (± 0.5), 22.4% (± 1.8), and 32.8% (± 1.4) at 37°C, 
respectively. Therefore, clearly this analysis showed an increase in the G1 and S phase 
populations and a reduction of cell entry into G2/M. Importantly, there was no significant 
difference in subG0/G1 between cells at 22°C 3.1% (± 0.1) and 37°C 3.3% (± 0.3) confirming 
that cooling is not detrimental (toxic) to the cells (Figure 4-4A and B). Thus, exposure of cells 
to 22°C appeared to ―slow down‖ entry to the cell cycle and causing a reduction in cell 
proliferation rate evident by the increase in G1 and S phase peaks and reduction in G2/M 
phase (Figure 4-4C).  
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Figure ‎4-4 Effects of cooling at 22°C vs physiological temperature on HaCaTa cell 
cycle distribution 
9x105 HaCaTa cells were cultured 10 cm2 dish in KSFM medium and cells were incubated 
overnight in 37°C / 5% CO2. Cells were incubated for 2h at 22°C and 37°C as a control. Both 
attached and floating cells were harvested and fixed in 70% ethanol, DNA stained with PI. 
10,000 cells were acquired on a Guava EasyCyte flow cytometer and results analysed using 
GuavaSoft software. Results reprehensive plots of one set of triplicates experiments and the 
distribution percentages of cells in each cell cycle phase distribution means values were 
calculated from triplicate experiments. Regions 1, 2, 3 and 4 on each panel represent G0/G1, 
S, and G2/M and subG0/G1 phase of the cell cycle, respectively. A) Control cells at 37°C B) 
Cells incubated at 22°C C) Bars correspond to mean (±S.E.M.) form three independent 
biological experiments, each consisting of 2 technical replicates. n.s., non-significant; *, p < 
0.05; ***, p < 0.001. 
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4.5.3  The effects of cooling in the prevention of the changes in the cell cycle 
induced by chemotherapy drugs 
Understanding the mechanisms via which cooling may modulate the cell cycle in cells 
treated with chemotherapy drugs is essential for defining the mechanisms behind the 
cytoprotective effect of cooling from chemotherapy drug-induced cytotoxicity. The 
distributions of cells in individual cell cycle phases at different time points were investigated 
in order to a) perform a time course study to follow up cell cycle distribution changes 
following a 2h drug treatment, b) determine if cooling can prevent the changes in the cell 
cycle distribution caused by individual drugs and c) investigate what is the required time 
length for each individual drug needed for cell cycle distribution to return to a normal pattern, 
by comparing cell cycle analysis data for 37°C versus cooling conditions.  
The effects of cooling in cell cycle distribution in HaCaTa cells at various times after 
chemotherapy drug treatment at 37°C, 22°C or 18°C compared to untreated control cells 
were investigated. HaCaTa cells were treated with 0.5 µg/mL doxorubicin, 0.01 µg/mL 
docetaxel, and 7.5 µg/mL 4-OH-CP as previously and cell cycle analysis was performed at 
various time points post the 2h treatment. Specifically, cell cycle analysis was carried out at 
0, 1, 2, 4, 8 and 24h and treated cells were compared with incubation in drug-free medium at 
22°C and at 2 and 36h at 18°C (Materials and Methods section 2.12.4).  
Tests were performed at 22°C and 37°C in HaCaTa cells treated with doxorubicin, 
docetaxel and 4-OH-CP at T=0h (post the 2h treatment) (Figures 4-5 and 4-6). In agreement 
with previous findings (section 3-5), there was a significant change in cell cycle phase 
distribution in untreated cells post incubation for 2h at 22°C compared with untreated cells at 
37°C (Figure 4-4). As shown in Figure 4-5, there was no significant change in cell cycle 
phase in HaCaTa cells treated with doxorubicin or docetaxel at 37°C (T = 0h) compared with 
the control (untreated) cells. Cells treated with doxorubicin and docetaxel whilst incubated at 
22°C, showed little change in the percentage of cells in different phases of the cell cycle 
phases compared with the treated cells at 37°C (Figure 4-5 D and F). Cells treated with 4-
OH-CP at 22°C showed a decrease in cells in the G1 population 37.5% (± 1.7) and an 
increase in G2/M 42.6% (± 1.3) (Figure 4-5G) compared with G1 and G2/M of the control at 
37°C 41.7% (± 0.6) and 32.8% (± 3.9) respectively (Figure 4-5A). However, untreated cells 
incubated at 22°C followed by rewarming at 37°C were recovered rapidly and returned to the 
normal cell cycle distribution after (T=1h) (Figure 4-7B). This indicates a correlation between 
cell growth and temperature and that cell cycle progression is temperature sensitive and 
reversible.  
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The second test series was performed comparing the effect of chemotherapeutic 
drugs on HaCaTa cell cycle (T=1h) post chemotherapy treatment after the cells were 
incubated at 22°C and 37°C (Figures 4-7 and 4-8). The result showed that in cells treated 
with doxorubicin at 37°C there was a small reduction in G1 phase compared to 22°C (Figure 
4-7A and B). However, for cells treated with 4-OH-CP at 37°C (Figure 4-7G) or 22°C (Figure 
4-7H) there was no difference in cell cycle distribution. On the other hand, for cells treated 
with docetaxel at 37°C, the percentages of cells in G1, S and G2/M were 33.4% (± 3.7), 
27.1% (± 1.4), and 37.3% (± 2.6), while at 22°C the corresponding values were 41.7% (± 
0.7), 21.5% (± 0.9) and 34.2% (± 0.9) (Figure 4-7E and F). This was compared to the values 
for untreated control cells at 37°C of 39.8% (± 1.2), 21.1% (± 2) and 36.6% (± 1.2), 
respectively. In the presence of docetaxel, the depolymerisation of the microtubules is 
interrupted, which results in stabilization of the microtubules. These results indicate that 
docetaxel treatment causes cell cycle disturbance more quickly than that which occurs with 
doxorubicin and 4-OH-CP.  
Cell cycle distribution analyses at T=2h is shown in Figures 4-9 and 4-10. Doxorubicin 
induced a marked increase in the subG0/G1 population at 37°C (Figure 4-9C) and 22°C 
(Figure 4-9D) which was 6% (± 0.2) and 5.3% (± 1) respectively compared to controls 
(untreated cells) 2.8% (± 0.5) (Figure 4-9A). The population of G1 in cells treated at 37°C 
was decreased significantly compared with cells treated at 22°C or controls. Two hours after 
docetaxel treatment at 37°C the percentage of cells in G1 was decreased significantly to 
28.8% (± 2.2) in comparison to cells incubated at 22°C 41.3% (± 1) and control cells at 37°C 
38.7% (± 4) (Figure 4-9A). In addition, the percentage of G2/M phase increased to 45.5% (± 
3.7) for cells at 37°C compared to 22°C 33.9% (± 1.9) or the control at 37°C 36.8% (± 3).   
The results of the cell cycle analysis at T=4h after treatment are shown in Figures 4-
11 and 4-12. This data showed that doxorubicin caused cell arrest at G2/M phase at 37°C 
and unexpectedly at 22°C as well, although G2/M phase at 37°C 39.4% (± 3) (Figure 4-11C) 
was higher than at 22°C 38.2% (± 1.2) (Figure 4-11D) compared to the control 34.4% (± 0.7). 
Four hours after docetaxel treatment at 37°C were cells arrested at G2/M 45.1% (± 0.1) 
(Figure 4-11E) compared to treated cells at 22°C 31.3% (± 1.8) (Figure 4-11F) or control 
cells at 37°C this was 34.4% (± 0.7) (Figure 4-11A). By contrast, there were significantly 
fewer cells in G1 after docetaxel treatment at 37°C 20.9% (± 1.6) compared to control at 
37°C 42.6% (± 2.5) but importantly this was almost completely restored for the cells 
incubated at 22°C 38.9% (± 1). This protective effect of cooling also reduced the apoptotic 
cell population peak (subG0/G1) which was for cells incubated at 37°C 10.8% (± 0.3) 
compared to at 22°C 5% (± 0.3).  
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Cell cycle distributions at T=8h post treatment are provided in Figures 4-13 and 4-14. 
Cells were treated with doxorubicin and results shown in Figure 4-13 indicate for cells treated 
at 37°C and 22°C, that G1 phase was significantly less than in control cells (Figure 4-13A). 
However, the percentages of cells in G2/M after doxorubicin treatment increased significantly 
at both 37°C and 22°C compared to the control. In cells treated with docetaxel (T=8h) at 
37°C, it was observed that 17.3% (± 0.6) were in the apoptotic subG0/G1 phase (Figure 4-
13E) indicating that after mitotic arrest a larger number of cells undergo apoptosis and again 
cooling to 22°C significantly reduced subG0/G1 to 5.9% (± 0.1). In addition, the G2/M arrest 
induced by docetaxel at 37°C was higher than at 22°C 50.1% (± 1.2) and 35% (± 3), 
respectively, indicating that the cytotoxicity of docetaxel was reduced. In addition, there were 
significantly less G1 cells at 37°C 15.5% (± 0.7) compared with at 22°C 40.7% (± 0.6). By 
contrast with earlier time points, there were significant changes in cell cycle distribution after 
treatment with 4-OH-CP at both 37°C and 22°C (Figure 4-11G and H) with the percentage of 
subG0/G1 at 37°C 15.6% (± 1.8) was significantly higher than, at 22°C 6.6% (± 0.2). This 
was accompanied by a significantly lower number of G2/M cells after treatment at 37°C 
20.3% (± 0.8) compared with at 22°C 36.5% (± 2.2).  
Experiments on cell cycle distribution at T=24h post treatment are summarised in 
Figures 4-15 and 4-16. Experiments involving treatment with doxorubicin (T=24h) showed 
that many cells appeared to be arrested at the S and G2/M phase at both 37°C (Figure 4-
15C) and at 22°C (Figure 4-15D). As shown in Figure 4-15, at T=24h after treatment with 
docetaxel at 37°C higher percentages of cells are in subG0/G1 and G2/M phase was 
observed compared to the cells treated at 22°C. These results suggest that docetaxel at 
37°C is able to stimulate cell death (indicated by the increase in subG0/G1) and this may be 
the result of increased G2/M arrest; reducing the temperature to 22°C clearly reduced these 
effects. In cells treated with 4-OH-CP, at 37°C there was a distinct peak representing a cell 
population arrested in S phase (Figure 4-15G), with 55.1% (± 3.2) of cells being in S phase 
compared to 18.4% (± 2.8) at 22°C (Figure 4-15H) and compared to control cells 23.5% (± 
2.7) (Figure 4-15A). Cells maintained 16% (± 2.8) at 37°C were in G1 compared to 32.5% (± 
0.7) at 22°C, which was significantly reduced compared with the control cells at both 37°C 
42.6 (± 0.7%) and 22°C 43.7% (± 0.7). On the other hand, cells in the G2/M population 
increased to 46.6% (± 4) at 22°C and this was reduced to 25.4% (± 0.4) at 37°C. This 
compares to 30.7% (± 1.6) for control cells (Figure 4-15A). These findings support results 
presented in chapter 3 that temperatures lower than the physiological temperature protect 
cells from 4-OH-CP cytotoxic effects.  
Collectively, the above results indicate that treatment of HaCaTa cells with 
chemotherapy drugs at 37°C altered cell cycle progression at different phases according to 
124 
 
the mechanism of action of these drugs (Morgan, 2003). However, treating the cells under 
cooling conditions inhibited the effects of the chemotherapy drugs and reduced induced 
apoptosis (indicated by the observed reduction in the percentage of subG0/G1 cells).  
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Figure ‎4-5 Cell cycle analysis of HaCaTa cells after 0h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 0h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG0/G1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively. 
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Figure ‎4-1 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 0h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-2. Bars represent mean values of % of cells 
(±S.E.M.).  
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Figure ‎4-6 Cell cycle analysis of HaCaTa cells after 1h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 1h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG0/G1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively.  
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Figure ‎4-2 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 1h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-7. Bars represent mean values of % of cells 
(±S.E.M.)  
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Figure ‎4-7 Cell cycle analysis of HaCaTa cells after 2h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 2h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG0/G1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively.  
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Figure ‎4-8 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 2h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-9. Bars represent mean values of % of cells 
(±S.E.M.).  
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Figure ‎4-9 Cell cycle analysis of HaCaTa cells after 4h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 4h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicates 
experiments and the distribution and percentage of cell cycle in subG1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively.  
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Figure ‎4-10 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 4h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-11. Bars represent mean values of % of 
cells (±S.E.M.). 
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Figure ‎4-11 Cell cycle analysis of HaCaTa cells after 8h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 8h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively.  
2
3
A Con 37°C
1. 41.6 % ± 1.1
2. 16.6 % ± 1.2
3. 38.2 % ± 2
4. 3.6 % ± 0.2
2
3
B Con 22°C
1. 40.2 % ± 1
2. 20.3 % ± 1.6
3. 36.6 % ± 0.6 
4. 2.8 % ± 0.1
2
3
E Docetaxel 37°C
1. 15.5 % ± 0.7
2. 17.4 % ± 0.5
3. 50.1 % ± 1.2
4. 17.3 % ± 0.6
2
3
Docetaxel 22°C
1. 40.7 % ± 1.3
2. 18.1 % ± 1
3. 35 % ± 3
4. 5.9 % ± 0.1
F
2
3
Doxorubicin 37°C
1. 21.3 % ± 2.5
2. 27.4 % ± 0.8
3. 39.6 % ± 2.6
4. 11.6 % ± 0.6
C
2
3
Doxorubicin 22°C
1. 25.5 % ± 0.2
2. 21.5 % ± 0.1
3. 47 % ± 0.2
4. 6 % ± 0.6
D
4-OH-CP 37°C
1. 45.4 % ± 3
2. 18 % ± 3.1
3. 20.3 % ± 0.8
4. 15.6 % ± 1.8
G
2 2
H 4-OH-CP 22°C
1. 37.8 % ± 2.7
2. 19 % ± 0.2
3. 36.5 % ± 2.2
4. 6.6 % ± 0.2
C
o
u
n
t
DNA content
134 
 
 
Figure ‎4-12 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 8h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-13. Bars represent mean values of % of 
cells (±S.E.M.). 
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Figure ‎4-13 Cell cycle analysis of HaCaTa cells after 24h chemotherapeutic drug 
treatment at 22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 24h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively.  
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Figure ‎4-14 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 24h chemotherapeutic drug treatment 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-15. Bars represent mean values of % of 
cells (±S.E.M.). 
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Moreover, results in this chapter have shown that untreated (non-drug-treated) cells 
at 22°C at different time points after treatment (0–36h) quickly return to exponential growth 
when re-warmed to 37˚C and the cell cycle returns to the normal phase distribution after 1h 
compared to the control cells at 37°C (Figure 4-7B). Data showed that there was no 
significant difference between the controls (non-drug-treated cells) at 22°C after 1h of re-
warming to 37°C and non-drug-treated cells incubated at 37°C. For this reason, for 
comparison between treated and non-treated control, we will use control at 37°C. These data 
suggested that the cell cycle progression is temperature sensitive and returns to normal 
when the temperature increases to physiological temperature (37°C); thus proliferation 
changes induced by cooling are reversible and there was a significant correlation between 
cell growth rate and temperature.  
Tables 4-1, 4-2, and 4-3 summarize all flow cytometric data obtained for HaCaTa 
cells treated with doxorubicin, docetaxel and 4-OH-CP, to permit comparison of flow 
cytometric data at 37°C and 22°C for each drug in a simple and understandable fashion. 
These tables summarise cell cycle progression analysis at different time point and statistical 
analysis of cell cycle phase distribution shown in Figures 4-5 to 4-16.  
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0.5 µg/mL doxorubicin  
Time-point G0/G1 % S % G2/M % subG0/G1 % 
37°C 22°C 37°C 22°C 37°C 22°C 37°C 22°C 
Con 39.8% ± 1.2  40.1% ± 0.8  21.1% ± 2  24.1% ± 0.2  36.6% ± 1.2  33.7% ± 1.1 2.5% ± 0.3  2.2 ± 0.2 
0h 44.8% ± 0.7  44.6% ± 0.5  17.4% ± 2.1  22% ± 0.1  35.7% ± 2.1  31% ± 0.7  4.2% ± 0.3  2.4 ± 0.1  
1h 37.2% ± 0.1  41.4% ± 0.6  23.6% ± 1.2 22.6% ± 0.7  36.6% ± 0.3  33.6% ± 0.6  2.4% ± 0.6 2.4 ± 0.1  
2h 34.3% ± 1.1  38% ± 1.6  27.3% ± 3.6  27.6% ± 2.5  32.4% ± 2.6  28.4% ± 3  6% ± 0.2  5.3 ± 1  
4h 26.9% ± 1.2  33.6% ± 1.2  25.3% ± 0.2  24.4% ± 0.2  39.4% ± 3  38.2% ± 1.2  8.4% ± 1.7  3.6 ± 0.2  
8h 21.3% ± 2.5  25.5% ± 0.2  27.4% ± 0.8  21.5% ± 0.1  39.6% ± 2.6  47% ± 0.2  11.6% ± 0.6  6 ± 0.6  
24h 5% ± 1.1  14.3% ± 0.5  15.5% ± 1.7  15.4% ± 1.4  76.3% ± 3.7 68.9% ± 2.9  3.1% ± 0.9  2.2 ± 0.7  
 
Table ‎4-1 Cell cycle distribution of HaCaTa cells between control (untreated cells) and cells treated with doxorubicin 
The table summarizes the percentage mean values ± S.E.M of each cell cycle phase in HaCaTa cells treated with 0.5 µg/mL of doxorubicin at 
37°C and 22°C (representing normal and cooling conditions, respectively) compared with vehicle control (cells treated with medium containing 
the solvent in which the reagent was dissolved) at various time-point (0, 1, 2, 4, 8, and 24h). Data points were obtained from three independent 
biological experiments, each consisting of 2 technical replicates.  
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0.01 µg/mL docetaxel  
Time-point G0/G1 % S % G2/M % subG0/G1 % 
37°C 22°C 37°C 22°C 37°C 22°C 37°C 22°C 
Con 39.8% ± 1.2  40.1% ± 0.8  21.1% ± 2  24.1% ± 0.2  36.6% ± 1.2  33.7% ± 1.1 2.5% ± 0.3  2.2% ± 0.2 
0h 41.5% ± 0.1  45.9% ± 0.1  21.2% ± 0.6  22.1% ± 0.4  35.2% ± 1.2  29.3% ± 2.5  3.8% ± 0.2  3.5% ± 1.8  
1h 33.4% ± 3.7  41.7% ± 0.7  27.1% ± 1.4  21.5% ± 0.9  37.3% ± 2.6  34.2% ± 0.9  2.3% ± 0.7  2.6% ± 0.2  
2h 28.8% ± 2.2  41.3% ± 1  20.3% ± 1.9  20.8% ± 1  45.5% ± 3.7  33.9% ± 1.9  5.4% ± 0.2  3.9% ± 0.2  
4h 20.9% ± 1.6  38.9% ± 1  23.1% ± 1.3  24.1% ± 0.5  45.1% ± 0.1  31.3% ± 1.8  10.8% ± 0.3  5% ± 0.3  
8h 15.5% ± 0.7  40.7% ± 1.3  17.4% ± 0.5  18.1% ± 1  50.1% ± 1.2  35% ± 3  17.3% ± 0.6  5.9% ± 0.1  
24h 14.7% ± 0.1  44.5% ± 2.2  11.9% ± 0.2  20.5% ± 0.7  50.8% ± 0.6  27.3% ± 1  22.6% ± 0.5  8.2% ± 1.7  
 
Table ‎4-2 Distribution of HaCaTa cells between cell cycle phases in control (untreated cells) and treated with docetaxel 
The table summarizes the percentage mean values ± S.E.M of each cell cycle phase cell populations of HaCaTa cells were treated with 0.01 
µg/mL of docetaxel at 37°C and 22°C (representing normal and cooling conditions, respectively) compared with vehicle control (cells treated 
with medium containing the solvent in which the reagent was dissolved) at various time-point (0, 1, 2, 4, 8, and 24h). Data points obtained from 
three independent biological experiments, each consisting of 2 technical replicates.  
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7.5 µg/mL 4-OH-CP  
Time-point G0/G1 % S % G2/M % subG0/G1 % 
37°C 22°C 37°C 22°C 37°C 22°C 37°C 22°C 
Con 39.8% ± 1.2  40.1% ± 0.8  21.1% ± 2  24.1% ± 0.2  36.6% ± 1.2  33.7% ± 1.1 2.5% ± 0.3  2.2% ± 0.2 
0h 37.5% ± 1.7  47.9% ± 1.3  18% ± 2.2  29% ± 0.1  42.6% ± 1.3  21.1% ± 1.4  2.2% ± 0.8  2% ± 0.3  
1h 39.4% ± 0.4  42.2% ± 2.2  21.8% ± 3.6  18.7% ± 2.1  36.9% ± 3.1  36.7% ± 0.1  2.6% ± 0.1  2.2% ± 0.2  
2h 36.8% ± 0.5  39.1% ± 0.3  20% ± 1.4  19.4% ± 0.4  35% ± 2.3  39.4% ± 0.9  8% ± 0.6  2.4% ± 0.1  
4h 46% ± 2.5  39.1% ± 1.8  24% ± 0.7  23.3% ± 0.8  26.4% ± 1.3  34.1% ± 1.8  3.7% ± 0.3  3.6% ± 0.7  
8h 45.4% ± 3  37.8% ± 2.7  18% ± 3.1  19% ± 0.2  20.3% ± 0.8  36.5% ± 2.2  15.6% ± 1.8  6.6% ± 0.2  
24h 16% ± 2.8 32.5% ± 0.7  55.1% ± 3.2  18.4% ± 2.8  25.1% ± 0.4  46.6% ± 4  3.5% ± 0.1  2.8% ± 0.1  
 
Table ‎4-3 Distribution of HaCaTa cells between cell cycle phases in control (untreated cells) and treated with 4-OH-CP 
The table summarizes the percentage mean values ± S.E.M of each cell cycle phase cell populations of HaCaTa cells were treated with 7.5 
µg/mL of 4-OH-CP at 37°C and 22°C (representing normal and cooling conditions, respectively) compared with vehicle control (cells treated 
with medium containing the solvent in which the reagent was dissolved) at various time-point (0, 1, 2, 4, 8, and 24h). Data points obtained from 
three independent biological experiments, each consisting of 2 technical replicates. 
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4.5.3.1 Determining the efficacy of cooling in protecting from 
chemotherapy drug-mediated cytotoxicity  
The results of this study showed that lowering the temperature below 22°C results in 
improved cytoprotection against chemotherapy drug-mediated keratinocyte cytotoxicity 
(Chapter 3). Another key finding was that cooling at 22°C protected from chemotherapy drug 
induced cell cycle arrest in HaCaTa cells. To investigate whether temperature values below 
22°C could provide further protection against cell cycle arrest induced by doxorubicin, 4-OH-
CP and docetaxel cell, cycle analysis was performed at 18°C.  
To compare the cell cycle phase distribution of HaCaTa at 37°C and 18°C, two 
different sets of experiments were performed, i.e. 2h and 36h at the 18°C post 2h treatment 
with chemotherapeutic drugs. As shown by the DNA content histograms in Figure 4-17 and 
4-19, the effects of doxorubicin on cell cycle distribution were significantly reduced at 18°C 
compared with at 22°C, evident by representative results shown in T=2h (Figures 4-17 and 4-
18) and T=36h (Figures 4-19 and 4-20). The most striking results were observed in Figure 4-
17F, where cell cycle distribution after docetaxel at 18°C was close to that of the untreated 
control cells compared with cells treated at 37°C and 22°C. These results provided strong 
evidence that lowering the temperature from 22°C to 18°C, dramatically protected cells 
further from cytotoxicity.  
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Figure ‎4-15 Cell cycle analysis of HaCaTa cells after 2h chemotherapeutic drug treatment at 
22°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 2h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively. 
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Figure ‎4-16 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 2h chemotherapeutic drug treatment at 18°C 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-17. Bars represent mean values of % of 
cells (±S.E.M.). 
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Figure ‎4-17 Cell cycle analysis of HaCaTa cells after 36h chemotherapeutic drug 
treatment at 18°C and 37°C 
9x105 HaCaTa cells were cultured in 10 cm2 dishes in KSFM medium and cells were 
incubated overnight in 37°C / 5% CO2. HaCaTa cells were treated with 0.5 µg/mL of 
doxorubicin (Doxo), 0.01 µg/mL docetaxel (Doce), and 7.5 µg/mL 4-OH-CP for 2h at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; dishes 
were rinsed with PBS to remove any traces of drug and cultures incubated in fresh medium. 
Both attached and floating cells were harvested after 36h and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Results reprehensive plots of one set of triplicate 
experiments and the distribution and percentage of cell cycle in subG1, G1, S, and G2/M 
phase of the cell cycle are indicated. Percentages of cells in each cell cycle phase 
distribution mean values were calculated from three independent biological experiments, 
each consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent 
G0/G1, S, and G2/M and subG0/G1 phase of the cell cycle, respectively. 
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Figure ‎4-18 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after 36h chemotherapeutic drug treatment at 18°C 
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-19. Bars represent mean values of % of 
cells (±S.E.M.). 
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For ease of interpretation and to permit easier direct comparisons to be made, data in 
Figures 4-17 to 4-20 are presented in Table 4-4, which summarizes the flow cytometric data 
obtained for HaCaTa cells treated with doxorubicin, docetaxel and 4-OH-CP respectively at 
37°C and 18°C. These results supported the hypothesis that lowering the temperature from 
22°C to 18°C resulted incrementally in a better degree of rescue from drug cytotoxicity.  
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A 
0.5 µg/mL doxorubicin 
Time-point 
G0/G1 % S % G2/M % subG0/G1 % 
37°C 18°C 37°C 18°C 37°C 18°C 37°C 18°C 
Con 45.7% ± 3.5  41.2% ± 0.1  17.7% ± 2.2  18.2% ± 0.4  33.9% ± 1.4  39.1% ± 0.5  3.2% ± 0.2  1.7% ± 0.2  
2h 34.8% ± 0.3  42.1% ± 0.1  26.5% ± 0.4  22% ± 1.1  33.3% ± 0.6  33.7% ± 1.5  5.2% ± 0.4  2.2% ± 0.3  
36h 9.6% ± 0.5 34.9% ± 1.6  7.7% ± 0.7  18.8% ± 2  76.8% ± 0.5  42.9% ± 0.3  5.8% ± 0.5  4.5% ± 0.1  
B 
0.01 µg/mL docetaxel  
Time-point 
G0/G1 % S % G2/M % subG0/G1 % 
37°C 18°C 37°C 18°C 37°C 18°C 37°C 18°C 
Con 45.7% ± 3.5  41.2% ± 0.1  17.7% ± 2.2  18.2% ± 0.4  33.9% ± 1.4  39.1% ± 0.5  3.2% ± 0.2  1.7% ± 0.2  
2h 32.9% ± 0.2  43.6% ± 0.1  20.7% ± 1.7  20.6% ± 2  41.4% ± 1.7  32.8% ± 1.6  5% ± 0.1  2.7% ± 0.1  
36h 15% ± 0.5  46.2% ± 1.3  10.1% ± 1  19.1% ± 0.3  36.8% ± 0.6  30% ± 0.7  37.6% ± 1.9  4.6% ± 1.1  
C 
7.5 µg/mL 4-OH-CP  
Time-point 
G0/G1 % S % G2/M % subG0/G1 % 
37°C 18°C 37°C 18°C 37°C 18°C 37°C 18°C 
Con 45.7% ± 3.5  41.2% ± 0.1  17.7% ± 2.2  18.2% ± 0.4  33.9% ± 1.4  39.1% ± 0.5  3.2% ± 0.2  1.7% ± 0.2  
2h 36.8% ± 0.5  44% ± 0.8  20% ± 1.4  19.8% ± 1  35% ± 2.3  33.4% ± 2.3  8% ± 0.6  2.7% ± 0.7  
36h 13% ± 2.6  44.6% ± 0.7  56.2% ± 3.2  18.3% ± 0.3  22.3% ± 0.7  33.4% ± 0.2  8.4% ± 0.2  4% ± 0.5  
 
Table ‎4-4 Distribution of HaCaTa cells between cell cycle phases in control (untreated cells) and treated at at 37°C and 18°C  
The table summarizes the percentage mean values ± S.E.M of each cell cycle phase cell populations of HaCaTa cells were treated with A) 0.5 
µg/mL doxorubicin, B) 0.01 µg/mL docetaxel, and C) 7.5 µg/mL of 4-OH-CP at 37°C and 18°C (representing normal and cooling conditions, 
respectively) compared with vehicle control (cells treated with medium containing the solvent in which the reagent was dissolved) at various 
time-point (2 and 36h). Data points obtained from three independent biological experiments, each consisting of 2 technical replicates.  
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4.6 Short-term starvation protects HaCaTa cells against 
chemotherapy drugs 
Anti-cancer drugs cause different side effects by mediating toxicity to normal cells 
and tissues, for instance cardiotoxicity and hair loss are associated with doxorubicin and 
cisplatin (Wang et al., 2004). Thus, decrease of undesired chemotoxicity by selective 
protection of normal cells without compromising the killing of cancer cells represents a 
promising strategy to enhance cancer treatment (Safdie et al., 2009). Previous studies 
showed that short-term fasting could be effective in protecting normal cells and mice but not 
cancer cells against high dose anticancer drugs (Raffaghello et al., 2008).  
We hypothesised that cooling may protect cells from cytotoxic drugs, partly by 
decreasing the metabolic activity of the cells, which inhibits proliferation (Lemieux, 2012). 
Thus, we tested whether cooling combined with short-term starvation could enhance the 
scalp cooling method against chemotherapy drug effects. HaCaTa cells were incubated in 
supplements (supps)-free medium (KSFM without supplements EGF and bovine pituitary 
extract BPE)) for 24h. HaCaTa cells were then treated with three concentrations of 
doxorubicin, docetaxel, and 4-OH-CP at 37°C and 22°C in KSFM with and without 
supplements then cell viability was assessed as previously.  
Data showed that pre-starvation of cells (incubated cells in KSFM without supps) for 
24h then treatment with doxorubicin, docetaxel, 4-OH-CP, provided consistent and significant 
protection from drug-mediated cytotoxicity at 37°C compared with cells incubated and treated 
at 37°C in KSFM complete with supps (KSFMc) (Figure 4-21). Interestingly, cells at 22°C in 
KSFMc showed better or similar protection compared to cells treated at 22°C in KSFM 
without supps (Figure 4-21). These results suggest that starvation can be effective in 
protecting HaCaTa cells against chemotherapy at physiological temperature but cooling 
alone protects better. Short-term starvation is more effective to prevent chemotherapy drug 
toxicity since starved cells switch off signals for growth, however, cooling alone was more 
effective than exposure the cells to both cooling and starvation. 
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Figure ‎4-19 Cytoprotective role of cooling and short-term starvation protects against 
chemotherapy drug-mediated toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. The medium were then removed and HaCaTa cells 
were incubated in KSFM free supps for 24h, compared with cells incubated in KSFMc. 
HaCaTa cells were treated for 2h with a range of concentrations of doxorubicin (Doxo), 
docetaxel (Doce) and 4-OH-CP at 37°C and 22°C (representing normal and cooling 
conditions, respectively) compared with vehicle control (cells treated with medium containing 
DMSO, in which the reagent was dissolved. The solvent represents the maximum amount of 
DMSO corresponding to the highest drug concentration). The drugs were then removed, 
wells were rinsed with PBS to remove any traces of drug and cultures incubated for a further 
72h, and after which 20 µL of CellTiter 96® AQueous One solution was added to the wells 
and plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm and % cell biomass was 
calculated as described in Materials and Methods (Chapter 2). A) Absorbance (raw data) 
were B) % cell biomass shown in bar graph are also shown in bar graph form (lower panels) 
for clarity and presentation of statistical significance. Data points correspond to mean % cell 
biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. n.s., non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
Key: No supps: KSFM with no supplements  
KSFMc: KSFM medium with complete supplements 
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4.7 Cytoprotective role of the PD153035 against chemotherapy 
drug-mediated toxicity in HaCaTa cells 
EGFR is a receptor tyrosine kinase involved in regulation of apoptosis, and 
particularly proliferation and angiogenesis (Cole et al., 2005) and it plays an important role in 
HF homeostasis by acting as an important regulator of cell proliferation. It has thus been 
suggested that topical inhibition of EGFR signalling might permit protection from CIA (Bichsel 
et al., 2013). We hypothesised that ―artificial‖ deceleration of cell growth by blockade of the 
cell cycle may reduce the cytotoxic effects of chemotherapy drugs; i.e. ―protective pre-
conditioning‖ (PPC) by pharmacological inhibition of EGFR, might represent a strategy to 
reduce the effects of chemotherapy drugs and perhaps enhance the cytoprotective effect of 
cooling. We therefore inhibited the kinase activity of the EGF receptor by the use of the 
specific EGFR inhibitor PD153035, which is a reversible tyrosine kinase activity inhibitor that 
inhibits auto-phosphorylation of EGFR and efficiently blocks EGFR signalling as shown by 
ourselves (Georgopoulos et al., 2014) and others (Bos et al., 1997; Fry et al., 1994; Grunt et 
al., 2007).  
We initially determined the optimal PD153035 concentration to be used in HaCaTa by 
pre-titration experiments (using inhibitor concentrations in the range of 0.25-10 µM) and 
cytotoxicity was determined by measuring cell absorbance (using the CellTiter assay) 72h 
later (Figure 4-22). Data confirmed that the optimal concentration for PD153035 was 3 µM 
compared to the control (cells not treated with PD153035). Indeed, HaCaTa cells treated with 
lower inhibitor concentrations of PD153035 exhibited higher viability than control cells and 
higher concentrations exhibited increasing cytotoxicity (Figure 4-22).  
We ultimately aimed to determine whether PPC using PD153035 could enhance the 
efficacy of cooling. First, we examined the effect of pre-treatment of HaCaTa cells for 2h with 
3μM of PD153035 on the effects of cytotoxic drugs (doxorubicin, docetaxel, 4-OH-CP) at 
37°C. As shown in Figure4-23, there was no significant increase in biomass in cells treated 
with doxorubicin compared with cells treated with KSFM with and without supplements. 
However, cells treated with docetaxel showed a slightly better protection, but only at low 
concentrations in cells treated with PD153035. Similar observations were made with cells 
treated with 4-OH-CP as they too showed a slight increase (Figure 4-23). These data 
suggested that when EGFR signalling was inhibited for only 2h before drug treatment, the 
protection from drug toxicity was minimal and only significant for lower drug doses. To 
examine whether an increase in the pre-treatment time period may offer a better level of 
protection from cytotoxicity, cells were pre-treated for 24h with PD153035. Interestingly, 24h 
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pre-treatment with PD153035 exhibited a marked ability to significantly protect cells from 
cytotoxicity for all three compounds tested (Figure 4-24), which confirmed that PPC could, at 
least in part, rescue cells from drug toxicity.  
We then investigated the effect of combination of PPC and cooling by testing the 
response of HaCaTa to these chemotherapy drugs at 37°C and 22°C. For each temperature, 
there were 4 types of pre-treatment conditions: 1) cells treated with KSFMc, 2) cells treated 
in medium without supps, 3) cells treated with KSFMc + PD153035, 4) cells treated in 
medium without supps + PD153035. As shown in Figures 4-25 to 4-27, that combination of 
PD153035 and cooling during chemotherapy drug treatment provided consistent and 
significant protection from drug-mediated cytotoxicity for nearly all concentrations tested for 
doxorubicin, 4-OH-CP and, though to a lesser extent, docetaxel.  
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Figure ‎4-20 Viability of HaCaTa cells after incubation with the tyrosine kinase inhibitor 
PD 153035 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were incubated with a range of 
concentrations of the tyrosine kinase inhibitor PD153035; two controls included were cells 
incubated in KSFMc and cells in No sup medium. After 72h incubation, 20 µL of CellTiter 
96® AQueous One solution was added to the appropriate wells and plates were incubated at 
37°C in 5% CO2 for a total of 4hours. Bars correspond to mean absorbance at 492 nm 
(±S.E.M.) from three independent biological experiments, each consisting of 6-8 technical 
replicates. n.s., non- significant; *, p < 0.05. 
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium complete with all supplements 
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Figure ‎4-21 Cytoprotective role of 2h pre-treatment by PD153035 against 
chemotherapy drug-mediated toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with 3 µM PD153035 
or in KSFMc or KSFM free supps (No supps) for 2h. HaCaTa cells were treated for 2h with 
(0.5, 0.75, and 2.5 µg/mL) doxorubicin (Doxo), (0.005, 0.025, and 0.1 µg/mL) docetaxel 
(Doce) and (2.5, 5, and 10 µg/mL) 4-OH-CP, in KSFM with PD153035, or in KSFMc or KSFM 
(No supps) at 37°C compared with vehicle control (cells treated with medium containing 
DMSO, in which the reagent was dissolved. The solvent represents the maximum amount of 
DMSO corresponding to the highest drug concentration). The drugs were then removed, 
wells were rinsed with PBS to remove any traces of drug and cells, which pre-treated 
incubated with PD153035 and the both other groups were incubate in fresh KSFMc for 72h, 
after which 20 µL of CellTiter 96® AQueous One solution was added to the wells and plates 
were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was measured 
spectrophotometrically at a wavelength of 492nm and % cell biomass was calculated as 
described in Materials and Methods (Chapter 2). Data are presented as A) Absorbance (raw 
data) B) % cell biomass shown in a bar graph. Data points correspond to mean % cell 
biomass (±S.E.M.) from three independent biological experiments, each consisting of 6-8 
technical replicates. n.s., non- significant; *, p < 0.05. 
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium with complete supplements 
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Figure ‎4-22 Cytoprotective role of 24h pre-treatment by PD153035 against 
chemotherapy drug-mediated toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with 3 µM PD153035 
or in KSFMc or KSFM (No sup) for 24h. HaCaTa cells were treated for 2h with (0.5, 0.75, 
and 2.5 µg/mL) doxorubicin (Doxo), (0.005, 0.025, and 0.1 µg/mL) docetaxel (Doce) and (2.5, 
5, and 10 µg/mL) 4-OH-CP, in KSFMc with PD153035, or in KSFM (No supps) at 37°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cells, which pre-treated incubated with 
PD153035 and the both other groups were incubated in fresh KSFMc for 72h, after which 
20µL of CellTiter 96® AQueous One solution was added to the wells and plates were 
incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was measured 
spectrophotometrically at a wavelength of 492nm and % cell biomass was calculated as 
described in Materials and Methods (Chapter 2). Data is presented as A) Absorbance (raw 
data) B) % cell biomass shown in bar graph. Data points correspond to mean % cell biomass 
(±S.E.M.) from three independent biological experiments, each consisting of 6-8 technical 
replicates. n.s., non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium with complete supplements 
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Figure ‎4-23 Cytoprotective role of cooling + PD153035 against doxorubicin-mediated 
toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with 3 µM PD153035 
or in KSFMc or KSFM (No supps) for 24h. HaCaTa cells were treated for 2h with (0.5, 0.75, 
and 2.5 µg/mL) doxorubicin (Doxo), in 4 types of medium, 1) KSFMc, 2) KSFM (No supps) 3) 
KSFMc contained 3 µM PD153035 4) KSFM (No supps) contained 3 µM PD153035 at 37°C 
and 22°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cells, which pre-treated incubated with 
PD153035 and the both other groups were incubate in fresh KSFMc. 72h, after which 20 µL 
of CellTiter 96® AQueous One solution was added to the wells and plates were incubated at 
37°C in 5% CO2 for a total of four hours. Absorbance was measured spectrophotometrically 
at a wavelength of 492nm and % cell biomass was calculated as described in Materials and 
Methods (Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass 
shown in bar graph. Data points correspond to mean % cell biomass (±S.E.M.) from three 
independent biological experiments, each consisting of 6-8 technical replicates. ***, p < 
0.001.  
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium with complete supplements 
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Figure ‎4-24 Cytoprotective role of cooling + PD153035 against 4-OH-CP-mediated 
toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with 3 µM PD153035 
or in KSFMc or KSFM (No supps) for 24h. HaCaTa cells were treated for 2h with (2.5, 5, and 
10 µg/mL) 4-OH-CP, in 4 types of medium, 1) KSFMc, 2) KSFM (No supps) 3) KSFMc 
contained 3 µM PD153035 4) KSFM (No supps) contained 3 µM PD153035 at 37°C and 
22°C compared with vehicle control (cells treated with medium containing DMSO, in which 
the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cells, which pre-treated incubated with 
PD153035 and the both other groups were incubate in fresh KSFMc. 72h, after which 20 µL 
of CellTiter 96® AQueous One solution was added to the wells and plates were incubated at 
37°C in 5% CO2 for a total of four hours. Absorbance was measured spectrophotometrically 
at a wavelength of 492nm and % cell biomass was calculated as described in Materials and 
Methods (Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass 
shown in bar graph. Data points correspond to mean % cell biomass (±S.E.M.) from three 
independent biological experiments, each consisting of 6-8 technical replicates. ***, p < 
0.001.  
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium with complete supplements 
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Figure ‎4-25 Cytoprotective role of cooling + PD153035 against docetaxel-mediated 
toxicity in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with 3 µM PD153035 
or in KSFM with complete supps or KSFM free supps for 24h. HaCaTa cells were treated for 
2h with (0.005, 0.025, and 0.1 µg/mL) docetaxel (Doce), in 4 types of medium, 1) KSFMc, 2) 
KSFM (No supps) 3) KSFMc contained 3 µM PD153035 4) KSFM (No supps) contained 3 
µM PD153035 at 37°C and 22°C compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cells, which pre-
treated incubated with PD153035 and the both other groups were incubate in fresh KSFMc. 
72h, after which 20 µL of CellTiter 96® AQueous One solution was added to the wells and 
plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm and % cell biomass was 
calculated as described in Materials and Methods (Chapter 2). Data is presented as A) 
Absorbance (raw data) B) % cell biomass shown in bar graph. Data points correspond to 
mean % cell biomass (±S.E.M.) from three independent biological experiments, each 
consisting of 6-8 technical replicates. *, p < 0.05; ***, p < 0.001.  
Key: No supps: KSFM with no supplement  
KSFMc: KSFM medium with complete supplements 
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4.7.1 Cell cycle analysis after growth inhibition 
As shown in section 4.7, the combination of PD153035 treatment (PPC) and cooling 
(compared with incubation cells in KSFM with and without supps) showed that there was 
decrease in HaCaTa cells proliferation after 24h and this resulted in a significant increase in 
rescue from drug cytotoxicity. We therefore sought to determine whether a) removal of 
medium supps alone, b) PD153035 treatment alone, or c) combination of medium supps 
removal and PD153035 and the changes in cell viability observed correlated with changes in 
cell cycle distribution.  
Interestingly, cell proliferation was inhibited by removal of growth factors (supps) as 
indicated by the observed cell cycle arrest in G0/G1 phase (Figure 4-28). The percentage of 
the G1 in cells incubated in KSFMc (normal growth medium with full set of supps) was 47.2% 
(± 0.5) and this percentage increased to 49.4% (± 0.4) in cells incubated in KSFM containing 
bovine pituitary extract (BPE) extract only but no recombinant EGF ligand (Figure 4-28B). 
This percentage increased further to 53.7% (± 0.9) when cells were incubated for 24h in 
KSFM without any supps (Figure 4-28C). In HaCaTa cells treated with 3 µM PD153035, the 
percentage of G1 was 55.0% (± 0.8) (Figure 4-28D). Importantly, the most dramatic change 
was observed in cells treated for 24h in KSFM without supps and in the presence of 
PD153035 inhibitor and the percentage was 63.1% (± 0.6) (Figure 4-28E). In these groups, 
the percentage of cells undergoing S phase was reduced from 15.3 (± 1.3) to 13.5% (± 1.5), 
11.8% (± 0.5), 10.6% (± 0.4), and 8.8% (± 0.7), respectively (Figure 4-28). These findings 
confirmed that the ability of PPC to enhance protection from drug cytotoxicity could be 
attributed to its property to regulate the cell cycle.  
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Figure ‎4-26 Effects of EGFR signalling pathway inhibition by PD153035 vs removal of 
growth factors (starvation) on HaCaTa cell cycle distribution 
9x105 HaCaTa cells were cultured 10 cm2 dish in KSFMc and cells were incubated overnight 
in 37°C / 5% CO2. Cells were incubated at 37°C/5% CO2 for 24h in A) KSFMc; B) in BPE 
without EGF; C) KSFM (No supps); D) KSFMc + PD153035; E) in KSFM (No supps) + 
PD153035. Both attached and floating cells were harvested and fixed in 70% ethanol, DNA 
stained with PI. 10,000 cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. The results represent plots of one set of triplicate 
experiments and the distribution percentages of cells in each cell cycle phase distribution 
means values were calculated from three independent biological experiments, each 
consisting of 2 technical replicates. Regions 1, 2, 3 and 4 on each panel represent G0/G1, S, 
and G2/M and subG0/G1 phase of the cell cycle, respectively. 
 Key: No supps: KSFM with no supplement 
KSFMc: KSFM medium with complete supplements 
BPE: Bovine pituitary extract 
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Figure 4-29 Summary of independent replicate experiments for cell cycle analysis of 
HaCaTa cells after EGFR signalling pathway inhibition by PD153035 vs removal of 
growth factors (starvation)  
Bar graph summarises data obtained from three independent biological experiments, each 
consisting of 2 technical replicates as in Figure 4-28. Bars represent mean values of % of 
cells (±S.E.M.). 
Key: No supps: KSFM with no supplements    
KSFMC: KSFM medium with complete supplements 
BPE: Bovine pituitary extract 
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4.8 Summary  
 The main aims of this chapter were to a) identify the influence of the chemotherapy 
drugs doxorubicin, docetaxel and 4-OH-CP on the cell cycle in HaCaTa using flow 
cytometry and explore the effects of cooling on cell cycle distribution with and 
without drugs; and b) to determine whether protective pre-conditioning (PPC) 
using EGFR signalling blockade could enhance the ability of cooling to rescue 
cells from drug cytotoxicity.  
 The results have demonstrated that cooling cells did not fully block cell 
progression through G1, S phase or M phases, but we did observe an increase in 
the G1 phase peak and a decrease in G2/M phase directly after 2h of cooling 
(T=0h). However, this effect was temporary and reversible as cell cycle distribution 
returned to normal rapidly (after 1h). This result indicated that perhaps a cell cycle 
checkpoint is involved triggered by cooling that regulates progression through G1 
and cell cycle entry or G2/S transition; alternatively, it could be purely that cell 
metabolism overall is slowed down due to cooling, resulting in cell cycle 
deceleration.  
 Flow cytometer results demonstrated that chemotherapy drugs induced cell cycle 
redistribution at 37°C: treatment with doxorubicin arrested the cells in G2/M 
phases, docetaxel showed a high subG0/G1 population and arrest in G2/M, and 4-
OH-CP treatment appeared to arrest cells in S phase.  
 When chemotherapy drug-exposed cells treated at 37°C were compared with cells 
treated at 22°C and 18°C at different time points, it was shown that cooling 
protects from drug-induced changes in cell cycle distribution. Different drugs 
(doxorubicin, docetaxel, and 4-OH-CP) responded to cooling in different ways (as 
expected, based on the different molecular mechanisms that underlie the ability of 
individual drugs to cause cell cycle changes). 
 Importantly, cooling induced the recovery from DNA damage checkpoint arrest 
when the temperature was reduced from 22°C to 18°C, which is supportive of the 
findings in Chapter 3, where a further reduction in temperature provided better 
rescue.  
 The effects of 0.5 µg/mL doxorubicin in HaCaTa cells were tested at different time 
points (0-24h). After 2h at 37°C there was a decreased G1 and an increased G/M 
phase compared to control cells. However, in cells treated at 22°C there was a 
decreased G2/M phase. After 4h the result at 37°C and 22°C showed further 
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decrease in G1 and the increase in both G2/M and subG0/G1 population, but the 
cells treated at 22°C showed a less subG0/G1 population. After 8h, 37°C 
conditions showed higher G2/M and subG0/G1 % populations than did 22°C. The 
results showed that most cells become arrested in G2/M phase at 24h after cells 
were exposed to doxorubicin and the results showed high peaks in G2/M phase for 
both temperatures 37°C and 22°C. However, G1 phase at 22°C was slightly higher 
than G1 at 37°C. When cells were treated with doxorubicin at 18°C they showed 
better inhibition of doxorubicin effects on cell cycle redistribution.  
 A concentration of 0.01 µg/mL docetaxel in HaCaTa cells was able to induce G2/M 
arrest, starting as early as 1h after treatment at 37°C compared to control and this 
significantly increased after 4h with an accompanying reduction in the G1 
population and this continued to increase up to 24h. This was significantly 
attenuated when the cells were incubated at 22°C and virtually abolished at 18°C.  
 When HaCaTa were exposed to 7.5 µg/mL 4-OH-CP at 37°C there was a 
significant increase in G1 and decrease of G2/M phase compared to the control 
between 2 and 8h after treatment. This effect was reduced when the cells, which 
were treated at 22°C. After 24h in the cells, which were treated at 37°C, 
proliferation was significantly inhibited via induction arrested at the S phases 
compared to control cells after 24h. In cells treated at 22°C the effects of 4-OH-CP 
were significantly inhibited and at 18°C the cell cycle distribution was close to the 
distribution of the control. These findings are compatible with the hypothesis that 
cyclophosphamide induces DNA cross-links as a result of that cause changes of 
the cell cycle, and this is inhibited by cooling.  
 Moreover, we investigated the responses of HaCaTa cells to starvation as well as 
EGFR tyrosine kinase inhibitor PD153035 with and without treatment of 
chemotherapy drugs. We showed that short-term starvation (by incubating cells 
without supplements) resulted in a higher biomass compared with cells treated 
with complete KSFM medium (KFSM medium with complete supplements) which 
provided evidence that the slowing cell growth rate correlates with protection from 
the cytotoxicity of the chemotherapy drugs. Pre-treatment with the EGFR inhibitor 
PD153035 significantly protected from drug-mediated cytotoxicity for all 
compounds tested confirming that PPC could, at least partly, rescue cells from 
drug toxicity.  
 Importantly, combination of PD153035 and cooling during chemotherapy drug 
treatment provided significant protection from drug-mediated cytotoxicity for nearly 
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all concentrations tested for doxorubicin, 4-OH-CP and, though to a lesser extent, 
docetaxel.  
 Finally, cell cycle analysis provided evidence that the ability of PPC to enhance 
protection from drug cytotoxicity could be attributed to its property to regulate the 
cell cycle distribution.  
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4.9 Discussion 
4.9.1 Role of cooling on the effect of chemotherapy drugs on cell cycle 
progression and cytotoxicity  
Cell cycle analysis was conducted to evaluate the activity of the chemotherapeutic 
drugs used in this study (doxorubicin, docetaxel, and 4-OH-CP) and to identify if they induce 
cell cycle arrest in vitro. Once this analysis was complete, the aim was to investigate the 
effects of cooling in cell cycle changes induced by chemotherapy drugs.  
The control apparatus of the cell (also referred to as the ‗cell cycle clock‘) consists of 
a variety of proteins that monitor the extra- and intracellular environment of the cell and its 
division status. Monitoring the environment is imperative, as, for example, cells can respond 
to stress (e.g genotoxic stress). As part of these monitoring mechanisms, there are several 
checkpoints within the cell cycle at which the cycle can be paused; one of these is the G2/M 
checkpoint where, if the environmental conditions appear optimal and the cell has reached a 
particular size and successfully replicated its DNA, will it then proceed into M-phase.  
Chemotherapy generally interferes with cell proliferation or directly stimulates death. 
Some anticancer drugs act only on a particular part or parts of the cell cycle (cell cycle-
specific) while others act throughout the cell cycle (cell cycle-nonspecific) (Payne and Miles, 
2008). When chemotherapy drugs induce DNA damage, either the cell cycle can be arrested 
temporarily to allow for DNA repair (Di Leonardo et al., 1994 420) or the cells could be 
eliminated by apoptosis (Liebermann et al., 1995 421), a decision-making process in which 
the tumour suppressor p53 is critical.  
Doxorubicin is a drug that intercalates the DNA by inserting itself between nucleotide 
bases and thereby interferes with DNA and RNA synthesis, mainly affecting the cells in S 
phase due to the formation of DNA adducts that inhibit DNA replication (Swift et al., 2006). In 
this work, when HaCaTa cells were treated with doxorubicin (0.5 µg/mL) for 2h and cell cycle 
analysis performed 36h post-treatment, results showed that the cells accumulated in the late 
S and predominantly G2/M phase (Figure 4-2B). This might be explained by the ability of 
doxorubicin, following DNA intercalation, to inhibit the enzyme topoisomerase II, which is 
responsible for replicating the two strands of DNA and thus when inhibited, this prevents the 
synthesis of nucleic acids (Payne and Miles, 2008; Trigg and Flanigan-Minnick, 2011). At 0.5 
µg/mL doxorubicin, cell viability was about 40% at 37°C (Chapter 3); this was the 
concentration of choice, as higher doses would be expected to induce apoptosis, thus 
making it difficult to perform cell cycle analysis. These observations are in agreement with 
previous findings in HCT116 cells where treatment with 1μM dose of doxorubicin for 1h 
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followed by 72h incubation in drug-free medium caused G2/M arrest (Lüpertz et al., 2010). 
Treatment with doxorubicin induced DNA damage can result in DNA double-strand breaks, 
which leads to apoptosis (Kaina, 2003). In our study, keratinocytes arrested in G2/M in 
response to doxorubicin treatment, which is in agreement with a previous study by Zeng et 
al., (2000) showing that doxorubicin may cause predominantly G2 phase arrest rather than 
mitotic arrest in the human breast tumour cell line BCap37 (Zeng et al., 2000). Zeng et al., 
(2000) suggested that because it is difficult to distinguish between both G2 and M phase in 
the flow cytometer, as both phases are included in the G2/M peak, the G2/M phase arrest by 
doxorubicin was predominantly G2 arrest (Zeng et al., 2000). Another study showed that 
treatment of Swiss 3T3 fibroblasts with doxorubicin arrested the cells at G2/M at 48h post-
treatment (Siu et al., 1999). 
Docetaxel belongs to a class of cytotoxic drugs that inhibit microtubule 
depolymerisation, resulting in mitotic arrest, with large cells forming with approximately twice 
the typical cellular DNA content; these cells are unable to divide into two daughter cells and 
subsequently undergo ‗crisis‘ and die (apoptosis) (Mooberry, 2011). The results of this study 
showed that treatment of HaCaTa cells with docetaxel (0.01 µg/mL) at 37°C was able to 
induce a remarkably high subG0/G1 population and mitotic arrest at 36h post-exposure 
(Figure 4-2C). Hernandez-Vargas et al.,(2007) showed that as low concentrations as 2-4 nM 
docetaxel induced mitotic arrest followed by apoptosis in breast carcinoma MCF7 and MDA-
MB-231 cell lines (Hernández-Vargas et al., 2007). When cells are triggered to undergo 
apoptosis, genomic DNA is cleaved into small fragments, observed as distinct subG0/G1 
peaks by flow cytometry (Kroemer et al., 2009). The detection of a subG0/G1 DNA peak is a 
specific marker (hallmark) of apoptosis since death by necrosis in most cases does not 
induce a subG0/G1 peak (Nicoletti et al., 1991). In this work, docetaxel-treated cells showed 
a greater subG0/G1 population than the other drugs tested. A previous study showed that 
H134, IGROV-1 and OVCAR-3 cell lines treated with docetaxel accumulated in the G2/M 
phase and the a prolonged G2/M arrest induced caspase-3 activation, which initiates 
apoptosis, DNA fragmentation, whilst an increased subG0/G1 population was observed 
by flow cytometry (Kolfschoten et al., 2002).   
Cyclophosphamide is a cell cycle-nonspecific drug and thus acts against cells at any 
phase of the cycle, including the resting phase (Payne and Miles, 2008). The activated form 
of cyclophosphamide (4-hydroxycyclophosphamide, 4-OH-CP) is an alkylating agent which 
adds an alkyl group to DNA, thus blocking DNA replication and arresting cells in S phase 
(Alkan et al., 2014). The data in this study showed that the cell cycle distribution at 37°C in 
response to 4-OH-CP treatment induced cells arrest in S phase. This is in agreement with 
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Schwartz et al., (2001) who showed that 9L tumour cells treated with 4-OH-CP arrested in S 
phase (Schwartz and Waxman, 2001). 
4.9.2 Effects of low temperature (cooling) on cell cycle distribution in human 
keratinocytes  
The cell cycle is a tightly regulated vital process by which new cells are generated 
and grow. Here it has been confirmed that temperature is an important factor in regulating 
cell growth, an effect that was anticipated because the enzymes that control many 
biochemical reactions need an optimal temperature of around 37°C to function at an optimum 
rate and thus this may have a general effect on cell growth. The effect of temperature on the 
cell cycle and viability are not well understood (Ramirez and Mutharasan, 1990) and 
there have been relatively few studies that have examined this. Two specific aspects 
investigated in this work, which had not been previously reported, are a) the effect of cooling 
on the cell cycle of human keratinocytes, and b) the connection between the cell protection 
caused by cooling and the cell cycle distribution of these cells after treatment with cytotoxic 
agents.  
A series of experiments was designed to determine the effect of cooling on the cell 
cycle of keratinocytes by using HaCaTa cells at 0, 1, 2, 4, 8 and 24h after treatment 
(cooling). The flow cytometry data in this study indicate that low temperature affects all parts 
of the cell cycle phases (Figure 4-3) thus indicating a state of reduced/slow proliferation. 
Lowering the temperature from 37°C to 22°C for 2h (time point 0h) resulted in a decrease in 
the number of cells in G2/M phase and accumulation of the cells in G1/S phase compared to 
control cells at 37°C. These observations suggest that cooling may act specifically on the 
transition from G1 to S phase and the control point of G2 is affected by temperature. This 
supports the observation from a previous study-using mouse leukemic and HeLa cells, which 
showed prolongation of cell cycle at 25°C-33°C and a temporal dilation of the G1 and S 
phase. HeLa cells were cultured at different temperatures and this was shown to modify all 
phases of the cell cycle (Rao and Engelberg, 1965) whilst M phase was more sensitive than 
G1, S, G2 phase to temperature (Rao and Engelberg, 1965). Our data are in agreement with 
the hypothesis that cooling during drug exposure may decelerate growth rates and thus 
protect cells from chemotherapy-induced toxicity. However, the specific molecular 
mechanisms by which cooling decelerates the cell cycle remain unclear and require further 
future studies.  
Interestingly, after the 2h incubation at 22°C, when cell cultures were subsequently 
re-warmed to physiological temperature 37°C, the mitotic index rose rapidly within 1h, and 
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the cells appear to be dividing normally (as at 37°C. This indicates that moderate cooling for 
a short period only temporarily reduces growth rate and is not detrimental to long-term cell 
growth. Cooling might act by blocking cell cycle progression at G2 or may have reduced the 
cell cycle in all checkpoints. Moreover, cooling may force reduction of metabolic activity of 
cells (compared to cells incubated at physiological temperature 37°C) (Si et al., 1997).  
4.9.3 Time and temperature dependence of cytotoxic agent-induced cell cycle 
arrest and apoptosis under cooling conditions  
Treatment of HaCaTa cells with cytotoxic agents resulted in temperature dependent 
induction of cell cycle arrest and apoptosis. Intercalating drug doxorubicin at 37°C induced 
G2/M arrest progressively. Doxorubicin activates p53 and p21/Waf1, which leads to inhibition 
of G1/S cyclin CDK complex activity, thus cells were arrested in G1 phase. G1 arrest was 
relatively transient and the cells moved into S and G2 phase. However, cell arrest at the G2 
checkpoint was permanent because of that cells accumulated in G2 Phase (Siu et al., 1999).  
One unanticipated finding in this study was that the cell cycle distribution at 22°C in 
cells treated with doxorubicin was similar to 37°C. Although changes in cell cycle distribution 
at 22°C started, albeit delayed in comparison to 37°C, both temperatures showed arrest at 
G2/M after 24h. Data on cell viability (Chapter 3), showed that biomass at 22°C was higher 
than at 37°C ~ 69.1% and 41.9% respectively. A possible explanation for these observations 
is that cooling reduced DNA damage induced by doxorubicin by a process called checkpoint 
recovery, and arrested cell cycle progression to allow time for DNA repair. After completion 
of DNA repair, checkpoint recovery activation is terminated, cell cycle progression can be 
restarted (Morii et al., 2015); as a result, the cells recover and an increase in viability at 22°C 
observed. This may be supported by the low subG0/G1 levels at 22°C in comparison to 
37°C, which means arrested cells have less damage DNA bypass to G2 and do not undergo 
apoptosis (although flow cytometry can only detect fragmented DNA). Furthermore, these 
data showed a strong relationship between temperature and cell cycle arrest, which was 
confirmed by the findings at 18°C, which showed a reduction in the percentage of cells in 
G2/M phase and the percentage of subG0/G1 (a hallmark of apoptosis), compared to control 
cells. Moreover, doxorubicin-mediated DNA damage, which leads to induction of apoptosis 
and cell cycle arrest is a dose- and time-dependent effects (Kim et al., 2009; Lüpertz et al., 
2010).  
Cells treated with docetaxel at 37°C exhibited a time-dependent cell cycle arrest in 
G2/M phase and induction of apoptosis (evident by a high subG0/G1 phase), with 
morphological changes characteristic of cells undergoing apoptosis. The protective effect of 
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cooling on docetaxel-treated cells was enhanced further by changing cooling conditions from 
22°C to 18°C.  
HaCaTa cells treated with 4-OH-CP showed accumulation of cells in S phase and 
induction of apoptotic cell death at 37°C, however, cell arrest was substantially reduced in 
cells treated at 22°C and completely prevented at 18°C. These findings are compatible with 
the hypothesis that cyclophosphamide induces DNA cross-links, as a result of which it 
causes cell cycle arrest, and this is inhibited by cooling. It should be though noted that 
cyclophosphamide is cell cycle non-specific and can target cells in all phases.  
Moreover, we examined the responses of HaCaTa cells to ‗starvation‘ as well as the 
well-characterised EGFR tyrosine kinase inhibitor PD153035 with and without treatment of 
chemotherapy drugs. The short-term starvation (by incubating cells without supplements) 
showed in a higher biomass compared with cells treated with complete KSFM medium 
(complete KFSM medium with supplements), which provided evidence that slowing cell 
growth rate correlates with protection from the cytotoxicity of the chemotherapy drugs. 
Although the short-term starvation protected HaCaTa cells against chemotherapy at 37°C, 
cooling alone showed better protection than short-term starvation, possibly because of the 
cellular stress caused by the starvation. On the other hand, pre-treatment with the EGFR 
inhibitor PD153035 remarkably protected from chemotherapy drug-mediated cytotoxicity for 
all drugs tested confirming that ―protective pre-conditioning‖ (PPC) could improve protection 
from drug cytotoxicity. 
PD153035 has been reported as being a specific inhibitor of the EGF receptor (Bos et 
al., 1997; Fry et al., 1994). HaCaTa cells that have been treated with lower inhibitor 
concentrations of PD153035, were shown to stimulate an overall increase in biomass (see 
Figure 4- 22), in comparison with the control samples (untreated cells with PD153035). Such 
a result is in accordance with those found in a previous report, in which the viability of H211 
and H2373 cells that used the MTT assay were reduced only at a high concentration of 
PD153035. In contrast with this situation, at a reduced concentration of PD153035 cell 
viability was enhanced (Cole et al., 2005). 
An increase in cell growth when sub-lethal concentrations of otherwise cytotoxic 
drugs are used has been previously reported across an array of different cell types 
(Kayamba et al., 2013; Paus et al., 2013). Subthreshold cell damage that has been induced 
by cytotoxic agents may increase proliferative activity. However, this may only be a fleeting 
occurrence, seemingly just as a repair mechanism (Bodo et al., 2007). These results are 
more likely as a consequence of the induction of the repair mechanisms through reduced 
PD153035 concentrations. Ultimately, this results in increased proliferative activity. Based on 
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these established results, it would of interest for future research to investigate gene 
expression responses to application of PD153035 treatment.   
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5 CHAPTER 5: The effect of cooling on chemotherapy 
drug-mediated cell death induction, mitochondrial 
membrane potential disruption and Reactive Oxygen 
Species generation  
  
171 
 
5.1 Background 
Mitochondria play key roles in many fundamental biological processes and serve as 
the powerhouses of the cell. Their main task is to convert energy from nutrient molecules into 
ATP. Besides this, mitochondria can be involved in the induction of apoptosis and loss of the 
mitochondrial electrochemical potential gradient (ΔΨ) is an early event of apoptosis 
(Fransson et al., 2003). The intrinsic apoptosis pathway is mediated by the mitochondria 
(hence it is often referred to as the mitochondrial pathway) and is triggered by various 
intracellular stress signals, which include DNA damage such as due to treatment with 
chemotherapeutic agents, growth factor deprivation and reactive oxygen species (ROS). This 
results in mitochondrial outer membrane permeabilisation (MOMP) and a loss of 
mitochondrial membrane potential ΔΨm (Tait and Green, 2010) and in most cases triggers 
the caspase-dependent (caspase-9 and subsequently caspase-3) apoptosis pathway (Tait 
and Green, 2010). 
 Depolarisation of the mitochondrial membrane potential is accompanied by an 
increase in the release of ROS due to the fact that damaged mitochondria have a faulty 
electron transfer within the respiratory chain, and this produces ROS (Fulda et al., 2010). 
This process can be stimulated by the substantial exogenous oxidisation of phospholipids 
that readily migrate to the mitochondria causing damage that is able to trigger the onset of 
the intrinsic apoptotic pathway (Chen et al., 2007). So far, it is not completely clear how the 
mitochondrial energy and redox machinery, which can be activated by chemotherapy drugs, 
interacts with the apoptotic machinery (Liu et al., 2013).  
5.1.1 Reactive oxygen species 
Reactive Oxygen Species (ROS) are produced during the cell‘s normal aerobic 
metabolism; these include hydroxyl radicals (OH∙), superoxide anions (O2-) and hydrogen 
peroxide (H2O2) and are short-lived, highly-reactive harmful forms of oxygen (O2) that can 
easily oxidise other molecules, and they are normally removed by various antioxidant 
mechanisms inside cells. As mentioned earlier, the mitochondrial respiratory chain is the 
main source of ROS (Brand, 2010). Besides mediating cell and tissue damage, ROS has an 
important regulatory function in aerobic cells. ROS are continuously released during various 
metabolic processes in different compartments of the cell, and low concentrations of ROS 
can act as signalling molecules and stimulate the growth of cells. However, at higher 
concentrations, because of their reactivity, ROS cause oxidative modification of cellular 
components such as proteins, nucleic acids and lipids and can trigger cell death via either 
programmed cell death (apoptosis) or necrosis (Burdon, 1995; Samson, 1997). 
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ROS have short life span, and thus one way to improve the ROS competence is by co-
localisation of their site of generation and their site of signalling role. In theory, the quantity of 
mitochondria within the cell has the ability to modify the quantity of ROS generated and, as a 
result modify their intracellular function. Mitochondrial biogenesis, which occurs by growth 
and division of pre-existing mitochondria, is regulated by PGC-1α (peroxisome-proliferator-
activated receptor γ co-activator-1α) (Ventura-Clapier et al., 2008). Mitochondrial biogenesis 
is triggered by different stimuli such as cell division, in response to an oxidative stimulus, to 
exercise training, to an increase in the energy requirements of the cells, in certain 
mitochondrial diseases etc. (St-Pierre et al., 2006; Valero, 2014). PGC-1α has dual 
activities—stimulating mitochondrial biogenesis while suppressing ROS levels (St-Pierre et 
al., 2006). The role of mitochondrial biogenesis as an antioxidant defence mechanism is well 
established. It has previously been shown that the increased production of mitochondria is a 
support mechanism that help maintain a satisfactory level of healthy mitochondria, which 
would be able to tolerate cellular energy needs in conditions when a large fraction of these 
mitochondria have suffered ROS-induced damage rendering them dysfunctional (Chou et al., 
2007; Yu, 2011). Previous studies have shown that mild hypothermia can regulate heat 
shock protein induction and mitochondrial biogenesis (Ning et al., 1998; Tissier et al., 2012).  
5.1.2 Apoptosis mechanisms of HF under pathological conditions 
Application of chemotherapeutic drugs can trigger apoptosis in both in vivo and in 
vitro (Hasmall and Roberts, 1999). It is generally thought that chemotherapeutic drugs induce 
apoptosis via the intrinsic mitochondrial pathway by activation of pro-apoptotic factors. The 
intrinsic pathway is controlled by members of the Bcl-2 family, which act as inhibitors (e.g., 
Bcl-2) and promoters of apoptosis (such as Bak and Bax) (see Chapter 1 (Figure1-6)) 
(Korsmeyer, 1999; Petros et al., 2004) and is associated with initiator caspase-9 activation 
(Schultz and Harringto Jr, 2003). Both the intrinsic (mitochondrial) and extrinsic (receptor-
mediated) mechanisms can lead to the activation of effector caspases-3, 6 and 7, which in 
turn mediate cleavage of a variety of substrates, including deoxyribonuclease, which is 
responsible for the cleavage of nuclear DNA (Schultz and Harringto Jr, 2003; Van Gurp et 
al., 2003). 
The classical anticancer drugs have distinctly different mechanisms of action for 
instance, cyclophosphamide occurs through the alkylation of DNA and disruption of the 
nuclear DNA (Valeriote and Van Putten, 1975). DNA damage induces activation of the pro-
apoptotic gene p53 (Botchkarev et al., 2000; Botchkarev et al., 2001) which migrates into the 
mitochondria and induces Bax and cytochrome c and apoptosis (Fulda et al., 2010). A 
previous study has shown that 4-OH-CP, the activated form of cyclophosphamide, induced 
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cytotoxicity in 9L gliosarcoma cells by stimulating apoptosis resulting in induction of plasma 
membrane blebbing, DNA fragmentation and caspase-3/7 (Schwartz and Waxman, 2001).  
Doxorubicin is an anthracycline that mainly acts via its intercalation into DNA, 
inducing ROS generation and DNA damage, which occurs via inhibition of topoisomerase II 
resulting in apoptosis (Sliwinska et al., 2009). 5-Fluorouracil (5FU) also appears to act via 
p53-mediated apoptosis through the generation of ROS in the mitochondria (Ahrendt et al., 
2000; Hwang et al., 2001). 5FU is an antimetabolite drug widely used in the treatment of 
cancer by suppressing essential biosynthetic processes through inhibition of thymidylate 
synthase and p53 activation (Longley et al., 2003; Müller et al., 1998).  
Docetaxel interferes with microtubule stabilisation, which leads to accumulation of the 
cells in G2/M phase. Previous studies showed caspase-3 activation in cells treated with 
docetaxel and G2/M arrest using four human ovarian cell lines (A2780, H134, IGROV-1 and 
OVCAR-3) (Kolfschoten et al., 2002) and a clear connection exists between mitotic arrest 
and apoptosis in response to docetaxel (Morse et al., 2005).  
5.1.3 Measurement of intracellular ROS and mitochondrial membrane integrity  
To study the generation of ROS by chemotherapy drugs (and ultimately assess the 
effects of cooling), the fluorescent probe 2', 7'-dichlorofluorescin diacetate (H2DCFHDA) was 
used (Kalyanaraman et al., 2012). After entry through the cell membrane, the acetyl groups 
of the stable non-polar non-fluorescent DCFH-DA are cleaved by intracellular esterase 
activity. The reduced non-fluorescent DCFH accumulates in the cell due to its polarity; in the 
presence of ROS (mainly H2O2) it is oxidised to green fluorescent DCF (Figure 5-1). The 
resulting fluorescence is proportional to the amount of active ROS and can be quantified by 
flow cytometry (Bass et al., 1983). 
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Figure ‎5-1 The principle of ROS detection using H2DCFDA 
6-carboxy-2', 7‘-dichlorodihydrofluorescein diacetate (H2DCFDA) is a derivative of reduced 
fluorescein that has cell permeability. The reduced forms of fluorescein lack any fluorescence 
until acetyl groups are removed by intracellular esterase(s) and oxidation is occurring within 
the cells. When this occurs, the charge of the molecules makes it much less likely to leave 
the cell and also emits detectable fluorescence. The levels of fluorescence intensity are 
therefore an indication of the intracellular concentration of ROS. Adapted from (Held, 2012). 
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5.1.4 Use of JC-1 dye for mitochondrial membrane potential detection 
Some of the most frequently used anticancer drugs in the clinic, for example 
doxorubicin, exert their cytotoxic effect via formation of ROS and direct intervention in the cell 
cycle machinery of the cells, as well as loss of mitochondrial membrane potential (Tsang et 
al., 2003). Using the fluorescence dye 5,5- 6,6-tetrachloro-1,1- 3,3-tetraethylbenzimidazolyl 
carbocyaniniodid (JC-1) mitochondrial membrane potential in cells can be studied. The 
measurement of mitochondrial membrane depolarisation is particularly useful for the 
investigation of apoptosis. JC-1 is a cationic, membrane-permeable fluorescent dye that 
enters the mitochondria of living cells with intact membrane potential (membrane potential 
dependent) (Bortoletto et al., 2004), where it forms red fluorescent aggregates. Events such 
as apoptosis, which lead to loss of mitochondrial membrane potential, prevent the 
accumulation of the JC-1 dye in the mitochondria. This leads to a diffuse distribution of the 
dye in the whole cell and to a shift of red fluorescence (JC-1 aggregates) to green 
fluorescence (JC-1 monomers) and this can be measured by fluorimetric analysis and 
subsequent calculation of the ratio (590 nm / 530 nm) using a plate reader or by direct 
detection of fluorescence changes using a flow cytometer (Figure 5-2) (Bortoletto et al., 
2004; Sakamuru et al., 2012). 
 
 
 
Figure ‎5-2 The principle of the fluorescent JC-1 dye 
ΔΨm is an important parameter of mitochondrial function used as an indicator of cell health. 
JC-1 can be used to study mitochondrial behaviour in a variety of conditions, including 
apoptosis. JC-1, a lipophilic dye, selectively enters mitochondria and reversibly changes 
colour from green to red with increasing membrane potential. In healthy cells with high 
mitochondrial ΔΨm, JC-1 spontaneously forms complexes known as J-aggregates with 
intense red fluorescence. However, in apoptotic cells or unhealthy low ΔΨm, JC-1 remains in 
the monomeric form, showing only green fluorescence (Sakamuru et al., 2012).  
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5.2 Apoptosis assays for the detection of cell death induced by 
chemotherapeutic agents on human keratinocytes 
Most chemotherapeutic agents trigger apoptosis in dividing cells (Fabbri et al., 2006). 
Because of the rapid division rate of hair matrix kertinocytes, the HF represents a target for 
many chemotherapeutic agents (Paus and Cotsarelis, 1999). Cells undergoing death can be 
detected by their morphological changes and biochemical changes which can be measured 
by different commercial assays. Previously published guidelines regarding the use of assays 
for detecting cell death (Galluzzi et al., 2009) have recommended that at least two 
independent assays are utilised for the detection of cell apoptosis. The apoptosis assays 
used in this study to detect the cytotoxic effects of chemotherapeutic drugs at physiological 
temperture vs cooling conditions were the commercially available the CytoTox-Glo 
cytotoxicity assay, Sensolyte Homogenous Caspase-3/7 assay and the DNA fragmentation 
ELISA assay. In addition western blotting was used to explore the apoptotic pathways 
activated (Chapter 6).  
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5.3 Chapter Aims  
In light of the cytotoxicity caused by chemotherapy drugs and effects of cooling in 
protecting from the deleterious effects of these drugs shown in previous chapters, the work 
described in this chapter was designed to examine mitochondrial trans-membrane potential 
and ROS production levels in human keratinocytes treated with chemotherapy drugs at 
physiological temperature (37°C) and at cooling conditions. The hypothesis was that 
chemotherapy drugs may induce MOMP and ROS release and the experiments investigated 
whether these changes might be altered by cooling, thus providing functional evidence for its 
cytoprotective ability. Moreover, a variety of well-characterised cell apoptosis assays were 
used to investigate the cytoprotective role of cooling against the cytotoxic effects of 
commonly used chemotherapeutic agents. 
Specifically the aims of the work in this chapter were to:  
 Investigate the effect of chemotherapy drugs doxorubicin, 4-OH-CP and docetaxel on 
the mitochondrial membrane potential (ΔΨm) and the influence of cooling 
(temperatures 22°C, 18°C, and 14°C) was investigated for the first time using using 
the JC-1 dye.  
 Analyse the changes in ROS levels following chemotherapy drug administration, and 
an attempt was also undertaken to find out a correlation between ROS levels and 
culture temperature; the experiments involved use of H2DCFDA to quantify ROS 
induced by the chemotherapeutic drugs at 37°C and determine the effects of cooling 
on the accumulation of ROS after chemotherapy drug treatment.  
 Use the luminescence-based CytoTox-Glo assay (which measures the release of a 
proprietary protease released released by cells with compromised plasma 
membranes) as a surrogate marker of apoptosis.  
 Investigate the activation of caspase-3/7 activity as an additional marker of apoptosis 
at 37°C compared with cells treated at cooling conditions.  
 Detect chemotherapy drug–induced apoptosis by using a DNA fragmentation ELISA 
assay. 
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5.4 Optimisation of the JC-1 assay for the detection of changes in 
mitochondrial membrane potential (ΔΨm) 
The first part of this chapter focused on the optimisation of the JC-1 fluorescent probe 
using flow cytometry for detecting JC-1 aggregates (red fluorescence) and monomeric (green 
fluorescence) in HaCaTa cells. HaCaTa cells were treated with 7.5 µg/mL 4-OH-CP 
(concentration used for optimisation experiments) for 2h at 37°C. Loss of mitochondrial 
membrane potential (ΔΨm) is indicated by the reduced number of cells with red fluorescence 
and increases in the number of cells with green fluorescence. According to the 
manufacturer‘s instructions, the initial conditions for JC-1 assay may require modifications 
because of differences in cell types and culture conditions. Thus, the concentration of JC-1 
was optimised and three concentrations were initially tested (1, 2, and 4 µM) to ensure that 
the JC-1 concentration used was sufficient for sensitive detection of ΔΨm loss (Figures 5-3 
and 5-4). Data showed that the optimal concentration for JC-1 was 2 µM compared to 1 µM, 
which was less sensitive than 2 µM on the other hand, there was no significant difference 
between 2 and 4 µM of JC-1, therefore 2 µM was used for all subsequent experiments. Also, 
as part of the optimisation, the time required for ΔΨm loss was investigated, and the time 
ranged from 6 to 48h (6 and 12h data are not shown as the induction of ΔΨm loss and the 
green fluorescence was very low compared to the positive control).  
 Three types of controls were used for all JC-1 experiments: 1) positive control for 
ΔΨm loss detection (positive green fluorescence control) in which the cells were treated in 
each experiment with carbonyl cyanide m-chlorophenyl (CCCP) hydrazone because it 
causes rapid mitochondrial membrane depolarisation, 2) negative control in which untreated 
cells were stained with JC-1, thus providing a pure red signals, 3) unstained cells as 
background control (without drug treatment and no JC-1 probe). Representative results with 
appropriate gating strategies are shown in Figures 5-3 and 5-4.  
Following these initial experiments, the JC-1 assay was carried out in cells cultured 
under cooling conditions; to investigate the ability of cooling to protect against chemotherapy 
drugs-induced ΔΨm loss at 37°C and 18°C. When cells were examined after 24h treatment, 
there was a temperature dependent reduction of the red/green fluorescence (red = polarised 
mitochondria and green = depolarised mitochondria) with the mean value being ~38% and 
19% at 37°C and 18°C respectively. After 36h, the values were ~70% and 27% at 37°C and 
18°C respectively (Figures 5-5 and 5-6), clearly demonstrating that cooling significantly 
reduced chemotherapy drug-induced ΔΨm loss, i.e. prevented mitochondrial damage 
thereby rescuing HaCaTa cells from drug cytotoxicity.   
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Figure ‎5-3 Optimisation of JC-1 dye assay at 37°C 
HaCaTa cells were seeded in 6-well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. Cells were then treated with 7.5 µg/mL 4-OH-CP for 
2h at 37°C compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; wells were 
rinsed with PBS to remove any traces of drug before the cells were incubated in fresh 
medium. Both attached and floating cells were harvested 36h later and a total of 20,000 
events were analysed. ΔΨm loss-related depolarisation of the JC-1 dye was monitored by 
FACS analysis. A) Cells alone (without JC-1 dye) are shown, hence only auto-fluorescence 
is detectable (purple colour gate, bottom left-hand corner). B) Control (untreated) cells 
labelled with 2μM JC-1 dye as a negative control (normal healthy cells, gated region (red) 
includes cells with intact mitochondrial membranes). C) Positive control cells treated with 
1μM CCCP for 5 min and labelled with 2μM JC-1 (green gate includes cells with ΔΨm loss). 
D, E and F) Cells at 36h post-exposure to 7.5 µg/mL 4-OH-CP at 37°C and labelled with JC-
1 dye (1, 2 and 4μM); red gate indicates healthy cells, green gate dead cells, and brown gate 
represents late apoptotic/dead cells. Data obtained from three independent biological 
experiments, each consisting of 2 technical replicates. 
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Figure ‎5-4 Summary of optimisation of JC-1 concentration at 37°C 
The bar graph summarises ΔΨm loss (green fluorescence (R2 region) data obtained data 
obtained from as shown in Figure 5-3. Bars represent mean values of the percentage of cells 
(± S.E.M.). n.s., non-significant. *, p < 0.05.  
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Figure ‎5-5 Preliminary experiments on detection of chemotherapy drug-induced ΔΨm 
loss using JC-1 and the effect of cooling in HaCaTa cells 
HaCaTa cells were seeded in 6-well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. Cells were then treated with 7.5 µg/mL 4-OH-CP for 
2h at 37°C and 18°C compared with vehicle control (cells treated with medium containing 
DMSO, in which the reagent was dissolved. The solvent represents the maximum amount of 
DMSO corresponding to the highest drug concentration). The drugs were then removed, 
wells were rinsed with PBS to remove any traces of drug before the cells were incubated in 
fresh medium. Both attached and floating cells were harvested 24h and 36h later and a total 
of 20,000 events were analysed. ΔΨm loss-related depolarisation of the JC-1 dye was 
monitored by FACS analysis. A) Cells alone (without JC-1 dye) are shown, hence only auto-
fluorescence. B) Control (untreated) cells labelled with 2μM JC-1 dye as a negative control 
(normal healthy cells) incubated at 37°C. C) Control (untreated) cells labelled with 2μM JC-1 
dye as a negative control (normal healthy cells) incubated at 18°C. D) Positive control cells 
treated with 1μM CCCP for 5 min and labelled with 2μM JC-1. E) Cells at 24h post-exposure, 
F) Cells at 36h post-exposure to 7.5 µg/mL 4-OH-CP at 37°C and labelled with 2μM JC-1 
dye; red fluorescence indicates healthy cells, green fluorescence dead cells and late 
apoptotic/dead cells. G) Cells at 24h, H) Cells at 36h post-exposure to 7.5 µg/mL 4-OH-CP at 
18°C and labelled with 2μM JC-1 dye; red fluorescence indicates healthy cells, green 
fluorescence dead cells and late apoptotic/dead cells. Data obtained from three independent 
biological experiments, each consisting of 2 technical replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of % cells with ΔΨm loss. 
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Figure ‎5-6 Summary of replicate preliminary experiments on detection of 
chemotherapy drug-induced ΔΨm loss using JC-1 and the effect of cooling 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) data obtained 
from three independent biological experiments, each consisting of 2 technical replicates. as 
shown in Figure 5-5. Bars represent mean values of % of cells (±S.E.M.). *** p < 0.001. 
*Gating was performed as in Figures 5-3 and 5-4 for the identification of green and red 
fluorescence and the calculation of percentage cells with ΔΨm loss. 
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5.5 Cytoprotective role of cooling against chemotherapy drug-
induced ΔΨm disruption in HaCaTa cells 
As mentioned above disruption of the ΔΨm can indicate mitochondrial dysfunction and it is a 
crucial stage in the mitochondrial death pathway induced by chemotherapy drugs (Charvat 
and Arrizabalaga, 2016). Therefore, modulation of the mitochondrial death pathway by 
cooling conditions was examined using the fluorogenic probe JC-1. In cells treated with 
chemotherapy drugs at 37°C a significant increase in green fluorescence of JC-1 monomers 
was detected indicating a reduction in ΔΨm. Treatment of HaCaTa cells with chemotherapy 
drugs under cooling conditions and the changes of the ratio of red/green fluorescence of the 
JC-1 probe were examined.  
5.5.1 Effects of 4-OH-CP on ΔΨm and role of cooling  
7.5 µg/mL 4-OH-CP at 37°C caused a ΔΨm loss evident by the reduced red, and 
increased green fluorescence, as shown in section 5.3. As shown in Figures 5-7 and 5-8, 
that cooling significantly reduced the 4-OH-CP-induced loss of ΔΨm and there was a strong 
correlation between ΔΨm loss of the cells and the temperature. A significant inhibition in 
green fluorescence was observed in HaCaTa cells at 36h post-exposure to 7.5 µg/mL 4-OH-
CP and being 36.4% (± 2.4), 22.6 (± 0.4), and 16.1% (± 0.3) at 22°C, 18°C, and 14°C 
respectively, compared to 62.6% (± 0.4) at 37°C. Furthermore, 48h post-exposure to 7.5 
µg/mL 4-OH-CP, green fluorescence at 37°C was 73.7% (± 0.9) compared to 31.3% (± 1.3), 
27.7% (± 2) and 13.9% (± 1.3) at 22°C, 18°C, 14°C respectively. These data confirmed that 
cooling prevented mitochondrial damage thereby rescuing the HaCaTa cells from 4-OH-CP 
toxicity. Taken together, it can be concluded that cooling has anti-apoptotic effects and 
reduces the extent of cell death induced by 4-OH-CP in HaCaTa cells. 
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Figure ‎5-7 Cooling inhibits 4-OH-CP- induced ΔΨm loss in HaCaTa cells 
HaCaTa cells were seeded in 6 well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with 7.5 µg/mL 4-OH-CP 
for 2h at 37°C 22°C, 18°C and 14°C compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug before the cells 
were incubated in fresh medium. Both attached and floating cells were harvested 36h and 
48h later and a total of 20,000 events were analysed. ΔΨm loss-related depolarisation of the 
JC-1 dye was monitored by FACS analysis. A) Cells alone (without JC-1 dye) are shown, 
hence only auto-fluorescence. B) Positive control cells treated with 1μM CCCP for 5 min and 
labelled with 2μM JC-1. C, D, E, and F) Control (untreated) cells labelled with 2μM JC-1 dye 
as a negative control (normal healthy cells) incubated at 37°C, 22°C, 18°C and 14°C 
respectively. G) Cells at 36h, K) Cells at 48h post-exposure to 7.5g/mL 4-OH-CP at 37°C 
and labelled with 2μM JC-1 dye. H) Cells at 36h, L) Cells at 48h post-exposure to 7.5 µg/mL 
4-OH-CP at 22°C and labelled with 2μM JC-1 dye. I) Cells at 36h, M) Cells at 48h post-
exposure to 7.5 µg/mL 4-OH-CP at 18°C and labelled with 2μM JC-1 dye. J) Cells at 36h, N) 
Cells at 48h post-exposure to 7.5 µg/mL 4-OH-CP at 14°C and labelled with 2μM JC-1 dye. 
Data obtained from three independent biological experiments, each consisting of 2 technical 
replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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Figure ‎5-8 Summary of independent replicate experiments on the role of cooling in 4-
OH-CP-mediated disruption of ΔΨm in HaCaTa cells 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) data obtained 
from three independent biological experiments, each consisting of 2 technical replicates as 
shown in Figure 5-7. Bars represent mean values of % of cells (±S.E.M.). *** p < 0.001. 
*Gating was performed as in Figure 5-4 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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5.5.2 Effects of docetaxel on ΔΨm and role of cooling  
To determine the level of mitochondrial dysfunction after exposure to docetaxel, 
HaCaTa cells were treated with 0.01μg/mL docetaxel and ΔΨm measured at 36h and 48h 
post-exposure (Figures 5-9 and 5-10). Docetaxel treated cells showed a significantly greater 
collapse in ΔΨm with high green fluorescence percentage after 36h at 37°C and peaked at 
48h at 37°C (Figure 5-9G and K). However, the effect of docetaxel was reduced remarkably 
by cooling and the percentage of green fluorescence was decreased significantly at 36h 
post-exposure to docetaxel was 24.6% (± 0.7), 15.1% (± 0.5), and 22.9% (± 2.1) at 22°C, 
18°C and 14°C respectively, compared with 59.1% (± 3.3) at 37°C (Figure 5-10). The 
percentage of the green fluorescence associated cells (impaired ΔΨm) steadily increased, 
reaching 70.6% (± 2.5) at 37°C of cells 48h after treatment, compared with cells treated at 
cooling conditions being 25.4% (± 2.1), 24.9% (± 1.5), and 8% (± 0.1) at 22°C, 18°C and 
14°C respectively, compared with 70.6% (± 2.5) at 37°C (Figure 5-10). These results suggest 
that the docetaxel-induced death of HaCaTa cells activates the mitochondrial pathway, and 
the cytoprotective effects of cooling relate to inhibition of the mitochondrial apoptosis 
pathway. 
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Figure ‎5-9 Cooling inhibits docetaxel induced ΔΨm loss in HaCaTa cells 
HaCaTa cells were seeded in 6 well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with 0.01 µg/mL docetaxel 
for 2h at 37°C 22°C, 18°C and 14°C compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug before the cells 
were incubated in fresh medium. Both attached and floating cells were harvested 36h and 
48h later and a total of 20,000 events were analysed. ΔΨm loss-related depolarisation of the 
JC-1 dye was monitored by FACS analysis. A) Cells alone (without JC-1 dye) are shown, 
hence only auto-fluorescence. B) Positive control cells treated with 1μM CCCP for 5 min and 
labelled with 2μM JC-1. C, D, E, and F) Control (untreated) cells labelled with 2μM JC-1 dye 
as a negative control (normal healthy cells) incubated at 37°C, 22°C, 18°C and 14°C 
respectively. G) Cells at 36h, K) Cells at 48h post-exposure to 0.01 µg/mL docetaxel at 37°C 
and labelled with 2μM JC-1 dye. H) Cells at 36h, L) Cells at 48h post-exposure to 0.01 µg/mL 
docetaxel at 22°C and labelled with 2μM JC-1 dye. I) Cells at 36h, M) Cells at 48h post-
exposure to 0.01 µg/mL docetaxel at 18°C and labelled with 2μM JC-1 dye. J) Cells at 36h, 
N) Cells at 48h post-exposure to 0.01 µg/mL docetaxel at 14°C and labelled with 2μM JC-1 
dye. Data obtained from three independent biological experiments, each consisting of 2 
technical replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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Figure ‎5-10 Summary of independent replicates experiments the role of cooling in 
inhibits docetaxel disruption of the ΔΨm in HaCaTa cells 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) data obtained 
from three independent biological experiments, each consisting of 2 technical replicates as 
shown in Figure 5-9. Bars represent mean values of % of cells (±S.E.M.). **, p < 0.01; ***, p 
< 0.001. 
*Gating was performed as in Figure 5-4 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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5.5.3 Effects of doxorubicin on ΔΨm and role of cooling 
One of the primary targets of doxorubicin is mitochondria and it induces apoptosis 
through a mitochondrial pathway (Tomankova et al., 2015). HaCaTa cells exposed to 
0.5μg/mL doxorubicin for 2h at 37°C and then incubated in drug free media for 36h exhibited 
a collapse of ΔΨm (Figures 5-11 and 5-12). By contrast, when HaCaTa cells were exposed 
to 0.5μg/mL doxorubicin at 22°C, 18°C and 14°C, the ΔΨm was better maintained in a 
temperature dependent manner (Figure 5-11). The percentage of the green fluorescence 
(loss of ΔΨm) after 36h was 38.8% (± 1.7), 32.3% (± 2.3), and 16.3% (± 0.3) at 22°C, 18°C 
and 14°C respectively, compared with 59.2% (± 0.9) at 37°C (Figure 5-12). After 48h at 
37°C, the percentage of the green fluorescence associated cells increased significantly 
~71.5% (± 2.6); while at cooling conditions green fluorescence decreased significantly being 
34.2% (± 1.8), 29.6% (± 2.4), and 13% (± 0.6) at 22°C, 18°C and 14°C respectively (Figure 
5-12). These results indicate that mitochondria fail to maintain their ΔΨm after treatment with 
doxorubicin, and cooling can inhibit doxorubicin-mediated reduction of ΔΨm of cells.  
The data obtained with the JC-1 assay indicated that cooling protects from collapse of 
ΔΨm in cells exposed to doxorubicin, 4-OH-CP or docetaxel, which provides evidence that 
cooling can be an effective anti-apoptotic mediator. Collectively, these observations are in 
support of our data on cell viability / biomass (Chapter 3) and the cell cycle (Chapter 4), by 
not only demonstrating the cytoprotective role of cooling, but also providing further evidence 
that the lower the cooling temperature employed, the more significant the cytoprotective 
effect.  
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Figure ‎5-11 Cooling inhibits doxorubicin induced ΔΨm loss in HaCaTa cells 
HaCaTa cells were seeded in 6 well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated with 0.5 µg/mL doxorubicin 
for 2h at 37°C 22°C, 18°C and 14°C compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug before the cells 
were incubated in fresh medium. Both attached and floating cells were harvested 36h and 
48h later and a total of 20,000 events were analysed. ΔΨm loss-related depolarisation of the 
JC-1 dye was monitored by FACS analysis. A) Cells alone (without JC-1 dye) are shown, 
hence only auto-fluorescence. B) Positive control cells treated with 1μM CCCP for 5 min and 
labelled with 2μM JC-1. C, D, E, and F) Control (untreated) cells labelled with 2μM JC-1 dye 
as a negative control (normal healthy cells) incubated at 37°C, 22°C, 18°C and 14°C 
respectively. G) Cells at 36h, K) Cells at 48h post-exposure to 0.5 µg/mL doxorubicin at 37°C 
and labelled with 2μM JC-1 dye. H) Cells at 36h, L) Cells at 48h post-exposure to 0.5 µg/mL 
doxorubicin at 22°C and labelled with 2μM JC-1 dye. I) Cells at 36h, M) Cells at 48h post-
exposure to 0.5 µg/mL doxorubicin at 18°C and labelled with 2μM JC-1 dye. J) Cells at 36h, 
N) Cells at 48h post-exposure to 0.5 µg/mL doxorubicin at 14°C and labelled with 2μM JC-1 
dye. Data obtained from three independent biological experiments, each consisting of 2 
technical replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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Figure ‎5-12 Summary of independent replicates experiments the role of cooling in 
inhibits doxorubicin disruption of the ΔΨm in HaCaTa cells 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) data obtained 
from three independent biological experiments, each consisting of 2 technical replicates as 
shown in Figure 5-11. Bars represent mean values of % of cells (±S.E.M.). **, p < 0.01; ***, p 
< 0.001. 
*Gating was performed as in Figures 5-3 and 5-4 for the identification of green and red 
fluorescence and the calculation of percentage cells with ΔΨm loss. 
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5.6 Cytoprotective role of cooling against chemotherapy drug-
induced ΔΨm disruption in NHEK cells 
 Following investigations in HaCaTa cells, for the first time the effect of chemotherapy 
drugs on ΔΨm of NHEKs was measured and the effect of cooling conditions was examined 
to confirm the validity of our results using HaCaTa cells as an in vitro model to study CIA. 
NHEKs cells were treated with 4-OH-CP, docetaxel or doxorubicin at 37°C and 
compared with cells treated at 18°C. Based on the results in chapter 3, these cells appeared 
to be less sensitive than HaCaTa cells and higher drug concentrations of the drugs were 
used, i.e.: 10 µg/mL 4-OH-CP, 0.025 µg/mL docetaxel, and 3 µg/mL doxorubicin; doses 
which were confirmed to induce depolarisation (ΔΨm loss) (Figures 5-13 and 5-14). 
Importantly, cells treated at cooling conditions showed a significantly greater red and lower 
green fluorescence than cells treated at 37°C. More specifically, data showed that lower 
temperatures, protected from a loss of ΔΨm with the percentage of green fluorescence of 
cells after treatment with 4-OH-CP being 61.5% (± 2) and 22.7% (± 3.8) at 37°C and 18°C 
respectively (Figure 5-13E and F). In cells treated with docetaxel the values were 55.75% (± 
4.3) and 31.48% (± 1.8) at 37°C and 18°C respectively (Figure 5-13G and H), and for 
doxorubicin 74.2% (± 2.1) and 31.6% (± 1.2) at 37°C and 18°C respectively (Figure 5-13 I 
and J). Therefore, despite the fact that they act via different molecular mechanisms, these 
drugs induced ΔΨm disruption and cooling consistently rescued cells from ΔΨm disruption 
for all three compounds in concordance with our observations with HaCaTa cells. The ability 
of cooling to protect from ΔΨm disruption was an indicator of the cytoprotective properties of 
cooling. 
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Figure ‎5-13 Cooling inhibits chemotherapy drugs-induced ΔΨm loss in NHEK cells 
NHEK cells (passages 1–3) were seeded in 6 well plates at 2.3x105 cells/well in KSFM 
medium and were incubated overnight at 37°C/5% CO2. NHEKs cells were treated with 
10μg/mL 4-OH-CP; 0.025μg/mL docetaxel (Doce); and 3μg/mL doxorubicin (Doxo) for 2h at 
37 and 18, compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed; wells were 
rinsed with PBS to remove any traces of drug before the cells were incubated in fresh 
medium. Both attached and floating cells were harvested 48h later and a total of 20,000 
events were analysed. ΔΨm loss-related depolarisation of the JC-1 dye was monitored by 
FACS analysis. B) Positive control cells treated with 1μM CCCP for 5 min and labelled with 
2μM JC-1. C, D) Control (untreated) cells labelled with 2μM JC-1 dye as a negative control 
(normal healthy cells) incubated at 37°C and 18°C respectively. E, G, and I) Cells at 48h 
post-exposure to 4-OH-CP; docetaxel; and doxorubicin respectively at 37°C and labelled with 
2μM JC-1 dye. F, H, and J) Cells at 48h post-exposure to 4-OH-CP; docetaxel; and 
respectively at 18°C and labelled with 2μM JC-1 dye. Data obtained from three independent 
biological experiments, each consisting of 2 technical replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
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Figure ‎5-14 Summary of independent replicates experiments the role of cooling in 
inhibits chemotherapy drugs disruption of the ΔΨm in NHEK cells 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) data obtained 
from three independent biological experiments, each consisting of 2 technical replicates as 
shown in Figure 5-13. A) Cells treated with 4-OH-CP, B) cells treated with docetaxel C) cells 
treated with doxorubicin. Bars represent mean values of % of cells (±S.E.M.). **, p < 0.01; 
***, p < 0.001. 
*Gating was performed as in Figure 5-4 for the identification of green and red fluorescence 
and the calculation of percentage cells with ΔΨm loss. 
 
 
 
 
 
 
 
 
 
 
 
195 
 
5.7 Cytoprotective role of cooling against chemotherapy drug-
induced ΔΨm disruption in HHFK cells  
To further support our observations above in HaCaTa and NHEKs, HHFK cells, which are 
specifically isolated from the HF area, were used to investigate the effects of chemotherapy 
drugs on ΔΨm, as HHFK cells are a closer representative to the HF matrix keratinocytes. 
HHFK cells were treated with 4-OH-CP, docetaxel or doxorubicin at 37°C and compared with 
cells treated at 18°C. Similarly, to NHEKs, HHFK cells were treated with 10 µg/mL 4-OH-CP, 
0.025 µg/mL docetaxel, and 3 µg/mL doxorubicin to induce depolarisation (ΔΨm loss) 
(Figure 5-15 and 5-16). Cells treated at cooling conditions showed a significantly greater red 
and lower green fluorescence than cells treated at 37°C. The percentage of cells 
demonstrating green fluorescence after treatment with 10 µg/mL 4-OH-CP was 67.6% (± 1.5) 
and 29.5% (± 1.6) at 37°C and 18°C respectively (Figure 5-15E and F), for cells treated with 
0.025 µg/mL docetaxel it was 64.6% (± 2.2) and 29.2% (± 0.4) at 37°C and 18°C respectively 
(Figure 5-15G and H), and for cells treated with 3 µg/mL doxorubicin it was 74.2% (± 2) and 
31.6% (± 1.3) at 37°C and 18°C respectively (Figure 5-15I and J). 
These findings confirmed that cooling consistently rescued cells from ΔΨm disruption 
induced by the chemotherapy drugs. Moreover, these experiments further attested to our 
approach of using HaCaTa cells as a representative keratinocyte in vitro model. 
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Figure ‎5-15 Cooling inhibits chemotherapy drugs-induced ΔΨm loss in HHFK cells 
HHFK cells (passages 1–3) were seeded in 6 well plates at 2.3x105 cells/well in KSFM 
medium and were incubated overnight at 37°C/5% CO2. HHFK cells were treated with 
10μg/mL 4-OH-CP; 0.025μg/mL docetaxel (Doce); and 3μg/mL doxorubicin (Doxo) for 2h at 
37 and 18, compared with vehicle control (cells treated with medium containing DMSO, in 
which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug before the cells were incubated in fresh 
medium. Both attached and floating cells were harvested 48h later and a total of 20,000 
events were analysed. ΔΨm loss-related depolarisation of the JC-1 dye was monitored by 
FACS analysis. A) Cells alone (without JC-1 dye) are shown, hence only auto-fluorescence. 
B) Positive control cells treated with 1μM CCCP for 5 min and labelled with 2μM JC-1. C, D) 
Control (untreated) cells labelled with 2μM JC-1 dye as a negative control (normal healthy 
cells) incubated at 37°C and 18°C respectively. E, G, and I) Cells at 48h post-exposure to 4-
OH-CP; docetaxel; and doxorubicin respectively at 37°C and labelled with 2μM JC-1 dye. F, 
H, and J) Cells at 48h post-exposure to 4-OH-CP; docetaxel; and respectively at 18°C and 
labelled with 2μM JC-1 dye. Data obtained from three independent biological experiments, 
each consisting of 2 technical replicates. 
*Gating was performed as in Figure 5-3 for the identification of green and red fluorescence 
and the calculation of % cells with ΔΨm loss. 
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Figure ‎5-16 Summary of independent replicates experiments the role of cooling in 
inhibits chemotherapy drugs, disruption of the ΔΨm in HHFK cells 
The bar graph shows summarises ΔΨm loss (green fluorescence (R2 region)) Data obtained 
from three independent biological experiments, each consisting of 2 technical replicates as 
shown in Figure 5-15. A) Cells treated with 4-OH-CP, B) cells treated with docetaxel C) cells 
treated with doxorubicin. Bars represent mean values of % of cells (±S.E.M.) **, p < 0.01; ***, 
p < 0.001. 
*Gating was performed as in Figures 5-3 and 5-4 for the identification of green and red 
fluorescence and the calculation of percentage cells with ΔΨm loss. 
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5.8 Optimization of the H2DCFDA assay for the detection of 
intracellular Reactive Oxygen Species  
To investigate ROS production after treatment with chemotherapy drugs that induce 
CIA and the potential role of temperature, the H2DCFDA assay was optimised. To 
investigate ROS production the ROS-associated marker 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA) was used. H2DCFDA is a non-fluorescent 
molecule, however, it fluoresces green when oxidised by intracellular ROS, and thus, the 
level of fluorescence is relative to the oxidative state of the cells (see Materials and Methods 
section 2.11.8).  
In initial experiments, HaCaTa cells treated with (0–2.5 µg/mL) doxorubicin were used 
in conjunction with three concentrations of H2DCFDA (2.5, 5, and 10 µM) to determine the 
concentration that would sensitively determine levels of intracellular ROS, as a high reagent 
concentration can result in misleadingly high fluorescence levels in cells (Figure 5-17). 
Exposure to doxorubicin for 2h significantly increased ROS production above the control, as 
shown by microtiter plate analysis and spectrophotometric measurements. 5μM of H2DCFDA 
consistently discriminated between intracellular concentrations of ROS in cells treated with 
different concentrations of doxorubicin (Figure 5-17).  
H2DCFDA can be measured using microtiter plate analysis (Takada et al., 2002), 
flow cytometry, fluorescence microscopy (Yang et al., 2005) or video microscopy (Leach et 
al., 2001). In this study, following microtiter plate analysis above (Figure 5-17), flow 
cytometry was also used for the quantification of intracellular ROS, to allow direct 
comparison of ROS levels in HaCaTa cells exposed to doxorubicin, docetaxel and 4-OH-CP 
at 37°C and cooling conditions. 
A series of titration experiments using flow cytometry were performed to optimise the 
assay conditions, including (a) H2DCFDA concentration; and (b) incubation periods, in order 
to determine not only the dose, but also equally importantly the optimal time-point for ROS 
measurement after treatment with each drug. It was found that the best time point for 
induction of ROS by doxorubicin was 30 min (Figure 5-18) and the concentration of 5μM 
H2DCFDA (Figures 5-19 and 5-20) sensitively and consistently discriminated between 
intracellular concentrations of ROS; these optimised methods for H2DCFDA-based ROS 
detection were applied for all experiments. Similar optimisations were then carried out for 4-
OH-CP (Figures 5-21 and 5-22) and docetaxel (Figures 5-23 and 5-24) from 0 to 6h post-
treatment. 
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Figure ‎5-17 Microtiter plate-based spectrophotometric detection of ROS levels after 
H2DCFDA staining in HaCaTa cells treated with doxorubicin 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with a range of 
concentrations of doxorubicin at 37°C, compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a 30 min, after which H2DCFDA reagent (as a fluorescent probe) at different 
concentrations (2.5, 5, and 10μM) was added to the wells and plates were incubated at 37°C 
in 5% CO2 for a 30 min. Fluorescence was measured at Excitation 485nm/Emission 520nm 
in the presence of PBS. Bars represent mean RFU values (±S.E.M) and results are 
representative of three independent experiments each consisting of 6–8 technical replicates. 
**, p < 0.01; ***, p < 0.001. 
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Figure ‎5-18 Time-dependent ROS production measured by flow cytometry analysis 
using H2DCFDA after treatment with doxorubicin in HaCaTa cells 
HaCaTa cells were seeded in 6-well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 2.5 µg/mL 
doxorubicin (Doxo) at 37°C, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for the indicated time points (0, 30min, 1h and 3h), and after which 5μM H2DCFDA reagent 
was added to the wells and plates were incubated at 37°C in 5% CO2 for 30 min. Cells were 
harvested by trypsinisation and ROS generation measured by flow cytometry. A) 
Representative flow cytometric histograms, B) bars represent median fluorescence intensity 
(MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results analysed using 
GuavaSoft software. Bars show MFI (±S.E.M) for three independent biological experiments, 
each consisting of 2 technical replicates. *, p < 0.05; ***, p < 0.001.  
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Figure ‎5-19 ROS levels measured by flow cytometry analysis after drug treatment with 
and without H2DCFDA reagent in HaCaTa cells 
HaCaTa cells were seeded in 6-well plates at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 2.5 µg/mL 
doxorubicin (Doxo) at 37°C, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a 30 min, after which 5μM H2DCFDA reagent was added to the wells and plates were 
incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation ROS 
generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. A) 
Representative flow cytometric histograms, B) bars represent median fluorescence intensity 
(MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results analysed using 
GuavaSoft software. Bars show MFI (±S.E.M) for three independent biological experiments, 
each consisting of 2 technical replicates. ***, p < 0.001. 
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Figure ‎5-20 ROS induction determined using 2.5 and 5 μM [H2DCFDA] in HaCaTa Cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 2.5 µg/mL 
doxorubicin (Doxo) at 37°C, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a 30 min and after which (2.5 and 5μM) H2DCFDA reagent were added to the wells and 
plates were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation 
ROS generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. 
A) Representative flow cytometric histograms, B) bars represent median fluorescence 
intensity (MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Bars show MFI (±S.E.M) for three independent 
biological experiments, each consisting of 2 technical replicates. ***, p < 0.001. 
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Figure ‎5-21 Time-dependent reactive oxygen species (ROS) production measured by 
flow cytometry analysis after treatment with 4-OH-CP and 5 and 10 μM [H2DCFDA] in 
HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 7.5 µg/mL 4-
OH-CP at 37°C, compared with vehicle control (cells treated with medium containing DMSO, 
in which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a (0, 30 min, 1h and 
3h and after which (5 and 10μM) H2DCFDA reagent were added to the wells and plates were 
incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation ROS 
generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. A and 
C) Representative flow cytometric histograms, B and D) bars represent median fluorescence 
intensity (MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results 
analysed using GuavaSoft software. Bars show MFI (±S.E.M) for three independent 
biological experiments, each consisting of 2 technical replicates. n.s., non-significant; *, p < 
0.05; **, p < 0.01. 
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Figure ‎5-22 Time-dependent reactive oxygen species (ROS) production measured by 
flow cytometry analysis after treatment with 4-OH-CP and 5 μM [H2DCFDA] in HaCaTa 
cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 7.5 µg/mL 4-
OH-CP at 37°C, compared with vehicle control (cells treated with medium containing DMSO, 
in which the reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a (4, 5 and 6h) and 
after which (5 and 10μM) H2DCFDA reagent were added to the wells and plates were 
incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation ROS 
generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. A) 
Representative flow cytometric histograms, B) bars represent median fluorescence intensity 
(MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results analysed using 
GuavaSoft software. Bars show MFI (± S.E.M.) for three independent biological experiments, 
each consisting of 2 technical replicates. n.s., non-significant; **, p < 0.01. 
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Figure ‎5-23 Time-dependent reactive oxygen species (ROS) production measured by 
flow cytometry analysis after treatment with docetaxel and 5 μM [H2DCFDA] in 
HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 0.01 µg/mL 
docetaxel (Doce) at 37°C, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a (0, 30 min, 1h and 3h and after which 5μM H2DCFDA reagent were added to the wells 
and plates were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by 
trypsinisation ROS generation were analysed by flow cytometry using H2DCFDA as a 
fluorescent probe. A) Representative flow cytometric histograms, B) bars represent median 
fluorescence intensity (MFI). Cells were acquired on a Guava EasyCyte flow cytometer and 
results analysed using GuavaSoft software. Bars show MFI (±S.E.M.) for three independent 
biological experiments, each consisting of 2 technical replicates. n.s., non-significant; *, p < 
0.05. 
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Figure ‎5-24 Time-dependent reactive oxygen species (ROS) production measured by 
flow cytometry analysis after treatment with docetaxel and 5 μM [H2DCFDA] in 
HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were treated for 2h with 0.01 µg/mL 
docetaxel (Doce) at 37°C, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a (4, 5 and 6h) and after which (5 and 10μM) H2DCFDA reagent were added to the wells 
and plates were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by 
trypsinisation ROS generation were analysed by flow cytometry using H2DCFDA as a 
fluorescent probe. A) Representative flow cytometric histograms, B) bars represent median 
fluorescence intensity (MFI). Cells were acquired on a Guava EasyCyte flow cytometer and 
results analysed using GuavaSoft software. Bars show MFI (±S.E.M.) for three independent 
biological experiments, each consisting of 2 technical replicates. *, p < 0.05 
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5.9 Effect of cooling on chemotherapy drug-induced ROS  
The ability of some chemotherapy drugs to trigger oxidative stress seems to play an 
important role in the anti-carcinogenic potential of these drugs, as is believed to be the case 
for one of the most frequently used drugs in the clinic, doxorubicin (Luanpitpong et al., 2012). 
To further understand the mechanisms by which cooling protects from drug-induced 
cytotoxicity in HaCaTa cells, we measured intracellular ROS production at normal 
temperature and tested the effect of cooling on ROS production when cells were treated with 
doxorubicin (2.5 µg/mL), docetaxel (0.05 µg/mL) and 4-OH-CP (7.5 µg/mL).  
5.9.1 Influence of temperature on ROS production induced by doxorubicin in 
HaCaTa cells  
It has been reported that hypothermia can reduce the level of intracellular ROS while 
hyperthermia may increase their production (Hsu et al., 2011). Cellular ROS levels in 
HaCaTa cells 30 min after a 2h treatment with 2.5 µg/mL doxorubicin at 37°C or 22°C were 
assessed by H2DCF-DA labelling and flow cytometry. As shown in Figure 5-25 A and B, 
doxorubicin increased ROS generation and this was significantly reduced at 22°C. To further 
investigate the effect of temperature on ROS generation, cells were treated with doxorubicin 
at 18°C and (Figure 5-25C and D) and 14°C (Figure 5-25E and F). Results showed that the 
cellular ROS generation was further reduced at 18°C and almost abolished at 14°C indicating 
that ROS produced by cells in response to doxorubicin treatment are suppressed by cooling 
and that the lower the temperature the better the inhibition of ROS. 
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Figure ‎5-25 Temperature-dependent reactive oxygen species (ROS) production after 
treatment with doxorubicin in HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 2.5 µg/mL 
doxorubicin (Doxo) at 37°C, 22°C, 18°C, and 14°C compared with vehicle control (cells 
treated with medium containing DMSO, in which the reagent was dissolved. The solvent 
represents the maximum amount of DMSO corresponding to the highest drug concentration). 
The drugs were then removed, wells were rinsed with PBS to remove any traces of drug and 
cultures incubated for a 30 min and after which 5μM H2DCFDA reagent were added to the 
wells and plates were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by 
trypsinisation ROS generation were analysed by flow cytometry using H2DCFDA as a 
fluorescent probe. A, C and E) Representative flow cytometric histograms at 22°C, 18°C, 
14°C respectively, B, D and F) bars represent median fluorescence intensity (MFI) at 22°C, 
18°C, and 14°C respectively. Cells were acquired on a Guava EasyCyte flow cytometer and 
results analysed using GuavaSoft software. Bars show MFI (±S.E.M.) for three independent 
biological experiments, each consisting of 2 technical replicates. ***, p < 0.001. 
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5.9.2 Influence of temperature on ROS production by 4-OH-CP in HaCaTa cells  
It has been reported that cyclophosphamide can induce ROS generation (Gonzalez 
et al., 2015; Sulkowska et al., 1998); therefore the effect of cooling on oxidative stress was 
investigated to further understand the mechanism by which cyclophosphamide induces CIA 
and explain the protective effect of cooling. HaCaTa cells were treated with 7.5 µg/mL of 4-
OH-CP and ROS levels determined as previously described after 30 min (as doxorubicin 
experiments in section 5.1.8 indicated that ROS elevation is rapid and short-lived). Results 
showed a slight increase in ROS generation was observed at 30 min after treatment at 37°C 
compared with the control (non-drug-treated cells). Hence, although 4-OH-CP does induce 
the generation of ROS it is was lower than that induced by doxorubicin and furthermore the 
level of ROS at 22°C was higher than that at 37°C (Figure 5-26A and B).  
To further investigate the effect of cooling on cyclophosphamide generation of 
intracellular ROS, temperature was further reduced to 18°C, and this decreased intracellular 
ROS compared with 22°C (Figure 5-26C and D). Moreover, 4-OH-CP-induced ROS 
generation at 14°C was investigated; surprisingly ROS generation at 14°C was higher than 
that at 18°C (Figure 5-26E and F).  
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Figure ‎5-26 Temperature-dependent reactive oxygen species (ROS) production after 
treatment with 4-OH-CP in HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 7.5 µg/mL 4-
OH-CP at 37°C, 22°C, 18°C, and 14°C compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a 30 min and after which 5μM H2DCFDA reagent were added to the wells and 
plates were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation 
ROS generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. 
A, C and E) Representative flow cytometric histograms at 22°C, 18°C, 14°C respectively, B, 
D and F) bars represent median fluorescence intensity (MFI) at 22°C, 18°C, and 14°C 
respectively. Cells were acquired on a Guava EasyCyte flow cytometer and results analysed 
using GuavaSoft software. Bars show MFI (±S.E.M.) for three independent biological 
experiments, each consisting of 2 technical replicates. n.s., non-significant; *, p < 0.05. 
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5.9.3 ROS production mediated by docetaxel and effects of cooling  
Next, ROS generation in HaCaTa cells treated with docetaxel and the effects of 
cooling were examined. As shown in Figure 5-27, treatment of 0.01 µg/mL docetaxel and 5 
µM of H2DCFDA produced elevated levels of ROS at 14°C compared with cells treated at 
37°C. These results suggested that docetaxel failed to affect the basal levels of ROS in 
HaCaTa cells. 
 
 
Figure ‎5-27 Temperature-dependent reactive oxygen species (ROS) production after 
treatment with docetaxel in HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 0.01 µg/mL 
docetaxel (Doce) at 37°C and 14°C compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a 30 min and after which 5μM H2DCFDA reagent were added to the wells and plates 
were incubated at 37°C in 5% CO2 for 30 min. Cells were harvested by trypsinisation ROS 
generation were analysed by flow cytometry using H2DCFDA as a fluorescent probe. A) 
Representative flow cytometric histograms, B) bars represent median fluorescence intensity 
(MFI). Cells were acquired on a Guava EasyCyte flow cytometer and results analysed using 
GuavaSoft software. Bars show MFI (±S.E.M.) for three independent biological experiments, 
each consisting of 2 technical replicates. *, p < 0.05. 
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As already described in this chapter, NHEK, HHFK, and HaCaTa cells treated with 
chemotherapeutic drugs showed a significant disruption in their mitochondrial membrane 
potential, and this was demonstrated using the JC-1 assay. The impairment of the integrity of 
the mitochondrial potential coincides with the decoupling of the respiratory chain and 
subsequently increased production of ROS, an effect that has been demonstrated for 
doxorubicin, which has been shown to induce ROS in HaCaT cells (Luanpitpong et al., 
2012). Disruption of mitochondrial function can have devastating consequences for the cell 
and led to death. The mitochondrial apoptosis pathway requires disruption of the ΔΨm and 
the release of mitochondrial proteins. To provide evidence for apoptosis induction and to 
confirm the protective roles of cooling against chemotherapy drugs induced cell death, 
assays that specifically detect cell death (apoptosis) were used. 
5.10  Detection of chemotherapy drug mediated HaCaTa cell death 
using the CytoTox-Glo assay and assessment of the effect of 
cooling  
To determine the efficacy of cooling in the prevention from chemotherapy-
induced cell death in HaCaTa cells, the CytoTox-Glo™ assay was conducted. Initially the 
effects of various concentrations of the drugs (doxorubicin, docetaxel, 4-OH-CP as well as 5-
FU) were measured 24h after treatment at either 37°C or 18°C (Figure 5-28). 
A significant increase in cell death occurred 24h after treatment with 0.5, 0.75 and 
2.5 µg/mL doxorubicin and 0.005, 0.025, and 0.1 µg/mL docetaxel at 37°C compared 
with cells treated at 18°C. However, cells treated with 2.5, 5 and 10 µg/mL 4-OH-CP 
showed no significant effects (Figure 5-28). Data showed that using the CytoTox-Glo 
assay with the concentrations of drugs chosen was relatively modest effects after 24h. 
This indicated that a longer time period as well as higher concentrations of 
chemotherapy drugs might be necessary to observe a more significant cell death 
induction.  
Therefore, a second protocol was followed in which cells were treated with 2.5 
and 5 µg/mL doxorubicin, 0.025 and 0.1 µg/mL docetaxel and 10 and 30 µg/mL 4-OH-CP 
for 2h at 37°C and 18°C and cell death was assessed at 48h post treatment. A 
significantly greater cytotoxic effect was observed when the cells were exposed to the 
drugs at 37°C compared to cells treated at 18°C (Figure 5-29). Thus, the induction of 
apoptosis assessed with the CytoTox-Glo assay after 48h of treatment was far more 
marked compared to 24h. More importantly, although some protection was observed at 24h 
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(Figure 5-28), there was a more significant reduction of apoptosis in cells treated at cooling 
condition (18°C) at 48h, providing evidence that cooling could protect cells from cytotoxicity 
induced by chemotherapeutic drugs. Moreover, the cytotoxicity in HaCaTa cells treated with 
10 and 25 µg/mL 5-FU was measured at 37°C and 18°C (Figure 5-30). The data showed that 
there was a significant decrease in cell death at 18°C compared to at 37°C. Taken together, 
these observations suggest that reduction in viability is due to active induction of cell death. 
Since the CytoTox-Glo assay was not sensitive to detect cell death at low 
concentrations, in addition, CytoTox-Glo assay was not able to distinguish between cell 
death via apoptosis or necrosis develops, an alternative test system was used to investigate 
the extent chemotherapy drugs have a damaging effect. For this, the SensoLyte assay was 
used, where the activity of effector proteases programmed cell death via a special 
fluorescence detectable test substrate, which can measure caspase-3/7 activity. 
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Figure ‎5-28 Detection of the cytoprotective role of cooling against chemotherapy drug-
mediated cell death in HaCaTa cells after 24h using CytoTox-Glo 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 24h, after 
which 50 µL CytoTox-Glo substrate was added. After 15 min incubation at room temperature, 
luminescence was measured using a plate reader. RLU readings were deduced as described 
in Materials and Methods section 2.10.2. A) Results are plotted as raw luminescence data, 
B) Results are presented as fold change (from raw RLU data used in A) by comparing drug 
treated cells versus controls. Bars correspond to mean values of three technical replicates 
(±S.E.M.) for three independent biological experiments, each consisting of 6-8 technical 
replicates. n.s., non-significant; *, p < 0.05; **, p < 0.01, ***, p < 0.001. 
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Figure ‎5-29 Detection of the cytoprotective role of cooling against chemotherapy drug-
mediated cell death in HaCaTa cells after 48h using CytoTox-Glo 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 48h, after 
which 50 µL CytoTox-Glo substrate was added. After 15 min incubation at room temperature, 
luminescence was measured using a plate reader. RLU readings were deduced as described 
in Materials and Methods section 2.10.2. A) Results are plotted as raw luminescence data, 
B) Results are presented as fold change (from raw RLU data used in A) by comparing drug 
treated cells versus controls. Bars correspond to mean values of three technical replicates 
(±S.E.M.) for three independent biological experiments, each consisting of 6-8 technical 
replicates. **, p < 0.01, ***, p < 0.001. 
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Figure ‎5-30 Detection of cytoprotective role of cooling against 5-fluorouracil (5-FU)-
mediated toxicity in HaCaTa cells after 48h using CytoTox-Glo 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of 5FU at 37°C and 18°C compared with vehicle control compared with 
vehicle control (cells treated with medium containing DMSO, in which the reagent was 
dissolved. The solvent represents the maximum amount of DMSO corresponding to the 
highest drug concentration). The drugs were then removed, wells were rinsed with PBS to 
remove any traces of drug and cultures incubated for a further 48h, after which 50 µL 
CytoTox-Glo substrate was added. After 15 min incubation at room temperature, 
luminescence was measured using a plate reader. RLU readings were deduced as described 
in Materials and Methods section 2.10.2. A) Results are plotted as raw luminescence data, 
B) Results are presented as fold change (from raw RLU data used in A) by comparing drug 
treated cells versus controls. Bars correspond to mean values of three technical replicates 
(±S.E.M.) for three independent biological experiments, each consisting of 6-8 technical 
replicates. n.s., non-significant; ***, p < 0.001. 
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5.11  Detection of chemotherapy drug-induced activation of 
caspases-3/7 using the SensoLyte assay and assessment of 
the effect of cooling  
Caspases-3 and 7 have some similarities, but also some distinct roles in programmed 
cell death (apoptosis). They are both key effector (executioner) caspases and as a result are 
involved in both the extrinsic and intrinsic (mitochondrial) pathways (Lakhani et al., 2006). 
Chemotherapeutic drugs often induce apoptosis via the intrinsic pathway by MOMP induction 
and subsequent caspase-3/7 activation (Scabini et al., 2011). Caspase-3/7 are required for 
the execution phase of the apoptotic process, and their activities are commonly used as 
indicators (markers) of apoptosis (Jänicke et al., 1998). Caspase-3 has an important role in 
driving DNA fragmentation and the morphological changes of apoptosis, while caspase-7 
plays a minor role in these processes (Lakhani et al., 2006). The SensoLyte caspase-3/7 
assay was used for detection of caspase-3/7 activity in HaCaTa cells treated with 
doxorubicin, docetaxel and 4-OH-CP for 2h at 24 and 48h post-treatment.  
A significant increase in caspase-3/7 activity occurred 24h after treatment with (0.5, 
0.75 and 2.5 µg/mL) doxorubicin and (0.005, 0.025, and 0.1 µg/mL) docetaxel and (2.5, 5 
and 10 µg/mL) 4-OH-CP at 37°C compared with cells treated at 18°C (Figure 5-31). Data 
showed that there was a correlation between doxorubicin concentration and caspase-3/7 
activity and there was a significant rise in caspase-3/7 activity with the escalation of the 
concentration. Moreover, there was a significant increase in caspase-3/7 at 37°C compared 
to at 18°C (Figure 5-31).  
The activity of caspase-3/7 was increased significantly in cells treated with docetaxel 
for nearly all concentrations tested at 37°C after 24h, compared with cells treated at 18°C 
(Figure 5-31). These data suggested that the cells treated with docetaxel even at low 
concentrations might induce high levels of active caspase-3/7 and apoptosis.  
The results of HaCaTa cells 24h after treatment with different concentrations of 4-OH-
CP at 37°C and 18°C, also showed a positive correlation between the caspase-3/7 activation 
and 4-OH-CP concentration for both temperatures, with a significant increase of caspase-3/7 
activation compared with cells treated at 18°C where the activation was decreased 
significantly (Figure 5-31). Surprisingly, a lower level of caspase-3/7 activity was observed 
after the 48h incubation period (Figure 5-32), compared with that after 24h. These results are 
likely due to the effects of drugs, which is generally on cellular caspase-3 activation and this 
may occur in phases of the cell cycle earlier than 48h, as demonstrated in the cell cycle 
analysis. 
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Figure ‎5-31 The role of cooling in caspase-3/7 activation induced by chemotherapy 
drugs in HaCaTa cells after 24h using the SensoLyte assay 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 24h, after 
which 50 µL substrate of the Ansapec assay was added. After 60 min incubation in the dark 
at room temperature, fluorescence was measured using a plate reader. The Relative 
Fluorescence Units (RFU) readings were deduced as described in Materials and Methods 
section 2.10.3. A) Results are plotted as raw Fluorescence data; B) Results are presented as 
fold change (from raw RFU data used in A) by comparing drug treated cells versus controls. 
Bars correspond to mean values (±S.E.M.) for three independent biological experiments, 
each consisting of 6-8 technical replicates. *, p < 0.05; **, p < 0.01, ***, p < 0.001. 
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Figure ‎5-32 The role of cooling in caspase-3/7 activation induced by chemotherapy 
drugs in HaCaTa cells after 48h using the SensoLyte assay 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 48h, after 
which 50 µL substrate of the Ansapec assay was added. After 60 min incubation in the dark 
at room temperature, fluorescence was measured using a plate reader. The Relative 
Fluorescence Units (RFU) readings were deduced as described in Materials and Methods 
section 2.10.3. A) Results are plotted as raw Fluorescence data; B) Results are presented as 
fold change (from raw RFU data used in A) by comparing drug treated cells versus controls. 
Bars correspond to mean values (±S.E.M.) for three independent biological experiments, 
each consisting of 6-8 technical replicates. n.s., non-significant, *, p < 0.05; **, p < 0.01. 
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5.12  Detection of DNA fragmentation after HaCaTa cell exposure to 
chemotherapeutic drugs and assessment of the role of cooling  
In addition to the detection of apoptosis by Cytotox-Glo (as a surrogate marker of loss 
of membrane integrity) and SensoLyte/Anaspec (for the detection of caspase activity), cell 
death (apoptosis) was also measured by means of a DNA fragmentation ELISA assay 
(Materials and Methods section 2.10.4). DNA fragmentation detection can be a reliable, well 
characterised method to assess apoptotic cell death (Shaw et al., 2005), as it detects one of 
the hallmarks of apoptosis. For the DNA fragmentation assay, staurosporine was used as a 
positive control. Staurosporine, which is derived from Streptomyces staurosporeus, inhibits a 
range of protein kinases essential for normal cell function and is often used as a positive 
control of apoptosis induction by the intrinsic apoptotic pathway (via MOMP) and leads to 
caspase-mediated cell death (Zhang et al., 2004). Two types of controls were used in every 
experiment: positive control of apoptosis induction via treatment with 5μM staurosporine and 
negative control (untreated cells) for each temperature condition (normal versus cooling). 
The DNA fragmentation assays were performed on HaCaTa cells treated for 2h with 
0.5 µg/mL doxorubicin, 0.005 µg/mL docetaxel and 7.5 µg/mL 4-OH-CP at 37°C and 18°C 
after 24 and 48h. There was a significant increase in DNA fragmentation in cells treated with 
doxorubicin and docetaxel (and staurosporine) compared to untreated controls, however, 
there was low level in DNA fragmentation in cells treated with 4-OH-CP at 37°C after 24h 
(Figure 5-33). Cell treated with doxorubicin showed higher DNA fragmentation than the 
positive control at 37°C at the same time point (Figure 5-33). The greatest 
DNA fragmentation was observed at 48h for doxorubicin, docetaxel, and staurosporine. 4-
OH-CP, by contrast, induced only a very small increase in DNA fragmentation (Figures 5-33 
and 5-34). To evaluate the effects of cooling on the DNA fragmentation cells were exposed 
to drugs at 18°C. As shown in Figures 5-33 and 5-34, cooling reduced DNA fragmentation 
significantly compared to cells treated at 37°C at both 24 and 48h. 
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Figure ‎5-33 The effect of cooling on DNA fragmentation induced by chemotherapy 
drugs in HaCaTa cells after 24h using the DNA fragmentation assay 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration) was used as negative control and cells 
were treated with 5 µM staurosporine (positive control). The drugs were then removed; wells 
were rinsed with PBS to remove any traces of drug. DNA fragmentations were measured 
after 24h absorbance (455nm) was measured by a plate reader and percentage was 
calculated as described in Materials and Methods section 2.10.4. A) Results are plotted as 
raw absorbance data, B) Result are also presented as fold change by comparing drug 
treated versus positive control. Bars correspond to mean values (±S.E.M.) for three 
independent biological experiments, each consisting of 3 technical replicates. n.s., non-
significant; *, p < 0.05; ***, p < 0.001. 
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Figure ‎5-34 The role of cooling in the inhibition of DNA fragmentation induced by 
chemotherapy drug in HaCaTa cells after 48h using the DNA fragmentation assay 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C / 5% CO2. HaCaTa cells were treated for 2h with the 
indicated dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP at 37°C and 18°C 
compared with vehicle control compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration) was used as negative 
control and cells were treated with 5 µM staurosporine (positive control). The drugs were 
then removed; wells were rinsed with PBS to remove any traces of drug. DNA 
fragmentations were measured after 48h absorbance (455nm) was measured by a plate 
reader and percentage was calculated as described in Materials and Methods section 2.10.4. 
A) Results are plotted as raw absorbance data, B) Result are also presented as fold change 
by comparing drug treated versus positive control. Bars correspond to mean values 
(±S.E.M.) for three independent biological experiments, each consisting of 3 technical 
replicates. n.s., non-significant; *, p < 0.05; ***, p < 0.001. 
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5.13 Summary  
 One of the main objectives of this chapter was to examine the hypothesis that 
chemotherapy drugs may disrupt mitochondrial membrane potential (ΔΨm) and 
induce MOMP as well as ROS release as part of their mechanism of cytotoxicity, 
and whether these changes are altered by cooling, to provide functional evidence 
for its cytoprotective effect. Moreover, a variety of well-characterised cell apoptosis 
assays were used to investigate the cytoprotective role of cooling against 
chemotherapy induced cytotoxicity.  
 The cationic and lipophilic dye JC-1 was used to determine the changes in ΔΨm. 
The results showed that the optimal concentration of JC-1 was 2μM in HaCaTa 
cells treated with 4-OH-CP at 37°C compared with the positive control (cells 
treated with CCCP (carbonyl cyanide m-chlorophenylhydrazone)).  
 4-OH-CP caused a significant reduction of the red / green ratio (red = polarized 
mitochondria, green = depolarized mitochondria) in cells at 37°C after 24-48h post 
treatment.  
 Data showed that alterations in mitochondrial membrane potential (ΔΨm) in 
HaCaTa, NHEK and HHFK cells at physiological temperature (37°C) on the 
challenge with cytotoxic drugs were significantly reduced when the cells were 
treated at cooling conditions (22°C and 18°C) during drug exposure. This is the 
first study showing that cooling provides protection from the change in ΔΨm 
induced by three routinely used chemotherapy drugs.  
 HaCaTa cells were more sensitive to the cytotoxic drugs than NHEK and HHFK. 
For this reason the concentrations of chemotherapy drugs used to treat NHEK and 
HHFK cells were higher than that used to treat HaCaTa cells.  
 Using H2DCFDA as a ROS-detection probe, ROS generation was explored by 
flow cytometry. The data in this study provide evidence that ROS is a key mediator 
of doxorubicin induced apoptosis through the mitochondrial pathway in HaCaTa 
cells. Time-course measurements showed that the maximum response was 30 
min after a 2h doxorubicin exposure. However, ROS induced by doxorubicin was 
inhibited by cooling and this also inhibited apoptosis induced by doxorubicin and 
thus this further supported the role of ROS in apoptosis. In addition, further cooling 
of cells to 14°C incrementally reduced further ROS production.  
 Results showed that HaCaTa cells treated with 4-OH-CP did not proportionally 
cause increases in ROS generation after treatment (0-6h). This is not in 
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accordance with published observations that have reported cyclophosphamide-
mediated ROS generation and apoptosis (Abraham and Kanakasabapathy, 2008; 
Karbowski et al., 1999). It is possible that further experiments might be required to 
detect ROS increases by 4-OH-CP in keratinocytes (perhaps due to the extremely 
short ROS life span that could not be detected by H2DCFDA probe).  
 Although previous studies reported that docetaxel increased mitochondrial 
generation of ROS (Mizumachi et al., 2008; Taniguchi et al., 2005); in this study, 
data did not show a significant induction of ROS apart from a slight increase after 
5h post exposure to docetaxel in HaCaTa cells at 37°C.  
 Results revealed doxorubicin, docetaxel, 4-OH-CP and 5-FU-mediated cytotoxicity 
and apoptosis in HaCaTa cells in a dose- and time-dependent manner. No 
significant increase in cell death was found after 24h in cells treated with 
doxorubicin, docetaxel, and 4-OH-CP. However, a significant increase of 
cytotoxicity occurred after 48h at high concentrations of doxorubicin and 4-OH-CP, 
while cells treated with docetaxel showed high cell death even at low 
concentrations. This demonstrated cell death occurs after 48h, and that there was 
a clear dose-response relationship between doxorubicin and 4-OH-CP 
concentration and number of dead cells.  
 The results indicated for the first time that cooling protects from cytotoxicity, 
reduced caspase-3/7 activity and reduced DNA fragmentation. Doxorubicin 
showed the highest DNA fragmentation at 37°C after 24 and 48h compared to 
docetaxel and 4-OH-CP. By contrast, 4-OH-CP showed relatively to the other 
drugs the least cytotoxicity.  
 Overall, the results in this chapter have thus provided a more mechanistic 
explanation for the cytoprotective effects of cooling (based on biomass detection) 
reported in previous chapters.  
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5.14 Discussion 
5.14.1 Cytoprotective properties of cooling against chemotherapy drug-induced 
mitochondrial damage  
The main aim of this work was to the establishment of a model system for the study 
of pathobiology and management of CIA processed by cooling. A stable mitochondrial 
membrane potential is essential for mitochondrial function. Lowered membrane potential 
means less polarization of the mitochondrial membrane and thus an obstacle to the 
functioning of the respiratory chain and ATP formation. In our study, for the first time we 
determined that cooling reduced the effects of chemotherapy drugs, by protecting from ΔΨm 
changes and thus increased viability of cells after drug treatment, thus subsequently 
protecting keratinocytes from apoptosis in vitro. Previous reports have demonstrated that, 
following induction of DNA damage, doxorubicin can cause a collapse of ΔΨm and apoptosis 
in a p53 dependent fashion in cardiac myocytes (L'ecuyer et al., 2006).  
Mitochondrial damage results in activation of downstream caspases and apoptosis. 
The state of the mitochondrial membrane potential (ΔΨm) was measured by the 
fluorescent cationic dye JC-1 and flow cytometry. Mitochondrial depolarisation is considered 
an irreversible step in the apoptosis process, which leads to release of apoptogenic factors 
(Kluck et al., 1997). JC-1 staining measures whether mitochondrial membrane is polarized 
(viable cells) or depolarized (apoptotic cells) (for an example see (Perry et al., 2011)). The 
results obtained by JC-1 staining and other apoptosis determination methods were closely 
similar, supporting the reliability of this method (Salvioli et al., 1997). For these studies, three 
types of cells were used (HaCaTa, NHEK, and HHFK) at different time points and treated 
with 4-OH-CP, docetaxel, and doxorubicin to identify the specific changes in the ΔΨm.  
The present results in keratinocytes showed that the toxicity of chemotherapy drugs 
at clinically relevant concentrations in vitro induced alteration of mitochondrial membrane 
potential followed by apoptosis. These processes would involve the formation of Bak/Bax 
channels in the outer mitochondrial membrane (OMM), release of cytochrome c and finally 
activation of caspases. So far, little is known concerning the molecular mechanism involved 
in signal transduction and apoptosis at low temperature on chemotherapy treated cells. A 
previous study showed that treatment with doxorubicin at 32°C in human HeLa cells, and U-2 
OS cells, provided protection from doxorubicin-mediated cytotoxicity by suppressing 
caspase-9 activation and mitochondrial-mediated apoptosis. However, the exact mechanism 
has not been fully understood (Sakurai et al., 2005). Our data showed a decrease in ΔΨm 
following 24h drug exposure, a further decrease after 36h and maximum MOMP following 
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48h at 37°C. However, cooling at 22°C showed protection from the ΔΨm in HaCaTa cells. 
Interestingly, cooling at 18°C and even more so at 14°C resulted in better protection from 
mitochondria ΔΨm loss.  
The effects of cooling on ΔΨm loss induced by 4-OH-CP at 36h and 48h post 
treatment in HaCaTa, NHEK, and HHFK cells were investigated. The data showed that 
cooling caused inhibition of 4-OH-CP-mediated ΔΨm loss and the maximum levels of 
restoration of ΔΨm were after 48h post treatment at 22°C, 18°C and 14°C. The obtained 
results indicate that cooling inhibits 4-OH-CP. NHEK and HHFK cells treated with 4-OH-CP 
at 37°C and 18°C at 48h post-treatment showed essentially the same results as shown in 
HaCaTa cells. These observations provide molecular evidence for the cytoprotective role of 
cooling as well as attesting to the fact that HaCaTa cells are a good model to study the 
cytotoxic effects of drugs clinically associated with CIA in vitro.  
Apoptosis induced by docetaxel can proceed via the mitochondrial pathway, evident 
by changes in ΔΨm as reported elsewhere (Mhaidat et al., 2007). The triggering mechanism 
is believed to involve changes in the expression of anti- and pro-apoptotic members of the 
Bcl-2 family (Rowinsky et al., 1992). Analysis of changes in the ΔΨm by JC-1 labelling and 
flow cytometry in HaCaTa cells at 37°C after 36 and 48h post treatment with docetaxel 
showed that the drug induced loss of ΔΨm, as HaCaTa cells treated with docetaxel at 22°C 
showed a decrease in the percentage of the green cells and an increase in red fluorescence 
compared to 37°C. Moreover, when cells were treated at 18°C and 14°C they exhibited a 
significant reduction of green fluorescence, suggesting that cooling protects from 
mitochondrial ‗rupture‘ induced by docetaxel. These data provided evidence that docetaxel-
induced death in HaCaTa, NHEK and HHFK cells involved activation of the mitochondrial 
pathway, and the cytoprotective effect of cooling relates to its ability to reduce the level of cell 
death induced by docetaxel. 
The observation of the ability of doxorubicin to cause changes in the mitochondrial 
membrane potential are in agreement with its ability to cause mitochondrial membrane 
permeability, release of cytochrome c, cell death and ultimately cytotoxicity in keratinocytes 
(Bedard and Krause, 2007; Fu et al., 2010; Tsang et al., 2003), findings that were confirmed 
here in chapter 3. Of note, it is clear that there is a correlation between temperature and 
doxorubicin stimulated intracellular peroxide production (Figure 5-26). Moreover, doxorubicin 
has been shown to down-regulate Bcl-2 and up-regulate Bax and PUMA as well as causing 
rupture of mitochondrial membrane, and activation of caspase-9 and 3 (Liu et al., 2008; 
Nithipongvanitch et al., 2007). In addition, doxorubicin has been shown to simultaneously 
increase p53 and collapse ΔΨm. Our data clearly suggest that cooling significantly reduced 
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chemotherapy drug-induced ΔΨm loss, i.e. it efficiently prevented mitochondrial damage 
thereby rescuing HaCaTa, NHEK and HHFK cells from drug cytotoxicity. 
5.14.2 Effects of cooling on chemotherapy drug-induced ROS generation in 
HaCaTa cells  
Chemotherapy drugs, such as doxorubicin, are intended to increase ROS levels to 
induce irreparable damage to cancer cells subsequently resulting in apoptosis (Korkmaz et 
al., 2007; Wang et al., 2004). As the majority of the drugs tested in this study have been 
reported to induce oxidative stress in the form of ROS, the hypothesis examined was that an 
increase in ROS levels would be caused following drug treatment in keratinocytes. The level 
and timing of ROS production were measured using spectrophotometry and flow cytometry 
and utilising the oxidation of the detection reagent dichlorofluorescin diacetate (H2DCFDA). It 
should be noted that the H2DCFDA is a non-specific indicator of ROS levels (Kalyanaraman 
et al., 2012) and more specific reagents for the detection of individual types of ROS (such as 
hydrogen peroxide, hydroxyl radicals etc.) are commercially available.  
In this study, we demonstrated that induction of apoptosis by doxorubicin in HaCaTa 
cells is mediated via mitochondrial death pathway and in association with ROS-generation, a 
change that could be reduced significantly by cooling. The role of ROS in doxorubicin toxicity 
was previously reported in several studies including for instance neonatal mouse primary 
cardiomyocyte cultures (Fu et al., 2010). However, the effects of cooling on doxorubicin-
induced ROS generation have not been investigated before. Here for the first time we found 
that there is a correlation between ROS induced by doxorubicin and cooling. These results 
support the hypothesis that cooling reduces the intracellular ROS generation in HaCaTa 
cells. Interestingly, ROS induction by doxorubicin was higher than ROS induced by docetaxel 
and 4-OH-CP. Furthermore, ROS generation was rapid and the highest level of ROS was 
observed within 30 min after a 2h treatment with doxorubicin (Figure 5-10). 
Many chemotherapy drugs have been shown to produce ROS, yet anthracyclines 
(e.g., doxorubicin, epirubicin and daunorubicin) generate the highest levels of ROS (Conklin, 
2004). Furthermore, a number of reports supported the role of ROS as a mediator of 
apoptosis and caspase-3 activation (Chung et al., 2003; Yuan et al., 2001). The Bcl-2 family 
of proteins can regulate the generation of ROS with their elimination from the scavenging 
system or by preventing the generation of ROS (Chung et al., 2003).  
Previous studies suggested that docetaxel induces ROS production (Hung et al., 
2015), however, in this study, this induction was very low. This may be due to dose 
dependent generation and more concentrations might need to be tested. Furthermore, ROS 
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has a short life span and more optimization might be required to determine the optimal time 
point of induction. So far, it is not clear what the role of ROS in apoptosis induced by 
docetaxel is (Cao et al., 2004). Interestingly, cooling at 14°C increased ROS generation 
compared with at 37°C, which might indicate a stress response evident by the induction of 
ROS levels. This would be in complete accordance with the induction of p53 activation and 
up-regulation of p21 demonstrated in this study (see subsequent parts of this Discussion).  
Although previous studies showed that cyclophosphamide induced the generation of 
ROS (Abraham and Kanakasabapathy, 2008; Karbowski et al., 1999), this study showed that 
4-OH-CP did not consistently cause increases in ROS generation (Figure 5-25). A slight 
increase in ROS generation was evident at 30 min after drug treatment at 37°C, however, at 
22°C was slightly higher than at 37°C. Further research should be undertaken to investigate 
the effect of the cooling on ROS generation by 4-OH-CP. The temperature of 18°C was 
tested and the results showed at 18°C the level of ROS was slightly reduced compared with 
at 22°C, however, this was not statistically significantly different than the ROS levels at 37°C. 
The lack of marked ROS induction is in agreement with the observations on docetaxel. 
Interestingly, once again, at 14°C, the level of ROS generation was higher than at 18°C, 
perhaps again indicating a stress response to cooling this data suggesting that ROS at 
cooling samples works as the messenger to induce growth.  
Although not all drugs tested showed significant ROS induction, more recent studies 
in our laboratory have provided evidence that 4-OH-CP can induce ROS in HaCaTa cells 
(Dunnill and Georgopoulos, unpublished observations produced during the preparation of 
this thesis). The induction of ROS in human keratinocytes by drugs such doxorubicin and 4-
OH-CP could be important in the understanding of CIA and more importantly may provide 
novel complimentary cytoprotective approaches to treat and prevent chemotherapy-induced 
hair loss (see subsequent sections). 
5.14.3 Chemotherapy drug-induced apoptosis in HaCaTa cells is attenuated by 
cooling 
Doxorubicin, docetaxel, and cyclophosphamide are chemotherapeutic drugs 
commonly used for treating metastatic breast cancer (Ho and Mackey, 2014) and they work 
through different mechanisms (Payne and Miles, 2008). In this study, these drugs were 
shown to induce varying degrees of cell death in HaCaTa cells. Studying the effect of cooling 
on drug-mediated apoptosis was important in order to further characterise the molecular 
mechanisms of cooling-mediated cytoprotection.   
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This study has extensively used the CellTiter assay, which is based on the same 
principle as the traditional MTT assay, to assess cell viability. However, it is important to 
consider that CellTiter assay is based on cellular metabolic activity (Quent et al., 2010) or 
appropriately reflect induction of cell death in particular. Therefore, in addition to assessing 
cell viability using CellTiter in keratinocyte cells treated with different chemotherapy drugs, a 
number of cell death detection assays in particular CytoTox-Glo, a caspase detection assay 
and DNA fragmentation, were used to assess the cytotoxic effects of chemotherapy drugs on 
keratinocytes.  
Using the CytoTox-Glo assay, we showed that there was a substantial increase in cell 
death 24h post-exposure to doxorubicin and docetaxel at 37°C; however, this was 
significantly reduced under cooling conditions (18°C). Initial experiments with cells treated 
with 2.5, 5 and 10 µg/mL 4-OH-CP showed no significant effects (Figure 5-28) at both 
temperatures compared with doxorubicin and docetaxel. However, when the protocol was 
revised and we tested higher 4-OH-CP doses (10 and 30 µg/mL) after 48h post-exposure, a 
significantly greater cytotoxic effect at 37°C was observed and cooling at 18°C rescued from 
cell death. These findings provided more evidence that cooling protects cells from 
cytotoxicity induced by chemotherapeutic drugs by preventing induction of cell death. These 
observations were extended to 5-FU where cooling caused significant reduction in cell death 
induced by 5-FU.  
Many chemotherapeutic drugs have been developed to control cancer by triggering 
apoptosis via caspases because they play crucial roles in apoptosis. The measurement of 
caspase activation in cells helps in the understanding of the molecular mechanisms of 
apoptosis, in addition to the evaluation of the effect of anticancer drugs on apoptotic 
pathways (Sha et al., 2012). Previous studies have shown that doxorubicin (Luanpitpong et 
al., 2012), docetaxel (Kolfschoten et al., 2002), and cyclophosphamide (Schwartz and 
Waxman, 2001) can induce cleavage of executioner caspase-3.  
As mentioned in previous sections, apoptotic pathways dependent on caspase 
inducing apoptosis pathway-specific proteases, associated with the intrinsic and extrinsic 
pathway, the latter mainly engaging initiator caspase-8 (Hengartner, 2000); these two 
pathways can often converge downstream of initiator caspases to joint activation of effector 
caspases (specific executors of apoptosis), in particular caspase-3, as well as caspases-6 
and -7 (Green and Kroemer, 1998). The BH3-only protein Bid provides the link between the 
two pathways, which is activated after caspase-8-mediated cleavage of Bid to tBid (Winter et 
al., 2014). In this study, tBID was detected after chemotherapy drug treatment in HaCaTa 
cells (see subsequent sections). The intrinsic apoptotic pathway is the principal pathway of 
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chemotherapy-induced cell death triggered by formation of the apoptosome (cytochrome 
c/Apaf-1/caspase-9), which triggers the activation of caspase-3 (Ditsworth et al., 2003; Ricci 
and Zong, 2006).  
Therefore, in addition to the CytoTox-Glo assay, the SensoLyte caspase-3/7 assay 
was used to further understand drug mediated apoptosis. Activation of caspase-3/7 in 
HaCaTa cells over a range of drug treatments and the effect of cooling were examined. For 
the first time caspase-3/7 activation was detected in HaCaTa cells at 37°C, 24h after 
treatment with chemotherapy drugs. However, under cooling conditions (18°C) there was a 
significant reduction in caspase-3/7 activation, particularly in the case of doxorubicin and 
docetaxel. Interestingly the level of caspase-3/7 activation differed between 24 and 48h post 
treatment, suggesting that the assay more sensitively detected caspase activation at earlier 
time points, and diminished as cells became late apoptotic / necrotic later on during cell 
death. Activation of caspase-3/7 occurs after proteolytic cleavage, which leads to a cascade 
of activation that may occur even earlier than disruption of mitochondria because this 
process does not require transcription/translation related regulation (Cullen and Martin, 2009) 
which is in agreement with the observation that caspase-3/7 activation after 48h at 37°C was 
lower. Importantly, at 18°C less caspase-3/7 activation occurs which is in agreement with the 
cytoprotective effect of cooling thus resulting in higher cell survival.  
Previous studies showed that doxorubicin triggers the intrinsic apoptotic pathway in 
human keratinocytes and is associated with caspase-9 activation, as shown after treatment 
of HaCaT cells with doxorubicin, with caspase-9 and caspase-3/7 activation reported (Cullen 
and Martin, 2009; Luanpitpong et al., 2012). Another study showed that doxorubicin induced 
caspase-3 in a dose-dependent manner after 24h in HaCaT cells (Sauter et al., 2010). In this 
study, cooling inhibited doxorubicin-induced apoptosis in HaCaTa cells as demonstrated by 
the reduction of the activity of caspase-3/7 after 24h post treatment compared with cells 
treated at 37°C.  
Moreover, in HaCaTa cells treated with docetaxel, there was caspase-3/7 activation 
that was higher than that observed for doxorubicin and 4-OH-CP (Figure 6-4 and 6-5). This 
relates closely to our findings from experiments where HaCaTa cells were investigated upon 
exposure to docetaxel for 2h, and docetaxel induced arrest in G2/M and a significantly higher 
subG0/G1 population (compared to HaCaTa cells treated with doxorubicin and 4-OH-CP), 
whilst apoptosis induction was evidenced by a decrease of mitochondrial membrane 
potential. As expected the low concentrations show low activation of caspase-3/7 activation 
at 18°C compared to 37°C. These results therefore confirmed data from CellTiter and JC-1 
assays that cooling protects from cytotoxicity. These findings suggest that docetaxel-
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mediated apoptosis occurs via a caspase-dependent, although more specific functional 
experiments (e.g. involving use of caspase inhibitors or RNA interference) would be required 
to address this.  
Our 4-OH-CP results are in agreement with a previous study on cyclophosphamide-
induced apoptosis reporting that caspase-9 may be the initiating caspase triggering 
apoptosis and had an important role in the apoptotic cascade, utilising a caspase-3-
dependent pathway (Schwartz and Waxman, 2001). This study showed activation of 
caspase-3/7 after treatment with 4-OH-CP, which correlated with drug concentration and was 
attenuated by cooling.  
Another hallmark of apoptosis is the induction of DNA fragmentation. Previous 
studies have shown that doxorubicin can induce DNA fragmentation and cell death after 24h 
in the breast cancer MCF7 cells (Kim et al., 2006b; Li et al., 2007). Furthermore, it has been 
previously shown that cyclophosphamide induced caspase-3 activation and 
DNA fragmentation in murine vascular endothelial cell (Ohtani et al., 2006). To confirm 
apoptosis induction in HaCaTa cells following drug treatment, DNA fragmentation was 
detected using a DNA fragmentation ELISA. A higher level of DNA fragmentation was 
induced by doxorubicin and docetaxel in comparison with 4-OH-CP as detected using this 
assay, however cooling significantly reduced DNA fragmentation. The lack of significant DNA 
fragmentation observed here is in agreement with previous studies in MCF-7 cells 
demonstrating that although morphological apoptotic features were observed following cell 
treatment with cyclophosphamide, cell death caused by cyclophosphamide (and 5-FU) did 
not involve DNA-fragmentation (Kugawa et al., 2004). Our findings agree with the result in 
the above report and thus suggest that death induced by cyclophosphamide might be 
characterised by a mixture of apoptotic and non-apoptotic features. 
Collectively, our CytoTox-Glo assay, caspase-3/7 assay and the DNA fragmentation 
test data provided clear and consistent evidence that cooling protects cells from drug 
cytotoxicity apoptosis. This study therefore increased our understanding of the mechanisms 
via which cooling may protect against chemotherapy induced cell damage.  
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6 CHAPTER 6: Investigations on the effects of cooling on 
the activation and functional involvement of key 
intracellular mediators in chemotherapy drug-mediated 
apoptosis in human keratinocytes 
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6.1 The selective induction of apoptosis as a therapeutic strategy 
Most chemotherapy drugs act by inducing apoptosis in treated cells without 
selectivity. When DNA is damaged by UV irradiation or by chemotherapeutic drugs, the p53 
protein is activated and performs a critical role, which includes transcriptional regulation of a 
wide range of genes. Such p53-responsive genes include the gene WAFL/CIPL/p21, which is 
a classical cyclin-dependent kinase inhibitor, thus capable of blocking the cell cycle to allow 
the cell to repair its DNA (Bai and Zhu, 2006). If the DNA damage exceeds the ability of 
cellular repair mechanisms, apoptosis is induced as a result of the up-regulation and 
subsequent activation of apoptosis-associated signalling proteins; in this case, active 
(phosphorylated) p53 activates the mitochondrial pathway of apoptosis which leads to 
"suicide" of the cell experiencing genotoxic damage (Bai and Zhu, 2006).  
6.2  Control of DNA damage responses by p53: regulation of cell 
cycle and induction of apoptosis   
As the ―guardian of the genome‖, the transcription factor p53 has a critical role in 
controlling the integrity of the genome prior to (and after) DNA replication. The level of p53 
protein is low in normal cells, owing to the very short half-life of the protein and expression of 
p53 is monitored continuously by the MDM2 protein, which is an ubiquitin ligase that binds to 
p53 and leads to its degradation by the proteasome (Sakurai et al., 2005). When the genome 
undergoes alterations, the binding between p53 and MDM2 is inhibited by different post-
translational mechanisms and p53 accumulates, inducing expression of its target genes 
(Slee et al., 2004). p53 levels within cells rise dramatically in response to stress signals, such 
as the application of chemotherapy drugs. p53-inducible genes can be generally placed into 
two groups: a) those induced rapidly after low levels of stress (generally cell-cycle arrest) 
such as p21; b) those that are induced by higher levels of p53/stress, such as the pro-
apoptotic genes whose promoters contain p53-binding sites (generally apoptotic targets) 
such as Bax, DR5, Fas, PUMA, and Noxa. Stopping the cycle permits DNA repair and 
repression of p53 (Sablina et al., 2005; Slee et al., 2004). Apoptosis is triggered when, for 
instance, Bax, PUMA, and Noxa localize to the mitochondria and promote the loss of ΔΨm 
(MOMP) and release of cytochrome c, resulting in the formation of the apoptosome complex 
(Bai and Zhu, 2006; Nakano and Vousden, 2001) and subsequent activation of initiator 
caspase-9. Moreover, induced ROS production subsequently caused mitochondrial 
dysfunction and initiate apoptosis (Polyak et al., 1997). Previous studies showed that mouse 
embryo fibroblasts lacking Noxa or PUMA are resistant to apoptotic death in response to 
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DNA damage, a process known to be mediated by p53 (Shibue et al., 2003; Yu and Zhang, 
2003). 
6.3 Mechanisms of action of the Bcl-2 family members 
The Bcl-2 family of proteins regulate MOMP (i.e. permeabilization of the OMM) and are 
critical regulators of apoptosis and each protein has a role to play in the apoptotic process 
(Billen et al., 2008). The Bcl-2 family is subdivided to anti-apoptotic, such as Bcl-XL and Bcl-
w, containing four regions of homology with Bcl-2 (BH regions 1–4) and the pro-apoptotic 
Bcl-2 family proteins. The pro-apoptotic proteins can be divided into the multi-BH-domain 
(BH regions 1–3 proteins), such as Bax and Bak, and the activator BH3-only proteins such 
as Bid, Bim and Puma, which can directly induce Bax/Bak to cause MOMP (Kim et al., 
2006a) and these proteins can be seized by anti-apoptotic proteins. The second subgroup, 
which is termed sensitizer BH3-only proteins, such as Bad, Noxa, Bmf, Hrk, as they induce 
apoptosis by binding to anti-apoptotic proteins to release the activator BH3-only proteins 
(Letai et al., 2002) or activated Bax and Bak (Willis et al., 2005). Of note, the death receptor-
mediated apoptosis pathway can also be regulated by p53, as p53 can induce expression of 
DR5 (TRAIL receptor 1), Fas and PIDD (Takimoto and El-Deiry, 2000). Previous studies 
demonstrated that p53 activation is essential in chemotherapy-induced alopecia (CIA) in 
mice (Botchkarev et al., 2000). Also in vivo studies showed that a chemical inhibitor of p53 
decreased the toxicity of chemotherapy drugs (Komarov et al., 1999). These findings suggest 
that local pharmacological inhibition of p53 may be useful in preventing CIA.  
Bcl-2 family members interact with each other, forming homodimers or heterodimers. 
The relative amount of each protein in the cell determines the sensitivity to a death signal 
(Adams and Cory, 1998). A large majority of members of this protein family contains a 
hydrophobic carboxy-terminal domain, which is predicted to allow them to anchor to a variety 
of cell membranes such as to the cytoplasmic face of the outer mitochondrial membrane 
(OMM), the endoplasmic reticulum (ER) and nuclear membranes (Torrecillas et al., 2007). 
The pattern of membrane localization differs among the anti- and pro-apoptotic proteins. For 
example, Bax is kept inactive in the cytosol of healthy cells by association with 14-3-3 
proteins and Ku-70, and only anchored to the outer membrane of the mitochondria (OMM) 
upon activation (Petros et al., 2004; Tsuruta et al., 2004). By contrast, Bak is located in the 
OMM where it is maintained in an inactive monomeric state via its interaction with VDAC2 
protein (Cheng et al., 2003; Willis et al., 2005). Moreover each of BH3-only proteins resides 
in a distinct cellular compartment and meets a specific apoptotic stimulus (Lomonosova and 
Chinnadurai, 2008; Opferman and Korsmeyer, 2003). Following an apoptotic stress, they 
head to the mitochondria where they interact with multi-BH-domain proteins (BH regions 1–3 
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proteins). Some BH3 proteins interact with proapoptotic proteins Bax and Bak to activate, 
others with anti-apoptotic proteins Bcl-2 and Bcl-x L to inactivate, and some would be able to 
interact with pro- and anti-apoptotic members (Strasser, 2005).  
6.4 Hypothesis and Specific Aims  
Clinical application of scalp cooling during chemotherapy drug administration can 
show good efficacy in the clinic (Breed et al., 2011) and results in this study have shown that 
cooling can protect cells from cytotoxicity of chemotherapy drugs in vitro. However, the 
molecular mechanisms underlying the protective effects of cooling remain unknown, as no 
such studies have been performed in vitro. For this purpose, the mechanism of doxorubicin, 
docetaxel, and 4-OH-CP-induced apoptosis was investigated in normal and cooling 
conditions. Previous reports have demonstrated that chemotherapy drugs stimulate 
apoptosis in the HFs (Botchkarev, 2003; Botchkarev et al., 2000), whilst a number of cell 
cycle arrest- and apoptosis-associated genes induced by genotoxic signals are up-
regulated by p53. Thus, the work in this chapter aimed to investigate whether p53 itself and 
p53-regulated proteins are induced by the panel of chemotherapy drugs tested in this study 
and whether cooling may interfere with this process, in order to understand a) the 
mechanisms of drug cytotoxicity and b) provide a molecular explanation for the 
cytoprotective effect of cooling.  
To study such intracellular mediators, the work employed immunoblotting (Western 
blotting) following preparation of whole cell lysates. This was a challenge as it required a high 
number of cells for the preparation of such lysates, hence it was particularly challenging in 
the case of studying primary cells NHEK and HHFK as a model (due to their limited life-span 
only limited amounts of cell lysate could be prepared). Therefore, although lysates from 
NHEK and particularly HHFK cells were tested for confirmatory purposes, for most of the 
experiments HaCaTa cells were used for investigating the effect of chemotherapy-induced 
cytotoxicity and the effect of cooling on the expression of these proteins. Moreover, as it was 
essential to ensure that equal loading could be achieved for both 37°C and for cooling 
conditions, as a loading control, the housekeeping protein -actin was used.  
The experiments examined the levels of intracellular signalling mediators and pro-
apoptotic protein expression following treatment with 5 µg/mL 4-OH-CP, 0.5 µg/mL 
doxorubicin, and 0.01 µg/mL docetaxel at 37°C and under cooling conditions (22°C, 18°C, 
and 14°C) at different time points post drug treatment. Controls involved keratinocyte 
cultures after 24h of seeding and incubation in drug-free medium.  
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The specific objectives of this chapter were to study: 
 The molecular mechanisms underlying cell cytotoxicity and the effects of cooling in 
keratinocyte lines HaCaTa (mainly), NHEK and HHFK  
 p53 regulation after exposure of keratinocytes to doxorubicin, docetaxel, and 4-OH-
CP at 37°C and if cooling had an effect on this regulation at different time points  
 Cooling effects on p53 target genes involved in chemotherapy-induced cell cycle 
arrest or apoptosis such as p21 and the pro-apoptotic proteins PUMA, Noxa, Bax, 
Bak, tBid, TRAIL, and FasL.  
 To employ a specific blocking monoclonal antibody for blockade of the FasL (CD95 
ligand) to determine if p53-dependent apoptosis after DNA damage is mediated by 
CD95 signalling.  
 To utilise the small-molecule pharmacological inhibitor pifithrin-α (PFT-α) to inhibit 
p53 function and whether it might be useful in preventing or at least reducing the 
toxicity triggered by the chemotherapy drugs. 
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6.5 Regulation of p53 activation in human keratinocytes after 
chemotherapy drug treatment at 37°C and the effect of cooling 
This is the first study to explore the effects of cooling on the expression of intracellular 
signalling proteins following chemotherapy drug treatment in human keratinocytes. In 
response to DNA damage, accumulation of activated, i.e. phosphorylated-p53 (which from 
here onwards will be denoted P-p53) is often detected, as part of the well-established 
relation between DNA damage and p53 activation.  
To clarify the molecular mechanism underlying chemotherapy drug-induced 
keratinocyte death, HaCaTa cells were used and immunoblotting experiments performed to 
assess whether functional p53 is up-regulated after 5 µg/mL 4-OH-CP, 0.5 µg/mL 
doxorubicin and 0.01 µg/mL docetaxel treatment at 37°C. To determine the effects of cooling 
on drug-mediated p53 activation, cells were treated with chemotherapy drugs at 22°C, 18°C, 
and 14°C. Protein expression was measured at different time-points (6, 12, and 24h) 
by Western blotting and results shown in Figures 6-1 to 6-4. The concentrations of 
chemotherapy drugs chosen for treatment were those which showed a correlation with 
reducing the temperature, as the biomass was increased with further reduction of 
temperature; as shown in HaCaTa cells treated with 4-OH-CP, doxorubicin and docetaxel, 
cell biomass increased with decreasing temperature. The drug concentration chosen was the 
one that demonstrated optimal protection in correlation with decreasing temperature 
conditions (see Appendix V).  
 The results showed that activated P-p53 protein expression was low in untreated cells 
(controls) at all temperature conditions (Figure 6-1). On the other hand, 5 µg/mL 4-OH-CP-
treated HaCaTa cells exhibited a strong induction of P-p53 which was rapid (already evident 
at 6h after treatment) compared with controls and continued to rise up to the 24h time point. 
p53 activation was visualised by detection of its phosphorylation at residue Ser-15 (Iyer et 
al., 2004). P-p53 levels dramatically decreased in cells treated under cooling conditions, 
especially after 24h compared to p53 level at 37°C. Strikingly, the response appeared to be 
incremental and temperature-dependent, as the levels of P-p53 decreased proportionally to 
and in parallel with the gradual reduction of the temperature, as decreasing the temperature 
from 22°C to 14°C caused a gradual decrease of P-p53 protein levels (see Figure 6-1A, B 
and C).  
For confirmatory purposes and to determine whether the effects of 4-OH-CP 
demonstrated in HaCaTa cells also occur in NHEK and HHFK primary cells, such cultures 
were also treated with 4-OH-CP. However, the concentration of 4-OH-CP used to treat 
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primary cells was 10 µg/mL, thus higher than the doses used in HaCaTa cells (as mentioned 
previously, HaCaTa cells were more sensitive to 4-OH-CP than NHEK and HHFK cells 
(Chapter 3). Cell cultures incubated at 37°C were compared with 18°C as representative 
cooling conditions. As shown in Figure 6-2A the expression of P-p53 in NHEK was up-
regulated as early as 6h following treatment with 4-OH-CP and continued to rise up to the 
24h time point, which was similar to our observations in HaCaTa cells. Next, the effect of 4-
OH-CP in HHFK was assessed using the same drug concentrations used with NHEK cells; 
the results showed that P-p53 levels at 37°C were higher than 18°C, with the most prominent 
down-modulation of P-p53 expression, as in both HaCaTa and NHEK, being observed after 
12h of exposure to 4-OH-CP (Figure 6-2B). 
To extend the above observations, we then investigated p53 activation in HaCaTa 
cells treated with 0.5 µg/mL doxorubicin. As seen in Figure 6-3, doxorubicin induced P-p53 at 
37°C compared with control untreated cells, however, the level of P-p53 was reduced at 
22°C (compared to 37°C) and a similar result was shown at 18°C. However, there was no 
substantial reduction at 18°C in comparison to 22°C (Figure 6-3A and B). The most striking 
effect was observed when cells were treated at 14°C as they showed a dramatic reduction in 
P-p53 levels at all-time points and particularly after 12h (Figure 6-3C).  
In order to evaluate the possibility of docetaxel-mediated induction of P-p53, HaCaTa 
cells were exposed to 0.01 µg/mL of docetaxel in similar time-course experiments. As shown 
in Figure 6-4, there was an induction in P-p53 levels at 37°C in comparison to controls, but 
cooling at 22°C, 18°C, or 14°C down-modulated expression, with 14°C showing the lowest 
level of P-p53 after 12h and 24h compared with all other temperatures.  
These results show that all three chemotherapy drugs (whether classical genotoxic 
agents, such as doxorubicin and 4-OH-CP, or an anti-mitotic compound, docetaxel) initiated 
a DNA damage response evident by the activation of p53 and that cooling inhibited this in a 
temperature-dependent fashion. 
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Figure ‎6-1 The role of temperature on the regulation of P-p53 expression in response 
to 4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-P-p53 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for 1h with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-2 The role of temperature on the regulation of P-p53 expression in response 
to 4-OH-CP in primary keratinocytes 
9x105 HHFK and NHEK cells (passages 1–3) were seeded in 10 cm2 culture dishes in KSFM 
medium and the cells were incubated overnight in 37°C/5% CO2. NHEK and HHFK cells 
were treated with a 10 µg/mL 4-OH-CP at 37°C and 18°C. 6, 12, and 24h after treatment, the 
cells were lysed 2X SDS-lysis buffer. The total protein loading 20 µg/well of lysate was 
separated by SDS-PAGE using 4-12% (W/V) Bis Tris gels and immunoblotted onto a PVDF 
membrane. The membrane was probed overnight with an anti-P-p53 antibody in TBS Tween 
0.1% (1:1000 dilution). The membrane was incubated for one hour with Goat anti-Rabbit IgG 
IRDye 800nm (1:10000 dilution). β-actin (AC-15-A5441) was used as specificity and loading 
control, the membrane was incubated with the antibody diluted at 1:50000 and secondary 
antibody goat-anti mouse IgG Alexa 680 diluted 1:10000. Membranes were scanned at 
700nm and 800nm on Licor Odyssey Infra-Red Imaging system and images are shown in 
black and white. A) NHEK cells were treated at 37°C and 18°C, B) HHFK cells were treated 
at 37°C and 18°C. Data obtained from two independent biological experiments. 
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Figure ‎6-3 The role of temperature on the regulation of P-p53 expression in response 
to doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-P-p53 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for 1h with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-4 The role of temperature on the regulation of P-p53 expression in response 
to docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-P-p53 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for 1h with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.6 The p53 inhibitor pifithrin-α (PFT-α)  
Previous studies have shown that PFT-α is a compound that inhibits the translocation 
of p53 to mitochondria and the nucleus, as a result of which it inhibits the binding of p53 to 
specific DNA sites and also suppresses the apoptotic cascade (Chou et al., 2011; Culmsee 
et al., 2001). To support a direct role of p53 activation in the cytotoxic responses observed 
after treatment with chemotherapeutic agents at 37°C and in response to cooling conditions, 
p53 function was blocked using the specific p53 inhibitor PFT-α. The aim was to determine 
whether p53 mitochondrial function blockade could help reduce the effects of chemotherapy 
drug treatment and also, ultimately, if we could improve the function of cooling for some 
drugs which poorly respond to cooling-mediated protection and whether improvement could 
be achieved also for combinations of drugs. To determine the optimal concentration of PFT-
α, pre-titration experiments were performed; HaCaTa cells were treated with different 
concentrations of PFT-α at 37°C (Figure 6-5). There experiments showed that there was a 
slight toxicity in cells treated with PFT-α at concentration over 15-20 µg/mL compared with 
untreated cells (controls).  
The ability of PFT-α to protect keratinocytes from cytotoxicity caused by 4-OH-CP (1 
and 2.5 µg/mL) was then investigated and p53 was blocked with the protective effect of PFT-
α concentrations (0.5 and 1 µg/mL). As shown in Figure 6-6, there was increased in biomass 
(and hence cytoprotection) in cells treated with 4-OH-CP in the presence of PFT-α compared 
with controls. However, the cytoprotective effects were relatively modest and PFT-α did not 
fully block cytotoxicity, yet previous studies have reported that PFT-α can completely block 
the cytotoxic effects of UV and a range of cytotoxic drugs in HCT116 cells (Sohn et al., 
2009). To exclude the possibility that lack of complete blockade of cytotoxicity was not 
because the concentrations used were not enough (in comparison to other studies), with a 
small range of concentrations PFT-α concentrations was assessed and 0-20 µg/mL PFT-α 
concentrations were tested against 1 µg/mL of 4-OH-CP. The result showed there was a 
slight increase in biomass for cells treated with PFT-α compared with cells treated with 4-OH-
CP alone (Figure 6-7).  
To extend our observations to more chemotherapy drugs, the possibility that PFT-α may 
protect from cytotoxicity induced by doxorubicin was investigated. However, surprisingly, the 
result showed that PFT-α did not block yet instead increased doxorubicin-induced cytotoxicity 
(Figure 6-8) or caused no detectable protection for lower drug doses (Figure 6-9). These 
findings suggest that p53 inhibition by PFT-α might not represent an adequately efficient (or 
even at all appropriate) tool to enhance the protective effect of cooling against cytotoxic 
drugs.  
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Figure ‎6-5 Viability of HaCaTa cells after incubation with Pifithrin- α (PFT-α) 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were incubated with a range of 
concentrations of the PFT-α, compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution was added to 
the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. Bars 
correspond to mean absorbance at 492 nm (±S.E.M.) for three independent biological 
experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p < 0.05; **, 
p < 0.01. 
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Figure ‎6-6 Protection against 4-OH-CP drug cytotoxicity by lower concentrations of 
PFT-α in HaCaTa 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2.HaCaTa cells were pre-treated with and without 0-1 
µg/mL PFT-α for 30 min at 37°C. HaCaTa cells were treated for 2h with 1 and 2 µg/mL 4-OH-
CP with and without PFT-α at 37°C compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution was added to 
the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. Data is 
presented as A) Absorbance (raw data) B) % cell biomass shown in a bar graph. Data points 
correspond to mean % cell biomass (±S.E.M.) Data points correspond to mean % cell 
biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. n.s., non-significant; *, p < 0.05. 
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Figure ‎6-7 : Protection against 4-OH-CP drug cytotoxicity by PFT-α in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2.HaCaTa cells were pre-treated with and without 0-20 
µg/mL PFT-α for 30 min at 37°C. HaCaTa cells were treated for 2h with 1 µg/mL 4-OH-CP 
with and without PFT-α at 37°C compared with vehicle control (cells treated with medium 
containing DMSO, in which the reagent was dissolved. The solvent represents the maximum 
amount of DMSO corresponding to the highest drug concentration). The drugs were then 
removed, wells were rinsed with PBS to remove any traces of drug and cultures incubated 
for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution was added to 
the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. Data is 
presented as A) Absorbance (raw data) B) % cell biomass shown in bar graph. Data points 
correspond to mean % cell biomass (±S.E.M.) Data points correspond to mean % cell 
biomass (±S.E.M.) for three independent biological experiments, each consisting of 6–8 
technical replicates. *, p < 0.05.  
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 Figure ‎6-8 Protection against doxorubicin drug cytotoxicity by PFT-α in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2.HaCaTa cells were pre-treated with and without 0-15 
µg/mL PFT-α for 30 min at 37°C. HaCaTa cells were treated for 2h with 0.5-2.5 µg/mL 
doxorubicin (Doxo) with and without PFT-α at 37°C compared with vehicle control (cells 
treated with medium containing DMSO, in which the reagent was dissolved. The solvent 
represents the maximum amount of DMSO corresponding to the highest drug concentration). 
The drugs were then removed, wells were rinsed with PBS to remove any traces of drug and 
cultures incubated for a further 72h, and after which 20 µL of CellTiter 96® AQueous One 
solution was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of 
four hours. Data is presented as % cell biomass shown in bar graph. Data points correspond 
to mean % cell biomass (±S.E.M.) Data points correspond to mean % cell biomass (±S.E.M.) 
for three independent biological experiments, each consisting of 6–8 technical replicates.  
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Figure ‎6-9 Protection against doxorubicin drug cytotoxicity by lower concentrations of 
PFT-α in HaCaTa cells 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2.HaCaTa cells were pre-treated with and without (0-1) 
µg/mL PFT-α for 30 min at 37°C. HaCaTa cells were treated for 2h with 0.25-0.5 µg/mL 
doxorubicin (Doxo) with and without PFT-α at 37°C compared with vehicle control (cells 
treated with medium containing DMSO, in which the reagent was dissolved. The solvent 
represents the maximum amount of DMSO corresponding to the highest drug concentration). 
The drugs were then removed, wells were rinsed with PBS to remove any traces of drug and 
cultures incubated for a further 72h, and after which 20μL of CellTiter 96® AQueous One 
solution was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of 
four hours. Data is presented as % cell biomass shown in bar graph. Data points correspond 
to mean % cell biomass (±S.E.M.) Data points correspond to mean % cell biomass (±S.E.M.) 
for three independent biological experiments, each consisting of 6–8 technical replicates. 
n.s., non-significant; *, p < 0.05. 
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6.7 Regulation of p21 in response to chemotherapy drug treatment 
and the effects of cooling 
Work described in previous chapters showed by flow cytometry based analysis that 4-
OH-CP treatment appeared to arrest keratinocytes in the S phase and doxorubicin arrested 
cells in G2/M, whilst docetaxel induced a high subG0/G1 population (characteristic of 
apoptosis) and arrest in G2/M.  
The expression of p21 in response to treatment with 4-OH-CP, doxorubicin and 
docetaxel was investigated in HaCaTa cells to provide evidence on p53-mediated 
transcriptional activity and to assess whether cooling could affect p21 up-regulation. The p21 
protein is a major target of p53, as p53 acts as the ―instructor‖ and p21 the ―executioner‖ in 
cell cycle arrest induction, for which p21 activation is largely responsible (Waldmann et al., 
1992). Moreover, both p21 and p53 are critical in maintaining cell cycle control in response to 
chemotherapy-induced DNA damage (Ahrendt et al., 2000). Therefore, p21 protein 
expression was analysed by Western blotting using cell lysates form HaCaTa, NHEK and 
HHFK cells.  
Following treatment of HaCaTa cells with 4-OH-CP at 37°C, 6h later an increase in 
the expression of p21 was observed and cooling appeared to down-modulate p21, which 
was particularly evident for the 18°C cooling conditions (Figure 6-10). However, it became 
obvious that extensive cooling alone was progressively causing some induction of p21 (see 
controls) and as a result after 12h of treatment, p21 levels at 37°C actually were lower than 
p21 levels at cooling temperatures (particularly 14°C) (Figure 6-10). Therefore, although 
cooling mediated down-modulation of p21 to an extent, it is possible that extensive (24h) or 
extreme (14°C) cooling might independently also trigger a p21-related ―stress‖ response.  
To extend these observations, NHEK cells were treated with 4-OH-CP and the results 
were similar to those observed in HaCaTa cells (Figure 6-11). However, when similar 
experiments were carried out in HHFK cells, the response observed was slightly different, as 
enhanced reduction in p21 expression was observed at 18°C. Although the reasons for these 
discrepancies remain unknown, future investigation into additional cooling conditions 
(temperatures other than 18°C) could address these disparities.  
The expression of p21 in response to doxorubicin was investigated in HaCaTa cells 
to assess whether cooling at different temperatures could have an effect on p21 expression. 
The results showed that doxorubicin induced an increase in p21 levels after 24h at all the 
temperatures tested and cooling appeared to down-modulate p21 expression (as seen in 
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Figure 6-12), with 14°C showing the lowest p21 expression level compared with other 
temperatures tested (Figure 6-12C).  
The ability of cooling to down-modulate p21 was even more evident in experiments 
where the expression of p21 in response to docetaxel was investigated in HaCaTa cells, 
where particularly at 24h cooling significantly reduced p21 expression (Figure 6-13). The 
induction of p21 by docetaxel suggests that p53 is most likely involved in the apoptosis 
induction (evident by the subG0/G1 peak) and that p21 protein plays a role in docetaxel-
induced cell cycle arrest observed (Chapter 4).  
The study of p21 and its regulation has allowed us to successfully demonstrate an 
increase in p21 expression when cells were treated with different chemotherapy drugs, 
consistent with the observed p53 activation (phosphorylation), as well as the confirmation 
that cooling, via the evident inhibition of P-p53, attenuates subsequent p21 induction. 
However, as noted above, untreated cells exhibited p21 bands particularly following 
extensive (24h) or extreme (14°C) cooling, which might reflect a p21-related ―stress‖ 
response and subsequent p21-mediated arrest, which is in accordance with our observation 
that cooling arrested cells in G1 (cell cycle analysis) and this mechanism (ability to take cells 
out of cycle) might be a contributory factor to its cytoprotective effect.  
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Figure ‎6-10 The role of temperature on the regulation of p21 expression in response to 
4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-p21 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-11 The role of temperature on the regulation of p21 expression in response to 
4-OH-CP in primary keratinocytes 
9x105 HHFK and NHEK cells (passages 1–3) were seeded in 10 cm2 culture dishes in KSFM 
medium and the cells were incubated overnight in 37°C/5% CO2. NHEK and HHFK cells 
were treated with a 10 µg/mL 4-OH-CP at 37°C and 18°C. 6, 12, and 24h after treatment, the 
cells were lysed 2X SDS-lysis buffer. The total protein loading 20 µg/well of lysate was 
separated by SDS-PAGE using 4-12% (W/V) Bis Tris gels and immunoblotted onto a PVDF 
membrane. The membrane was probed overnight with an anti-p21 antibody in TBS Tween 
0.1% (1:1000 dilution). Following that, the membrane was incubated for one hour with goat-
anti mouse IgG Alexa 680 (1:10000 dilution). β-actin (AC-15-A5441) was used as specificity 
and loading control, the membrane was incubated with the antibody (1:50000 dilution) and 
secondary antibody Goat anti-Mouse IgG Alexa 680 (1:10000 dilution). Membranes were 
scanned at 700nm and 800nm on a Licor Odyssey Infra-Red Imaging system and images 
are shown in black and white. A) NHEK cells were treated at 37°C and 18°C, B) HHFK cells 
were treated at 37°C and 18°C. Data obtained from two independent biological experiments. 
  
4-OH-CP 
18 C   NHEK
42
21
β-actin
p21
Time          6h                   12h                24h                 Con
37°C   18°C      37°C   18°C    37°C   18°C       37°C  18°CkDa
A
18 C   HHFK
42
21
β-actin
p21
Time        6h                   12h                24h                 Con
37°C   18°C      37°C   18°C    37°C   18°C     37°C  18°CB
253 
 
 
 
Figure ‎6-12 The role of temperature on the regulation of p21 expression in response to 
doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-p21 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-13 The role of temperature on the regulation of p21 expression in response to 
docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-p21 antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.8 Regulation of PUMA protein in response to chemotherapy drug 
treatment and the effects of cooling 
PUMA, was identified in 2001 by three groups by the method of double hybrid with 
Bcl-2 as a gene that may be activated by p53 in cells where apoptosis is induced by p53 
(Han et al., 2001). PUMA plays a critical role in p53-mediated apoptosis, it has a very high 
affinity for the anti-apoptotic Bcl-2 proteins (Jeffers et al., 2003; Shen and White, 2001). To 
determine whether following p53 activation there was an increase in PUMA 
protein expression. HaCaTa cells were treated with 5 µg/mL 4-OH-CP and PUMA expression 
detected by immunoblotting. The most noticeable changes in PUMA expression in HaCaTa 
cells were observed at 6h post-treatment with 4-OH-CP, where there was a consistent 
induction of PUMA which was down-modulated by cooling at all temperatures. PUMA levels 
peaked during the first 6h of drug treatment, followed by a progressive decline towards basal 
levels after 24h (Figure 6-14). When similar experiments were performed in NHEK cells 
treated with 4-OH-CP, PUMA expression patterns observed were similar to those in HaCaTa 
cells (Figure 6-15). Furthermore, immunoblotting showed that PUMA was induced in HaCaTa 
cells as early as 6h following treatment with doxorubicin (Figure 6-16) and docetaxel (Figure 
6-17) and the results were relatively similar to those obtained in cells treated with 4-OH-CP.  
Of note, however, untreated cells exhibited PUMA-specific bands, indicating basal 
expression of the PUMA protein, whilst interestingly, and in agreement with our p21 
observations, untreated cells (no drug treatment controls) at cooling temperatures showed 
higher PUMA levels compared to control at 37°C (Figures 6-14 to 6-17) indicating a cooling 
related response.  
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Figure ‎6-14 The role of temperature on the regulation of PUMA expression in response 
to 4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-PUMA antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-15 The role of temperature on the regulation of PUMA expression in response 
to 4-OH-CP in NHEK cells 
9x105 NHEK cells (passages 1–3) were seeded in 10 cm2 culture dishes in KSFM medium 
and the cells were incubated overnight in 37°C/5% CO2. NHEK cells were treated with a 10 
µg/mL 4-OH-CP at 37°C and 18°C. 6, 12, and 24h after treatment, the cells were lysed 2X 
SDS-lysis buffer. The total protein loading 20 µg/well of lysate was separated by SDS-PAGE 
using 4-12% (W/V) Bis Tris gels and immunoblotted onto a PVDF membrane. The 
membrane was probed overnight with an anti-PUMA antibody in TBS Tween 0.1% (1:1000 
dilution). The membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm 
(1:10000 dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the 
membrane was incubated with the antibody diluted at 1:50000 and secondary antibody goat-
anti mouse IgG Alexa 680 diluted 1:10000. Membranes were scanned at 700nm and 800nm 
on Licor Odyssey Infra-Red Imaging system and images are shown in black and white. Data 
obtained from two independent biological experiments. 
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Figure ‎6-16 The role of temperature on the regulation of PUMA expression in response 
to doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-PUMA antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-17 The role of temperature on the regulation of PUMA expression in response 
to docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-PUMA antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.9 Regulation of Noxa protein expression in response to 
chemotherapy drug treatment and the effects of cooling 
In addition to PUMA, the expression of BH3-only Bcl-2 family member Noxa was also 
investigated to assess its regulation following treatment with chemotherapy drugs at different 
temperatures and at different time points as above. Noxa is the smallest known BH3-only 
protein with an approximate size of ~10 kDa.  
Immunoblotting analysis revealed increased protein expression of Noxa in HaCaTa 
cells treated with 4-OH-CP at 37°C (Figure 6-18). Treatment with 4-OH-CP resulted in up-
regulation of Noxa as quickly as 6h; however, the levels of Noxa declined progressively until 
24h. Importantly, cooling consistently down-regulated Noxa expression when it was at its 
peak (6h), however, no significant reduction in Noxa was observed after 6h, although this 
might be due to the decline of Noxa protein expression at 37°C (Figure 6-18). Interestingly, 
these results are consistent with the findings on the expression of the related (and similarly 
p53-regulated pro-apoptotic PUMA, above), thus suggesting similarities in the regulation of 
these two proteins. 
The effect of doxorubicin treatment on pro-apoptotic Noxa protein expression was 
then tested. Noxa expression was substantially induced after 6h at 37°C and markedly 
reduced by cooling at 22°C and particularly at 14°C (yet it should be noted that for unknown 
reasons the observations differed at 18°C as for that condition no such reduction was 
observed) (Figure 6-19). Finally, expression of Noxa following treatment with docetaxel was 
investigated, and the results indicate that the level of Noxa did not decline as it did for 4-OH-
CP and doxorubicin and the level kept increasing. However interestingly, at 14°C there was a 
significant reduction in Noxa expression (Figure 6-20).  
Collectively, in addition to the observation that PUMA and Noxa demonstrated similar 
patterns of expression in response to chemotherapy drugs and cooling appeared to have 
similar effects on both proteins, also our results indicate that in both cases cooling alone 
resulted in PUMA and Noxa protein expression indicating a cooling related response. 
Interestingly, also, although the mechanisms by which these drugs (4-OH-CP, doxorubicin, 
and docetaxel) induce cytotoxicity/apoptosis differ significantly, a similar trend was observed 
in the regulation of both PUMA and Noxa after treatment with these drugs and cooling 
appeared to regulate expression of these proteins in a similar fashion.  
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Figure ‎6-18 The role of temperature on the regulation of Noxa expression in response 
to 4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Noxa antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-19 The role of temperature on the regulation of Noxa expression in response 
to doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Noxa antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-20 The role of temperature on the regulation of Noxa expression in response 
to docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Noxa antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.10  Regulation of pro-apoptotic Bak protein in response to 
chemotherapy drug treatment and the effects of cooling  
The two main pro-apoptotic proteins of the Bcl-2 family, Bax and Bak are important 
inducers of the mitochondrial apoptotic pathway. Loss of function of these proteins (e.g. 
genetic deletion) inhibits the release of cytochrome c from the mitochondria and apoptosis 
(Cheng et al., 2003; Wei et al., 2001). The three chemotherapy drugs used in this study have 
all been reported to induce mitochondrial apoptosis pathway via activation of Bax and Bak 
(Panaretakis et al., 2002; Strauss et al., 2008).  
In order to investigate the importance of Bak in our study, an antibody that recognizes 
the active conformation of Bak was used to detect the ~26 kDa protein. HaCaTa, NHEK and 
HHFK cells were treated for 2h with 4-OH-CP and expression assessed at 37°C versus 
cooling conditions (at 22°C, 18°C and 14°C). Although a basal level of Bak expression was 
detectable in HaCaTa cells, 6h of treatment with 4-OH-CP the level of Bak expression 
increased significantly. Importantly, under cooling conditions, and depending on the exact 
temperature, there was a remarkable reduction in Bak expression, and in some cases drug- 
mediated Bak induction was completely attenuated by cooling (Figure 6-21). The most 
consistent down-modulation of Bak by cooling was observed at 24h post-treatment (Figure 6-
21). However, as indicated by the results obtained at 14°C at 12 and 24h, although cooling 
protects from cytotoxic drugs, very low temperature (extreme cooling, such as 14°C) might 
induce some level of ―stress‖ on the cells. To strengthen these observations, similar 
investigations were performed for NHEK and HHFK cultured after treatment with 10 µg/mL 4-
OH-CP at 37°C and 18°C and the level of Bak protein was analysed. Bak protein expression 
levels in NHEK and HHFK showed a similar pattern of up-regulation to that observed for 
HaCaTa cells, particularly at 6h. However, in the case of HHFK cells some inconsistency 
was observed at 12h in comparison to HaCaTa and NHEK cells (Figure 6-22).  
When the effect of doxorubicin was assessed, a rapid induction of Bak was observed 
at 6h at 37°C and cooling could down-modulate this induction particularly at 18°C and to a 
lesser extent at 14°C; however, the levels of Bak gradually declined with time and the level of 
the protein was evidently reduced for all the groups by 24h (Figure 6-23). Similar results 
were observed following HaCaTa cell treatment with docetaxel shown in Figure 6-24, 
however, for unknown reasons, there was an increase in Bak expression at cooling 
conditions in drug treated cells in comparison to treatment at 37°C (Figure 6-24).  
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These results indicated that Bak protein is induced during apoptosis induction by the 
three drugs used in this study and cooling can down-regulate Bak levels significantly, 
particularly in the case of 4-OH-CP.  
 
Figure ‎6-21 The role of temperature on the regulation of Bak expression in response to 
4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bak antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-22 The role of temperature on the regulation of Bak expression in response to 
4-OH-CP in primary keratinocytes 
9x105 HHFK and NHEK cells (passages 1–3) were seeded in 10 cm2 culture dishes in KSFM 
medium and the cells were incubated overnight in 37°C/5% CO2. NHEK and HHFK cells 
were treated with a 10 µg/mL 4-OH-CP at 37°C and 18°C. 6, 12, and 24h after treatment, the 
cells were lysed 2X SDS-lysis buffer. The total protein loading 20 µg/well of lysate was 
separated by SDS-PAGE using 4-12% (W/V) Bis Tris gels and immunoblotted onto a PVDF 
membrane. The membrane was probed overnight with an anti-Bak antibody in TBS Tween 
0.1% (1:1000 dilution). The membrane was incubated for one hour with Goat anti-Rabbit IgG 
IRDye 800nm (1:10000 dilution). β-actin (AC-15-A5441) was used as specificity and loading 
control, the membrane was incubated with the antibody diluted at 1:50000 and secondary 
antibody goat-anti mouse IgG Alexa 680 diluted 1:10000. Membranes were scanned at 
700nm and 800nm on Licor Odyssey Infra-Red Imaging system and images are shown in 
black and white. A) NHEK cells were treated at 37°C and 18°C, B) HHFK cells were treated 
at 37°C and 18°C. Data obtained from two independent biological experiments. 
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Figure ‎6-23 The role of temperature on the regulation of Bak expression in response to 
doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bak antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-24 The role of temperature on the regulation of Bak expression in response to 
docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bak antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.11  Changes in Bax protein expression following chemotherapy 
drug treatment and the effects of cooling  
Following investigations on Bak activation, the role of cooling in Bax regulation 
following drug treatment was investigated as above. HaCaTa cells were treated with the 
panel of chemotherapy drugs at 37°C or at cooling conditions (22°C, 18°C, and 14), and Bax 
expression analysed by immunoblotting to detect the ~21 kDa protein. 
When HaCaTa cells were tested by immunoblotting there was clearly a high level of 
Bax expression and treatment with 4-OH-CP caused only minor up-regulation of Bax at 37°C 
versus cooling conditions. Interestingly, Bax levels diminished at 18°C however, this 
appeared to be unique for that specific temperature, as no similar trend was noted for other 
conditions (Figure 6-25). Similar expression patterns were observed in experiments where 
the effect of doxorubicin on Bax was assessed. In such experiments, though some changes 
were noted in Bax protein levels, they were clearly non-significant and no clear differences 
were observed (Figure 6-26). By contrast, as shown in Figure 6-27, an induction in Bax 
expression was observed at 37°C at 6h in docetaxel-treated HaCaTa cells. However, for all 
the groups after 12h and 24h treatment with docetaxel Bax levels appeared to exhibit little if 
any difference from basal levels.   
Therefore, unlike our observation on Bak (previous section) where clear Bak 
induction by chemotherapy drugs was observed and cooling appeared to modulate Bak 
expression, no such pattern was observed for Bax; this might be because either Bax might 
not be involved in apoptosis in these cells, or due to the already high basal expression levels 
of Bax protein in HaCaTa cells, which made comparisons between conditions difficult. It is 
possible that rather than absolute proteins levels measured here, the exact localisation 
pattern of proteins such as Bax, might provide a better idea of its role in cytotoxicity and its 
regulation by cooling.  
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Figure ‎6-25 The role of temperature on the regulation of Bax expression in response to 
4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bax antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
 
 
 
4-OH-CP
HaCaTa cells 
Time         6h                   12h                24h                 Con
37°C   22°C    37°C   22°C     37°C   22°C     37°C  22°C
22 C
β-actin
21
42
kDa
Bax
A
18 C
42
21
β-actin
Bax
Time        6h                   12h                24h                 Con
37°C   18°C    37°C   18°C    37°C   18°C     37°C  18°C
B
14 C
42
21
β-actin
Bax
Time         6h                   12h                24h                 Con
37°C   14°C    37°C   14°C     37°C   14°C     37°C  14°C
C
271 
 
 
 
 
Figure ‎6-26 The role of temperature on the regulation of Bax expression in response to 
doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bax antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-27 The role of temperature on the regulation of Bax expression in response to 
docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-Bax antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with goat-anti mouse IgG Alexa 680 (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.12  Regulation of Fas ligand (FasL) in response to chemotherapy 
drug treatment and the effects of cooling  
In addition to the induction of the intrinsic apoptotic cell death pathway, which can be 
triggered by stimuli such as chemotherapy drugs and UV irradiation, several studies have 
suggested that the extrinsic (receptor-mediated) pathway, for instance CD95/APO-1/Fas 
receptor activation or TNF-alpha-mediated apoptosis, may also participate in chemotherapy 
drug induced-DNA damage (Friesen et al., 1996; Poulaki et al., 2001). Keratinocytes cells 
carry on their surface the Fas receptor, which is activated by its natural ligand, FasL, and 
induces apoptosis in the cell (Aragane et al., 1998). Previous studies demonstrated p53-
mediated induction of Fas in cyclophosphamide-induced apoptosis in the HFs of C57BL/6 
mice (Botchkarev et al., 2000). Chemotherapy drugs such as doxorubicin, 
cyclophosphamide, etoposide, cisplatin, mitoxantrone, and 5-fluorouracil have been shown to 
trigger nuclear accumulation of p53 (Müller et al., 1997). As shown in (Section 6.5) 4-OH-CP, 
doxorubicin and docetaxel caused activation of p53 at 37°C and cooling regulated the level 
of active p53.  
As p53 is activated in human keratinocytes following treatment with the panel of 
chemotherapy drugs tested in this study, we hypothesised that the apoptotic pathway may 
also be associated with p53-mediated induction of death ligands. Therefore, experiments 
were carried out to investigate whether these drugs induce the Fas/FasL system to mediate 
their cytotoxic effects as part of p53-mediated apoptosis and to examine the effect of cooling 
in this context. HaCaTa were treated with the chemotherapy drugs as above at 37°C and 
compared with cells treated under cooling conditions (22°C, 18°C and 14°C), and the level of 
FasL protein was analysed by immunoblotting (Figure 6-28 to Figure 6-30). Results showed 
that there was some basal expression of FasL in controls (untreated cells). On the other 
hand, 4-OH-CP-treated HaCaTa cells exhibited a strong induction of FasL which was rapid 
(already evident at 6h after treatment) compared with controls. Interestingly, FasL levels 
dramatically decreased in cells treated at 14°C and 18°C after 24h compared to 37°C (Figure 
6-28). In addition, the results showed that both doxorubicin and docetaxel induced an 
increase in FasL levels after 6h at all the temperatures tested and cooling appeared to down-
modulate FasL expression. 
Treatment of HaCaTa cells with all three drugs 4-OH-CP, doxorubicin and docetaxel, 
though these drugs have distinct mechanisms of action, resulted in FasL up-regulation in all 
cases. Importantly, FasL induction was significantly attenuated in most cases by cooling, 
particularly at 22°C and 18°C (and to a lesser extent at 14°C). These findings suggested that 
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as part of the apoptotic response, and in addition to activation of p53 targets such as p21 or 
pro-apoptotic mediators such as PUMA/Noxa, the classical pro-apoptotic TNF ligand FasL is 
also induced; yet cooling can attenuate the induction of FasL.  
 
Figure ‎6-28 The role of temperature on the regulation of FasL expression in response 
to 4-OH-CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-FasL antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-29 The role of temperature on the regulation of FasL expression in response 
to doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
doxorubicin at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-FasL antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-30 The role of temperature on the regulation of FasL expression in response 
to docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-FasL antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.13  Effect of functional blockade of FasL/Fas interaction on drug-
mediated apoptosis in HaCaTa cells 
As FasL was detected to be up-regulated in HaCaTa cells, its functional implication in 
chemotherapy drugs-mediated apoptosis was addressed. For this purpose, HaCaTa cells 
were treated with 4-OH-CP and doxorubicin in the presence of the classical antagonistic 
antibody NOK-1, which blocks FasL and thus inhibits FasL/CD95 mediated signalling and 
apoptosis. The NOK-1 mAb specifically binds to the region of FasL (CD178) that normally 
interacts with the Fas receptor (CD95) (Kayagaki et al., 1995). As shown in Figure 6-31, the 
blocking antibody had no effect on cytotoxic drug-induced apoptosis. Although this appears 
unexpected, it is possible that FasL might remain functional. As previous studies from our 
laboratory have demonstrated, death ligands, such as FasL, may be expressed and be 
functional via intracellular compartments (Steele et al., 2006). In other words, during 
chemotherapy drug-mediated apoptosis, FasL may exert its effect not by paracrine or 
juxtacrine presentation but by intracellular signalling, thus different approaches (such as 
siRNA-mediated knockdown would be necessary to address such hypotheses).  
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Figure ‎6-31 Effect of the blocking anti-FasL antibody NOK1 on drug-mediated 
apoptosis 
HaCaTa cells were seeded in 96-well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with ± 10 
μg/mL of the NOK1 (monoclonal antibody (mAb) to block FasL for 1h at 37°C (as well as the 
isotype control mAb MR106). HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), and 4-OH-CP at 37°C compared with vehicle control (cells treated with 
medium containing DMSO, in which the reagent was dissolved. The solvent represents the 
maximum amount of DMSO corresponding to the highest drug concentration). The drugs 
were then removed, wells were rinsed with PBS to remove any traces of drug and cultures 
incubated for a further 72h, and after which 20 µL of CellTiter 96® AQueous One solution 
was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods (Chapter 2). Data is 
presented as A) Absorbance (raw data) B) % cell biomass shown in bar graph. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. n.s., non-significant.  
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6.14  Expression of TRAIL ligand in response to chemotherapy drug 
treatment and the effects of cooling  
Sharova et al., (2014) suggested that the Tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) signalling plays an important role in doxorubicin mediating 
-induced hair loss. A study on microarray gene expression analysis, using human scalp HFs 
cultures treated with doxorubicin showed changes in expression of 504 genes in doxorubicin-
treated HF versus the controls, among these genes Fas and TRAIL receptors were up-
regulated (Sharova et al., 2014). Based on this previously published evidence, and having 
demonstrated that chemotherapy drugs induced FasL expression and cooling could 
modulate expression of this pro-apoptotic ligand, we investigated whether these 
chemotherapy drugs induced TRAIL expression to exert their cytotoxic effects and whether 
cooling had any effect on TRAIL expression. When HaCaTa cells were treated with each of 
the three drugs (4-OH-CP, doxorubicin, and docetaxel), no TRAIL protein expression was 
detected using two different antibodies (results for one of these antibodies are shown in 
Figure 6-32). As expected based on the lack of TRAIL expression at 37°C, cooling at 22°C 
had no effect on the levels of TRAIL in the cells.   
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Figure ‎6-32 The role of temperature on the regulation of TRAIL expression in response 
to chemotherapy drugs in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-TRAIL antibody in TBS Tween 0.1% (1:1000 dilution). Following that, 
the membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.15  Changes in Bid protein in response to chemotherapy drugs 
treatment and the effects of cooling 
Bid, is a pro-apoptotic Bcl-2 family member, capable of binding to pro-apoptotic Bax, 
and it is a key intracellular protein that acts as the point of cross-talk between the extrinsic 
and intrinsic (mitochondrial) apoptotic pathways. Bid is cleaved mainly by caspase-8 during 
death receptor-mediated signalling (such as signalling triggered by FasL and TRAIL). 
Protease-cleaved Bid migrates to mitochondria were it induces MOMP that is dependent on 
the pro-apoptotic proteins Bax and/or Bak, and thus Bid acts as a sentinel for protease-
mediated death signals. During apoptosis, Bid ~21 kDa is proteolytically cleaved to tBid (~15 
kDa), thus is inserted into the mitochondrial membrane and allows the activation of the 
mitochondrial apoptosis pathway (Billen et al., 2008). 
We therefore examined the possibility that the activation of FasL might represent a 
mechanism of cross-talk via which chemotherapy drugs induce apoptosis in HaCaTa cells by 
assessing drug-induced cleavage of Bid to its active form tBid. Treatment of HaCaTa cells 
with 4-OH-CP induced a small degree of Bid cleavage was seen after 6h and 12h, and a 
modest reduction in tBid levels at 18°C (Figure 6-33B) and 14°C (Figure 6-33C) was 
observed. By contrast, a far more marked induction of Bid cleavage was observed following 
HaCaTa treatment with doxorubicin (Figure 6-34) and docetaxel (Figure 6-35) and cooling at 
various temperatures attenuated Bid cleavage at most time points investigated. This 
observation is quite striking, as it coincides with the FasL expression data (previous section), 
were doxorubicin and docetaxel caused more significant induction of FasL than did 4-OH-
CP. Therefore, the pattern of FasL expression and its regulation by cooling closely mirrors 
the pattern of Bid cleavage and the effects of cooling in its formation.  
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Figure ‎6-33 The role of cooling on Bid cleavage (tBid formation) in response to 4-OH-
CP in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 5 µg/mL 4-OH-
CP at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells were 
lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-12% 
(W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-BID antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-34 The role of cooling on Bid cleavage (tBid formation) in response to 
doxorubicin in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.5 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-BID antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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Figure ‎6-35 The role of cooling on Bid cleavage (tBid formation) in response to 
docetaxel in HaCaTa cells 
9x105 HaCaTa cells were seeded in 10 cm2 culture dishes in KSFM complete medium and 
the cells were incubated overnight in 37°C/5% CO2. Cells were treated with 0.01 µg/mL 
docetaxel at 37°C as well as 22°C, 18°C and 14°C. 6, 12, and 24h after treatment, the cells 
were lysed 2X SDS-lysis buffer. 20 µg/well of lysate was separated by SDS-PAGE using 4-
12% (W/V) Bis Tris gels and blotted onto a PVDF membrane. The membrane was probed 
overnight with an anti-BID antibody in TBS Tween 0.1% (1:1000 dilution). Following that, the 
membrane was incubated for one hour with Goat anti-Rabbit IgG IRDye 800nm (1:10000 
dilution). β-actin (AC-15-A5441) was used as specificity and loading control, the membrane 
was incubated with the antibody (1:50000 dilution) and secondary antibody Goat anti-Mouse 
IgG Alexa 680 (1:10000 dilution). Membranes were scanned at 700nm and 800nm on a Licor 
Odyssey Infra-Red Imaging system and images are shown in black and white. Cells were 
treated at A) 37°C and 22°C, B) 37°C and 18°C, C) 37°C and 14°C. Data obtained from two 
independent biological experiments. 
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6.16  Summary  
 The main objective of this chapter was to investigate the intracellular signalling 
mediators involved in chemotherapy-induced toxicity and their regulation by 
cooling in NHEK, HHFK, and HaCaTa cells. Interestingly, for most of the proteins 
investigated in this study rapid changes were observed as early as 6h post 
treatment. 
 Western blotting results demonstrated dramatic and rapid increase in the level of 
P-p53 at 37°C and maximal expression was occurred 24h post treatment with 
cytotoxic agents. However, the level P-p53 was reduced significantly by cooling 
and in some cases completely attenuated. 
 The expression of P-p53 in NHEK cells treated with 4-OH-CP was up-regulated as 
early as 6h following treatment and continued to rise up 24h, which was similar to 
the expression of P-p53 in HaCaTa cells. Similar results were observed in HHFK 
cells, where there was a prominent down-modulation of P-p53 expression, as was 
the case in HaCaTa and NHEK, being observed after 12h post exposure to 4-OH-
CP. 
 There was a marked reduction in P-p53 levels at all-time points and particularly 
after 12h in HaCaTa cells treated with doxorubicin under cooling conditions 
compared with at 37°C. Interestingly, there was also reduction in P-p53 levels in 
cells treated with docetaxel under cooling conditions compared with cells treated at 
37°C, indicating that all three chemotherapy drugs (whether classical genotoxic 
agents, such as doxorubicin and 4-OH-CP, or an anti-mitotic compound, 
docetaxel) initiated a DNA damage response evident by the activation of p53 and 
that cooling inhibited this in a temperature-dependent fashion.  
 The small chemical p53 inhibitor, PFT-α, only slightly inhibited or reduced drug-
mediated apoptosis after treatment with 4-OH-CP, and there was no effect after 
treated with doxorubicin. The low concentrations of PFT-α were not sufficient to 
significantly inhibit cell death, whilst high concentrations exhibited toxic effects.  
 p21 induction at 37°C was observed at 6h and this up-regulation was reduced by 
cooling and in particularly evident for the 18°C after exposure to 4-OH-CP in 
HaCaTa cells. Furthermore, p21 levels in NHEK cells treated with 4-OH-CP 
showed similar results with those observed in HaCaTa cells. Interestingly, 
extensive cooling alone was progressively causing some induction of p21 in 
untreated cells (controls) and as a result after 12h of treatment, p21 levels at 37°C 
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were lower than p21 levels at cooling temperatures (particularly 14°C). These 
results suggested that, although cooling mediated down-modulation of p21 to an 
extent, it is possible that extensive (24h) or extreme (14°C) cooling might 
independently also trigger a p21-related ―stress‖ response. 
 Western blot experiments demonstrated increases in the level of pro-apoptotic 
protein PUMA in HaCaTa and NHEK cells at 6h post-treatment with 4-OH-CP, 
however, PUMA levels progressively declined towards basal levels after 24h. 
PUMA induction was down-modulated by cooling at all temperatures.  
 Of note, PUMA-specific bands were observed in untreated cells, indicating basal 
expression of the PUMA protein, and these bands at cooling temperatures showed 
higher PUMA levels compared to control at 37°C indicating a cooling related 
response.  
 Interestingly, the p53-regulated pro-apoptotic Noxa and PUMA both showed the 
same trend of expression after 4-OH-CP treatment. These results suggested 
similarities in the regulation of these two proteins. In HaCaTa cells treated with 
doxorubicin the results showed that Noxa expression was substantially induced 
after 6h at 37°C and markedly reduced by cooling at 22°C and particularly 14°C, 
however, at 18°C there was no such reduction in Noxa level. Furthermore, there 
was no decline in Noxa levels and the level kept increasing in HaCaTa cells 
treated with docetaxel at 22°C and 18°C, but there was a significant reduction in 
expression at 14°C. 
 In untreated HaCaTa cells, basal Bak expression was detected. Following 
treatment with 4-OH-CP, the level of Bak expression increased significantly as 
early as 6h post treatment, and under cooling conditions there was a remarkable 
reduction in Bak expression. This regulation was temperature-dependent and the 
greatest down-modulation of Bak by cooling was observed at 24h post-treatment. 
Interestingly the results obtained at 14°C showed a significant reduction at 12 and 
24h. Moreover, Bak protein expression levels in NHEK and HHFK showed a 
similar pattern of up-regulation to that observed for HaCaTa cells, particularly at 
6h.  
 The results showed that the expression of Bak protein in HaCaTa cells treated with 
doxorubicin was up-regulated 6h after treatment at 37°C and cooling down-
regulated Bak induction particularly at 18°C and 14°C. However, for unknown 
reasons there was an increase in Bak expression in HaCaTa cells treated with 
docetaxel at cooling conditions compared to cells treated at 37°C. Overall, our 
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results showed that there was clear induction of Bak protein and cooling 
successfully appeared to modulate this expression.  
 In Bax expression investigations, though some changes were noted in Bax protein 
levels, they were clearly non-significant and no clear differences were observed. 
Although an induction in Bax expression was observed at 37°C at 6h in docetaxel-
treated HaCaTa cells, for all treratment groups after 12h and 24h treatment with 
docetaxel Bax levels appeared to exhibit little if any difference from basal levels. 
 Thus, overall, no clear Bax induction was observed in this work; one main reason 
was the high basal expression levels of Bax protein in HaCaTa cells, which made 
comparisons between conditions difficult or, perhaps, unlike Bak, Bax might not be 
involved in apoptosis in these cells. It is however important to consider that rather 
than absolute protein levels, the exact localisation pattern of proteins such as Bax, 
might provide a better idea of its role in cytotoxicity and its regulation by cooling. 
 FasL expression was investigated in HaCaTa cells treated with 4-OH-CP, 
doxorubicin and docetaxel; although there was some basal expression of FasL in 
untreated cells, HaCaTa cells treated with 4-OH-CP, doxorubicin and docetaxel 
exhibited a strong induction of FasL at 6h post treatment compared with controls. 
Interestingly, cooling (14°C and 18°C) dramatically decreased FasL levels. These 
findings suggest activation of p53-induced target proteins such as p21, pro-
apoptotic mediators such as PUMA/Noxa, and the classical pro-apoptotic ligand 
FasL are all induced in drug-mediated apoptosis and, cooling can reduce their 
induction.  
 However the classical antagonistic antibody NOK-1, which specifically binds to the 
region of FasL that normally interacts with the Fas receptor (CD95), did not show 
any effect on viability in cells treated with chemotherapy drugs; these data 
suggested that FasL may exert its effect not via paracrine or juxtacrine 
presentation but via intracellular signalling. 
 TRAIL expression was also investigated, however no TRAIL protein expression 
was observed after treatment at any temperature tested (at all time points). 
 A small degree of Bid cleavage was seen after 6h and 12h, and a modest 
reduction in tBid levels at 18°C and 14°C in HaCaTa cells treated with 4-OH-CP. 
However, HaCaTa treated with doxorubicin and docetaxel showed a far more 
marked induction of Bid cleavage than 4-OH-CP, and cooling conditions 
attenuated Bid cleavage at most time points tested.  
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 Interestingly, the pattern of FasL expression and its regulation by cooling closely 
mirrored the pattern of Bid cleavage and the effects of cooling in its formation, thus 
providing strong evidence for the existence of a cross talk with an extrinsic 
apoptotic pathway (although more studies would be necessary to provide a clear 
functional link). This observation was quite striking, as tBid expression coincides 
with FasL expression data, were doxorubicin and docetaxel caused more 
significant induction of FasL than did 4-OH-CP.   
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6.17 Discussion 
6.17.1 Cooling reduces p53 activation and subsequent p21 induction triggered 
by chemotherapy drug treatment 
To provide a more detailed understanding of the precise mechanisms underpinning 
the cytoprotective role of cooling against chemotherapy drug-mediated toxicity at the 
molecular level, this work for the first time examined the expression and activation patterns of 
important intracellular signalling mediators that could be critical in cell cycle arrest, 
cytotoxicity and more specifically apoptosis induction.   
As discussed above, most anticancer drugs used clinically to date have been able to 
induce apoptosis in rapidly dividing cancer cells in vitro and in vivo. Apoptotic pathways 
initiated by anti-cancer treatments are multiple and can differ depending on the type of drug 
used and the cell type. Any such agent that can induce damage of nuclear DNA is capable of 
activating p53 and its turn induce apoptosis (Henseleit et al., 1997; Payne and Miles, 2008), 
although under some circumstances genotoxic drugs can also induce apoptotic pathways 
independent of p53. The key role of p53 in the intrinsic apoptotic pathway is well established 
(Henseleit et al., 1997). 
The present work demonstrated the up-regulation of P-p53 by all three well-known 
chemotherapeutic drugs doxorubicin, cyclophosphamide, and docetaxel in HaCaTa, NHEK, 
and HHFK cells. Moreover, this study showed that cooling could completely abrogate the 
induction of p53 activation in a temperature dependent fashion (with gradually reduced P-p53 
at temperature values 22°C, 18°C and 14°C).  
More specifically, using an antibody that recognizes specifically p53 phosphorylated 
at Ser-15, a very low basal level of P-p53 in untreated keratinocytes was detected; however 
P-p53 protein was rapidly induced in HaCaTa cells as early as 6h following exposure to 
doxorubicin, 4-OH-CP and docetaxel, suggesting an important role for p53 in cell cycle 
control and apoptosis in response to drug treatment 37°C. The levels of P-p53 was reduced 
dramatically at cooling conditions, and was particularly striking as the temperature was 
reduced further from 22°C to 14°C 24h post exposure to 4-OH-CP. Importantly, the same or 
very similar results were obtained in NHEK and HHFK primary cells after treatment with 4-
OH-CP at 18°C (as representative cooling conditions). Also cooling showed reduced P-p53 
expression after doxorubicin treatment especially at 14°C after 12h post-treatment. Similar 
observation were made for doxorubicin and docetaxel at 14°C particularly after 12h post 
treatment, in agreement with the accumulation of cells in subG0/G1 phase at 37°C and the 
significant inhibition of this population by cooling after 24h of treatment.  
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Inactive p53 is localized predominantly in the cytoplasm; in response to DNA 
damage, p53 is activated and migrates to the nucleus to regulate the expression of pro-
apoptotic genes, such as PUMA, Noxa, Bax and Bak (Sakurai et al., 2005). MDM2 controls 
the activity of p53; it acts by blocking the function of p53 as a transcription factor and 
accelerates its degradation. Interestingly, previous studies reported that MDM2 mRNA levels 
were nearly double when BALB c/3T3 cells were cultured at 32°C, whilst increases in p53 
degradation and nuclear export of p53 were observed (Sakurai et al., 2005). 
To provide functional evidence for the involvement of p53 in triggering cell cycle 
arrest or particularly cytotoxicity by the chemotherapy drugs, the p53 inhibitor Pifithrin-α 
(PFT-α) was exploited. Several reports have shown that PFT-α is a reversible inhibitor of 
p53-dependent gene transcription and p53-mediated apoptosis (Hoagland et al., 2005; Sohn 
et al., 2009). The mechanism of action of PFT-α is still unknown; it is only known; that it 
blocks the transcriptional activity of p53 and the nuclear transport interrupts which inhibits the 
p53-dependent apoptosis (Sohn et al., 2009; Walton et al., 2005). PFT-α slightly reduced the 
viability rate in chemotherapy drug-untreated HaCaTa cells, which is probably due to the 
significant cytotoxicity of PFT-α. Co-administered PFT-α and 4-OH-CP showed a very slight 
increase in cell biomass compared to only 4-OH-CP; however, co-administered PFT-α and 
doxorubicin showed a reduction in viability compared with cells only treated with doxorubicin. 
These findings are in accordance with a previous report showing that PFT-α is unstable in 
media and converted to PFT-β and both forms exhibited cytotoxic effects (Walton et al., 
2005). It would be important for future studies to investigate the functional role of p53 in 
these responses, e.g. by functional inactivation (Shaw et al., 2005) or RNA interference, and 
more importantly the precise mechanisms involved in cooling mediated regulation of p53 
activation.  
The p53 protein has the ability to interrupt cell cycle and thus cell proliferation to 
prevent a suspect or genomics degenerate cell, to allow the cell time to repair DNA damage. 
p53 transcriptionally up-regulates the p21 protein, which is a potent cyclin dependent kinase 
(CDK) inhibitor. Because p21 can block most cyclin-cdk complexes, the cell cycle can be 
stopped in most phases depending on the specific trigger. Also a previous study showed that 
ROS regulate the expression and activity of p21 (Qiu et al., 1996). Cell cycle analysis 
(Chapter 4) showed that the growth rate of untreated keratinocytes (controls that were not a 
chemotherapy drug treated) incubated at cooling conditions was reduced. Western blotting 
showed p21 induction in response to chemotherapy drug treatment in HaCaTa cells, thus 
providing evidence on p53-mediated transcriptional activity.  
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There was a marked increase in the level of p21 at 37°C after exposure to 4-OH-CP, 
and cooling seemed to down-modulate p21, mainly at 18°C. Interestingly, there was an 
induction of p21 in untreated cells at 14°C compared to normal temperature after 24h 
exposure to cooling alone. It is possible that extreme cooling (14°C) might independently 
trigger a p21-related ―stress‖ response. Importantly, normal keratinocytes (NHEKs) showed 
similar results with HaCaTa cells after 4-OH-CP exposure, providing more evidence that 
HaCaTa cells are a suitable keratinocyte cell line model for investigating chemotherapy drug 
induced toxicity relating to CIA. The above analysis does not enable us to determine whether 
cell growth arrest was p21 dependent and functional experiments would be necessary. 
Moreover, the extreme cooling associated p21 induction is very interesting and merits further 
investigation. Also, other p53 targets could be investigated, such as such as p27. 
Keratinocytes treated with doxorubicin showed increased levels of p21 at 37°C 
compared with cooling conditions, with the lowest level of p21 seen at 14°C. Doxorubicin 
induced p21 expression as early as 6h post-treatment, consistent with previous work in 
HCT116 and HT29 cells treated with doxorubicin (Ravizza et al., 2004). Doxorubicin can lead 
to p53 accumulation (Bender et al., 2011), stabilisation and activation (Oren, 1999); it is 
possible that the sensitivity of cells to doxorubicin is associated with an increase of p21. 
Finally, there was marked p21 induction after docetaxel treatment in HaCaTa cells, however, 
cooling significantly reduced p21 expression particularly at 24h post treatment. As docetaxel 
caused significant SubG0/G1 peak, also induction of P-p53 and p21, collectively these data 
suggest that p53 is most probably involved in the apoptosis induction (evident by the 
subG0/G1 peak) and that p21 protein may play an important role in the docetaxel-induced 
cell cycle arrest observed. 
Results showed that the role of p53 in apoptosis in HaCaTa cells induced by 
doxorubicin, 4-OH-CP, and docetaxel is different. The role of cooling in proteins, which were 
involved in this work, is still poorly determined and merits further study. For this, two 
experiments will be carried out: firstly, block the expression of p53 in our lines and secondly, 
work with a p53 deficient control line.  
6.18  Cooling attenuates induction of p53-dependent pro-apoptotic 
BH3-only proteins PUMA and Noxa   
One major finding in this study was that cooling progressively and in a temperature-
dependent fashion blocked the activation of p53-dependent pro-apoptotic signalling 
pathways in human keratinocytes. As activation of p53 leads to induction of downstream pro-
apoptotic "BH3-only" proteins such as PUMA and Noxa, these proteins were investigated, as 
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they represent major signalling players contributing to apoptosis. A main role of the pro-
apoptotic members of the BH3-only family is to control anti-apoptotic Bcl-2 proteins. Bravo-
Cuellar et al have previously shown that doxorubicin induced both Noxa and PUMA in 
HaCaT cells (Boccellino et al., 2010; Bravo-Cuellar et al., 2010), consistent with other studies 
showing that 4-OH-CP induced PUMA and Noxa in Eμ-Myc cell lines (Happo et al., 2010), as 
well as docetaxel in MCF-7 (Kontos et al., 2014). 
Up-regulation of PUMA was observed 6h post-treatment with chemotherapy drugs 4-
OH-CP, doxorubicin and docetaxel. PUMA expression was down-modulated by cooling at all 
temperatures; PUMA levels peaked during the first 6h, followed by a progressive decline 
towards basal levels after 24h in both HaCaTa and NHEK cells. One interesting finding in 
this work was that both PUMA and p21 exhibited detectable bands in untreated (control) cells 
and higher protein levels were detected at later time points compared to controls at 37°C, 
suggesting that cooling alone might be modulating expression. In HaCaTa cells after 
treatment with 4-OH-CP the pattern of Noxa protein expression was similar to that of PUMA 
protein and Noxa was up-regulated as quickly as 6h, however the levels of Noxa declined 
progressively during the course of 24h. It would be appropriate for future studies to identify 
the functional role of PUMA or Noxa (by RNAi) and to determine their importance in 
apoptosis after treatment with chemotherapeutic drugs.  
Noxa and PUMA are direct targets of the transcriptional control of p53; however, in 
this work the relationship between p53 activity and Noxa / PUMA proteins was not 
investigated and therefore represents an interesting topic for future study. Generation of cells 
with inactive or absent p53 would permit investigations as to whether in such cells PUMA 
and Noxa are induced by chemotherapy drugs. Importantly, however, p53 activation is 
suppressed by cooling and in turn, PUMA and Noxa expression is attenuated.  
6.18.1 Effects of cooling on the expression of pro-apoptotic proteins Bax and 
Bak   
Bax and Bak proteins play central roles in the induction of the mitochondrial apoptotic 
pathway; since the deletion of these proteins inhibits the release of cytochrome c from the 
mitochondria (Wei et al., 2001). Bak is located in the outer membrane of the mitochondria 
where it is maintained in an inactive monomeric state via its interaction with the protein 
VDAC2 (Cheng et al., 2003). Bax was the first member of this group shown to be induced by 
p53 (Thornborrow et al., 2002). Bax is itself kept inactive in the cytosol of healthy cells by 
association with 14-3-3 and Ku-70 proteins (Thornborrow et al., 2002; Tsuruta et al., 2004). 
Triggered by an apoptotic stress signal, Bax is activated and translocates to the OMM where 
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it forms multimeric complexes that can serve as pores for cytochrome c release (Basañez et 
al., 2002). Several mechanisms could be responsible for the activation of Bax. p53 protein 
associates with Bax to induce a conformational change and result in its activation (Chipuk et 
al., 2004). The BH3-only proteins Bid, Bim, Noxa, and PUMA are also capable of inducing 
activation of Bax (Cartron et al., 2004).  
Investigations in HaCaTa, NHEK and HHFK cells treated with 4-OH-CP showed that 
Bak was detectable and induced 6h after exposure to 4-OH-CP; the level of Bak was 
significantly high in HaCaTa cells at 37°C. Importantly, under cooling conditions, and 
depending on the precise temperature, there was a significant reduction in Bak expression 
and the lowest down-modulation of Bak by cooling mostly was observed at 24h post-
treatment at 18°C. However, at 14°C although there was protection against drug cytotoxicity 
the level of the protein was higher than at 18°C. These data indicate that extreme cooling, 
such as 14°C, might induce some level of ―stress‖ on the cells, an observation in line with our 
findings on p21 and PUMA expression. An important finding of this work was that a similar 
pattern of up-regulation of Bak was observed in primary NHEK cells, too, in similarity to what 
was observed for HaCaTa cells at 18°C after exposure to 4-OH-CP. Moreover, Bak 
expression increased after doxorubicin treatment and cooling down-modulated this induction 
particularly at 18°C (and to a lesser extent at 14°C). These data strongly suggested that 
cooling modulated Bak, which is significant as Bak represents a critical regulator of the 
mitochondrial pathway and interfere with this pathway provides further evidence for its ability 
to confer protection against chemotherapy drugs induced cytotoxicity.  
Our findings on the role of 4-OH-CP and doxorubicin in Bax expression and its 
regulation by cooling were more difficult to interpret due to the high basal level of Bax in 
these cells. Thus, it was impossible to distinguish between 37°C and 22°C conditions. It is 
possible that despite our observation for p53 activation, Bax will not be transcriptionally 
induced in our system. Cytosolic p53 can promote apoptosis directly by inducing the 
oligomerization and activation of pro-apoptotic Bax (Chipuk et al., 2004) and transcription-
dependent and independent pathways of p53-mediated apoptosis do exist (Chipuk and 
Green, 2004; Chipuk et al., 2004). Future studies should address these possibilities.  
6.18.2  Investigation on possible cell death signalling cross-talk in apoptosis 
induction and the effects of cooling  
Increased p53 activity leads to HF damage by up-regulation of Fas (Lindner et al., 
1997; Sharov et al., 2004). The up-regulation of FasL and receptors and a reduction of Bcl-2 
/ Bax ratio has a pro-apoptotic effect in HFs during the catagen phase of the hair cycle 
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(Lindner et al., 1997). It is believed that FasL and receptors are also important in the process 
of dystrophic restructuring of HF during CIA (Sharov et al., 2004). Chemotherapy drugs such 
as etoposide, cytarabine, cisplatin, methotrexate and doxorubicin have been shown to 
activate the Fas / FasL system and induce apoptosis by both intrinsic and extrinsic pathways 
(Harris, 1996; Müller et al., 1998). To determine the potential role of the Fas/FasL system in 
chemotherapy drug-mediated keratinocyte death and assess the possible role of cooling, 
Western blotting analysis was performed and showed marked up-regulation of FasL induced 
by doxorubicin, 4-OH-CP, and docetaxel.  
Death domain-containing receptors such as TNF-R1, Fas (CD95) or TRAIL (TNF-
Related Apoptosis Inducing Ligand) receptors activate signalling pathways leading to cell 
death by apoptosis (Micheau and Tschopp, 2003). Previous studies showed that the ligand 
TRAIL represents one p53 transcriptional target gene after treatment of HCT116 cells with 5-
Fluorouracil (5FU) (Kuribayashi et al., 2008). More relevant to this work, Sharova et al., 
(2014), based on work utilising ex vivo cultured human HFs, suggested that the Tumour 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) signalling plays an 
important role in doxorubicin-induced hair loss (Sharova et al., 2014). 
No TRAIL was detected following treatment with doxorubicin, 4-OH-CP and docetaxel 
in drug treated HaCaTa cells (and no basal activity was detectable in untreated control cells). 
Therefore, at least in HaCaTa cells, TRAIL does not appear to be induced suggesting lack of 
involvement in cytotoxicity. Collectively, our findings suggest that the Fas/FasL system, but 
not TRAIL-R/TRAIL system might be critical in apoptosis induction and regulation of FasL 
expression has added another piece of evidence for the ability of cooling to protect from 
drug-mediated cytotoxicity. This is in agreement with previous studies demonstrated p53-
mediated induction of Fas in cyclophosphamide-induced apoptosis in the HFs of C57BL/6 
mice (Botchkarev et al., 2000). HaCaTa cells treated with 4-OH-CP, doxorubicin and 
docetaxel exhibited a strong induction of FasL at early time point post treatment, however, 
cooling dramatically decreased FasL levels. These findings suggest activation of p53-
induced target proteins such as p21, pro-apoptotic mediators such as PUMA/Noxa, and the 
classical pro-apoptotic ligand FasL are all induced in drug-mediated apoptosis and, cooling 
can reduce their induction.  
The majority of studies on BH3-only protein Bid demonstrate that cleavage of this 
protein by caspase-8 is required to initiate, in functional association with Bax, the release of 
cytochrome c from the mitochondria to the cytoplasm (Roy and Nicholson, 2000; Tang et al., 
2000). Bid cleavage evident by the generation of tBid was detected following treatment with 
cytotoxic drugs in HaCaTa cells with a different pattern for each drug. A small degree of 
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Bid cleavage was seen after 6h and 12h, and a modest reduction in tBid levels at 18°C and 
14°C in HaCaTa cells treated with 4-OH-CP. By contrast, HaCaTa cells treated with 
doxorubicin and docetaxel showed a far more marked induction of Bid cleavage than 4-OH-
CP, and cooling conditions attenuated Bid cleavage at most time points tested. These 
findings suggest a signalling cross-talk between extrinsic and intrinsic apoptosis pathways in 
HaCaTa cells post drug treatment and cooling appears to suppress this pathway.  
The role of tBid has mostly been described in the context of cell death triggered by 
death receptors (Roy and Nicholson, 2000). It seems that Bid is induced during apoptosis 
triggered by doxorubicin and docetaxel in particular in HaCaTa cells; it is possible that Bid 
might play a role via direct association with Bax to increase mitochondrial permeability (Wei 
et al., 2000) which are hypotheses that could form the basis for future studies. Moreover, tBid 
formation tends to be mediated by caspase-8 of the extrinsic pathway or caspase-2 (Lassus 
et al., 2002). Interestingly, previous studies showed that docetaxel induced apoptosis via 
activation of caspase-2 (Mhaidat et al., 2007); it would be interesting to investigate the 
induction of caspase-2 and the effects of cooling on its induction. Notably, the pattern of 
FasL expression and its regulation by cooling closely mirrored the pattern of Bid cleavage 
and the effects of cooling in its formation. This provides strong evidence for the existence of 
cross talk with an extrinsic apoptotic pathway (although more studies would be necessary to 
provide a clear functional link). This observation was quite striking, as tBid expression 
coincides with FasL expression data, where doxorubicin and docetaxel caused more 
significant induction of FasL than 4-OH-CP. Data in this work provides strong evidence for 
the existence of a cross talk with an extrinsic apoptotic pathway (although more studies 
would be necessary to provide a clear functional link). This observation was quite striking, as 
tBid expression coincides with FasL expression data, where doxorubicin and docetaxel 
caused more significant induction of FasL than did 4-OH-CP.   
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7 CHAPTER 7: The effect of antioxidant-mediated 
blockade of ROS in cooling-induced cytoprotection: 
combinatorial treatment with N-acetyl-cysteine (NAC) 
and cooling protects against chemotherapy drug 
cytotoxicity 
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7.1  Oxidative stress and cellular antioxidant mechanisms  
Oxidative stress refers to a state in which highly reactive molecules (such as reactive 
oxygen species, ROS) occur at high levels in cells, which can have a damaging effect on 
these cells. ROS, as mentioned previously in chapter 5, are constantly formed in an 
organism, and they are not merely metabolic by-products but can also perform physiological 
functions, and there are different enzymes to degrade (detoxify) them. However, once the 
generation of ROS reaches beyond the capacity of the redox-regulating mechanisms in the 
cell, proteins and DNA (as well as other structures such as lipids) are damaged, and once 
the damage is beyond repair, cell death is induced (Simon et al., 2000; Yu, 1994).  
In order to cope with oxidative stress, mammalian cells have developed a very 
complex system of cytoprotective mechanisms against such stress. These include non-
enzymatic antioxidants such as a glutathione (or GSH) (Atkuri et al., 2007). GSH is a 
molecule that the body makes from various nutrients, including the amino acid cysteine 
(Sprietsma, 1999). GSH is the main line of defence against such harmful substances, and 
plays several physiological roles including signal transduction, regulation, intracellular 
defences against oxidative stress and other important functions in the neoplastic process 
(Schumacker, 2015). Effective regulation of the cellular balance between oxidation and anti-
oxidation (reduction) is physiologically vital, hence, for instance, when GSH levels 
drop below baseline, this can disrupt the functioning of immune cells and make the body 
more sensitive to the toxic effects of certain drugs (Kerksick and Willoughby, 2005). 
7.2 N-acetyl-cysteine (NAC) and its antioxidant properties  
 Radical scavengers such as N-acetylcysteine (NAC), ascorbate (vitamin C), Trolox 
(vitamin E) and folate (vitamin B12) can cause a decrease in the intracellular accumulation of 
ROS (Huang et al., 2002). NAC is a relatively low-molecular weight compound (MW = 
163.20) with chemical formula C5H9NO3S (Prasad et al., 2012). NAC is a derivative of the 
amino acid L-cysteine, which is a source of sulfhydryl (SH) groups, and is converted into 
metabolites capable of stimulating glutathione (GSH) synthesis (Atkuri et al., 2007; Kelly, 
1998). The SH groups in NAC can easily be oxidised, which form a disulfide bond to give a 
compound of two linked NAC molecules, by targeting ROS radicals, NAC causes these to be 
simultaneously reduced, and thus lose their damaging effect. NAC reduces such species in a 
way quite similar to glutathione, and shows preference for hydrogen peroxide (H2O2) and 
hydroxyl radicals (OH•) (Jaworska et al., 1995). Below is a representation of the reaction of 
NAC with hydrogen peroxide: 
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 2 (NAC-SH) +H2O2         NAC-S-S-NAC + 2H2O 
Due to its efficient antioxidant properties, NAC constitutes a compound with an 
impressive array of protective mechanisms, as it can protect against DNA damage and is 
thus its anti-carcinogenic effects (both linked directly to its antioxidant activity), whilst 
mediating modulation of metabolism, detoxification, DNA repair, it has anti-inflammatory 
activity and related immunological effects (De Flora et al., 2001). NAC has an influence on 
cell cycle progression, and in the context of cancer, it causes inhibition of invasion and 
metastasis. Moreover, by directly inactivating ROS, it can protect towards the adverse effects 
of cancer chemotherapeutic agents (De Flora et al., 2001). 
Several studies showed evidence that NAC has anti-apoptotic activity, for instance, in 
beta-nerve cells and pancreatic cells (Luanpitpong et al., 2011; Luanpitpong et al., 2012; 
Savion et al., 2014) and more recent work in our laboratory has confirmed the strong anti-
apoptotic capacity of NAC. It is believed that NAC is capable of impairing the apoptotic 
program, which might be due to its antioxidant activity, and more specifically due to its role 
as a precursor to GSH thus can protect cell membranes against lipid peroxidation and 
protein oxidation (Yan et al., 1995), whilst GSH can regulate the activity of some pro-
apoptotic proteins such as JNK. Previous studies also showed that NAC has a protective 
effect against chemotherapy drug cytotoxicity and its protective function was demonstrated 
by in vivo and in vitro experiments, which showed that NAC reduces the antitumor activity of 
paclitaxel (Alexandre et al., 2006). 
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7.3 Chapter Aims  
Work in previous chapters demonstrated that cancer chemotherapy drugs induce 
death and engage critical mediators of the intrinsic (mitochondrial) apoptosis pathway in 
human keratinocytes. As part of this response, in addition to mitochondrial MOMP we also 
observed rapid increases in ROS levels. Due to the importance of ROS in the induction of 
apoptosis as demonstrated previously and more recently in our laboratory (Dunnill, et al., In 
Press), we hypothesised that ROS are critical in mediating the cytotoxic effects of these 
chemotherapy drugs.  
This study also showed that cooling could have a strong cytoprotective effect against 
chemotherapy drug-induced cytotoxicity. Yet, notably, the in vitro work demonstrated that the 
temperature during cell cooling is critical in determining the strength of the cytoprotective 
capacity of cooling, as temperatures in the region of 22°C are moderately cytoprotective, 
however, reduction of temperature by an additional 4°C (18°C) can have a significant impact 
and renders cooling significantly more cytoprotective. Strikingly, these findings are supported 
by recently published clinical studies demonstrating that the efficacy of scalp cooling during 
chemotherapy is temperature dependent and the best results appear to be obtained when 
the scalp temperature decreases to or below 18°C (Komen et al., 2016).  
As it is clear that the scalp temperature reached during scalp cooling varies amongst 
individuals (Komen et al., 2013b; Van Den Hurk et al., 2012b), in some patients scalp cooling 
might not be efficient at reducing the temperature of the scalp adequately to provide 
cytoprotection, as only sub-optimal cooling conditions might be achieved in such individuals. 
Therefore, collectively, we hypothesised that it may be possible to compensate for such sub-
optimal temperatures by combination of cooling with treatment with an antioxidant, as part of 
a possible therapeutic intervention of cooling plus topical treatment with an antioxidant 
compound to prevent CIA without compromising the anticancer effects of chemotherapy.  
Specifically the aims of the work in this chapter were to: 
 Examine the effects of N-acetylcysteine (NAC) during chemotherapy drug-
treatment of human keratinocytes.  
 Test the effects of combination of cooling and NAC treatment on cell viability in 
order to understand whether NAC could further enhance the cytoprotective effects 
of cooling. 
 Test the efficacy of ―sub-optimal temperature conditions‖ in protecting from 
cytotoxicity and, more importantly, examine for the first time the possibility that 
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treatment with antioxidant NAC may compensate for the inability of ―sub-optimal‖ 
cooling to protect cells from drug-mediated toxicity.  
7.4 Optimisation (titration) of NAC  
In order to assess the cytoprotective effects of NAC, whether alone or in combination with 
cooling, HaCaTa cells were treated with NAC (0-20 mM) as part of initial pre-titration 
experiments (and viability was determined by the CellTiter assay after 72h of exposure, see 
Materials and Method section 2.2.3). Interestingly, a significant difference in cell viability 
arose in cultures and there was a dramatic increase in viability (as indicated by the rise in 
absorbance) in cells treated with NAC in comparison with controls (cells cultured in medium 
only without the addition of NAC). The highest increase in cell viability was observed at 5 
mM. NAC alone after 72h of incubation showed cytotoxicity only at very high concentrations 
(20mM) (Figure 7-1).  
The potential of NAC alone to directly protect from chemotherapy drug-mediated cytotoxicity 
was assessed in HaCaTa cells using the lower range concentrations of NAC (0.625 and 1.25 
mM), as those were the does with the weakest effect on cell viability. Cells were pre-treated 
with 0.625 and 1.25 mM NAC for 30 min, before being treated with 0.5, 0.75, and 2.5 µg/mL 
doxorubicin, 0.005, 0.025, and 0.1 µg/mL docetaxel and 2.5, 5, and 10 µg/mL 4-OH-CP. The 
data showed that cells treated with 0.625 mM NAC showed a significant increase in viability 
and thus were rescued significantly from drug cytotoxicity compared to cells treated without 
NAC; interestingly, a better protection from the cytotoxicity was observed with the lower NAC 
concentration that with 1.25 mM NAC. The most dramatic protection was observed with 4-
OH-CP and in particular for the lower drug dose, ―drug + NAC‖ treated cells showed a 
significant increase in biomass >20% compared to cells without NAC (Figure 7-2). Overall, 
notably, in cells treated with 1.25 mM NAC for all three drugs tested, the viability was lower in 
the presence of NAC compared with drug-treated cells treated without NAC (Figure 7-2). 
Based on these data, the 0.625 mM dose was selected for all subsequent experiments.  
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Figure ‎7-1 Titration of NAC on HaCaTa cells 
HaCaTa cells were seeded in 96-well plates at 5000 cells/well in KSFM complete medium 
and were incubated overnight at 37°C/ 5% CO2. HaCaTa cells were treated with a range of 
concentrations of NAC and 72h post-treatment the culture medium was removed and fresh 
medium added. 20 µL of CellTiter 96® AQueous One solution was added to the wells and 
plates were incubated at 37°C in 5% CO2 for a total of four hours. Absorbance was 
measured spectrophotometrically at a wavelength of 492nm. Bars correspond to mean 
absorbance values (± S.E.M.) of three independent biological experiments, each consisting 
of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001. 
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Figure ‎7-2 Protection against chemotherapy drug cytotoxicity by NAC 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
and 0.125 mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated 
dose of doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
A
b
so
rb
a
n
ce
 (
4
9
2
n
m
)
Drug dose (µg/mL)
0mM NAC
0.625 mM NAC
1.25 mM NAC
A
0
20
40
60
80
100
120
140
%
 C
e
ll 
B
io
m
as
s
Drug dose (µg/mL)
B
**
n.s.
*
n.s.
*
**
*
*
**
***
***
***
**
***
**
n.s.
*
n.s.
303 
 
7.5 Determining the efficacy of combination of cooling and NAC in 
protecting from chemotherapy drug-mediated cytotoxicity 
Our findings on the ability of NAC to reduce chemotherapy drug-mediated cytotoxicity are in 
agreement with a previous study which showed that NAC has chemoprotective activity 
(Muldoon et al., 2001), however, for the first time these effects were tested for a range of 
drugs and on human keratinocytes. To understand whether NAC could further enhance the 
significant cytoprotective effects of cooling as shown in previous chapters (Chapter 3), the 
effect of combination of cooling and NAC treatment on cell viability was investigated. 
HaCaTa cells were pre-incubated with and without 0.625 mM of NAC 30 min prior to 
exposure to doxorubicin, docetaxel, and 4-OH-CP for 2h at 37°C versus 22°C and 18°C and 
cytotoxicity was assessed after 72h by cell viability assays. Notably, the results showed 
significant increases in biomass (thus indicating cytoprotection) in cells treated with cooling in 
the presence of NAC compared with cells without NAC (Figures 7-3 and 7-4) and the positive 
impact of NAC was detectable for both 22°C and 18°C cooling conditions. Interestingly, these 
drugs act via different molecular mechanisms, yet there was a significant increase in 
biomass in cells treated with NAC under cooling conditions in all cases, thus providing 
evidence for the first time that NAC can significantly enhance the cytoprotective effects of 
cooling against a variety of drugs. 
As the doses of 4-OH-CP employed in the studies described above were relatively lower in 
comparison to those used in chapter 3 were a wider range of doses was investigated, 
cytoprotection by combinatorial treatment of cooling and NAC against higher concentrations 
of 4-OH-CP was investigated. HaCaTa cells were treated with 5, 10, 30, and 50 µg/mL 4-OH-
CP at 37°C and 22°C. As shown in Figure 7-5, a remarkable protection against all 
concentrations was observed, particularly with very high drug concentrations 30 and 50 
µg/mL 4-OH-CP. The cytotoxicity was clearly further reduced in cells treated with cooling and 
NAC over the cytoprotection levels reached with cooling alone; the percentage of biomass 
increased from 35 to 70% and from 10 to 50% in cells treated with 30 and 50 µg/mL with 
cooling plus NAC, respectively (Figure 7-5). Although not as dramatic, marked increases in 
cell viability were also observed in the case of doxorubicin treatments. 
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Figure ‎7-3 Cytoprotective role of combination of cooling and NAC treatment against 
chemotherapy drug-mediated toxicity in HaCaTa cells at 37°C and 22°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C and 22°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph form. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. *, p < 0.05; **, p < 0.01; 
***, p < 0.001. 
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Figure ‎7-4 Cytoprotective role of combination of cooling and NAC treatment against 
chemotherapy drug-mediated toxicity in HaCaTa cells at 37°C and 18°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C and 18°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph form. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure ‎7-5 Cytoprotective role of combination of cooling and NAC treatment against 
high concentrations of 4-OH-CP at 37°C and 22°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), and 4-OH-CP with and without NAC at 37°C and 22°C compared with 
vehicle control (cells treated with medium containing DMSO, in which the reagent was 
dissolved. The solvent represents the maximum amount of DMSO corresponding to the 
highest drug concentration). The drugs were then removed, wells were rinsed with PBS to 
remove any traces of drug and cultures incubated for a further 72h, after which the culture 
medium was removed and fresh medium added then 20 µL of CellTiter 96® AQueous One 
solution was added to the wells and plates were incubated at 37°C in 5% CO2 for a total of 
four hours. Absorbance was measured spectrophotometrically at a wavelength of 492nm and 
% cell biomass was calculated as described in Materials and Methods (Chapter 2). Data is 
presented as A) Absorbance (raw data) B) % cell biomass shown in bar graph form. Data 
points correspond to mean % cell biomass (±S.E.M.) for three independent biological 
experiments, each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001. 
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7.6 Investigations on the ability of NAC to enhance protection from 
chemotherapy drug-mediated cytotoxicity under sub-optimal 
cooling conditions  
Previous studies in our laboratory, involving the use of Paxman cooling caps and 
infra-red camera measurements to determine scalp temperature during cooling on healthy 
volunteers, demonstrated that the temperature of the scalp for certain individuals did not 
reach optimal values, i.e. temperatures of 22°C or below – in some cases only temperatures 
ranging from 25-27°C were actually reached (unpublished observations). Although it was an 
important observation that NAC could enhance the cytoprotective effect of optimal cooling 
conditions (i.e. temperature values that offered significant cytoprotection), it was equally 
important to investigate the cytoprotective capacity of cooling in combination with NAC at 
sub-optimal conditions (i.e. at temperature values higher than 22°C such as 24°C and 26°C 
were less protection would be expected).  
HaCaTa cells were pre-treated with and without 0.625 mM NAC for 30 min before 
incubation with a range of doxorubicin and 4-OH-CP doses at 37°C and 26°C. Results 
showed that HaCaTa biomass increased significantly in cells treated with NAC compared 
with cells treated without NAC (Figure 7-6). These data provided strong evidence for 
enhanced cytoprotective effects mediated by addition of NAC at sub-optimal cooling 
conditions. Furthermore, additional experiments were performed to assess the effects the 
combinatorial treatment (sub-optimal cooling and NAC) against doxorubicin over a wider 
range of drug concentrations. Interestingly, there was a clear and significant rescue from 
cytotoxicity for all doxorubicin concentrations in cells treated with a combination of NAC and 
cooling compared with cooling alone, even at very high drug concentrations, as biomass 
increased from 10% to nearly 65% (Figure 7-7). Finally, to expand the above observations on 
the ability of NAC to enhance cooling mediated cytoprotection, further experiments were 
performed, where cells were treated at 24°C to represent sub-optimal cooling conditions. As 
shown in Figure 7-8, NAC in combination with sub-optimal cooling provided a significant 
enhancement in protection when compared to cooling alone for cells treated with 4-OH-CP 
and doxorubicin. It remains unknown, however, why cells treated with doxorubicin exposed 
to NAC and cooling at 26°C showed better protection than at 24°C.  
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Figure ‎7-6 Cytoprotective role of combination of cooling and NAC against 
chemotherapy drug-mediated toxicity in HaCaTa cells at 37°C and 26°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C and 26°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 
0.001.  
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Figure ‎7-7 Cytoprotective role of combination of cooling and NAC against 
doxorubicin-mediated toxicity in HaCaTa cells at 37°C and 26°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C and 26°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure ‎7-8 Cytoprotective role of combination of cooling and NAC against 
chemotherapy drug-mediated toxicity in HaCaTa cells at 37°C and 24°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. HaCaTa cells were treated for 2h with the indicated dose of 
doxorubicin (Doxo), docetaxel (Doce) and 4-OH-CP with and without NAC at 37°C and 24°C 
compared with vehicle control (cells treated with medium containing DMSO, in which the 
reagent was dissolved. The solvent represents the maximum amount of DMSO 
corresponding to the highest drug concentration). The drugs were then removed, wells were 
rinsed with PBS to remove any traces of drug and cultures incubated for a further 72h, after 
which the culture medium was removed and fresh medium added then 20 µL of CellTiter 96® 
AQueous One solution was added to the wells and plates were incubated at 37°C in 5% CO2 
for a total of four hours. Absorbance was measured spectrophotometrically at a wavelength 
of 492nm and % cell biomass was calculated as described in Materials and Methods 
(Chapter 2). Data is presented as A) Absorbance (raw data) B) % cell biomass shown in bar 
graph. Data points correspond to mean % cell biomass (±S.E.M.) for three independent 
biological experiments, each consisting of 6–8 technical replicates. n.s., non-significant; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001.  
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7.7 Effect of combination of cooling and NAC treatment on AC and 
TAC-mediated cytotoxicity in HaCaTa cells 
Work presented in chapter 3 demonstrated that although cooling can protect human 
keratinocytes substantially (in some cases 100%) and rescue from single drug treatments, it 
was less effective at protecting from combinatorial drug treatment and in particular from TAC 
(Chapter 3). Therefore, the ability of combinatorial treatment with cooling and NAC to protect 
from the cytotoxic effects of the AC (doxorubicin/cyclophosphamide) and TAC regimes at 
different temperatures was assessed. 
For the AC regimen, cells were treated with doxorubicin (A) followed by 4-OH-CP (C) 
with 10% of the doxorubicin dose (denoted ‗AC (+10%)‘) at 37°C versus 22°C, 18°C and the 
sub-optimal temperature 26°C as detailed in Materials and Methods section 2.7.3. The 
results showed consistently improved, though relatively modest, degrees of cytoprotection at 
22°C (Figure 7-9), 18°C (Figure 7-10), and 26°C (Figure 7-11) when cooling was combined 
with NAC, in comparison to treatment with cooling alone (without NAC co-treatment). The 
TAC regimen at 26°C on HaCaTa cells was also tested and based on the previous studies in 
chapter 3 regimen ‗TAC (+10%)‘ was followed and the drug concentrations chosen were 
doses that corresponded to the maximal observed cytoprotection upon cooling in HaCaTa 
cells (Figure 7-12). Collectively, these results showed that in addition to the cytoprotection by 
cooling observed against combinatorial drug treatments, cells co-treated with NAC during 
cooling showed higher viability than cells treated without NAC at all temperatures, which 
indicates that NAC can have a positive, though modest for AC and TAC, influence on 
cooling-mediated chemoprotection against such combinatorial drug regimes.  
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Figure ‎7-9 Effect of combination of cooling and NAC on AC-mediated cytotoxicity in 
HaCaTa cells at 37°C and 22°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. Cells were treated with the combinatorial drug protocols ‗AC 
(+10%)‘ with and without NAC at 37°C and 22°C compared with vehicle control (cells treated 
with medium containing DMSO, in which the reagent was dissolved. The solvent represents 
the maximum amount of DMSO corresponding to the highest drug concentration) as detailed 
in section 2.7.3. The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which the culture medium was 
removed and fresh medium added then 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods section 2.7.3. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001.  
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Figure ‎7-10 Effect of combination of cooling and NAC on AC-mediated cytotoxicity in 
HaCaTa cells at 37°C and 18°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. Cells were treated with the combinatorial drug protocols ‗AC 
(+10%)‘ with and without NAC at 37°C and 18°C compared with vehicle control (cells treated 
with medium containing DMSO, in which the reagent was dissolved. The solvent represents 
the maximum amount of DMSO corresponding to the highest drug concentration) as detailed 
in section 2.7.3. The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which the culture medium was 
removed and fresh medium added then 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods section 2.7.3. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001.  
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Figure ‎7-11 Effect of combination of cooling and NAC on AC-mediated cytotoxicity in 
HaCaTa cells at 37°C and 26°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium and were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. Cells were treated with the combinatorial drug protocols ‗AC 
(+10%)‘ with and without NAC at 37°C and 18°C compared with vehicle control (cells treated 
with medium containing DMSO, in which the reagent was dissolved. The solvent represents 
the maximum amount of DMSO corresponding to the highest drug concentration) as detailed 
in section 2.7.3. The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which the culture medium was 
removed and fresh medium added then 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods section 2.7.3. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. **, p < 0.01.  
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Figure ‎7-12 Effect of combination of cooling and NAC on TAC-mediated cytotoxicity in 
HaCaTa cells at 37°C and 26°C 
HaCaTa cells were seeded in 96 well plates at 5000 cells/well in KSFM medium were 
incubated overnight at 37°C/ 5% CO2. HaCaTa cells were pre-treated with and without 0.625 
mM NAC for 30 min at 37°C. Cells were treated with the combinatorial drug protocols ‗TAC 
(+10%)‘ with and without NAC at 37°C and 18°C compared with vehicle control (cells treated 
with medium containing DMSO, in which the reagent was dissolved. The solvent represents 
the maximum amount of DMSO corresponding to the highest drug concentration) as detailed 
in section 2.7.3. The drugs were then removed, wells were rinsed with PBS to remove any 
traces of drug and cultures incubated for a further 72h, after which the culture medium was 
removed and fresh medium added then 20 µL of CellTiter 96® AQueous One solution was 
added to the wells and plates were incubated at 37°C in 5% CO2 for a total of four hours. 
Absorbance was measured spectrophotometrically at a wavelength of 492nm and % cell 
biomass was calculated as described in Materials and Methods section 2.7.3. Data points 
correspond to mean % cell biomass (±S.E.M.) for three independent biological experiments, 
each consisting of 6–8 technical replicates. **, p < 0.01; ***, p < 0.001.  
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7.8 Summary  
 The objective of this chapter was to investigate for the first time the hypothesis that 
cooling combined with the antioxidant N-acetylcysteine (NAC) may enhance the 
cytoprotective effect of cooling, and particularly for sub-optimal cooling conditions, 
as a potential novel therapeutic intervention.  
 Initial pre-titration experiments allowed the determination of an optimal 
concentration of NAC, according to these experiments the optimal concentration of 
NAC was 0.625 mM. 
 HaCaTa cells were pre-treated with NAC for 30 min, then co-treated with 
chemotherapy drugs (doxorubicin, docetaxel, and 4-OH-CP) at 37°C. The results 
showed that NAC significantly protected from drug-mediated cytotoxicity for all 
compounds tested, and rescued cells from drug toxicity. Furthermore, 4-OH-CP 
showed the best results in comparison with doxorubicin and docetaxel.  
 NAC not only showed protection from chemotherapy drugs that act through the 
production of ROS to induce apoptosis such as doxorubicin, but also against 
docetaxel, which interferes with microtubule stabilisation in cells. Furthermore, 
data in this work showed that 4-OH-CP did not induce ROS generation (Chapter 
4). However, in this chapter NAC showed protection from 4-OH-CP-induced 
cytotoxicity in HaCaTa cells, these results suggested that NAC might act 
independently of ROS.  
 Combination of NAC and cooling during chemotherapy drug treatment provided 
significant protection from drug-mediated cytotoxicity for nearly all concentrations 
tested for doxorubicin, docetaxel and 4-OH-CP. NAC was effective at reducing 
drug toxicity even at high drug doses such as 50 µg/mL of 4-OH-CP and the 
toxicity was reduced from 10% to 65%.  
 Significantly, when experiments were carried out to investigate the efficacy of 
cooling at sub-optimal conditions (24°C and 26°C) in combination with NAC, the 
combination significantly protected against a range of doxorubicin and 4-OH-CP 
doses at 37°C and 26°C with cells treated without NAC. These data provided 
strong evidence for enhanced cytoprotective effects against chemotherapy 
drugs by combination of NAC and sub-optimal cooling conditions.  
 Interestingly the result showed that there was a significant rescue from cytotoxicity 
in HaCaTa cells treated with the combinatorial treatment 26°C and NAC against a 
wider range of doxorubicin concentrations compared with cells treated without 
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NAC. Furthermore, the results showed that when HaCaTa cells were treated with 
combinatorial treatment 24°C and NAC there was an enhancement in protection 
for cells treated with 4-OH-CP and doxorubicin in comparison to cooling alone. 
Strangely, NAC and cooling at 26°C showed better protection than at 24°C.  
 The chemoprotective effects of combinatorial treatment of cooling and NAC 
against the AC (doxorubicin/cyclophosphamide) and TAC regimes at different 
temperatures was also assessed. The results showed consistently enhanced, 
though relatively modest, degrees of cytoprotection at 22°C, 18°C, and 26°C in 
cells co-treated with NAC, in comparison to treatment with cooling alone. HaCaTa 
cells treated with TAC at with NAC and cooling at 26°C, showed improved, though 
relatively modest, cell viability. 
 An important and interesting finding is that NAC could not fully protect from drug 
induced toxicity, although a range of NAC concentrations should be investigated in 
future studies. Yet, in combination with cooling it showed significant enhancement 
of the cytoprotective effects of cooling.  
 Of note, although NAC showed effective chemoprotection, the molecular 
mechanisms underlying the cytoprotective effect of NAC and cooling have not 
been fully established here and must form the basis of future studies.  
 Nevertheless, the fact that antioxidant NAC enhances the chemoprotective effects 
of cooling at both sub-optimal (24°C and 26°C), moderately efficient (22°C) and 
optimal (18°C) cooling conditions, supports the promise of the combinatorial 
treatment as a strategy to improve the efficacy of scalp cooling which is currently, 
overall, 50% in cancer patients.  
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7.9 Discussion 
7.9.1 The chemoprotective agent and antioxidant N-acetylcysteine (NAC) 
blocks chemotherapy drug-induced cell death and enhances the 
cytoprotective effect of cooling 
The main aim of this study was to understand the pathway of cytotoxicity with the 
long-term aim to design new and more effective strategies to complement or improve the 
efficacy of scalp cooling. Ideally, the aim would be to design of a topical treatment to help 
protect from CIA without affecting chemotherapy treatment efficacy. Despite the fact that 
cooling can be effective against CIA, against the combined treatment (TAC) and 
monotherapies such as docetaxel at high concentrations, cooling shows limited efficacy. 
Furthermore, in some patients scalp cooling might not be efficient at reducing the 
temperature of the scalp effectively to provide cytoprotection, as only sub-optimal cooling 
conditions might be achieved in such individuals. In fact, the findings of this study have 
clearly demonstrated that even a small number of degrees in temperature difference may be 
significant in rescuing from drug-mediated cytotoxicity.  
As ROS appeared to be induced by chemotherapy drugs and these molecules are 
often central in mitochondrial apoptosis pathways, the hypothesis raised was that the 
cytoprotective effect of cooling might be enhanced via co-treatment with the antioxidant NAC. 
The idea behind this combinatorial treatment of ―cooling plus NAC‖, was that a) for drug 
regimes where cooling shows limited efficacy NAC may improve the cytoprotective effect, 
and b) NAC could enhance cytoprotection for patients where scalp cooling devices might not 
reduce the scalp temperature adequately, i.e. only achieve sub-optimal scalp temperatures 
(such as 24°C and 26°C). The aim was to test a possible therapeutic intervention of cooling 
plus topical treatment with antioxidant NAC to prevent CIA without compromising the 
anticancer effects of chemotherapy. 
The effectiveness of NAC has been shown experimentally as reported using in vitro 
and in vivo studies; it is clinically proven in humans to inhibit ROS, protect against DNA 
damage and carcinogenesis (De Flora et al., 2001). Other studies have demonstrated that 
the NAC can reduce the invasive and metastatic potential of the melanoma and fibrosarcoma 
cells (Tosetti et al., 2002). Moreover, a number of experimental studies reported the effects 
of NAC on different models, pre or post treatment, in various fields of toxicology or 
pharmacology. NAC protection of deleterious effects during the administration of anticancer 
drugs adriamycin, bleomycin, cisplatin (and its derivatives), doxorubicin, ifosfamide, 
methotrexate, or antimicrobials (amphotericin, vancomycin); these effects (but not all) appear 
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to be related to its ability to reduce oxidative stress (De Flora et al., 2001; Wu et al., 2005). 
Moreover, in several biological studies, NAC has been used as a tool for investigating ROS 
(Zafarullah et al., 2003) and more recently in studies in our laboratory have shown that NAC 
can rescue from apoptosis by members of the TNF receptor family that engage the 
mitochondrial pathway.  
This study for the first time examined a range of concentrations of doxorubicin, 
docetaxel and 4-OH-CP with and without NAC in HaCaTa cells and investigated the possible 
influence of NAC and temperature on drug-mediated cytotoxicity. NAC was able to prevent 
cell death induced by doxorubicin, docetaxel, and 4-OH-CP and caused increases in cell 
viability compared with cells treated without NAC. The improvement by NAC was particularly 
evident as sub-optimal cooling conditions. Despite the fact that doxorubicin, docetaxel and 4-
OH-CP act via different molecular mechanisms, the cytoprotective effect of NAC was 
significant and evident for all drugs tested, particularly 4-OH-CP. 
ROS are continually released during various metabolic processes in the cell and it 
has long been known that reactive oxygen species in the form of oxidative stress are 
involved in pathogenic processes. ROS also act as signalling intermediates in physiological 
regulatory mechanisms recognized for their involvement in the control of cell division 
(Luanpitpong et al., 2011; Schulze-Osthoff et al., 1996). Yet, extensive ROS induction is 
associated with toxicity and induction of apoptosis. Doxorubicin exerts its anti-cancer effect 
via the formation of oxygen radicals and direct interference with the cell cycle (Luanpitpong 
et al., 2012). Doxorubicin-mediated cytotoxicity appears to be dependent on ROS generation 
(Luanpitpong et al., 2011; Luanpitpong et al., 2012), however, cyclophosphamide in our 
study did not show induction of ROS whilst the mechanism of action of docetaxel is different 
and induces cell death via microtubule de-stabilisation (Bhardwaj et al., 2014). However, the 
observation that NAC caused a protection from all these three chemotherapy drugs suggests 
that NAC might also act independently of ROS and might have direct effects on these drugs.  
ROS are involved in the activation of JNK in response to stress, whilst activation of 
JNK and apoptosis induced by cisplatin is inhibited by NAC, but potentiated by the addition of 
hydrogen peroxide (Benhar et al., 2001). The role of oxidative stress in activation of JNK was 
also demonstrated after treatment with a topoisomerase inhibitor (Shiah et al., 1999). ERK 
pathways can also be activated by NAC to promote cell survival and prevent apoptosis, 
which lead to cell growth (Li et al., 2000b; Wung et al., 1999). NAC can block the induction of 
several DNA alterations in rat lung cells (Izzotti et al., 1999; Marnett, 2000).  
Finally, when the response to combinatorial therapies AC and TAC with and without 
NAC and cooling were examined, despite extensive toxicity in HaCaTa cell at 37°C, cooling 
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plus NAC showed that cooling-mediated cytoprotection improved consistently. This was 
particularly evident at 26°C, which showed better protection for both AC and TAC compared 
with all other temperatures tested in this study. However, it must be noted that the 
improvement achieved was relatively modest in comparison to monotherapies.  
However, recent work in our laboratory that took place during the preparation of this 
thesis, in collaboration with Paxman Coolers (Dunnill and Georgopoulos, unpublished 
observations), has investigated additional antioxidant compounds that alone as well in 
combination with NAC significantly improved the ability of cooling to cytoprotect. In particular, 
compounds such as quercetin have now been demonstrated to significantly enhance the 
cytoprotective effect of cooling when combined with NAC, particularly against combinatorial 
treatment AC, which is responsible for significant levels of CIA in the clinic. 
This more recent data, combined with the findings presented here, confirm that 
cooling protects from cytotoxicity induced by chemotherapy drugs, and the combination of 
cooling with antioxidants can rescue from drug-mediated cytotoxicity better than cooling 
alone. As a result, this more recent work has led to the submission of European patent 
application (Georgopoulos NT and Paxman Coolers) relating to the co-treatment of patients 
with cooling plus combinations of antioxidants to reduce or protect from chemotherapy 
induced hair loss.  
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8 CHAPTER 8: Concluding remarks 
The main aim of this work was to establish human keratinocyte models for the study 
of the cellular effects of cancer chemotherapy drugs in order to assess the ability of cooling 
to protect from drug-induced cytotoxicity and to determine the underpinning mechanisms of 
cytoprotection. By providing several novel observations, the findings presented in this thesis 
have enhanced both our understanding of the effects of chemotherapy drugs on keratinocyte 
cell growth and also the mechanisms of cooling-mediated cytoprotection. Figure 8.2 provides 
a summary of the mechanisms of cooling-mediated cytoprotection demonstrated in this 
study. 
  
 
Figure ‎8-1 Molecular mechanisms of cooling mediated cytoprotection against 
chemotherapy drug-mediated toxicity 
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8.1 Future work 
There are many avenues of future study that could be pursued, for instance: 
 One of the hypothesis mentioned above is that the rate of drug diffusion across a 
plasma membrane may be reduced by cooling, thus lowering the ‗effective‘ drug 
dose entering the cells. Future studies should determine the effects of cooling on 
cellular drug uptake. Preliminary work in our laboratory has provided some 
evidence that cooling may alter the amount of cellular drug uptake. However, 
cooling conditions that fully block cytotoxicity (shown in the present study) did not 
fully prevent drug uptake. This indicates that combination of both prevention of 
drug uptake as well as direct cellular effects are triggered by cooling. 
 This study has provided evidence that cooling decreased the level of cellular 
metabolic activity; by showing that human keratinocytes are exiting the cell cycle; 
the study has suggested reduced metabolic activity. Future studies should involve 
measuring the metabolic activity of cells as described elsewhere (Zhang et al., 
2012) using different techniques, for example the cytometric quantification of 
cellular fluorescence upon cleavage of fluorescein diacetate.  
 It would be interesting to determine the relationship between chemotherapy-
induced cell arrest and the checkpoint recovery induced by cooling using western 
blotting assay in order to understand the proteins involved.  
 To fully elucidate the role of p53, knockdown/knockout of p53 protein (by RNAi or 
CRISPR-Cas9 technologies) could be employed to investigate effects of 
chemotherapy drugs with and without cooling. Moreover, measurements of the 
levels of MDM2 in cells at different temperature would be important in 
understanding the mechanisms underpinning cooling effects.  
 The release of Cyto-c from mitochondria is a critical event in the activation of 
caspase-9, and as Bid is cleaved, it would be interesting to understand whether 
activation of caspase-8 mediated tBid production and downstream apoptosome 
formation; moreover, detection of the localisation of pro-apoptotic Bax by 
microscopy would allow a better understanding of its involvement and whether 
cooling regulates its localisation and activation. 
 The ability of cooling to protect from chemotherapy drug-mediated increases in 
ROS and loss of mitochondrial integrity in HaCaTa cells has generated an 
interesting avenue that would involve investigation on the nature of ROS involved 
in cytotoxicity and whether the exact types of ROS are altered by ROS.  
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 In response to chemotherapy drugs in this work, we detected P-p53 and p21 and 
apoptotic proteins, Bax, Bak, PUMA and Noxa; although cooling led to down-
regulation of these proteins, protein levels were detected at several time points 
following chemotherapy drug treatment and at different cooling conditions. Yet, the 
observation that extreme cooling alone or extended (24h) cooling caused induction 
of some of these important signalling mediators will form the basis of novel studies 
that might provide a better explanation for the cytoprotective effects of cooling. 
 To provide a better understanding of how antioxidants like NAC enhance the 
cytoprotective effect cooling against cytotoxic agents, the apoptotic signalling 
pathways could be investigated by detection of proteins involved in cell arrest and 
apoptosis (such as p53, p21, Bak, and FasL).  
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Appendix I 
List of Suppliers 
Supplier Webpage/Address 
Alpha labs www.alphalabs.co.uk 
Bio-Rad Laboratories Ltd www.bio-rad.com 
Biosera www.biosera.com 
Calbiochem Supplied by Merck 
Cambridge Bioscience www.bioscience.co.uk 
ENZO www.enzolifesciences.com 
Falcon Supplied by VWR 
Fisher Scientific UK Ltd www.fisher.co.uk 
Greiner Bio-one Ltd www.greinerbioone.com/en/england/start/ 
Insight Biotechnology Ltd www.insightbio.com 
Invitrogen Ltd www.invitrogen .com 
Invivogen www.invivogen.com 
Li-Cor Biosciences UK Ltd www.licor.com 
Merck www.merck.co.uk  
Microsoft Corporation www.microsoft.com 
Millipore www.merckmillipore.co.uk 
Molecular Probes Supplied by Invitrogen 
Nalgene Europe Ltd Supplied by Fisher Scientific 
New England Biolabs (UK) Ltd www.neb.uk.com 
Promega UK Ltd www.promega.com 
Qiagen Ltd www.qiagen.com 
Roche Diagnostics Ltd www.roche.co.uk/portal/uk/diagnostics 
Santa Cruz Biotechnology Supplied by Insight Biotechnology Ltd 
Sigma-Aldrich Company Ltd www.sigmaaldrich.com 
Starstedt Ltd www.sarstedt.com 
Statebourne Cryogenics Ltd www.statebourne.com 
Sterilin Ltd Supplied by Fisher 
Tebu-bio www.tebu-bio.co.uk 
ThermoFisher Scientific Inc www.fisher.com 
VWR international www.vwr.com 
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Appendix II 
Reagents  
Phosphate Buffer Saline (PBS) (Invitrogen 14200-67) 
Compound Concentration 
137 mM Sodium Chloride NaCl 
2.7 mM Potassium Chloride KCl 
3.2 mM Disodium hydrogen phosphate Na2HPO4 
147 mM Potassium hydrogen phosphate KH2PO4 
pH 7.2 dissolved in autoclaved dH2O. Prepared from 10X solution 
 
2x SDS lysis buffer: 
Amount(volume or mass) Material 
10 mL (2% W/V) Glycerol (Sigma) 
1 gram (2% W/V) SDS 
6.25 mL (Stock 1M Tris-HCl 
0.42g /200 mM  Sodium fluoride (NaF)(Sigma) 
0.446g Sodium pyrophosphate tetrabasic 
2 mM  Sodium Orthovandate 
Up to total volume of 
50mL 
Deionised water 
Chemicals used in preparation of SDS sample buffer. All chemicals were dissolved 
using magnetic heat block and then store at -20C in 2.5mL or aliquots.  
 
Standards: Cat# PN23208 
Standards Concentrations µg/mL BSA/ volume 
bovine serum albumin (BSA) 125, 250, 500, 750, 1000, 1500, 2000/ 3.5mL each 
Diluted in 0.9% saline and preserved with 0.05% sodium azide 
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Tris Buffered Saline (TBS) 
Volume or Weight Chemical 
1.21g Tris (Hydroxy methyl amino methan) 
8.18g Sodium hydrochloride (NaCl) (Sigma) 
Made up to 1L by deionised water pH 7.4  
 
 TBS-Tween 
Volume or Weight Chemical 
1.21g Tris (Hydroxy methyl amino methane) 
8.18g Sodium hydrochloride (NaCl) (Sigma) 
Made up to 1L by deionised water, and pH was adjusted (pH 7.4) then 1mL of 
Tween-20 was added.  
  
Transfer Buffer  
Volume or Weight Chemicals 
1.45 g Tris( 12 mM) 
7.2 g Glycine(96 mM) 
200 mL Methanol (20%) 
Make up to 1L by deionised water (*made fresh on day of use*) 
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The CellTiter 96® Cell proliferation assay 
Volume  Chemicals 
100mL CellTiter 96 
Cell Proliferation Assay 5,000 assays  
CellTiter 96® AQueous One Solution  
Ready to use / 20 µL/well- store the reagent at -20C for long term storage or for short 
up to 6 week at 4C protected from the light. 
 (www.promega.com)  
 
Caspase-3/7 activity reagents 
Components Volume 
Store 
components 
Caspase-3/7 substrate 270 µL -20 ºC 
AFC, Fluorescence reference standard 20 µL (in 10mM DMSO) -20 ºC 
Ac-DEVD-CHO a known caspase-3/7 
inhibitor 
5 mM DMSO solution 15 µL -20 ºC 
Assay buffer 30mL 4 ºC 
DTT 1mL -20 ºC 
Lysis buffer 20mL 4 ºC 
  The chemical compound used in the measurement of caspase-3/7 activity.   
(www.anaspec,com)   
 
 CytoTox-GloTM Cytotoxicity reagents  
Component  Bottle/Size  Storage Cat # 
Assay Buffer  5 x10mL  
-20 ºC 
 
G9291 AAF-GloTM substrate(Alanyle alanyl-phenylal 
alanyl-amino luciferin  
5 bottles 
Digitonin  175 µL 
   (www.promega.com)  
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Appendix III  
The concentrations of protein for all lysates; (HaCaTa, NHKE and HHFK cell line) at 
different time point (6h, 12h, 24h and controls) at different temperature (37°C vas 22°C, 
18°C, and14°C. The concentrations of protein for HaCaTa cell line at 37°C vas 22°C lysate 
are shown in the Table. 
 6h 12h 24h Con 
37°C 22°C 37°C 22°C 37°C 22°C 37°C 22°C 
 µg/mL 3117.3 4056.8 2805.7 3746.2 2788.6 2725.6 2880.5 2266.4 
 µg/µL 3.1 4.1 2.8 3.7 2.8 2.7 2.9 2.3 
Volume 
with20 µg 
6.42 4.93 7.13 5.34 7.17 7.34 6.94 8.82 
dH2O 6.58 8.07 5.87 7.66 5.83 5.66 6.06 4.18 
Sample 
volume 
13 13 13 13 13 13 13 13 
Reducing 
Agent 
2 2 2 2 2 2 2 2 
LDS 
sample 
buffer 
5 5 5 5 5 5 5 5 
Total (µL) 20 20 20 20 20 20 20 20 
Protein concentration in different cell lysates. The table also indicates the amount of 
other reagents added to the lysates preparation for western blotting. 
Standard curve 4-parameter-fit to measure protein concentration 
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Appendix IV  
Proliferation assay for NHEKs and HHFK 
 
Viability assay for NHK cell line 
Cell viability percentage was estimated by CellTiter 96® AQueous One Solution in 96-well 
plates following 24, 48 and 72h. NHEK cells at increasing cell densities (‗Low‘, ‗Medium‘ and 
‗High‘) under routine culture conditions (‗Cell number‘ represents number of cells seeded per 
well). Bars correspond to mean absorbance at 492 nm (±SD) for three independent biological 
experiments, each consisting of 6 technical replicates. 
 
Viability assay for HHFK cell line 
Cell viability percentage was estimated by CellTiter 96® AQueous One Solution in 96-well 
plates following 72h. HHFK cells at increasing cell densities (‗Low‘, ‗Medium‘ and ‗High‘) 
under routine culture conditions (‗Cell number‘ represents number of cells seeded per well). 
Bars correspond to mean absorbance at 492 nm (±SD) for three independent biological. 
Experiments, each consisting of 6 technical replicates. 
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Appendix V  
Microscopic observation of cooling-mediated cytoprotection of HaCaT cells from chemotherapy drug-mediated toxicity 
HaCaT cells were treated with the indicated doses of 0.5 µg/mL doxorubicin (A), 5 µg/mL 4-OH-CP (B) and 0.01 µg/mL docetaxel (C) at 37°C 
and 22°C. Solvent alone-treated (Control) HaCaT cultures served as negative controls. Phase contrast light microscopy was used to assess the 
viability of control and drug-treated cultures and representative photomicrographs are provided from two independent series of experiments. 
The presence of non-adherent, phase-bright cells following drug treatment was indicative of drug-mediated cytotoxicity. Phase contrast images 
were obtained using an EVOS XL core inverted microscope and at x100 magnification. 
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Appendix V  
 
 
 
 
ROS levels measured by flow cytometry analysis after treatment with doxorubicin and 
H2DCFDA(5 and 10 μM) in HaCaTa cells 
HaCaTa cells were seeded in 6 well plate at 1.5x105 cells/well in KSFM medium and were 
incubated overnight at 37°C/5% CO2. HaCaTa cells were treated for 2h with 2.5 µg/mL 
doxorubicin at 37°C, compared with vehicle control (cells treated with medium containing the 
solvent in which the reagent was dissolved. The drugs were then removed, wells were rinsed 
with PBS to remove any traces of drug and cultures incubated for a 30 min and after which (5 
and 10μm) H2DCFDA reagent were added to the wells and plates were incubated at 37°C in 
5% CO2 for 30 min. Cells were harvested by trypsinisation ROS generation were analysed by 
flow cytometry using H2DCFDA as a fluorescent probe. A) Representative flow cytometric 
histograms, B) bars represent median fluorescence intensity (MFI). Cells were acquired on a 
Guava EasyCyte flow cytometer and results analysed using GuavaSoft software. Bars show 
MFI ±S.E.M for 3 technical replicates. ***, p < 0.001. 
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